



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07J	A2	(11) International Publication Number: WO 99/46279 (43) International Publication Date: 16 September 1999 (16.09.99)
<p>(21) International Application Number: PCT/CA99/00205</p> <p>(22) International Filing Date: 10 March 1999 (10.03.99)</p> <p>(30) Priority Data: 60/077,510 11 March 1998 (11.03.98) US 60/095,623 7 August 1998 (07.08.98) US</p> <p>(71) Applicant: ENDORECHERCHE, INC. [CA/CA]; 2989 de la Promenade, Sainte-Foy, Québec G1W 2J5 (CA).</p> <p>(72) Inventors: LABRIE, Fernand; 2989 de la Promenade, Sainte-Foy, Québec G1W 2J5 (CA). BELANGER, Alain; 4031 Boisverdun, Cap-Rouge, Québec G1Y 3T7 (CA). GAUTHIER, Sylvain; 152, rue de la Modiste, Saint-Augustin-de-Desmaures, Québec G3A 2L2 (CA). LUU-THE, Van; 4460 de l'Estuaire, Charny, Québec G6X 1C6 (CA). MERAND, Yves; 3101 Montreux, Sainte-Foy, Québec G1W 3A1 (CA). POIRIER, Donald; 1588 des Cassandres, L'Ancienne-Lorette, Québec G2E 5V1 (CA). PROVENCHER, Louis; 7518 de la Sarcelle, Charny, Québec G6X 3R7 (CA). SINGH, Shankar, Mohan; 2816, rue de Lanoraie, Sainte-Foy, Québec G1W 1M6 (CA).</p> <p>(74) Agent: MITCHELL, Richard, J.; Marks & Clerk, P.O. Box 957, Station B, Ottawa, Ontario K1P 5S7 (CA).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published Without international search report and to be republished upon receipt of that report.</p>
<p>(54) Title: INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE</p>		
<p>(57) Abstract</p> <p>Novel methods of medical treatment and/or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and/or type 3 17β-hydroxysteroid dehydrogenase. Novel inhibitors of type 5 17β-hydroxysteroid dehydrogenase are also disclosed, as are novel inhibitors of type 3 17β-hydroxysteroid dehydrogenase.</p> <div data-bbox="787 1207 1437 1858"> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**INHIBITORS OF TYPE 5 AND TYPE 3 17 β -HYDROXYSTEROID
DEHYDROGENASE AND METHODS FOR THEIR USE**

5

FIELD OF THE INVENTION

10 The present invention relates to inhibitors of enzymes involved in the
biosynthesis of sex steroids from natural precursors and to their use in the
treatment of sex steroid dependent diseases. In particular, inhibitors are
disclosed which suppress the activity of type 3 and type 5
17 β -hydroxysteroid dehydrogenase, thus diminishing the production of
15 androgens catalyzed by these two enzymes. Pharmaceutical use of the
inhibitors may reduce the natural production of androgens such as
testosterone and dihydrotestosterone, and thereby beneficially treat
diseases whose onset or progress is aided by androgenic activity. Because
androgens formed by reactions catalyzed by type 3 or type 5 enzyme are
20 precursors to estrogens, the invention also has applicability to diseases
whose onset or progress is aided by estrogenic activity.

BACKGROUND OF THE RELATED ART

Many androgen-sensitive diseases, i.e. diseases whose onset or progress is aided by androgenic activity, are known. They include but are not limited to prostate cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, androgenic alopecia, precocious puberty, adrenal hyperplasia, and polycystic ovarian syndrome. Estrogen sensitive diseases, i.e. diseases whose onset or progress is aided by estrogenic activity are also known. They include but are not limited to breast cancer, endometriosis, leiomyoma, and precocious puberty.

Precocious puberty is usually associated with an excess of androgen secretion, usually of adrenal origin. The current treatments include blockade of adrenal secretion by glucocorticoids with its associated side effects. Blockade of type 5 17β -HSD would be an advantage, thus desirably reducing the dose or avoiding the use of glucocorticoids. Another treatment is the use of LHRH agonists to cause medical castration. A better controlled inhibition of androgen formation could be achieved with type 5 and 3 17β -HSD inhibitors.

Polycystic ovarian syndrome is associated with an excess of androgen secretion by the ovaries. LHRH agonists are used among other, as treatment, to cause medical castration. The use of an inhibitor of 17β -HSD would be advantageous.

Estrogen sensitive diseases may vary in their responses to androgens. They may, for example, respond favorably, unfavorably or not at all to androgens. Likewise, androgen-sensitive diseases may respond differently to estrogens. Thus, the treatment of sex steroid sensitive

diseases may involve increasing or decreasing androgenic activity depending on whether the disease in question responds favorably or unfavorably to androgenic activity. Treatment may also involve increasing or decreasing estrogenic activity depending on whether the disease in question responds favorably or unfavorably to estrogenic activity. Breast cancer, for example, is known to respond favorably to androgenic activity and negatively to estrogenic activity. Benign prostatic hyperplasia is believed to respond negatively to both androgenic and estrogenic activity.

Androgenic and estrogenic activity may be suppressed by administering androgen receptor antagonists ("antiandrogens") or estrogen receptor antagonists ("antiestrogens"), respectively. See e.g. WO 94/26767 and WO 96/26201. Androgenic and estrogenic activity may also be reduced by suppressing androgen or estrogen biosynthesis using inhibitors of enzymes that catalyze one or more steps of such biosynthesis or by suppressing ovarian or testicular secretions by known methods. See e.g. WO 90/10462, WO 91/00731, WO 91/00733, and WO 86/01105. Type 5 17 β -hydroxysteroid dehydrogenase is described in WO 97/11162.

Effective inhibitors of type 5 17 β -hydroxysteroid dehydrogenase enzyme are provided by the present invention. The prior art is not believed to have provided compounds sufficiently effective at simultaneously (1) inhibiting type 5 or type 3 17 β -hydroxysteroid dehydrogenase while (2) desirably failing to substantially inhibit other 17 β -hydroxysteroid dehydrogenases or other catalysts of sex steroid degradation. Medroxyprogesterone acetate, megestrol acetate, and chlormadinone acetate which the prior art as used as pharmaceutical agents for other

purposes are not believed to have been disclosed as inhibitors of type 5 17 β -hydroxysteroid dehydrogenase, although applicants' research has now shown them to inhibit that type 5 enzyme.

5

SUMMARY OF THE INVENTION

10

It is accordingly an object of the present invention to more selectively and effectively inhibit type 3 and/or type 5 17 β -hydroxysteroid dehydrogenase while preferably avoiding inhibition of other 17 β -hydroxysteroid dehydrogenases, type 1 or 2 3 α -hydroxysteroid dehydrogenases, or other androgen degradation enzymes.


15

It is another object to provide novel inhibitors of types 3 and 5 17 β -hydroxysteroid dehydrogenase and pharmaceutical compositions thereof.

It is another object to provide treatment and prevention regimens for androgen and estrogen sensitive diseases which regimens include inhibiting activity of type 3 or type 5 17 β -hydroxysteroid dehydrogenase.

- 5 -

In one embodiment, the invention provides a method of inhibiting activity of type 5 17β -hydroxysteroid dehydrogenase comprising administering to a patient in need of such treatment a therapeutically effective amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase having the molecular structure:



wherein the dotted line is optional pi bond;

wherein A is selected from the group consisting of straight or branched C_1 - C_4 alkyl, $-OR^c$ (R^c being a C_1 - C_8 alkyl radical), and $-N(R^d)R^e$ (R^d and R^e being independently hydrogen or C_1 - C_8 alkyl or aryl), and unsaturated analogs of any of the foregoing definitions for substituent A;

wherein R^1 is selected from the group consisting of hydrogen and methyl;

wherein R^6 is selected from the group consisting of hydrogen, and halogen, and C_1 - C_8 alkyl;

wherein R^a is selected from the group consisting of straight or branched C_1 - C_8 alkylene, C_3 - C_7 cycloalkylene; and


R^b is selected from the group consisting of hydrogen, substituted or unsubstituted phenyl, C_2 - C_{10} acyl, C_2 - C_{10} acyloxy, C_2 - C_{10} alkoxy carbonyl, and halogen;

provided that when A is methyl, R^a and R^b together have at least two carbon atoms, and R^1 is methyl.

It is preferred that the optional pi bond at 6 is present that R^6 is methyl, that R^a is C_1 - C_6 alkylene or that A is either methyl or $-N(R^d)R^e$.

It is also preferred when wherein A is $-N(R^d)R^e$ that R^d is methyl or that R^e is C_1 - C_6 alkyl or C_7 - C_{12} phenyl alkyl.

In another embodiment, the invention provides a method of inhibiting activity of type 5 17β -hydroxysteroid dehydrogenase comprising administering to a patient in need of such treatment a therapeutically effective amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase having the molecular structure:



wherein the dotted line is an optional pi bond;
 wherein $R^{16\beta}$ is selected from the group consisting of hydrogen, fluoro, chloro, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, a moiety which together with $R^{16\alpha}$ is C_4 - C_7 spirocycloalkyl, C_4 - C_7 halospirocycloalkyl, or $\text{---}R^{16}$ (R^{16} being C_1 - C_3 alkyl) and unsaturated analogs of any of the foregoing definitions of $R^{16\beta}$;

wherein $R^{16\alpha}$ is selected from the group consisting of hydrogen, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, a moiety which together with $R^{16\beta}$ forms

- 7 -

C₄-C₇ spirocycloalkyl, C₄-C₇ halospirocycloalkyl, or ---R^{16} (R¹⁶ being C₁-C₃ alkyl) and unsaturated analogs of any of the foregoing;

wherein R^{15α} is selected from the group consisting of hydrogen, C₁-C₄ alkyl, C₁-C₄ alkenyl and C₁-C₄ alkynyl;


5 wherein R¹⁹ is either -H or -CH₃; and

wherein R⁶ is selected from the group consisting of -H, CH₃, and halo;

Provided that R^{16β}, R^{16α}, and R^{15α} are not simultaneously hydrogen.

10 It is preferred that R^{16α} is a larger substituent than R^{16β}, that R⁶ is hydrogen, that the optional pi bond at position 1 is not present or that R^{16α} is a C₃-C₅ alkyl chain.

15 In another embodiment, the invention provides a method of inhibiting activity of type 5 17β-hydroxysteroid dehydrogenase comprising administering to a patient in need of such treatment a therapeutically effective amount of an inhibitor of type 5 17β-hydroxysteroid dehydrogenase having the molecular structure:



20

wherein the dotted line is optional pi bond

wherein X is C₁-C₃ alkyl;

wherein Y is hydrogen or an acyloxy moiety;

- 8 -


wherein R^6 is -H or -CH₃;

wherein R^{16} is -H or halo;

wherein R^1 is -H or -CH₃.

5 It is preferred that R^6 is methyl that the optional pi bond at position 1 is present, that Y is a C₃-C₆ fluoroacyloxy or that X is methyl.

10 In another embodiment, the invention provides a method of inhibiting activity of type 5 17 β -hydroxysteroid dehydrogenase comprising administering to a patient in need of such treatment a therapeutically effective amount of an inhibitor of type 5 17 β -hydroxysteroid dehydrogenase having the molecular structure:



15 wherein n is an integer from 1-2;

wherein the dotted lines are optional double bonds;

wherein X and Y are independently selected from the group consisting of -H, (C₁-C₃)alkyl, (C₂-C₃) alkenyl, and methoxycarbonyl;

20 wherein Z is selected from the group consisting of -H and (C₁-C₃)alkyl;

wherein R^3 is selected from the group consisting of hydrogen, acyl, carboxyl, alkoxycarbonyl, substituted or unsubstituted carboxamide,

- 9 -

cyano, alkoxy, alkoxyalkoxy, alkythioalkoxy, acyloxy; hydroxy, halo, -O-SO₂R^a (R^a being selected from the group consisting of C₁-C₆ alkyl and C₆-C₁₀ aryl), and a moiety which, together with R₂, is a 5-6 member ring containing at least one oxygen and one nitrogen atom;

5 wherein R² is selected from the group consisting of hydrogen, amido, acyloxy, carboxyl, carboxamide, alkoxycarbonyl, cyano, halo, nitro, C₁-C₈ alkyl, and CF₃ and a moiety which, together with R₃, is a 5-6 member ring containing at least one oxygen and one nitrogen atom;

 wherein R⁴ is hydrogen or halo;

10 wherein R⁶ is selected from the group consisting of hydrogen and oxo;

 wherein R⁹ is -H or -OH;


 provided that X, Y, and Z are not all hydrogens when R³ is methoxy.

15

It is preferred that R³ is alkoxyalkoxy, carboxamide, carboxyl or alkoxyl, that at least one of X, Y or Z is methyl, that both X and Y are methyl, that n is 1 or that R⁶ is oxo.

- 10 -

In another embodiment, the invention provides a method of inhibiting activity of type 5 17β -hydroxysteroid dehydrogenase comprising administering to a patient in need of such treatment a therapeutically effective amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase having the molecular structure:



wherein the dotted lines are optional pi bonds;

wherein $n = 1$ or 2 ; and

wherein a is either $-H$ or $-CH_3$;

wherein b and c are independently hydrogen or methyl;


wherein Z is oxygen or sulfur.

It is preferred that n is 1 , that at least one of b or c is methyl, both b and c are methyl or that Z is oxygen.


- 11 -

In another embodiment, the invention provides a method of inhibiting activity of type 5 17β -hydroxysteroid dehydrogenase comprising administering to a patient in need of such treatment a therapeutically effective amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase selected from the group consisting of:


EM-1291




EM-1195-CS




CS-243




- 12 -




CS-245




EM-1183



EM-1097




EM-1273-CS




EM-1401

- 13 -


EM-1404




CS-237



EM-1078




EM-1196-CS




- 14 -

EM-1394




EM-1424-CS




5

EM-1157-CS




EM-1125




- 15 -

EM-1402-CS




EM-1396




5


EM-1181



EM-1159




- 16 -



EM-1165


and



EM-1122-CS

5

It is preferred that the type 5 inhibitor is selected from the group consisting of:




EM-1404

10


- 17 -

and EM-1394




5


In another embodiment, the invention provides a method of inhibiting activity of type 5 17β -hydroxysteroid dehydrogenase comprising administering to a patient in need of such treatment a therapeutically effective amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase selected from the group consisting of:




medroxyprogesterone acetate



megestrol acetate




chlormadinone acetate




1-dehydromegestrol acetate


- 18 -




melengestrol acetate



nomegestrol acetate




1-dehydromelengestrol acetate



cyproterone acetate

and compounds having the molecular structure:



5

wherein the dotted lines are optional pi bonds;

wherein A is selected from the group consisting of straight or branched C₁-C₄ alkyl, -OR^c (R^c being a C₁-C₄ alkyl radical), and -N(R^d)R^e (R^d and R^e being independently hydrogen or C₁-C₈ alkyl or aryl), and unsaturated analogs of any of the foregoing definitions for substituent A;

10

wherein R¹ is selected from the group consisting of hydrogens, and methyl;


- 19 -

wherein R^6 is selected from the group consisting of hydrogen, halogen, and C_1 - C_8 alkyl;

wherein R_{16} is selected from the group consisting of H,H and CH_2 ;

5 wherein R^a is selected from the group consisting of straight or branched C_1 - C_8 alkylene, C_3 - C_7 cycloalkylene; and R^b is selected from the group consisting of hydrogen, substituted or unsubstituted phenyl, C_2 - C_{10} acyl, C_2 - C_{10} acyloxy, C_2 - C_{10} alkoxycarbonyl, and halogen.

10 In another embodiment, the invention provides a method of inhibiting activity of type 5 17β -hydroxysteroid dehydrogenase comprising administering to a patient in need of such treatment a therapeutically effective amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase having the molecular structure:



15

wherein the dotted line are optional pi bonds;

wherein $R^{16\beta}$ is selected from the group consisting of hydrogen, fluoro, chloro, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, a moiety which together with $R^{16\alpha}$ forms C_4 - C_7 spirocycloalkyl, C_4 - C_7 halospirocycloalkyl, or $\text{---}R'^{16}$ (R'^{16} being C_1 - C_3 alkyl) and unsaturated analogs of any
20 of the foregoing definitions of $R^{16\beta}$;

- 20 -

wherein $R^{16\alpha}$ is selected from the group consisting of hydrogen, C₁-C₈ alkyl, C₁-C₈ haloalkyl, a moiety which together with $R^{16\beta}$ forms C₄-C₇ spirocycloalkyl C₄-C₇ halospirocycloalkyl, or $\text{---}R^{16}$ (R^{16} being C₁-C₃ alkyl) and unsaturated analogs of any of the foregoing;

5

wherein $R^{15\alpha}$ is selected from the group consisting of hydrogen, C₁-C₄ alkyl, C₁-C₄ alkenyl and C₁-C₄ alkynyl;

wherein R^{19} is either -H or -CH₃; and


wherein R^6 is selected from the group consisting of -H, -CH₃, and halo;

10

provided that $R^{16\beta}$, $R^{16\alpha}$, and $R^{15\alpha}$ are not simultaneously hydrogen.

In another embodiment, the invention provides a method of inhibiting activity of type 5 17 β -hydroxysteroid dehydrogenase comprising administering to a patient in need of such treatment a therapeutically effective amount of an inhibitor of type 5 17 β -hydroxysteroid dehydrogenase having the molecular structure:

15



20

wherein $n=1$ or 2 ;

wherein the dotted lines are optional pi bonds;

- 21 -

wherein X and Y are independently selected from the group consisting of -H, , (C₁-C₃)alkyl, (C₂-C₃) alkenyl, and methoxycarbonyl;

wherein Z is selected from the group consisting of -H and (C₁-C₃)alkyl;

5 wherein R³ is selected from the group consisting of acyl, carboxyl, alkoxy carbonyl, substituted or unsubstituted carboxamide, cyano, alkoxy, alkoxyalkoxy, alkythioalkoxy, acyloxy; hydroxy, halo, -O-SO₂R^a (R^a being selected from the group consisting of C₁-C₆ alkyl and C₆-C₁₀ aryl), and a moiety which, together with R₂, is a 5-6 member ring containing at least
10 one oxygen and one nitrogen atom;

 wherein R² is selected from the group consisting of amido, acyloxy, carboxyl, carboxamide, alkoxy carbonyl, cyano, halo, nitro, C₁-C₈ alkyl and CF₃ and a moiety which, together with R₃, is a 5-6 member ring containing at least one oxygen and one nitrogen atom;

15 wherein R⁴ is hydrogen or halo;

 wherein R⁶ is selected from the group consisting of hydrogen and oxo;


 wherein R⁹ is -H or -OH;

 provided that X, Y, and Z are not hydrogens when R³ is methoxy.

20

It is preferred that R³ is alkoxyalkoxy, carboxamide, carboxyl or alkoxyl, that at least one of X, Y or Z is methyl, that both X and Y are methyl, that n is 1 or that R⁶ is oxo.

In another embodiment, the invention provides a method of inhibiting activity of type 5 17β -hydroxysteroid dehydrogenase comprising administering to a patient in need of such treatment a therapeutically effective amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase having the molecular structure:



wherein the dotted lines are optional pi bonds;


wherein $n = 1$ or 2 ; and

wherein a is either -H or -CH_3 ;

wherein b and c are independently hydrogen or methyl;

wherein Z is oxygen or sulfur.

In another embodiment, the invention provides a method of inhibiting activity of type 5 17β -hydroxysteroid dehydrogenase comprising administering to a patient in need of such treatment a therapeutically effective amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase having the molecular structure:



wherein the dotted line is an optional pi bond;

wherein A is selected from the group consisting of straight or branched C_1 - C_4 alkyl, $-OR^c$ (R^c being a C_1 - C_8 alkyl radical), and $-N(R^d)R^e$ (R^d and R^e being independently hydrogen or C_1 - C_8 alkyl or aryl), and unsaturated analogs of any of the foregoing definitions for substituent A;

wherein R^1 is selected from the group consisting of hydrogen, methyl, and ethyl;


wherein R^6 is selected from the group consisting of hydrogen, halogen, and C_1 - C_8 alkyl;

wherein R^a is selected from the group consisting of straight or branched C_1 - C_8 alkylene, C_3 - C_7 cycloalkylene; and

R^b is selected from the group consisting of hydrogen, substituted or unsubstituted phenyl, C_2 - C_{10} acyl, C_2 - C_{10} acyloxy, C_2 - C_{10} alkoxy carbonyl, and halogen;

provided that when A is methyl, R^1 is methyl.

In another embodiment, the invention provides a method of inhibiting activity of type 5 17β -hydroxysteroid dehydrogenase comprising administering to a patient in need of such treatment a therapeutically effective amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase having the molecular structure:



wherein the dotted lines are optional pi bonds

wherein X is C₁-C₃ alkyl;


wherein Y is hydrogen or an acyloxy moiety;

wherein R⁶ is -H or -CH₃;

wherein R¹⁶ is -H or halo;

wherein R¹ is -H or -CH₃.

In another embodiment, the invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient, diluent or carrier and a therapeutically acceptable amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase having the molecular structure:



5

wherein the dotted lines are optional pi bonds;

wherein A is selected from the group consisting of straight or branched C_1 - C_4 alkyl, $-OR^c$ (R^c being a C_1 - C_8 alkyl radical), and $-N(R^d)R^e$ (R^d and R^e being independently hydrogen or C_1 - C_8 alkyl or aryl), and unsaturated analogs of any of the foregoing definitions for substituent A;

10

wherein R^1 is selected from the group consisting of hydrogen and methyl;

wherein R^6 is selected from the group consisting of hydrogen, halogen, and C_1 - C_8 alkyl;

15

wherein R^a is selected from the group consisting of straight or branched C_1 - C_8 alkylene, C_3 - C_7 cycloalkylene; and

R^b is selected from the group consisting of hydrogen, substituted or unsubstituted phenyl, C_2 - C_{10} acyl, C_2 - C_{10} acyloxy, C_2 - C_{10} alkoxy carbonyl, and halogen;


20

provided that when A is methyl, R^a and R^b together have at least two carbon atoms, and R^1 is methyl.

It is preferred that the optional pi bond at 6 is present, that R^6 is methyl, that R^a is C_1 - C_6 alkylene or that A is either methyl or $-N(R^d)R^e$.

It is also preferred when A is $-N(R^d)R^e$, that R^d is methyl or that R^e is C_1 - C_6 alkyl or phenyl C_1 - C_6 alkyl.

In another embodiment, the invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient, diluent or carrier and a therapeutically acceptable amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase having the molecular structure:



wherein the dotted line is an optional pi bond;

wherein $R^{16\beta}$ is selected from the group consisting of hydrogen, fluoro, chloro, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, a moiety which together with $R^{16\alpha}$ is C_4 - C_7 spirocycloalkyl, C_4 - C_7 halospirocycloalkyl, or $\text{---}R'^{16}$ (R'^{16} being C_1 - C_3 alkyl) and unsaturated analogs of any of the foregoing definitions of $R^{16\beta}$;

wherein $R^{16\alpha}$ is selected from the group consisting of hydrogen, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, a moiety which together with $R^{16\beta}$ forms C_4 - C_7 spirocycloalkyl, C_4 - C_7 halospirocycloalkyl, or $\text{---}R'^{16}$ (R'^{16} being C_1 - C_3 alkyl) and unsaturated analogs of any of the foregoing;

- 27 -

wherein $R^{15\alpha}$ is selected from the group consisting of hydrogen, C_1 - C_4 alkyl, C_1 - C_4 alkenyl and C_1 - C_4 alkynyl;


wherein R^{19} is either -H or - CH_3 ; and

wherein R^6 is selected from the group consisting of -H, - CH_3 , and halo;

provided that $R^{16\beta}$, $R^{16\alpha}$, and $R^{15\alpha}$ are not simultaneously hydrogen.

It is preferred that $R^{16\alpha}$ is a larger substituent than $R^{16\beta}$ that R^6 is hydrogen, that the optional pi bond at position 1 is not present or that $R^{16\alpha}$ is a C_3 - C_5 alkyl chain.

In another embodiment, the invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient, diluent or carrier and a therapeutically acceptable amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase having the molecular structure:



wherein the dotted line is an optional pi bond

wherein X is C_1 - C_3 alkyl;

wherein Y is hydrogen or an acyloxy moiety;


wherein R^6 is -H or - CH_3 ;

wherein R^{16} is -H or halo;

wherein R^1 is -H or - CH_3 .

It is preferred that R^6 is methyl, that the optional pi bond at position 1 is present, that Y is a C₃-C₆ fluoroacyloxy or that X is methyl.

- 5 In another embodiment, the invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient, diluent or carrier and a therapeutically acceptable amount of an inhibitor of type 5 17 β -hydroxysteroid dehydrogenase having the molecular structure:



10

wherein n is an integer from 1-2;

wherein the dotted lines are optional pi bonds;

wherein X and Y are independently selected from the group consisting of -H, (C₁-C₃)alkyl, (C₂-C₃) alkenyl, and methoxycarbonyl;

15

wherein Z is selected from the group consisting of -H and (C₁-C₃)alkyl;

20

wherein R^3 is selected from the group consisting of hydrogen, acyl, carboxyl, alkoxycarbonyl, substituted or unsubstituted carboxamide, cyano, alkoxy, alkoxyalkoxy, alkythioalkoxy, acyloxy; hydroxy, halo, -O-SO₂R^a (R^a being selected from the group consisting of C₁-C₆ alkyl and C₆-C₁₀ aryl), and a moiety which, together with R₂, is a 5-6 member ring containing at least one oxygen and one nitrogen atom;

- 29 -

wherein R² is selected from the group consisting of hydrogen, amido, acyloxy, carboxyl, carboxamide, alkoxycarbonyl, cyano, halo, nitro, C₁-C₈ alkyl, and CF₃ and a moiety which, together with R₃, is a 5-6 member ring containing at least one oxygen and one nitrogen atom;

5 wherein R⁴ is hydrogen or halo;

wherein R⁶ is selected from the group consisting of hydrogen and oxo;


wherein R⁹ is -H or -OH;

10 provided that X, Y, and Z are not all hydrogen when R³ is methoxy.

It is preferred that R³ is alkoxyalkoxy, carboxamide, carboxyl or alkoxyl, that at least one of X, Y or Z is methyl, that both X and Y are methyl, that n is 1 or that R⁶ is oxo.

15

In another embodiment, the invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient, diluent or carrier and a therapeutically acceptable amount of an inhibitor of type 5 17 β -hydroxysteroid dehydrogenase having the molecular structure:



20

- 30 -

wherein the dotted lines are optional pi bonds;

wherein $n = 1$ or 2 ; and


wherein a is either H or CH_3 ;

wherein b and c are independently hydrogen or methyl;

5 wherein Z is oxygen or sulfur.


It is preferred that n is 1 , that at least one of b or c is methyl, that both b and c are methyl or that Z is oxygen.

10 In another embodiment, the invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient, diluent or carrier and a therapeutically acceptable amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase having a molecular structure selected from the group consisting of:




15

EM-1291




EM-1195-CS


- 31 -




CS-243




CS-245



EM-1183




EM-1097




EM-1273-CS

EM-1401




EM-1404




5

CS-237




EM-1078




- 33 -


EM-1196-CS




EM-1394



EM-1424-CS




EM-1157-CS




- 34 -


EM-1125




EM-1402-CS



EM-1396




EM-1181




- 35 -

EM-1159




EM-1165



and

EM-1122-CS




5

- 36 -


It is preferred that the type 5 inhibitor is selected from the group consisting of:

EM-1404




and

and EM-1394



10

In another embodiment, the invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient, diluent or carrier and a therapeutically acceptable amount of an inhibitor of type 5 17 β -hydroxysteroid dehydrogenase having the molecular structure:



- 37 -

wherein the dotted line is an optional pi bond;

wherein A is selected from the group consisting of straight or branched C₁-C₄ alkyl, -OR^c (R^c being a C₁-C₈ alkyl radical), and -N(R^d)R^e (R^d and R^e being independently hydrogen or C₁-C₈ alkyl or aryl), and unsaturated analogs of any of the foregoing definitions for substituent A;

wherein R¹ is selected from the group consisting of hydrogen and methyl;


wherein R⁶ is selected from the group consisting of hydrogen, and halogen, and C₁-C₈ alkyl;

wherein R^a is selected from the group consisting of straight or branched C₁-C₈ alkylene, C₃-C₇ cycloalkylene; and

R^b is selected from the group consisting of hydrogen, substituted or unsubstituted phenyl, C₂-C₁₀ acyl, C₂-C₁₀ acyloxy, C₂-C₁₀ alkoxy carbonyl, and halogen;

provided that when A is methyl, R¹ is methyl or ethyl.

In another embodiment, the invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient, diluent or carrier and a therapeutically acceptable amount of an inhibitor of type 5 17 β -hydroxysteroid dehydrogenase having the molecular structure:



- 38 -

wherein the dotted lines are optional pi bonds

wherein X is C₁-C₃ alkyl;


wherein Y is hydrogen or an acyloxy moiety;

wherein R⁶ is -H or -CH₃;

5 wherein R¹⁶ is -H or halo;

wherein R¹ is -H or -CH₃.

In another embodiment, the invention provides an inhibitor of type 5
17β-hydroxysteroid dehydrogenase having the molecular structure:



10

wherein the dotted line is optional pi bond;

wherein A is selected from the group consisting of straight or
branched C₁-C₄ alkyl, -OR^c (R^c being a C₁-C₈ alkyl radical), and -N(R^d)R^e
15 (R^d and R^e being independently hydrogen or C₁-C₈ alkyl or aryl), and
unsaturated analogs of any of the foregoing definitions for substituent A;

wherein R¹ is selected from the group consisting of hydrogen and
methyl;

wherein R⁶ is selected from the group consisting of hydrogen, and
20 halogen, and C₁-C₈ alkyl;

wherein R^a is selected from the group consisting of straight or
branched C₁-C₈ alkylene, C₃-C₇ cycloalkylene; and

- 39 -

R^b is selected from the group consisting of hydrogen, substituted or unsubstituted phenyl, C_2 - C_{10} acyl, C_2 - C_{10} acyloxy, C_2 - C_{10} alkoxy carbonyl, and halogen;


provided that when A is methyl, R^a and R^b together have at least two carbon atoms, and R^1 is methyl.

It is preferred that the optional pi bond at 6 is present, that R^6 is methyl; or that R^a is C_1 - C_6 alkylene.

It is preferred that A is either methyl or $-N(R^d)R^e$.

It is also preferred when A is $N(R^d)R^e$, that R^d is methyl or that R^e is C_1 - C_6 alkyl or phenyl C_1 - C_6 alkyl.

In another embodiment, the invention provides an inhibitor of type 5 17β -hydroxysteroid dehydrogenase having the molecular structure:



wherein the dotted line is an optional pi bond;

wherein $R^{16\beta}$ is selected from the group consisting of hydrogen, fluoro, chloro, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, a moiety which together with $R^{16\alpha}$ is C_4 - C_7 spirocycloalkyl, C_4 - C_7 halospirocycloalkyl, or $\text{---}R'^{16}$ (R'^{16} being C_1 - C_3 alkyl) and unsaturated analogs of any of the foregoing definitions of $R^{16\beta}$;

wherein $R^{16\alpha}$ is selected from the group consisting of hydrogen, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl and a moiety which together with $R^{16\beta}$ forms C_4 - C_7 spirocycloalkyl, C_4 - C_7 halospirocycloalkyl, or $\text{---}R^{16}$ (R^{16} being C_1 - C_3 alkyl) and unsaturated analogs of any of the foregoing;

wherein $R^{15\alpha}$ is selected from the group consisting of hydrogen, C_1 - C_4 alkyl, C_1 - C_4 alkenyl and C_1 - C_4 alkynyl;


wherein R^{19} is either $-H$ or $-CH_3$; and

wherein R^6 is selected from the group consisting of $-H$, $-CH_3$, and halo;

provided that $R^{16\beta}$, $R^{16\alpha}$, and $R^{15\alpha}$ are not simultaneously hydrogen.

It is preferred that $R^{16\alpha}$ is a larger substituent than $R^{16\beta}$, that R^6 is hydrogen, that the optional pi bond at position 1 is not present or that $R^{16\alpha}$ is a C_3 - C_5 alkyl chain.

In another embodiment, the invention provides an inhibitor of type 5 17β -hydroxysteroid dehydrogenase having the molecular structure:



wherein the dotted line is optional pi bond

wherein X is C_1 - C_3 alkyl;

wherein Y is hydrogen or an acyloxy moiety;

wherein R^6 is $-H$ or $-CH_3$;


- 41 -

wherein R^{16} is -H or halo;

wherein R^1 is -H or -CH₃.

It is preferred that R^6 is methyl that the optional pi bond at position 1 is present, that Y is a C₃-C₆ fluoroacyloxy or that X is methyl.

In another embodiment, the invention provides an inhibitor of type 5 17 β -hydroxysteroid dehydrogenase having the molecular structure:



wherein n is an integer from 1-2;

wherein the dotted lines are optional pi bonds;

wherein X and Y are independently selected from the group consisting of -H, (C₁-C₃)alkyl, (C₂-C₃) alkenyl, and methoxycarbonyl;

wherein Z is selected from the group consisting of -H and (C₁-C₃)alkyl;

wherein R^3 is selected from the group consisting of hydrogen, acyl, carboxyl, alkoxycarbonyl, substituted or unsubstituted carboxamide, cyano, alkoxy, alkoxyalkoxy, alkythioalkoxy, acyloxy; hydroxy, halo, -O-SO₂R^a (R^a being selected from the group consisting of C₁-C₆ alkyl and C₆-C₁₀ aryl), and a moiety which, together with R₂, is a 5-6 member ring containing at least one oxygen and one nitrogen atom;

wherein R^2 is selected from the group consisting of hydrogen, amido, acyloxy, carboxyl, carboxamide, alkoxycarbonyl, cyano, halo, nitro, C_1 - C_8 alkyl, and CF_3 and a moiety which, together with R_3 , is a 5-6 member ring containing at least one oxygen and one nitrogen atom;

5 wherein R^4 is hydrogen or halo;

wherein R^6 is selected from the group consisting of hydrogen and oxo;

wherein R^9 is $-H$ or $-OH$;


provided that X, Y, and Z are not hydrogen when R^3 is methoxy.

10

It is preferred that R^3 is alkoxyalkoxy; carboxamide, carboxyl or alkoxyl, that at least one of X, Y or Z is methyl, that X and Y are methyl, that n is 1 or R^6 is oxo.

15

In another embodiment, the invention provides an inhibitor of type 5 17β -hydroxysteroid dehydrogenase having the molecular structure:



wherein the dotted lines are optional pi bonds;

wherein $n = 1$ or 2 ; and

20


wherein a is either $-H$ or $-CH_3$;

wherein b and c are independently hydrogen or methyl;


wherein Z is oxygen or sulfur.

It is preferred that n is 1, that at least one of b or c is methyl, that both b and c are methyl or that Z is oxygen.


- 5 In another embodiment, the invention provides an inhibitor of type 5 17 β -hydroxysteroid dehydrogenase having a molecular structure selected from the group consisting of:



EM-1291




EM-1195-CS




CS-243


CS-245




EM-1183




EM-1097



EM-1273-CS




EM-1401




- 45 -

EM-1404




CS-237




5


EM-1078




EM-1196-CS



EM-1394




EM-1424-CS




5

EM-1157-CS




EM-1125




- 47 -


EM-1402-CS




EM-1396



EM-1181




EM-1159




- 48 -

EM-1165



and


EM-1122-CS



5

It is preferred that the type 5 inhibitor is selected from the group consisting of:

EM-1404




and


10

- 49 -

EM-1394



In another embodiment, the invention provides a method of inhibiting
 5 type 3 17 β -hydroxysteroid dehydrogenase comprising administering to a
 patient in need of such treatment a therapeutically effective amount of an
 inhibitor of type 3 17 β -hydroxysteroid dehydrogenase having the
 molecular structure:




10 wherein R is selected from the group consisting of alkoxy,
 alkylthio, alkoxyalkoxy, alkoxyalkylthio, alkylthioalkoxy, and
 alkylthioalkylthio,

15

- 50 -


or




5

wherein n is an integer from 1 to 4.


It is preferred that the said type 3 inhibitor is selected from the group consisting of:




EM-1071




EM-1065




EM-1066



EM-1064




EM-1074




EM-1073


- 51 -



EM-1070




CS-213




EM-1324-CS

In another embodiment, the invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient, diluent or carrier and a therapeutically acceptable amount of an inhibitor of type 3 17 β -hydroxysteroid dehydrogenase having the molecular structure:



wherein R is selected from the group consisting of alkoxy, alkylthio, alkoxyalkoxy, alkoxyalkylthio, alkylthioalkoxy, and alkylthioalkylthio,


or




5

wherein n is an integer from 1 to 4.


It is preferred that the said type 3 inhibitor is selected from the group consisting of:




EM-1071




EM-1065




EM-1066



EM-1064




EM-1074




EM-1073


- 53 -



EM-1070




CS-213



EM-1324-CS

In another embodiment, the invention provides an inhibitor of type 3 17β-hydroxysteroid dehydrogenase having the molecular structure:




5

wherein R is selected from the group consisting of alkoxyethoxy, alkoxyalkylthio, alkylthioalkoxy, and alkylthioalkylthio,

10


- 54 -

or




5 wherein n is an integer from 1 to 4.


It is preferred that the said type 3 inhibitor is selected from the group consisting of:




EM-1071




EM-1065




EM-1066




EM-1064




EM-1074




EM-1073



EM-1070



CS-213



EM-1324-CS

A patient in need of treatment or reducing the risk of onset of a given disease is one who has either been diagnosed with such disease or one who is particularly susceptible to acquiring such disease, for example, one at higher risk of acquiring the disease than the general population.

Except where otherwise stated, the preferred dosage of the active compounds of the invention is identical for both therapeutic and prophylactic purposes. The dosage for each active component discussed herein is the same regardless of the disease being treated (or prevented).

As used in the methods of medical treatment or methods of reduction of risk of onset of disease herein, an "inhibitor of type 5 or 3 17 β -hydroxysteroid dehydrogenase" means a compound whose IC₅₀ of inhibition for the enzyme in question (computed in the same manner as described in connection with Table 1 herein) is no higher than 500 nM. It is preferred that such inhibitor be no higher than 20 nM, most preferably lower than 10 nM. In some embodiments of the type 5 or type 3 inhibitor, it is also preferred that IC₅₀ of undesirable inhibition of type 2 17 β -hydroxysteroid dehydrogenase be more than 5 times that for inhibition of type 5, preferably more than 10 times, and most preferably more than 25 times. In some embodiments, it is preferred that the percentage of inhibition of the binding of [³H]R1881 on the androgen receptor (as described in D-Androgen Receptor (AR) assays, supra), by the inhibitor of type 5 or 3 17 β -hydroxysteroid dehydrogenase at the concentration of 10⁻⁶ M be less than 30% most preferably less than 20%.

Where two or more different active agents are discussed as part of a combination therapy herein (e.g. an enzyme inhibitor and an antiandrogen), a plurality of different compounds are administered rather than a single compound having multiple activities.

Except where otherwise noted or where apparent from context, dosages herein refer to weight of active compounds unaffected by pharmaceutical excipients, diluents, carriers or other ingredients, although such additional ingredients are desirably included, as shown in the examples herein. Any dosage form (capsule, tablet, injection or the like) commonly used in the pharmaceutical industry, is appropriate for use herein, and the terms "ingredient", "diluent" or "carrier" include such non active

ingredients as are typically, included together with active ingredients, used in such dosage form in the industry.

BRIEF DESCRIPTION OF THE DRAWINGS

5

Figures 1 a to 1d show autoradiographs of ^3H -labelled type 5 17β -HSD antisense and sense riboprobes (35 base pairs) hybridized *in situ* to human benign prostatic hyperplasia (BPH) tissue.

10

- Figure 1a shows semithin Epon section (0.7 μm -thick) hybridized with the antisense probe. Epithelial cells lining the tube-alveoli as well as some of the surrounding stromal cells are labelled. In the epithelium, the dashed line approximately indicates the boundary between the basal and the luminal cells. The basal cells are intensively labelled in comparison with the luminal cells where only a few grains are seen. (X 1000)

15

- Figure 1b shows similar area from the same prostate hybridized with the sense probe as a control. Only scattered silver grains can be detected. (X 1000)

20

- Figure 1c shows the antisense probe generates strong radioautographic signals in the wall of blood vessels (arrows). (X 600)

- Figure 1d shows similar blood vessels hybridized with the sense probe as a control. No significant labeling could be seen. (X 600)

25

Figure 2 shows the specificity of the antiserum used in the immunostaining of type 5 17β -HSD. Transfected human kidney cells (293) with human type 5 17β -HSD, types 1 and 3 3α -HSD and types 1 and 2 5α -reductase, were used for immunoblot analysis. The results indicate that the antiserum specifically reacts with type 5 17β -HSD. Types 1 and 3 3α -HSD which share 84 and 86% amino acid identity with type 5 17β -HSD,

respectively, and types 1 and 2 5 α -reductase, two other androgen-synthesizing enzymes present at high concentration in prostatic tissue were used as controls.

5 Figure 3a to 3e show paraffin sections of normal human prostate and cultured epithelial cells (PrEC 5500-1) immunostained with antibody to type 5 17 β -HSD (X 800).

- 10 - Figure 3a shows the staining reaction is observed in basal cells (arrows) and in most of the stromal cells situated below. The luminal cells of the epithelium (above the basal cells) are not reactive.
- Figure 3b shows all epithelial cells are immunoreactive.
- Figure 3c shows the basal cells are not very well seen (thick arrows) but they are labelled as well as some luminal cells (thin arrows) of the tube-alveoli.
- 15 - Figure 3d shows an immunostained paraffin section of normal human prostate epithelial cells (PrEC 5500-1). The staining reaction can be seen in the cytoplasm of most of the cells.
- Figure 3e shows the same cultured cells as in figure 3d, but the antiserum was incubated with an excess of antigen. No staining
20 reaction can be seen.

Figures 4a to g show paraffin sections of BPH tissue immunostained with antibody to type 5 17 β -HSD.

- 25 - Figure 4a shows all of the basal cells show a strong positive staining reaction (arrowheads). Note the absence of reaction in the luminal cells (L) while the fibroblasts of the stroma are stained (arrows) (X 500).
- Figure 4b shows some of the luminal cells are immunoreactive (arrows) as well as basal cells (arrowheads) (X500).

- Figure 4c shows a section consecutive to that shown in fig. 4a. Immunoabsorption of the antiserum with an excess of antigen completely prevents immunostaining (X500).
- Figure 4d shows, in the stroma, smooth muscle cells (arrows) are not labeled while the surrounding fibroblasts are stained (X800).
- Figure 4e shows the positive staining in the wall of a large vein (V). The endothelial cells of small blood vessels are well-labeled (arrows) (X 800).
- Figure 4f shows the low magnification of an artery showing the labelling of endothelial cells (arrows) and of fibroblasts of the tunica adventitia (arrowheads) while smooth muscle cells of tunica media (m) are weakly labeled (X 200).
- Figure 4g shows the high magnification of an artery which clearly demonstrates the labelling in the cytoplasm of endothelial cells (arrows) as well as of fibroblasts (arrow heads) while smooth muscle cells of the tunica media (m) are not labeled (X 800).

Figures 5a to e show paraffin sections of BPH tissue immunostained with antibodies for type 5 17β -HSD (a), 3β -HSD (b) and androgen receptor (c, d and e) (X800).

- Figures 5a and b show consecutive sections immunostained for type 5 17β -HSD (5a) and 3β -HSD (5b). Although the reaction for 3β -HSD is somewhat weaker than that obtained for type 5 17β -HSD, the distribution of the two enzymes in basal (arrowheads) and luminal cells (L) is similar.
- Figure 5c shows an androgen receptor immunoreactivity was found to be exclusively localized in the nuclei. In the epithelium, the reaction can be seen in the majority of the luminal cells (L) nuclei, but not in the nuclei of most basal cells (arrowheads).

- 60 -

- Figure 5d shows, in the fibromuscular stroma, most of the nuclei are labeled. Some smooth muscle cell nuclei are labeled (arrows) while others show not detectable reaction (arrowheads).
- Figure 5e shows the wall of the blood vessels shows labeled and unlabeled nuclei. Some of the nuclei of the endothelial cells lining the lumen of an arteriole are labeled (arrows), while others show no staining (arrowheads).

Figure 6 shows human skin hybridized with type 5 17 β -HSD cRNA probe.

Figure 7 shows monkey ovary hybridized with type 5 17 β -HSD.

Figure 8 is a schematic diagram showing the biosynthetic pathway of active androgens in human prostatic tissue.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

There are several types of 17 β -hydroxysteroid dehydrogenases. Of the various types of 17 β -hydroxysteroid dehydrogenases, type 1 catalyzes conversion of estrone to estradiol. Types 2 and 4 catalyze the reverse reaction. Type 1 also catalyzes conversion of DHEA to 5-diol while type 4 catalyzes the reverse reaction. Types 3 and 5 catalyze conversion of 4-dione to testosterone while type 2 catalyzes the reverse reaction. Types 3 and 5, the primary concern of the present application, catalyze *in vivo* the biosynthesis of androgenic compounds, such as the biosynthesis of testosterone from androst-4-ene-dione ("4-dione") or the conversion of androstanedione (A-dione) to DHT. The reaction catalyzed by type 3 or

type 5 17 β -hydroxysteroid dehydrogenase is a reversible reaction, and the reverse reaction can be catalyzed by type 2 17 β -hydroxysteroid dehydrogenase, whose activity is preferably not inhibited. It is also desirable to avoid inhibition, for example, of type 4 17 β -hydroxysteroid dehydrogenase which desirably (for androgen sensitive diseases) converts a different testosterone precursor to another compound.

For purposes of treating diseases which respond unfavorably to androgenic activity, it is desirable to inhibit androgen formation without hindering androgen degradation. Thus, in one aspect, the present invention endeavors to reduce the level of androgens by selectively inhibiting the type 3 and type 5 17 β -hydroxysteroid dehydrogenases while desirably allowing the type 2 and type 4 enzymes to remain free of inhibition. Thus, the equilibrium of the reversible androgen (or androgen precursor) synthesis reactions is beneficially affected by inhibiting the forward androgen synthesis reactions while permitting any androgens or precursors that are synthesized (either locally or systemically) to be reconverted to their precursors by action of the type 2 and/or type 4 17 β -hydroxysteroid dehydrogenases.

The type 5 enzyme is better inhibited by certain compounds discussed in more detail infra, while the type 3 enzyme is better inhibited by other compounds (also discussed infra). It is therefore possible to provide best inhibition of androgen synthesis by a combination therapy which includes administering both a type 5 inhibitor and a type 3 inhibitor.

Type 5 enzyme tends to predominate in liver, adrenal glands, prostate, and the peripheral tissues whereas type 3 enzyme tends to predominate

in the testes. In the prior art, testicular androgens have been suppressed by either surgical or chemical castration, frequently by administration of an LHRH agonist. The present invention provides inhibitors of type 3 17 β -hydroxysteroid dehydrogenase which, like the LHRH agonist of the prior art, reduce testicular androgen production. Thus, in some embodiments of the invention, the type 3 inhibitors of the invention may be used to inhibit testicular androgen secretion, either alone or in combination with prior art chemical or surgical castration. In some embodiments, antiandrogen and/or 5 α -reductase inhibitor is also provided. In some embodiments, the inhibitors of the type 3 enzyme are used in addition to chemical castration by LHRH agonist. An undesirable initial upward spike of androgenic production and secretion by the testes occurs during the very early portion of treatment with LHRH agonist, prior to the beginning of the beneficial effect of androgen reduction caused by LHRH agonist. Using type 3 17 β -hydroxysteroid dehydrogenase inhibitor in conjunction with LHRH agonist is expected to reduce that initial undesirable androgen elevation.

Both androgen-related and estrogen-related diseases may be treated with the 17 β -hydroxysteroid dehydrogenase inhibitors of the present invention. Androgen-sensitive diseases are those whose onset or progress is aided by androgen activation of androgen receptors, and should respond favorably to treatment with the present invention because of the reduction of androgen biosynthesis that is achieved thereby. Estrogen-sensitive diseases (diseases whose onset or progress is aided by activation of the estrogen receptor) should also benefit because many androgens whose biosynthesis is suppressed by the present invention are precursors to estrogens, and the present invention may therefore reduce

estrogen biosynthesis as well. Androgen-sensitive diseases include but are not limited to prostatic cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, androgenic alopecia, and polycystic ovarian syndrome. Estrogen-sensitive diseases include but are not limited to breast cancer, endometrial cancer, endometriosis, and endometrial leiomyoma.


For the treatment of androgen-sensitive diseases, it is of course preferred that the inhibitors of 17β -hydroxysteroid dehydrogenase that are administered (whether type 5 or type 3 or both) do not possess inherent androgenic activity. However, breast cancer (and some other estrogen-sensitive diseases, e.g. ovarian cancer, uterine cancer, and endometrial cancer) respond favorably to androgens. Therefore, a compound which inhibits type 5 or type 3 17β -hydroxysteroid dehydrogenase, and which is also androgenic, can be especially useful for the treatment of breast cancer and other diseases which respond negatively to estrogen and positively to androgen.

Type 5 and/or type 3 inhibitors of 17β -hydroxysteroid dehydrogenase may, in accordance with the invention, be utilized as part of a combination therapy with other strategies (listed below) which, attack androgen- or estrogen-sensitive diseases through other mechanisms, thus providing synergistic combinations. These combination therapies include in addition to type 3 or type 5 inhibitors of 17β -hydroxysteroid dehydrogenase one or more of the following strategies:

Strategy 1: Suppression of testicular or ovarian hormonal secretion by chemical or surgical castration. This is useful in treatment of diseases

which respond adversely to androgen or estrogen, respectively. When surgical or chemical castration is utilized, chemical castration is preferred utilizing either an LHRH-agonist, an LHRH antagonist or inhibitor of type 3 17 β -hydroxysteroid dehydrogenase (as discussed herein). Suitable LHRH agonists are reported in US Patent 4,659,695, but any LHRH agonist showing the ability to induce chemical castration can be used since they all act through the same mechanisms as described (Labrie et al., J. Androl. 1: 209-228, 1980). Dosages are known in the art. Some suitable LHRH antagonists are reported in U.S. Patent 4,666,885 but any LHRH antagonist is acceptable, if used according to the recommendation of the manufacturer.


Strategy 2: Utilizing androgen or estrogen receptor antagonists ("antiandrogens" or "antiestrogens") to prevent activation of androgen or estrogen receptors by androgens or estrogens. Strategy 2 is useful against diseases that respond adversely to androgenic or estrogenic activity, respectively. Antiandrogens, and dosages therefor, are known in the art (e.g. Flutamide (N-[4-nitro-3-(trifluoromethyl)phenyl]-2-methylpropanamide) at a dosage of 250 mg, 2 or 3 times a day, Nilutamide at a dosage of 150 mg/day, Casodex at a dosage of 50 to 500 mg/day or EM-250 of the following structure:



EM-250

Synthesized and used as reported in International Publication WO94/26767.

When antiestrogens are used in accordance with the invention, either alone or as part of one of the combination therapies described herein, the attending clinician should, at least initially, use the dosages recommended by the manufacturer. However, the attending clinician should monitor individual patient response and metabolism and adjust patient dosage accordingly. Indeed, that will be true of all of the strategies discussed herein. One preferred antiestrogen is EM-800 reported in PCT/CA96/00097 (WO 96/26201) The molecular structure of EM-800 is:



Other suitable antiestrogens include but are not limited to Tamoxifen ((Z)-2-[4-(1,2-diphenyl-1-butenyl)]-N,N-dimethylethanamine) and ICI 182780 (available from Zeneca, UK), Toremifene (available from Orion-Farmos Pharmaceuticla, Finland), Droloxifene (Pfizer Inc., USA), Raloxifene (Eli Lilly and Co., USA), LY 335563 and LY 353381 (Eli Lilly and Co., USA), Iodoxifene (SmithKline Beecham, USA), Levormeloxifene (Novo Nordisk, A/S, Denmark). Any antiestrogen used as required for efficacy, as recommended by the manufacturer, can be used. Appropriate dosages are known in the art. Any other antiestrogen commercially available can be used according to the invention.

Strategy 3: Suppression of sex steroid biosynthesis by inhibition of 3 β -hydroxysteroid dehydrogenase [e.g. Trilostane (2 α -cyano-4 α ,5 α -epoxy-17 β -hydroxyandrostane-3-one), Sterling-Winthrop Research Institute, Rensselaer, New York, USA] by administering such inhibitor at a dosage of 1 to 500 mg/day). Desirable serum levels of 3 β -hydroxysteroid dehydrogenase inhibitor range from 5 ng/ml to 500 ng/ml, preferably 10 ng/ml to 100 ng/ml. Strategy 3 is useful against both (1) diseases that respond adversely to androgenic activity and (2) some diseases that respond adversely to estrogenic activity.

Strategy 4: Suppression of conversion of the androgen testosterone to the more potent androgen dihydrotestosterone (DHT) by inhibiting the activity of testosterone 5 α -reductase (e.g. by administering Proscar, available from Merck Sharp and Dohme Canada, at the recommended dosage). Any other potent 5 α -reductase inhibitor can be used. The dosage used can be 2 to 20 mg daily orally. The dosage should be the one recommended by the manufacturer. Strategy 4 is useful against diseases that respond adversely to androgenic activity.

Strategy 5: Utilizing an aromatase inhibitor to reduce estrogen production. Strategy 5 is useful against diseases that respond adversely to estrogenic activity or estrogen receptor-mediated exacerbation of the type of androgen-sensitive diseases that are also estrogen-sensitive diseases (e.g. benign prostatic hyperplasia). When aromatase inhibitors are used in accordance with the invention, either alone or as part of one of the combination therapies described herein, the attending clinician should initially use the dosage recommended by the manufacturer. When administered orally, the dosage which is usually effective to provide the

desired serum levels is between 1.0 mg and 20 mg of active ingredient per day per 50 kg of body weight. For example, Arimidex (Zeneca) is taken at the oral dose of 1 mg daily. However, the attending clinician should monitor individual patient response and metabolism and adjust patient dosage accordingly. Aromatase inhibitors include those set forth in US patent 5,227,375. Aromatase inhibition may also be achieved, for example, by administering Arimidex (2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene bis (2-methylpropiononitrile)) available from Zeneca, UK, at a dosage of 1 mg/day. Any other aromatase inhibitor can be used according to the recommendations of the manufacturer.

Strategy 6: Administering an androgenic compound. Strategy 6 is useful against a disease which responds favorably to androgenic activity. Preferred androgens include but are not limited to medroxyprogesterone acetate, and megestrol acetate at a dosage of 5-200 mg/day. Desirable low dose and sustained release formulations of such androgens are described in US Patent 5,434,146.

Any of the above strategies useful against diseases that respond negatively to estrogenic activity may also be used to help alleviate estrogenic side effects that may result from treatment of purely androgen-sensitive diseases in accordance with the invention. For example, many androgen precursors are also estrogen precursors. Strategies which suppress formation of certain androgens may increase levels of precursors thereto which are also estrogen precursors thus undesirably increasing estrogen formation. For example, administering inhibitors of testosterone 5 α -reductase to suppress conversion of testosterone to dihydrotestosterone may increase the conversion of testosterone to estradiol. In that case, strategy 5 may desirably reduce

that unwanted estrogen production. Strategy 2 (estrogen antagonist aspect) and strategy 3 may also be helpful in that regard.

5 In general, for both androgen-sensitive diseases and estrogen-sensitive diseases, simultaneous treatment with inhibitors of sex steroid biosynthesis (inhibitors of enzymes which catalyze one or more steps of estrogen or androgen biosynthesis), and with estrogen receptor antagonists and/or androgen receptor antagonists, are believed to have additive rather than redundant effect because they are acting in a
10 beneficial manner by a different mechanism. Likewise, the activity of two different enzyme inhibitors (enzymes which catalyze one or more different steps of sex steroid biosynthesis) are believed to provide additive effect, especially where the inhibitors affect more than one synthetic pathway. Such an approach permits to achieve a more complete
15 effect.

Different sex steroid-dependent diseases respond differently to both androgen receptor activation and estrogen receptor activation. For example, breast cancer responds unfavorably to estrogen receptor
20 activation, but favorably to androgen receptor activation. On the other hand, benign prostatic hyperplasia responds unfavorably to activation of either the estrogen or androgen receptor. The type 5 and/or type 3 inhibitors of the invention may be used in any combination with any of the strategies 1-6 above whose effect (increasing or decreasing androgenic or estrogenic activity) is consistent with desirable effect on the disease in
25 question. With that in mind, set forth below are a list of representative diseases which may be treated, or risk of which may be reduced, in accordance with the present invention. Beneath each disease, is several preferred combination therapies for treatment, or risk reduction, of that

particular disease. However, these combinations may be supplemented using one or more of the six strategies listed above, limited only by whether a particular disease responds favorably or adversely to estrogenic activity or to androgenic activity.

5

A) Prostate cancer (responds adversely to androgenic activity, favorably to estrogenic activity)

10

1. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase + LHRH-agonist (or antagonist)
2. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase + inhibitor of type 3 17β -hydroxysteroid dehydrogenase.
3. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase + inhibitor of type 3 17β -hydroxysteroid dehydrogenase + LHRH agonist (or antagonist)

15

4. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase + LHRH-agonist (or antagonist) + antiandrogen
5. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase + inhibitor of type 3 17β -hydroxysteroid dehydrogenase + antiandrogen

20

6. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase + inhibitor of type 3 17β -hydroxysteroid dehydrogenase + LHRH agonist (or antagonist) + antiandrogen

25

7. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase + antiandrogen + 5α -reductase inhibitor + LHRH agonist (or antagonist)
8. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase + LHRH agonist + 5α -reductase inhibitor

9. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase +
inhibitor of type 3 17β -hydroxysteroid dehydrogenase +
5 α -reductase inhibitor
10. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase +
inhibitor of type 3 17β -hydroxysteroid dehydrogenase +
antiandrogen + 5 α -reductase inhibitor
11. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase +
inhibitor of type 3 17β -hydroxysteroid dehydrogenase + LHRH
agonist (or antagonist) + antiandrogen + 5 α -reductase inhibitor

B) Benign prostatic hyperplasia (responds adversely to both
androgenic activity and estrogenic activity)

1. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase
2. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase +
antiestrogen or aromatase inhibitor
3. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase +
antiandrogen
4. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase +
antiandrogen + 5 α -reductase inhibitor + antiestrogen or
aromatase inhibitor
5. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase +
5 α -reductase inhibitor
6. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase +
antiandrogen + 5 α -reductase inhibitor
7. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase +
5 α -reductase inhibitor + antiestrogen or aromatase inhibitor

C) Acne, seborrhea, hirsutism, androgenic alopecia (responds adversely to androgenic activity)

1. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase
2. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase + antiandrogen
3. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase + 5α -reductase inhibitor
4. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase + 5α -reductase inhibitor + antiandrogen

D) Polycystic ovarian syndrome (responds adversely to androgenic stimulation)

1. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase
2. Inhibitor of type 3 17β -hydroxysteroid dehydrogenase + Inhibitor of type 5 17β -hydroxysteroid dehydrogenase
3. Inhibitor of type 3 17β -hydroxysteroid dehydrogenase
4. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase + antiandrogen
5. Inhibitor of type 3 17β -hydroxysteroid dehydrogenase + Inhibitor of type 5 17β -hydroxysteroid dehydrogenase + antiandrogen
6. Inhibitor of type 3 17β -hydroxysteroid dehydrogenase + antiandrogen

E) Breast cancer (responds favorably to androgenic activity, adversely to estrogenic activity)

1. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase + antiestrogen

2. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase + antiestrogen + androgenic compound
 3. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase + antiestrogen + LHRH agonist (or antagonist)
 - 5 4. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase + antiestrogen + LHRH-agonist (or antagonist) + androgenic compound
- F) Endometriosis, leiomyoma (responds adversely to estrogenic activity)
- 10 1. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase
 2. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase + antiestrogen or inhibitor of aromatase
 3. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase + LHRH-agonist (or antagonist)
 - 15 4. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase + LHRH-agonist (or antagonist) + antiestrogen or aromatase inhibitor
- G) Precocious puberty (male and female) (responding adversely to androgenic activity)
- 20 1. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase
 2. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase + LHRH agonist (or antagonist) (male only)
 - 25 3. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase + antiandrogen
 4. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase + antiandrogen + LHRH agonist (or antagonist) (male only)

- 73 -

5. Inhibitor of type 5 17β -hydroxysteroid dehydrogenase + inhibitor of type 3 17β -hydroxysteroid dehydrogenase (male only)
6. Inhibitor of type 3 17β -hydroxysteroid dehydrogenase
- 5 7. Inhibitor of type 3 17β -hydroxysteroid dehydrogenase + LHRH agonist (or antagonist) (male only)
8. Inhibitor of type 3 17β -hydroxysteroid dehydrogenase + antiandrogen
9. Inhibitor of type 3 17β -hydroxysteroid dehydrogenase + antiandrogen + LHRH agonist (or antagonist) (male only)
- 10

When type 5 17β -hydroxysteroid inhibitors are used in accordance with the invention, either alone or as part of one of the combination therapies described herein, the attending clinician desirably will target patient serum concentration of the type 5 inhibitor between 0.5 ng/ml and 100 ng/ml, preferably between 1 ng/ml and 20 ng/ml, and most preferably between 1 ng/ml and 10 ng/ml. Serum concentration may be measured by LC/MS. When administered orally, the dosage which is usually effective to provide the desired serum levels is between 1.0 mg and 1,000 mg of active ingredient per day per 50 kg of body weight, preferably between 10 mg and 500 mg and most preferably between 10 mg and 100 mg. However, dosage should vary with the bioavailability of the chosen inhibitor and with individual patient response. For example, when EM-1394, or EM-1404 are chosen, oral dosage is preferably between 5 mg and 500 mg per day per 50 kg body weight, more preferably between 10 mg/day and 300 mg/day, for example between 20 mg/day and 100 mg/day. The attending clinician should monitor individual patient

response and metabolism and adjust patient dosage accordingly. When administered by injection, a lesser dosage is usually appropriate, e.g. 10 mg to 100 mg per day per 50 kg of body weight.

5 When type 3 17 β -hydroxysteroid inhibitors are used in accordance with the invention, either alone or as part of one of the combination therapies described herein, the attending clinician desirably will target patient serum concentration of the type 3 inhibitor between 0.5 ng/ml and 100
10 ng/ml, preferably between 1 ng/ml and 20 ng/ml and most preferably between 1 ng/ml and 10 ng/ml. When administered orally, the dosage is preferably between 1.0 mg and 1,000 mg of active ingredient per day per 50 kg of body weight, preferably between 5 mg and 500 mg and most preferably between 10 mg and 100 mg. However, the attending clinician should monitor individual patient response and metabolism and adjust
15 patient dosage accordingly.

All of the active ingredients used in any of the therapies discussed herein may be formulated in pharmaceutical compositions which include one or more of the other active ingredients. Alternatively, they may each be
20 administered separately but sufficiently simultaneous in time so that a patient eventually has elevated blood levels or otherwise enjoys the benefits of each of the active ingredients (or strategies) simultaneously. In some preferred embodiments of the invention, for example one or more active ingredients are to be formulated in a single pharmaceutical
25 composition. In other embodiments of the invention, a kit is provided which includes at least two separate containers wherein, the contents of at least one container differs in whole or in part from the contents of at least one other container with respect to active ingredients contained therein. Two or more different containers are used in these combination therapies

of the invention. Combination therapies discussed herein also include use of one active ingredient of the combination in the manufacture of a medicament for the treatment (or prevention) of the disease in question where the treatment or prevention further includes the other active ingredient(s) or strategy of the combination. Some embodiments of the methods of treating or preventing disease discussed herein, utilize the type 5 and/or type 3 inhibitors of 17β -hydroxysteroid dehydrogenase discussed herein (i.e. the molecular structures discussed herein).

It is believed that, in some situations, the desirability of using an inhibitor of type 5 17β -hydroxysteroid dehydrogenase implies the desirability of also using an inhibitor of type 3 17β -hydroxysteroid dehydrogenase and vice versa, depending upon the expression level of both types in implicated tissues. Type 3 17β -hydroxysteroid dehydrogenase is mainly expressed in the testis while type 5 17β -hydroxysteroid dehydrogenase is mainly expressed in liver, adrenal glands, prostate, ovary, skin, mammary gland, testis, and in a series of peripheral tissues. LHRH agonists and LHRH antagonists may be used interchangeably to suppress either testicular or ovarian hormonal secretions by known techniques, except where preferences are otherwise stated herein.

In other embodiment, pharmaceutical composition for combination therapy may contain one type 5 17β -hydroxysteroid dehydrogenase inhibitor and at least one of other active ingredients selected from the group consisting of type 3 17β -hydroxysteroid dehydrogenase inhibitor, antiestrogen, antiandrogen, aromatase inhibitor and 5α -reductase inhibitor.

In another embodiment, pharmaceutical composition for combination therapy contains one type 3 17β -hydroxysteroid dehydrogenase inhibitor and at least one of the other active ingredients selected from the group consisting of type 5 17β -hydroxysteroid dehydrogenase inhibitor, antiestrogen, antiandrogen, aromatase inhibitor and 5α -reductase inhibitor.

In another embodiment, kits for combination therapy may contain in two or more containers, one type 5 17β -hydroxysteroid dehydrogenase inhibitors and at least one of other active ingredients selected from the group consisting of type 3 17β -hydroxysteroid dehydrogenase inhibitor, antiestrogen, antiandrogen, aromatase inhibitor, 5α -reductase inhibitor, and an LHRH agonist or antagonist.

In another embodiment, kits for combination therapy may contain in two or more containers one type 3 17β -hydroxysteroid dehydrogenase inhibitors and at least one of other active ingredients selected from the group consisting of type 5 17β -hydroxysteroid dehydrogenase inhibitor, antiestrogen, antiandrogen, aromatase inhibitor, 5α -reductase inhibitor, and an LHRH agonist or antagonist.

It is desired that activation of glucocorticoid receptors be minimized when administering the active ingredients of the invention. In preferred embodiments, active ingredients have no more effect on glucocorticoid receptors than is provided by megestrol acetate.

Type 5 17β -HSD, 3β -HSD and AR in human prostate. In order to obtain precise information on the cellular distribution of type 5 17β -HSD and

- 77 -

gain a better knowledge of the role of this enzyme in the human prostate, we performed *in situ* hybridization and immunocytochemical localization studies in human hyperplastic prostatic tissue (BPH). Normal human prostate tissue and the epithelial prostate cell line (PrEC) were also investigated by immunostaining. In the same series of experiments, the immunocytochemical localization of 3 β -HSD was examined to compare the distribution of the two enzymes which are both involved in the biosynthesis of androgens from DHEA. In order to determine the site(s) of action of the locally produced androgens, we have also identified the immunocytochemical localization of the androgen receptor.

MATERIALS AND METHODS

Tissue preparation. Adult prostatic tissue was obtained from 12 patients with symptomatic benign prostatic hyperplasia (BPH) undergoing transurethral prostatectomy. The specimens were fixed by immersion in 2% glutaraldehyde, 4% formaldehyde and 3% dextran in 0.05 M phosphate buffer (pH 7.4). After 4 h, the specimens were processed and embedded in paraffin or frozen at -70°C. Four paraffin blocks of normal human prostate, fixed in 4% formaldehyde (age of patients between 37 and 73) were kindly provided by Dr. Bernard Tetu, Dep. of Pathology, Hotel-Dieu de Quebec.

Cultured cells. Normal prostate epithelial cells PrEC 5500-1 were cultured in PrEGM medium (Clonetics) and harvested after the third passage using a rubber policeman. The cells were then fixed in 2% glutaraldehyde, 4% formaldehyde and 3% dextran in 0.05M phosphate buffer for 20 min and centrifuged at 700 rpm for 5 min. After removing the supernatant, 2% agarose in 0.05 M phosphate buffer was added to the pellet at 55°C (the volume of agarose was twice the volume of the pellet).

After mixing the cells with agarose, the pellet was solidified at 4 °C and immersed in the same fixative for two hours, then washed, processed and paraffin embedded.

5 **In situ hybridization.** Two different procedures were used for *in situ*
hybridization of BPH tissue. In the first one, 10 µm sections were cut
from frozen tissue with a cryostat and processed. The second procedure
will be described in detail elsewhere (El-Alfy et al, unpublished data). In
brief, thick paraffin sections (20 µm) were cut and the unmounted sections
10 were deparaffinized in toluene. The sections were subsequently
rehydrated, postfixed in 2% glutaraldehyde, 4% formaldehyde and 3%
dextran in 0.05M phosphate buffer and washed in the same buffer
containing 7.5% glycine. Hybridization of the floating sections was
performed overnight at 40°C with a ³H-UTP riboprobe. Following
15 hybridization, they were postfixed in osmium tetroxide, flat-embedded in
Epon and cut at 0.7 µm with an ultramicrotome. Both frozen (10 µm) and
semithin (0.7 µm) sections were coated with liquid photographic emulsion
(Kodak NTB-2) and processed after 14 (semithin sections) or 28 days
(frozen sections) of exposure.

20 Sense and antisense riboprobes were generated by *in vitro* transcription
from the p-Bluescript phagemid containing a cDNA insert of 35
nucleotides of the human type 5 17β-HSD. [³⁵S]- and [³H]-UTP riboprobes
were used for hybridization with the frozen and floating deparaffinized
25 sections, respectively.

Immunocytochemistry. Twelve paraffin-embedded BPH samples, four
normal prostate specimens and PrEC cells in paraffin blocks were serially
cut at 4 µm. Sections were incubated overnight at 4°C with the human

type 5 17 β -HSD antiserum diluted at 1:1000 in Tris-saline, pH 7.6. The sections were then washed and incubated at room temperature for 4h with peroxidase-labelled goat anti-rabbit γ -globulin (Hyclone, Logon, UT) diluted 1:500. Endogenous peroxidase activity was eliminated by preincubation with 3% H₂O₂ for 30 min and peroxidase was then revealed during incubation with 10 mg of 3,3-diaminobenzidine in 100 ml of Tris-saline buffer containing 0.03% H₂O₂. The intensity of staining was controlled under the microscope. The sections were then counterstained with hematoxylin. On other sections, immunostaining was performed using a commercial kit (Vectastain ABC Kit; Vector Laboratories, Burlingame, CA) and diaminobenzidine was used as the chromogen to visualize the biotin streptavidin-peroxidase complex. A microwave retrieval technique was applied for the androgen receptor staining. Control experiments were performed on adjacent sections by substituting non-immunized rabbit serum (1:1000). In the case of type 5 17 β -HSD antiserum (diluted 1:1000), immunoabsorption with an excess (10⁻⁶ M) of the synthetic peptide used to raise the antibodies was also performed. The number of stained cells (type 5 17 β -HSD) and nuclei (AR) were counted from colored photographs and their number presented in Table 1. The intensity of staining was compared and evaluated between the different stained cell types of the prostate on the same section. Similarly, the density of silver grains was compared between the labeled cells on the same section. The intensity of immunostaining and in situ hybridization reaction was presented in Table 2. Paraffin sections of cultured cells were immunostained using type 5 17 β -HSD antiserum as mentioned above and the number of immunostained cells presented as a percentage of stained cells.

Antibody preparation

Type 5 17 β -HSD. The type 5 17 β -HSD peptide sequence N-GLDRNLHYFNSDSFASHPNYPYS located at amino acid position 297 to 320 of the human type 5 17 β -HSD was synthesized by "Le Service de Séquence de Peptides de l'Est du Québec" (SSPEQ) (CHUL Research Center, Quebec, Canada) and purified by HPLC. New Zealand rabbits (2.5 Kg) received a subcutaneous injection of 100 μ g of the peptide solubilized in 1 ml phosphate saline buffer containing 50% of complete Freund's adjuvant. The animals received at one-month intervals two successive booster injections with 50 μ g of the peptide in 1 ml of incomplete Freund's adjuvant. Two weeks after the last injection, the rabbits were killed and the blood collected. The antiserum was obtained by decantation and separation by centrifugation, then affinity purified and stored at -80°C.

Specificity of the antiserum was examined by immunoblot analysis. In brief, human embryonal kidney cells (293) were transfected with CMV-neo vectors expressing human type 5 17 β -HSD, types 1 and 3 3 α -HSD and types 1 and 2 5 α -reductase, respectively. Stable transfectants were selected by their resistance to 10⁻⁷M G-418. Positive clones were confirmed by their ability to efficiently transform the appropriate substrate (Luu-The, et al. unpublished data). Forty micrograms of protein of the homogenate of each cell line were electrophoresed on a 5-15% sodium dodecyl sulfate (SDS)-polyacrylamide gel, before being transferred to the nitrocellulose filter using a Bio-Rad apparatus for 4h at 60V. The blot was treated 3 times with 5% fat-free milk in PBS containing 0.1% Nonidet P-40 for 30 min. The antiserum developed against the type 5 17 β -HSD peptide was diluted to 1/1000 and the blot was then incubated

at 4°C for 18 h in the diluted antiserum. The blot was then washed three times with PBS containing 5% fat-free milk and 0.1% Nonidet P-40. After incubation with horseradish peroxidase-conjugated anti-rabbit IgG in solution for 2h, the membrane was washed and bound antibodies were detected with ECL detection reagents (Amersham) and finally the membrane was exposed to Hyperfilm.

3 β -HSD. The antiserum used for immunocytochemical studies was raised by immunizing rabbits with purified human placental 3 β -HSD. This antiserum has been widely used to localize the enzyme in tissues of several species including the human.

Androgen Receptor (AR). AR rabbit antiserum was generated against a synthetic peptide corresponding to the first 20 amino acid residues of the N-terminal domain of the human and rat AR. The antiserum was purified by immunoprecipitation and did not show any crossreactivity with estrogen or progesterone receptors. This antiserum was kindly provided by Dr. Théo H. van der Kwast, Dept. of Pathology, Erasmus University Rotterdam, The Netherlands.

RESULTS

Type 5 17 β -HSD

In situ hybridization. In the prostate specimens hybridized with the [³H]-labeled type 5 17 β -HSD probe, all basal cells are intensively labeled while the luminal secretory cells are poorly labeled (Fig. 1a). In the fibromuscular stroma, none or only few silver grains are located over smooth muscle cells, while the fibroblasts dispersed throughout the stroma or in association with the wall of blood vessels are well labeled (Fig. 1c). Interestingly, the endothelial cells lining blood vessels are

strongly labeled. The smooth muscle cells and fibroblasts of the tunica media and adventitia show variable labeling intensity. When the hybridization was performed using ^3H -labelled sense riboprobe as control, only a few scattered silver grains were detected over the epithelium (Fig. 1b) and blood vessels (Fig. 1d). The results obtained using ^{35}S -UTP riboprobes (not shown) were found to be similar to the above mentioned results.

Immunostaining

Type 5 17β -HSD Distribution. As illustrated in Fig. 2, immunoblot analysis indicates that the antiserum specifically reacts with type 5 17β -HSD. In fact, no crossreactivity was detected, either with types 1 or 3 3α -HSD which share 84% and 86% identity with type 5 17β -HSD, respectively, or with types 1 and 2 5α -reductase, two enzymes which are abundant in prostatic tissue

When immunostained paraffin sections of BPH specimens and normal prostatic tissues were examined, similar results were found (Figs 3a-c, 4a,b). Some variation in the distribution and intensity of immunostaining was observed between the twelve BPH specimens examined. A similar degree of variation was found between the normal prostate specimens, and the overall pattern was similar between normal and BPH prostatic tissues. The variation in staining of the epithelium lining the tube-alveoli was observed not only between the different specimens but also between the tube-alveoli of the same specimens. A constant finding was the positive reaction detected in the stromal fibroblasts while the smooth muscle cells were not stained (Figs. 3a-c, Figs 4a, b, d). Strong staining was consistently found in the basal cells of the epithelium (Figs. 3a, 4a,

5a). In contrast, the luminal secretory cells exhibited highly variable and usually low immunoreactivity. In fact, in most alveoli (about 85%), no luminal cells were labelled (Figs. 3a, 4a) while about 10% of alveoli contained a low detectable but positive reaction of all luminal cells (Fig. 3b), the basal cells being always strongly labelled. In some alveoli (about 5%), labeling of few luminal cells and all basal cells (Table 1) was found (Figs. 3c, 4b).

When the antiserum was immunoabsorbed with the antigen or when non-immunized rabbit serum was used, no staining could be detected (Fig. 4c). The endothelial cells of small (Fig. 4e) and large (Figs. 4e-g) blood vessels were strongly immunoreactive. The staining reaction was variable in the smooth muscle cells of the tunica media, while fibroblasts of the tunica adventitia were intensively stained. Veins appeared strongly labelled because of the large number of fibroblasts in their walls (Fig. 4e). In arteries, the tunica media was lightly stained (Figs. 4f, g), while the tunica adventitia was well stained (Fig. 4f).

When the paraffin sections of cultured epithelial cells were examined after immunostaining using type 5 17 β -HSD antibody, 58% of these cells were found to be positively stained (Fig. 3d).

3 β -HSD Distribution. The results obtained following immunostaining with antibody to 3 β -HSD were found to be very similar to those generated with the type 5 17 β -HSD antiserum (Figs. 5a, b). Although the staining reaction was generally weaker for 3 β -HSD, the cellular distribution of the enzyme corresponds very well to that described above for type 5 17 β -HSD. In the glandular epithelium of the prostate, all the

basal cells were generally labelled while, in the luminal cells, the staining was variable, being intense in some cells and weak or absent in most others. In the stroma, the staining was restricted to the cytoplasm of fibroblasts. As observed for type 5 17 β -HSD, specific immunolabelling was found in the endothelial cells and fibroblasts of blood vessel walls including arteries, veins and capillaries. In all the 3 β -HSD-containing cells, the staining was restricted to the cytoplasm, no significant nuclear staining being detected.

Androgen receptor distribution. The AR appears exclusively localized in the nuclei of prostate cells in all the specimens examined. In the epithelium, immunostaining is detected in almost all the nuclei of the luminal cells, while most of the basal cell nuclei do not exhibit positive staining (Fig. 5c and Table 1). In the stroma, the majority of nuclei of the fibromuscular cells are labelled, but unstained nuclei of smooth muscle cells are also observed (Fig. 5d and Table 1). In the blood vessels, several nuclei of the endothelial cells lining the lumen are positive, but some display no reaction (Fig. 5e). In the tunica media of the arteries, most of the nuclei of the smooth muscle cells are stained while some remain negative (not shown). Comparable results were obtained for the nuclei of fibrocytes of the tunica adventitia.

DISCUSSION

In the present study, we have used two complementary approaches, namely *in situ* hybridization (using BPH specimens) and immunocytochemistry (using BPH, normal prostate tissues and cultured epithelial cells), to identify the cells which express type 5 17 β -HSD in the human prostate. This enzyme was found mainly in the basal cells of the tube-alveoli, the fibroblasts of the stroma and blood vessels as well as in

the endothelial cells of the blood vessels (Table 1, 2). This double approach permits to identify not only type 5 17β -HSD mRNA but also the enzyme itself. The present data are in agreement with results from this laboratory, which indicated the presence of androgenic 17β -HSD activity in human and rhesus monkey prostates.

The stratified epithelium lining the tube-alveoli is divided into two layers, namely the basal layer made of low cuboidal cells and a layer of columnar secretory cells (luminal cells). It is generally believed that prostatic stem cells are located in the basal cell layer. As revealed by both *in situ* hybridization and immunocytochemistry, the basal cells are expressing type 5 17β -HSD at a much higher level than the luminal cells. In fact, while many luminal cells exhibited some detectable hybridization signal, they have shown a high degree of variation and usually low level of immunostaining (Figs. 3c, 4b). On the other hand, the majority of alveoli contained only strongly labeled basal cells (Figs. 3a, 4a). However, in a few alveoli, staining was detectable either in some luminal cells (Figs. 3c, 4b) or in all of them (Fig. 3b). This variable staining in luminal cells might be explained by variations in the biosynthetic activity among alveoli or among different luminal cells in the same alveolus. It is quite possible that the low level of the protein in an unknown proportion of luminal cells cannot be detected by immunocytochemistry. It is noteworthy to mention that very similar results were obtained with the antibody against 3β -HSD.

The cultured epithelial cells PrEC 5500-1 have shown approximately the same pattern of expression of type 5 17β -HSD as the epithelial cells of BPH and normal prostate tissues. We assumed that the cultured epithelial

cells are a mixture of basal and luminal cells. Therefore, it is not surprising to find that only 58% of these cells expressed the enzyme.

5 It has been reported that types 1 and 2 5 α -reductases are produced by both epithelial and stromal cells in the prostate. Using immunocytochemistry, it has been shown that staining for type 2 5 α -reductase could be seen in both basal and luminal epithelial cells. On the basis of studies performed with human prostatic *in vitro* models, it has been suggested that the basal cells exert a stem cell role. On the other
10 hand, *in vivo* studies performed in the rat prostate during maturation have established that both basal and secretory luminal cells are self-replicating cell types. The presence of type 5 17 β -HSD, 3 β -HSD and 5 α -reductase isoenzymes in the basal cells suggests that this cell type is actively involved in androgen production and cannot be considered as
15 being only a precursor of the luminal secretory cells.

Using cells transfected with the cDNAs of different types of 17 β -HSD, Luu-The et al have shown that types 1 and 3 17 β -HSD catalyze the reduction of estrone to estradiol and 4-androstenedione to testosterone,
20 respectively. They have also shown that these enzymes are substrate and orientation selective. In fact, type 3 and 5 17 β -HSDs have the same selective function, but type 3 was detected only in the testis and was not found in the human prostate. Therefore, in the prostate, the reduction of 4-Dione to testosterone is probably due to type 5 17 β -HSD. Since type 5
25 17 β -HSD and 3 β -HSD are both highly expressed in basal cells while the androgen receptor is mainly present in luminal cells (Fig. 5c and Table 1), it is tempting to suggest that testosterone synthesized in the basal cells reaches the luminal cells in a paracrine fashion to be ultimately

transformed into DHT in the luminal cells where the androgenic action is exerted and AR is highly expressed. DHT made in the luminal cells by the action of 5 α -reductase would then exert its action in the luminal cells themselves, thus meeting the definition of intracrine activity. The involvement of two cell types in the biosynthesis of steroids has already been shown to occur in the ovary. In fact, in the ovary, C19 steroids (androstenedione and testosterone) synthesized by theca interna cells are transferred to granulosa cells where they are aromatized into estrogens. The present data suggest the possibility of a similar two-cell mechanism of androgen formation in the human prostate: testosterone is first synthesized in the basal cells before diffusing into the luminal cells where transformation into DHT occurs.

In the present study, the fibroblasts present in the stroma as well as those associated with blood vessels are shown to contain type 5 17 β -HSD mRNA as well as the immunoreactive type 5 17 β -HSD and 3 β -HSD enzymes. The two types of 5 α -reductase have also been detected in this cell type by various techniques. The role of the steroidogenic enzymes in fibroblasts remains to be established but since androgen receptors are present in the nuclei of most stromal cells (Table 1), it is likely that DHT could act in the fibroblasts themselves (intracrine action) to modulate the activity of these cells.

Previous study has shown that in normal prostate, basal cells contained the mRNA for AR but lacked an immunodetectable receptor while in the luminal cells both mRNA and immunodetectable receptor were present. These authors have also stated that AR localization in BPH was identical to that observed in normal prostate. Similarly, it has been found that the

nuclei of the luminal and the majority of stromal cells were positive to androgen receptor antibody in hyperplastic as well as normal prostatic glands. It has also been found that primary, as well as metastatic, prostate carcinomas show nuclear staining for AR and that the proportion and the intensity of immunostained human prostate tumor cells decreased in the more aggressive tumors. The basal cells also express nuclear AR in normal and hyperplastic tissue. However, the receptor was most frequently expressed at lower levels in the basal cells when compared with the staining intensity detected in secretory luminal cells. It has been found that AR immunostaining was localized to the nuclei of luminal cells but was weak or absent in basal cells and of variable intensity in the stromal cells. In the present study, while 94% of luminal cells expressed nuclear AR, only 37% of basal cells were stained (Table 1) and their staining intensity was lower than that of luminal cells (Table 2). The majority (66%) of fibro-muscular stromal cells also expressed AR. The findings of the present study are thus in agreement with previous studies performed in human, rat and mouse tissue. Since the stroma/epithelium cell ratio is higher in the hyperplastic prostate, it can be hypothesized that androgens synthesized intracellularly by fibroblasts can influence the production of collagen and elastic fibers in the stroma.

An unexpected finding was the localization of type 5 17β -HSD and 3β -HSD in blood vessel walls, including the endothelial cells. This observation, however, correlates well with recent findings from this laboratory indicating the presence of types 1 and 2 5α -reductase mRNA in blood vessel walls in human prostate and skin. Recently, we have also observed that immunoreactive type 5 17β -HSD is present in the blood vessel walls in other tissues such as skin, breast, uterus and ovary. The

role of the steroidogenic intracrine enzymes in these vascular structures is unknown.

5 Previously, it has been shown that androgen receptors were present in vascular smooth muscle and endothelial cells of human skin. It has been found that nuclear androgen receptors were present in the muscular layer of almost all arteries within the rat testis. It has been suggested that testicular blood vessels could be a target organ for androgens and may mediate some of the effects of androgens on testicular microcirculation. 10 Furthermore, in the developing human prostate, AR was positive in the nuclei of vascular smooth muscle and endothelial cells. Since androgen receptors are present in the endothelial cells, smooth muscle cells and fibroblasts of blood vessels (Table 1), it may be speculated that locally biosynthesized androgens are exerting a paracrine and/or intracrine 15 action in blood vessels. It is also possible that these androgens are, up to an unknown extent, released into the blood circulation to reach some target tissues, although their global impact is likely to be minimal. Interestingly, it has been shown that in the rat prostate, testosterone could induce a rapid response of the vasculature which precedes growth of the glandular epithelium. It might well be that cells of the blood vessels are 20 stimulated by locally made androgens to produce paracrine growth factors, which could promote the growth of the secretory epithelium. Further studies are required to elucidate the role of the steroids synthesized by cells of the blood vessel walls. The present data clearly 25 indicate new mechanisms of androgen formation, which may play an important role, not only in normal human prostate physiology, but also in the pathogenesis of benign prostatic hyperplasia and possibly prostate cancer.

Table 1. Percentage of immunostained cells of BPH and normal human prostate tissues.

		Type 5 17 β -HSD	Androgen receptor
Epithelium	Basal cells	(%) 100	(%) 37
	Luminal cells	22 (*)	94
Fibro-muscular stromal cells	Fibrocytes	100	66 (o)
	Smooth muscle cells	0	
Blood vessels	Endothelial cells of tunica intima	100	75
	Smooth muscle cells of tunica media	35 (•)	82
	Fibrocytes of tunica adventitia	100	56

(*) This percentage represents the number of stained luminal cells only in about 5% of the alveoli, as shown in figures 3c and 4b. The vast majority of alveoli (about 85%) did not show stained luminal cells while all luminal cells were stained in about 10% of them (Fig. 3b).

(o) The number represents the percentage of stained nuclei of fibrocytes and smooth muscle cells together.

(•) The staining intensity is low in the stained smooth muscle cells of tunica media (as seen in figure 4f) as compared with other stained cells.

Table 2. Intensity of the *in situ* hybridization and immunostaining reactions in the different cell types of BPH and normal human prostatic tissue.

		<i>In situ</i> hybridization Type 5 17 β -HSD	Immunostaining		
			3 β -HSD	Type 5 17 β -HSD	Androgen receptor
Epithelium	Basal cells	+++	+++	+++	+/-
	Luminal cells	+	+/-	+/-	+++/-
Fibro-muscular stromal cells	Fibrocytes	+++	+++	+++	+++/-
	Smooth muscle cells	-	-	-	+++/-
Blood vessels	Endothelial cells of tunica intima	+++	+++	+++	+++/-
	Smooth muscle cells of tunica media	+/-	+/-	+/-	+++/-
	Fibrocytes of tunica adventitia	+/-	++	++	+++/-

5

The presence of silver grains or positive immunostaining reaction is indicated by (+), graded from 1 to 3. The number of (+) thus corresponding to the intensity of the reaction and takes into account the percentage of labelled cells.

10

The absence of reaction is indicated by (-).

The possibility of being positively or negatively labeled is indicated by (+/-).

Human skin hybridized with type 5 17 β -HSD cRNA probe. In a preliminary experiment of *in situ* hybridization, human skin has been hybridized with type 5 17 β -HSD antisense and sense riboprobes the results show that the epidermis (except stratum corneum) (Fig. 6a,b), the wall of blood vessels (Fig. 6c,d), hair follicles as well as most of the fibrocytes of the dermis are labeled.

When paraffin sections immunostained with a specific antibody to type 5 17 β -HSD were examined, the obtained results were in agreement with the *in situ* hybridization results. In the epidermis, few cells of the stratum granulosum were found to be heavily immunostained than all the other stained cells.

Localization of type 5 17 β -HSD in human mammary gland.

Immunostaining of tissue sections from several normal human mammary gland show that the epithelial cells lining the ducts and the alveoli are not stained while the connective tissue surrounding cells are stained. In the only one examined case of mammary gland tumor, the tumor cells themselves were not labeled but the epithelial cells lining the ducts were found to be heavily labeled (Fig. 7a, b).

Localization of type 5 17 β -HSD in monkey ovary. In a preliminary study of *in situ* hybridization, one of the growing follicles was examined.

Theca cells, granulosa cells and the oocyte were found to be labeled.

PREFERRED INHIBITORS OF TYPE 5
17 β -HYDROXYSTEROID DEHYDROGENASE


5 Set forth in the tables below are lists of compounds which we have found to be useful as inhibitors of type 5 17 β -hydroxysteroid dehydrogenase. The tables also include in many instances further tests of a particular compound on other important parameters such as androgenic and antiandrogenic activity and the effect of a compound on androgen receptors, androgen-sensitive cells, and other effects more fully explained

10 below. In each of tables 1-5 and 1'-5' below that do not include a "prime" (') in its table number, details of molecular structure of preferred inhibitors are set forth. The corresponding table with a "prime" (') in its table number shows certain information about the functional efficacy of each tested compound. The numbers in the column headings correspond

15 to a description at the end of all of the tables regarding what information is reported in each column and how it is determined. Entries left blank are not yet determined.

- 94 -

Table 1



Name	Example	A	R ¹ -CH	R ⁶	R _a	R _b	Δ1	Δ6
EM-996	1	CH ₃	NO	CH ₃	-C ₅ H ₁₀	Br	NO	YES
EM-1029	1	CH ₃	"	CH ₃	-C ₄ H ₈	Cl	"	YES
EM-950	1	CH ₃	"	CH ₃	cycloC ₅ H ₈	H	"	YES
CS-245	2	CH ₃	YES	CH ₃	-C ₃ H ₆	H	"	YES
EM-1003	1	CH ₃	NO	CH ₃	-C ₃ H ₆	Br	"	YES
EM-1291	1	CH ₃	"	CH ₃	-CH ₂	ΦOCH ₃	YES	YES
EM-1280	1	CH ₃	"	CH ₃	-C ₂ H ₄	H	YES	YES
CS-251	1	CH ₃	"	CH ₃	-(CH ₂) ₃	COCH ₃	NO	YES
CS-243	2	CH ₃	YES	CH ₃	-C ₂ H ₄	H	"	YES
EM-1195-CS	1	CH ₃	NO	CH ₃	-C ₄ H ₈	F	"	YES
EM-928	1	CH ₃	"	CH ₃	-C(CH ₃) ₂	H	"	YES
CS-241	1	CH ₃	"	CH ₃	-C ₃ H ₆	Cl	"	YES
EM-1182-CS	1	CH ₃	"	CH ₃	-C ₅ H ₁₀	F	"	YES
EM-1173-CS	1	CH ₃	"	CH ₃	-C ₄ H ₈	Br	"	YES
EM-1171	1	CH ₃	"	CH ₃	-C ₅ H ₁₀	Cl	"	YES
EM-949	1	CH ₃	"	CH ₃	-CH ₂	Φ	"	YES
EM-978	1	CH ₃	"	CH ₃	cycloC ₆ H ₁₀	H	"	YES

SUBSTITUTE SHEET (RULE 26)

- 95 -

Table 1 (Cont'd)

Name	Example	A	R ¹ -CH	R ⁶	R _a	R _b	Δ1	Δ6
EM-979	1	CH ₃	"	CH ₃	tBu	H	"	YES
EM-1044	1	CH ₃	"	CH ₃	CH ₂	ΦCl(p)	"	YES
CS-209	2	CH ₃	YES	CH ₃	-isoC ₃ H ₆	H	"	YES
CS-256	1	CH ₃	NO	CH ₃	-CH ₂	ΦF	"	YES
EM-1022	2	CH ₃	YES	CH ₃	-cycloC ₅ H ₈	H	"	YES
EM-1049	1	CH ₃	No	CH ₃	-CH ₂	ΦOCH ₃	"	YES
EM-1107	1	CH ₃	No	CH ₃	CH ₂	OCOTer	"	YES
EM-952	2	CH ₃	YES	CH ₃	-CH ₂	H	"	YES
Megestrol	nil	CH ₃	NO	CH ₃	-CH ₂	H	"	YES
Acetate EM-995	2	CH ₃	YES	CH ₃	-C ₅ H ₁₀	H	"	YES
EM-994	2	CH ₃	YES	CH ₃	-C ₄ H ₈	H	"	YES
CS-220	2	CH ₃	YES	CH ₃	-tBu	H	"	YES
CS-206	2	C ₄ H ₉	NO	CH ₃	-CH ₂	H	"	YES
EM-1023	2	C ₂ H ₅	NO	CH ₃	-CH ₂	H	"	YES
EM-1059	2	CH ₃	YES	CH ₃	CH ₂	Φ	"	YES
EM-1159	9	N-(CH ₃) ₂	NO	CH ₃	-CH ₂	H	"	YES
EM-1181-CS	9	-N(CH ₃)C ₂ H ₅	NO	CH ₃	-(CH ₂) ₃	Cl	"	YES
EM-1079	9	-N(CH ₃)C ₂ H ₅	NO	CH ₃	-CH ₂	H	"	YES
EM-1165	9	-N(CH ₃)C ₄ H ₉	NO	CH ₃	-CH ₂	H	"	YES
EM-1158	9	-N(CH ₃)Φ	NO	CH ₃	-CH ₂	H	"	YES
EM-1230-CS	9	-N(CH ₃)C ₂ H ₅	NO	CH ₃	-C(CH ₃) ₂	H	"	YES
EM-1264	9	-N(CH ₃)CH ₃	NO	CH ₃	-C ₂ H ₄	H	"	YES
EM-1268	9	-N(CH ₃)CH ₃	NO	CH ₃	-C ₃ H ₆	H	"	YES
EM-1315	9	-N(CH ₃)CH ₂ Φ	NO	CH ₃	-C ₃ H ₆	H	"	YES
EM-1316	9	-N(CH ₃)CH ₂ Φ	NO	CH ₃	-C ₂ H ₄	H	"	YES
EM-1326-CS	9	-N(CH ₃)C ₃ H ₇	NO	CH ₃	-C ₂ H ₄	H	"	YES
EM-1327	9	-N(CH ₃)C ₃ H ₇	NO	CH ₃	-C ₃ H ₆	H	"	YES
EM-1317	9	-N(CH ₃)C ₃ H ₅	NO	CH ₃	-C ₂ H ₄	H	"	YES

SUBSTITUTE SHEET (RULE 26)

- 96 -

Table 1 (Cont'd)

Name	Example	A	R ¹ -CH	R ⁶	R _a	R _b	Δ1	Δ6
EM-1318	9	-N(CH ₃)C ₃ H ₅	NO	CH ₃	-C ₃ H ₆	H	"	YES
EM-1321-CS	9	-N(CH ₃)CH(CH ₃) ₂	NO	CH ₃	-C ₂ H ₄	H	"	YES
EM-1322-CS	9	-N(CH ₃)CH ₂ CH(CH ₃)	NO	CH ₃	-C ₂ H ₄	H	"	YES
EM-1323-CS	9	-N(CH ₃)CH ₂ CH(CH ₃)	NO	CH ₃	-C ₃ H ₆	H	"	YES
EM-1271-CS	9	-N(CH ₃)CH ₃	NO	CH ₃	-C(CH ₃) ₂	H	"	YES
EM-1010	11	-OCH ₃	NO	CH ₃	-CH ₂	H	"	YES
EM-1106	10	CH ₂ Φ	NO	CH ₃	-CH ₂	H	"	YES
EM-923	1	CH ₃	NO	CH ₃	C ₄ H ₈	H	"	YES
EM-948	1	CH ₃	NO	CH ₃	-(CH ₂) ₂ cyclo	H	"	YES
EM-1007	4	CH ₃	NO	CH ₃	C ₃ H ₆ CO ₂ CH ₂	H	"	YES
EM-1081	10	C ₃ H ₇	NO	CH ₃	-CH ₂	H	"	YES
EM-917	1	CH ₃	NO	CH ₃	-C ₅ H ₁₀	H	NO	YES
EM-918	1	CH ₃	NO	CH ₃	-C ₂ H ₄	H	NO	YES
EM-920	1	CH ₃	NO	CH ₃	C ₃ H ₆	H	NO	YES
EM-946	1	CH ₃	NO	CH ₃	C ₂ H ₄	φ	NO	YES
EM-1018	2	CH ₃	YES	CH ₃	C ₆ H ₁₀	H	NO	YES
EM-1048	1	CH ₃	NO	CH ₃	C ₇ H ₁₄	Br	NO	YES
EM-1075	Not reported	CH ₃	NO	CH ₃	C ₃ H ₆	COφ	NO	YES
EM-1081	10	C ₃ H ₇	NO	YES	CH ₂	H	NO	YES
EM-1103	Not reported	CH ₃	NO	NO	CH ₂	H	NO	YES
EM-1127	1	CH ₃	NO	YES	C ₅ H ₁₀	H	NO	YES
EM-1188	2	CH ₃	YES	YES	CH ₂	φF(o)	NO	YES
EM-1175	10	-C(CH ₃)C ₂ H ₅	NO	YES	CH ₂	H	NO	YES
EM-1141	10	C(CH ₃) ₃	NO	YES	CH ₂	H	NO	YES
EM-1209	10	C ₄ H ₉	NO	YES	CH ₂	H	NO	YES
EM-1204	2	CH ₃	YES	YES	CH ₂	φF(p)	NO	YES
EM-1213	2	CH ₃	YES	YES	CH ₂	φOCH ₃ (NO	YES
EM-1216	2	CH ₃	YES	YES	CH ₂	φBr(p)	NO	YES

SUBSTITUTE SHEET (RULE 26)

Table 1 (Cont'd)

Name	Example	A	R ¹ -CH	R ⁶	R _a	R _b	Δ1	Δ6
EM-1217	2	CH ₃	YES	YES	CH ₂	φCl(p)	NO	YES
EM-1224	2	CH ₃	YES	YES	CH ₂	φOC ₂ H ₅	NO	YES
EM-1231	1	CH ₃	NO	YES	-CH(CH ₃)-	φ	NO	YES
EM-1240	2	CH ₃	YES	YES	CH ₂	φCH ₃ (o)	NO	YES
EM-1241	2	CH ₃	YES	YES	CH ₂	φCH ₃ (p)	NO	YES
EM-1242	2	CH ₃	YES	YES	CH ₂	φCH ₃ (NO	YES
EM-1243	2	CH ₃	YES	YES	CH ₂	φCF ₃ (p)	NO	YES
EM-1246	1	CH ₃	NO	YES	CH ₂	φCH ₃ (p)	NO	YES
EM-1253	1	CH ₃	NO	YES	-C(C ₂ H ₅)-	φ	NO	YES
EM-1263-CS	2	CH ₃	YES	YES	CH ₂	φNO ₂ (p)	NO	YES
EM-1279-CS	2	CH ₃	YES	YES	-C(C ₂ H ₅)-	φ	NO	YES
EM-1282-CS	1	CH ₃	NO	YES	-C(CH ₃) ₂	φ	NO	YES
EM-1290	2	CH ₃	YES	YES	CH ₂	φ-di-	NO	YES
EM-1292-CS	2	CH ₃	YES	YES	CH ₂	φOH(p)	NO	YES
EM-1297	1	CH ₃	NO	YES	CH ₂	φOH(p)	NO	YES
EM-1312	1	CH ₃	NO	YES	CH ₂	φCH ₃ (o)	NO	YES
EM-1339-CS	1	CH ₃	NO	YES	-CH(CH ₃)-	φOCH ₃ (NO	YES
EM-1340	1	CH ₃	NO	YES	CH ₂	φF(o)	NO	YES
EM-1343	1	CH ₃	NO	YES	CH ₂	φOCH ₃ (NO	YES
EM-910	1	CH ₃	NO	YES	CH ₂	H	YES	YES
EM-991	1	CH ₃	YES	YES	CH ₂	H	YES	YES
EM-1294	1	CH ₃	NO	YES	CH ₂	φ	YES	YES
EM-1308	1	CH ₃	NO	YES	-C(CH ₃) ₂ -	H	YES	YES
EM-1309	1	CH ₃	NO	YES	C ₃ H ₆	H	YES	YES
EM-1319-CS	1	CH ₃	NO	YES	-	H	YES	YES

SUBSTITUTE SHEET (RULE 26)

- 98 -

Table 1'

Name	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
	Oral Bioavailability AUC 0-7h (ng/mLh)	Inhibition Type V IC ₅₀ (nM) (% Inh. At (3.10 ⁻⁷ 3.10 ⁻⁴)	Reversibility (% of control)	Inhibition Type 1 IC ₅₀ (nM) (% Inh. At 3.10 ⁻⁷ 3.10 ⁻⁴)	Inhibition Type 2 IC ₅₀ (nM) (% Inh. At 3.10 ⁻⁷ 3.10 ⁻⁴)	Inhibition Type 3 IC ₅₀ (nM) (% Inh. At 3.10 ⁻⁷ 3.10 ⁻⁴)	Inhibition Type 1 IC ₅₀ (nM) (% Inh. At 3.10 ⁻⁷ 3.10 ⁻⁴)	Inhibition Type 3 IC ₅₀ (nM) (% Inh. At 3.10 ⁻⁷ 3.10 ⁻⁴)	Androgenic and Antandrogenic Activity Dihydrog E-7 E-8 DHT E-7 E-8 [IC ₅₀ (nM)]	ZR-75-1 Activity Basal E ₂ E-8 E-9 3E-8 E- [E-7 E-5] [E-7 E-5] [E-7 E-5]	% Inhibition Androgen Receptor [E-7 E-5] [E-7 E-5] [E-7 E-5]	% Inhibition Progesterone Receptor [E-7 E-5] [E-7 E-5] [E-7 E-5]	% Inhibition Glucocorticoid Receptor [E-7 E-5] [E-7 E-5] [E-7 E-5]	% Inhibition Estrogen Receptor [E-7 E-5] [E-7 E-5] [E-7 E-5]		
EM-996	ND	1.8±0.1							-11 -32 -78 -126 [158±59]	0 -8 -35-53	0 1 9 88	0 67 0 0	0 0 0 0			
EM-1029	10±2.5	3		[13]					-24 -15 -123 -146 [9.3]	0 -10 -62-64	1 5 80 8	0 98 0 0	0 0 0 0			
EM-950	ND	2.7±0.3 9							-23 -25 -79 -110 [44±5]	0 -39 -46	13 4 2 58	18 95 0 0	0 0 0 0			
CS-245	18±5	3.2±0.1							-28 -34 -106 -109 [12]	ND ND	5 71 0 26	0 43 0 2	0 0 0 0			
EM-1003	16±5	3.5±0.3							-17 -15 -83 -101 [35±6]	0 -9 -13 -67-73	0 67 9 85	2 79 0 0	0 0 0 0			
EM-1291	94 ± 23	7±1	27		[67]				-8 -44 -13 -48	ND ND	0 0 0 33	1 69 0 0	0 0 0 0			
EM-1280	18 ± 6.6	3 ± 0.5	31		[59]				0 0 -94 -111 [23]	ND ND	0 44 0 39	9 93 0 0	0 0 0 0			
CS-251	ND	11±1							5 -11 -22 -109 [11]	0 -23 0 -60-47	0 3 0 12	0 57 1 1	0 0 0 0			
CS-243	11±2.5	3.5±0.1							-13 -23 -102 -129	0 0 -60-57	0 33 0 27	0 29 1 0	0 0 0 0			

- 99 -

Table 1' (Cont'd)

Name	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
	Oral Bioavailability AUC 0-7h (ng/mL.h)	Inhibition Type V IC ₅₀ (nM) (% Inh. At 3.10 ⁻⁷ 3.10 ⁻⁶)	Reversibility (% of control)	Inhibition Type 1 IC ₅₀ (nM) (% Inh. at 3.10 ⁻⁶ M)	Inhibition Type 2 IC ₅₀ (nM) (% Inh. at 3.10 ⁻⁶ M)	Inhibition Type 3 IC ₅₀ (nM) (% Inh. at 3.10 ⁻⁶ M)	Inhibition Type 1 IC ₅₀ (nM) (% Inh. at 3.10 ⁻⁶ M)	Inhibition Type 3 IC ₅₀ (nM) (% Inh. at 3.10 ⁻⁶ M)	Androgenic and Antiangiogenic Activity Shionogi Basal E-6 E-7 E-8 DHT E-6 E-7 E-8 [IC ₅₀ (nM)]	ZR-75-1 Activity Basal E-2 E-8 E-9 3E-8 E-6	% Inhibition Androgen Receptor (E-7 E-5) (E-8 E-6)	% Inhibition Progesterone Receptor (E-7 E-5) (E-8 E-6)	% Inhibition Glucocorticoid Receptor (E-7 E-5) (E-8 E-6)	% Inhibition Estrogen Receptor (E-7 E-5) (E-8 E-6)		
EM-1195 CS	31±5.5	4±0.5			[40]				-27 -34	-105 -110	-11 18 -38 -40	1 62	0 70	3 90	0 0	
EM-928	ND	3.7±0.3			[27]			0	-13	-60 -107	0 -11 -50 -84	4 72	11 90	21 99	0 0	
CS-241	ND	4.1±0.6						5	23	-91 -93	ND	10 91	0 61	9 96	1 3	
EM-1182	ND	4.4±0.4			[50]			-14	-16	-94 -109	ND	0 51	18 78	5 90	0 0	
EM-1173 CS	4.1±1.4	4.6±1.1			[28]			-17	-54	-70 -121	197 196	0 0	6 76	5 89	0 0	
EM-1171	4±1.3	5.3±0.3			[14]			-6	-30	-82 -111	98 182	0 -29	1 36	5 76	8 90	0 0
EM-949	ND	5.5±1.1			[64]			-19	-13	-45 -102	-8 0 -23 -17	2 41	37 97	11 94	0 0	
EM-978	ND	6.8±0.4			[39]			-31	-48	-79 -132	-13 -13 -35 -48	7 17	0 48	14 93	0 0	
EM-979	ND	7.2±0.7			[20]			-15	-41	-39 -117	-12 0 -26 -40	6 7	1 41	7 88	0 0	

SUBSTITUTE SHEET (RULE 26)

Table 1' (Cont'd)

Name	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
	Oral Bioavailability (ng/mL.h)	Inhibition Type V IC ₅₀ (nM) (% inh. At (3.10 ⁻⁷ 3.10 ⁻⁶)	Reversibility (% of control)	Inhibition Type 1 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 2 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 3 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 1 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 3 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Androgenic and Antiestrogenic Activity DHT E-7 E-8 IC ₅₀ (nM)	Basal E2 E-8 E-6 3E-8 E-	ZR-75-1 Activity		% Inhibition Androgen Receptor (E-7 E-5) E-8 E-6	% Inhibition Progesterone Receptor (E-7 E-5) E-8 E-6	% Inhibition Glucocorticoid Receptor (E-7 E-5) E-8 E-6	% Inhibition Estrogen Receptor (E-7 E-5) E-8 E-6
EM-1044	53±23	5.1							4 -27 -21 -87		0 19 0 -24	0 0 0	0 0 0	0 74	0 81	0 0
CS-209	ND	10.5±2.7			[62]				13 -30 -67 -122		0 0 -44 -48	2 8 2	0 29 0	0 38	0 29	0 0
CS-256	33±7	5±1							-10 -24 -17 -89	ND	ND	4 5 2	2 75	2 51	2 8	0 0
EM-1022	ND	5.4±0.6			[62]				-12 -35 -68 -155	0 20 -30 -40	0 9 0	0 25 0	0 44	0 0	0 0	0 0
EM-1049	83±16	9±1							10 -33 -12 66	0 0 -52 -71	0 1 0	0 63	0 62	0 0	0 0	0 0
EM-1107	ND	17±3			[64]				-9 -6 3 -34	ND	ND	4 3 0	48	1 64	0 0	0 0
EM-952	ND	17.4±5.1							-19 -4 -88 -104	0 0 -17 -13	0 20 4	50	1 14	0 3	0 0	0 0
									[41±4]							
Megestrol Acetate	92±17	17.4±2.8							ND	[10±1.8]	ND	-70 -81	9* 92* 36* 97*	17* 98*	01* 08*	0 0
EM-995	ND	21.3±6.7							-4 -21 -51 -121	-29 -9 -12 -19	0 10 5	72	0 27	0 0	0 0	0 0

- 101 -

Table 1' (Cont'd)

Name	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
	Oral Bioavailability AUC 0-7h (ng/mL.h)	Inhibition Type V IC50 (nM) (% inh. At (3.10 ⁻⁷ 3.10 ⁻⁴)	Reversibility (% of control)	Inhibition Type 1 IC50 (nM) (% inh. at 3.10 ⁻⁷ M)	Inhibition Type 2 IC50 (nM) (% inh. at 3.10 ⁻⁷ M)	Inhibition Type 3 IC50 (nM) (% inh. at 3.10 ⁻⁷ M)	Inhibition Type 1 IC50 (nM) (% inh. at 3.10 ⁻⁷ M)	Inhibition Type 3 IC50 (nM) (% inh. at 3.10 ⁻⁷ M)	Androgenic and Antandrogenic Activity (nM)	Basal E-7 E-5	DHT E-7 E-5 [IC50 (nM)]	ZR-75-1 Activity Basal E2 E-8 E-6 3E-6 E-7	% Inhibition Androgen Receptor *(E-7 E-5) E-8 E-6 E-5	% Inhibition Progesterone Receptor *(E-7 E-5) E-8 E-6 E-5	% Inhibition Glucocorticoid Receptor *(E-7 E-5) E-8 E-6 E-5	% Inhibition Estrogen Receptor *(E-7 E-5) E-8 E-6 E-5
EM-994	ND	3115.1			[42]				-10 -27	-82 -122	0 -8 -10 -35	0 19 6 64	0 19 6 64	0 33 0 33	0 33 0 33	0 33 0 33
CS-220	ND	3123.3			[32]				0 -31	15 -106	0 11 -25 -11	0 0 0 20	0 0 0 20	0 23 0 23	0 23 0 23	0 23 0 23
CS-206	ND	4028.5			[80]				-18 -40	-75 -118	0 0 -12 -40	5 15 0 29	5 15 0 29	0 45 0 45	0 45 0 45	0 45 0 45
EM-1023	ND	5027			[20]				-11 -14	-108 -133	14 0 61 66	0 43 0 44	0 43 0 44	0 85 0 85	0 85 0 85	0 85 0 85
EM-1059	ND	(70 92)							-7 -12	-34 -81	ND ND	0 3 0 41	0 3 0 41	0 23 0 23	0 23 0 23	0 23 0 23
EM-923	10 ± 2	(94 96)			[31]				10 5	-73 -94	0 -12 60 -105	0 3 0 41	0 3 0 41	0 23 0 23	0 23 0 23	0 23 0 23
EM-948	ND	(91 93)			[49]				-26 -19	-49 -105	0 0 -29 -36	ND ND	ND ND	ND ND	ND ND	ND ND
EM-1007	16.4	(81 86)							0 -31	-14 -76	-8 0 -41 -52	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0
EM-1159	452 ± 170	1422							15 -14	1 -71	ND ND	1 1 2 4	1 1 2 4	8 59 0 1	8 59 0 1	8 59 0 1

- 102 -

Table 1' (Cont'd)

Name	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
	Oral Bioavailability (ng/mLh)	Inhibition Type V IC ₅₀ (nM) (% inh. At 3.10 ⁻⁷ 3.10 ⁻⁶)	Reversibility (% of control)	Inhibition Type 1 IC ₅₀ (nM) (% inh. At 3.10 ⁻⁷ 3.10 ⁻⁶)	Inhibition Type 2 IC ₅₀ (nM) (% inh. At 3.10 ⁻⁷ 3.10 ⁻⁶)	Inhibition Type 3 IC ₅₀ (nM) (% inh. At 3.10 ⁻⁷ 3.10 ⁻⁶)	Inhibition Type 4 IC ₅₀ (nM) (% inh. At 3.10 ⁻⁷ 3.10 ⁻⁶)	Inhibition Type 5 IC ₅₀ (nM) (% inh. At 3.10 ⁻⁷ 3.10 ⁻⁶)	Androgenic and Antiestrogenic Activity (nM)	Basal E-7 E-6 IC ₅₀ (nM)	Basal E ₂ E-8 E-9 3E-8 E ₂	2R-75-1 Activity	% Inhibition Androgen Receptor E-7 E-5 E-8 E-6	% Inhibition Progesterone Receptor E-7 E-5 E-8 E-6	% Inhibition Glucocorticoid Receptor E-7 E-5 E-8 E-6	% Inhibition Estrogen Receptor E-7 E-5 E-8 E-6
EM-1181	130 ± 35	5 ± 1		[45]					-6 -12 -89 -104 [15.1]	ND	ND	ND	0 27	ND	2 70 7	0
CS									-15 -23 -7 -71	ND	ND	ND	0 0	0 0 3	45 0	0
EM-1079	252 ± 61	17 ± 1		[28]					5 -17 -14 -102 [232]	ND	ND	ND	0 1	0 7 0	26 0	0
EM-1165	24 ± 3.6	2.5 ± 5							0 0 -16 -82	ND	ND	ND	1 2	0 6 0	53	
EM-1158	ND	25 ± 5							-9 -30 0 -66	ND	ND	ND	1 0	0 0 1	45 3	0
EM-1230	82 ± 15	8 ± 1		[65]					-25 -56 -25 -108 [535]	ND	ND	ND	0 0	0 5 7	80 3	0
CS									-25 -45 -86 -113 [101]	ND	ND	ND	0 12	1 7 14	90 1	6
EM-1264	257 ± 81	6 ± 1		[51]					-32 -62 -66 -121 [101]	ND	ND	ND	1 13	0 14 18	66 0	0
EM-1268	58 ± 10	5.8		[80]					-23 -64 -32 -118	ND	ND	ND	0 1	0 13 3	84 0	0
EM-1315	ND	6.8		[88]					-28 -56 -47 -116	ND	ND	ND	0 0	0 4 3	47 0	0
EM-1316	23 ± 5	11.6 ± 3		[87]					-41 -59 -101 -119	ND	ND	ND	0 19	0 7 12	40 0	0
EM-1326	ND	6 ± 1		[75]												
CS																
EM-1327	ND	6 ± 1														

SUBSTITUTE SHEET (RULE 26)

- 103 -

Table 1' (Cont'd)

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
Name	Oral Bioavailability AUC 0-7h (ng/mLh)	Inhibition Type V IC ₅₀ (nM) (% inh. At (3.10 ⁻⁷ 3.10 ⁻⁶)	Reversibility (% of control)	Inhibition Type 1 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 2 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 3 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 1 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 3 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Androgenic and Antiandrogenic Activity Shown!		ZR-75-1 Activity		% Inhibition Androgen Receptor (E-7 E-5) E-8 E-8	% Inhibition Progesterone Receptor (E-7 E-5) E-8 E-8	% Inhibition Glucocorticoid Receptor (E-7 E-5) E-8 E-8	% Inhibition Estrogen Receptor (E-7 E-5) E-8 E-8
									Basal E-7 E-8 DHT E-7 E-8 [IC ₅₀ (nM)]	Basal E ₂ E-8 E-5 3E-8 E-						
EM-1317	ND	8±1			[81]				-20 -56	-32 -113	ND	ND	0 0 0 0	1 64	0 0	
EM-1318	ND	7±1			[80]				-30 -53	-85 -121	ND	ND	0 15 0 11	5 68	0 0	
EM-1321- CS	ND	7±2			[84]				0 0	-25 -99	ND	ND	0 1 0 5	15 29	0 0	
EM-1322- CS	ND	4±1			[83]				-38 -40	-53 -112	ND	ND	0 2 0 3	0 45	0 0	
EM-1323- CS	ND	5±1			[79]				-33 -44	-92 -116	ND	ND	1 16 0 11	9 30	0 1	
EM-1271 -CS	181 ± 28	4.1			[73]				-25 -42	0 -68	ND	ND	0 0 0 0	9 82	0 0	
EM-1010	ND	31±3.4							-26 -25	-83 -109 0 [58±9]	0 -50 -60	0 28 0 47	0 45	0 0	0	
EM-1106	29 ± 1.6	(83 88)			[62]				-19 -33	-65 -108 [55]	ND	ND	1 23 1 24	1 50	1 0	
EM-917									-4 -19	-69 -109						
EM-918									43 11	-50 -97						
EM-920									88 78	-26 -50						

SUBSTITUTE SHEET (RULE 26)

Table 1' (Cont'd)

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
Name	Oral Bioavailability AUC 0-7h (ng/mL.h)	Inhibition Type V IC50 (nM) (% inh. At (3.10 ⁻⁷ 3.10 ⁻⁶)	Reversibility (% of control)	Inhibition Type 1 IC50 (nM) (% inh. at 3.10 ⁻⁷ M)	Inhibition Type 2 IC50 (nM) (% inh. at 3.10 ⁻⁷ M)	Inhibition Type 3 IC50 (nM) (% inh. at 3.10 ⁻⁷ M)	Inhibition Type 4 IC50 (nM) (% inh. at 3.10 ⁻⁷ M)	Inhibition Type 5 IC50 (nM) (% inh. at 3.10 ⁻⁷ M)	Androgenic and Antihypertensive Activity Shionogi		ZR-75-1 Activity Basal E2 E-8 E-6 3E-8 E-	% Inhibition Androgen Receptor (E-7 E-5) E-8 E-6	% Inhibition Progesterone Receptor (E-7 E-5) E-8 E-6	% Inhibition Glucocorticoid Receptor (E-7 E-5) E-8 E-6	% Inhibition Estrogen Receptor (E-7 E-5) E-8 E-6	
									Basal E-7 E-8	DHT E-7 E-6 [IC50 (nM)]						
EM-946									-25 -7	-39 -82						
EM-1018		(58 82)							-9 -36	-34 -142						
EM-1048		(51 84)							-4 -30	-18 -97						
EM-1075		(40 90)							10 -26	-10 -82						
EM-1081		(61 82)							-13 -23	-94 -108						
EM-1103		(59 86)							-5	-40 -104						
EM-1127		(71 91)							85 92							
EM-1188		(58 88)							-18 -32	-24 -61						
EM-1175		(32 86)							-30 -47	-35 -106						
EM-1141		(25 79)							0 -5	-8 -75						
EM-1209		(95 94)							-35 -40	-53 -105						

Table 1' (Cont'd)

Name	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
	Oral Bioavailability AUC 0-7h (ng/mLh)	Inhibition Type V IC ₅₀ (nM) (% inh. At 3.10 ⁻⁷ 3.10 ⁻⁶)	Reversibility (% of control)	Inhibition Type 1 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁷ 3.10 ⁻⁶)	Inhibition Type 2 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁷ 3.10 ⁻⁶)	Inhibition Type 3 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁷ 3.10 ⁻⁶)	Inhibition Type 4 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁷ 3.10 ⁻⁶)	Inhibition Type 5 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁷ 3.10 ⁻⁶)	Basal E-7 E-6	Androgenic and Antiandrogenic Activity Shown DHT E-7 E-6 IC ₅₀ (nM)	ZR-75-1 Activity Basal E ₂ E-8 E-6 3E-8 E- 3		% Inhibition Androgen Receptor (E-7 E-6 E-5)	% Inhibition Progesterone Receptor (E-7 E-6 E-5)	% Inhibition Glucocorticoid Receptor (E-7 E-6 E-5)	% Inhibition Estrogen Receptor (E-7 E-6 E-5)
EM-1204		(33 88)							3 -24	-22 -60						
EM-1213		(35 83)							-9 -32	-22 -51						
EM-1216		(33 77)							-14 -36	-22 -63						
EM-1217		(36 81)							-5 -36	-21 -59						
EM-1224		(2 22)							-6 -28	-18 -55						
EM-1231		(91 96)							-28 -36	-58 -112						
EM-1240		(47 89)							-10 -33	-8 -56						
EM-1241		(4 53)							-6 -41	-3 -56						
EM-1242		(19 78)							-6 -41	-12 -63						
EM-1243		(2 16)							-14 -52	-28 -89						
EM-1246		(74 95)							-17 -34	-25 -97						

Table 1' (Cont'd)

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
Name	Oral Bioavailability AUC 0-7h (ng/mL·h)	Inhibition Type V IC ₅₀ (nM) (% Inh. At (3.10 ⁻⁷ 3.10 ⁻⁴)	Reversibility (%) of control)	Inhibition Type 1 17β-HSD Activity IC ₅₀ (nM) (% Inh. at 3.10 ⁻⁴ M)	Inhibition Type 2 17β-HSD Activity IC ₅₀ (nM) (% Inh. at 3.10 ⁻⁴ M)	Inhibition Type 3 17β-HSD Activity IC ₅₀ (nM) (% Inh. at 3.10 ⁻⁴ M)	Inhibition Type 4 3α-HSD Activity IC ₅₀ (nM) (% Inh. at 3.10 ⁻⁴ M)	Inhibition Type 5 3α-HSD Activity IC ₅₀ (nM) (% Inh. at 3.10 ⁻⁴ M)	Androgenic and Antiandrogenic Activity Shionogi DHT E-7 E-6 IC ₅₀ (nM)	ZR-75-1 Activity Basal E2 E-6 E-6 3E-6 E-	% Inhibition Androgen Receptor (E-7 E-5) E-8 E-6	% Inhibition Progesterone Receptor (E-7 E-5) E-8 E-6	% Inhibition Glucocorticoid Receptor (E-7 E-5) E-8 E-6	% Inhibition Estrogen Receptor (E-7 E-5) E-8 E-6		
EM-1253		(39 85)							-25 -63 -41 -122							
EM-1263-CS		(7 22)							-13 -60 -32 -115							
EM-1279-CS		(10 43)							-32 -52 -52 -							
EM-1282-CS		(91 94)							-32 -59 -39 -114							
EM-1290		(9 3)							-25 -10 -48 -62							
EM-1292-CS		(45 87)							-14 -31 -19 -53							
EM-1297		(93 95)							-27 -49 -17 -65							
EM-1312		(93 96)							-7 -37 -28 -100							
EM-1339-CS		(69 85)							0 -44 -22 -97							
EM-1340		(81 82)							-5 -21 -25 -102							
EM-1343		(70 87)							7 -20 -1 -68							

- 107 -


Table 1' (Cont'd)



Name	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
	Oral Bioavailability AUC 0-7h (ng/mL.h)	Inhibition Type V IC ₅₀ (nM) (% inh. At (3.10 ⁻⁷ 3.10 ⁻⁴)	Reversibility (% of control)	Inhibition Type 1 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 2 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 3 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 1 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 3 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Androgenic and Antiandrogenic Activity Shionogi IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	DHT IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Basal E ₂ IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	ZR-75-1 Activity	% Inhibition Androgen Receptor (E ⁻⁷ E ⁻⁵)	% Inhibition Progesterone Receptor (E ⁻⁷ E ⁻⁵)	% Inhibition Glucocorticoid Receptor (E ⁻⁷ E ⁻⁵)	% Inhibition Estrogen Receptor (E ⁻⁷ E ⁻⁵)
EM-910																
EM-991		(44 87)														
EM-1294		(93 94)														
EM-1308																
EM-1309		(95 96)							79 72 -63 -84							
EM-1319-OS		(94 95)														

SUBSTITUTE SHEET (RULE 26)

- 108 -

Table 2



Name	Example	Δ^1	R ⁶	R ^{15α}	R ^{16α}	R ^{16β}	R ¹⁹
EM-1183	8	NO	H	H	C ₃ H ₇	F	CH ₃
EM-1134	8	NO	H	H	CH ₂ -isoC ₃ H ₇	CH ₃	CH ₃
EM-1211	5	NO	H	H	H	CH ₂ -isoC ₃ H ₇	CH ₃
EM-1061	6	NO	H	H	16-spiro C ₅ H ₈		H
EM-1273-CS	5	NO	H	H	CH ₂ -isoC ₃ H ₇	H	CH ₃
EM-1097	5	NO	H	H	C ₃ H ₇	H	CH ₃
EM-1082	6	NO	H	H	16-spiro C ₆ H ₁₀		H
CS-195	6	NO	H	H	16-spiro C ₅ H ₈		CH ₃
EM-1042	8	NO	H	H	C ₃ H ₇	CH ₃	CH ₃
EM-1077	6	NO (1α-CH ₃)	H	H	16-spiro C ₅ H ₈		CH ₃
EM-1151-CS	8	NO	H	H	 or H	H or 	CH ₃
EM-922	6	NO	H	H	16-spiroC ₆ H ₁₀		CH ₃
CS-204	6	YES	H	H	16-spiroC ₆ H ₁₀		CH ₃

SUBSTITUTE SHEET (RULE 26)

Table 2 (Cont'd)

Name	Example	Δ^1	R ⁶	R ^{15a}	R ^{16a}	R ^{16b}	R ¹⁹
EM-1261	12	NO	H	CH ₂ CH=CH ₂	H	H	CH ₃
EM-1277	13	NO	H	H	=CH-C ₂ H ₅		CH ₃
EM-1299	14	NO	H	H	spiro bicyclo [3.1.0] hexane		CH ₃
SA-208-59	15	NO	H	-C ₃ H ₆ -		H	CH ₃
CS-239	Not reported	NO	H	H	CH ₃	C ₃ H ₇	CH ₃
EM-1039	Not reported	YES	H	H	16-spiro C ₅ H ₈	CH ₃	
EM-1057	6	NO	CH ₃	H	16-spiro C ₅ H ₈	CH ₃	
EM-1135	8	NO	H	H	C ₃ H ₆ Cl	CH ₃	CH ₃
EM-1155-CS	8	NO	H	H	C ₃ H ₆ Br	CH ₃	CH ₃
EM-1192	8	NO	H	H	C ₅ H ₁₁	CH ₃	CH ₃
EM-1245	12	NO	H	C ₃ H ₇	H	H	CH ₃
EM-1257	8	NO	H	H	C ₄ H ₉	F	CH ₃
EM-1260	12	NO	H	C ₃ H ₇	H	H	CH ₃
EM-1262	8	NO	H	H	C ₃ H ₅	F	CH ₃
EM-1272-CS	Not reported	NO	H	H	16-spiro-C ₅ H ₈ (CH ₃) ₂		CH ₃
EM-1313	8	NO	H	H	C ₄ H ₇	H	CH ₃
EM-1314	8	NO	H	H	C ₃ H ₅	H	CH ₃
EM-1349-CS	8	NO	H	H	C ₃ H ₃ F ₂	CH ₃	CH ₃
EM-1353	13	NO	H	H	=CHCH(CH ₃) ₂		CH ₃
EM-1359	8	NO	H	H	C ₃ H ₅	Cl	CH ₃
EM-1361	12	NO	H	C ₄ H ₇	H	H	CH ₃

SUBSTITUTE SHEET (RULE 26)

- 110 -

Table 2' (Cont'd)

Name	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16						
	Oral Bioavailability AUC 0-7h (ng/mLh)	Inhibition Type V IC ₅₀ (nM) (% Inh. At (3.10 ⁻⁷ 3.10 ⁻⁶)	Reversibility (% of control)	Inhibition Type 1 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 2 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 3 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 1 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 3 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Androgenic and Antiluteal Activity (Shionogi) Basal E-7 E-8 DHT E-7 E-8 IC ₅₀ (nM)	ZR-75-1 Activity Basal E-8 E-8 E-8 E-8	% Inhibition Androgen Receptor (E-7 E-5) E-8 E-6	% Inhibition Progesterone Receptor (E-7 E-5) E-8 E-6	% Inhibition Glucocorticoid Receptor (E-7 E-5) E-8 E-6	% Inhibition Estrogen Receptor (E-7 E-5) E-8 E-6								
EM-1183	ND	4.6±4			[34]				0	-17	0	-51	ND	ND	0	1	9	45	0	12	0	0
EM-1134	ND	20±4							0	-13	-36	-85	ND	ND	1	7	0	13	0	2	0	1
EM-1211	ND	(87 95)			[46]				0	-20	-7	-18	ND	ND	1	3	0	2	1	0	0	0
EM-1061	ND	(85 95)							14	-6	0	-10	-10	0	0	0	0	0	0	0	0	1
EM-1273-CS	85 ± 26	9	40		[31]				12	-36	9	-43	0	0	0	0	0	0	0	1	0	0
EM-1097	122 ± 5.7	10	45		[64]		[53]	[82]	18	-12	-3	-71	-8	10	0	0	5	2	0	0	0	1
EM-1082	ND	36±11			[32]				4	-20	0	0	ND	ND	0	0	1	2	0	0	0	0
CS-195	ND	19.4±2			[09]				0	-18	-4	-31	-4	0	0	0	0	2	0	2	0	0
EM-1042	ND	35±5							0	-22	-14	-85	0	10	-12	-12	-11	0	0	0	0	0
EM-1077	ND	35± 4			[32]				0	-24	0	-34	ND	ND	0	1	0	0	4	3	0	3

SUBSTITUTE SHEET (RULE 26)

- 111 -

Table 2' (Cont'd)

Name	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
	Oral Bioavailability AUC 0-7h (ng/mLh)	Inhibition Type V IC ₅₀ (nM) (% Inh. At (3.10 ⁻⁷ 3.10 ⁻⁶)	Reversibility (% of control)	Inhibition Type 1 IC ₅₀ (nM) (% Inh. At 3.10 ⁻⁷ 3.10 ⁻⁶)	Inhibition Type 2 IC ₅₀ (nM) (% Inh. At 3.10 ⁻⁷ 3.10 ⁻⁶)	Inhibition Type 3 IC ₅₀ (nM) (% Inh. At 3.10 ⁻⁷ 3.10 ⁻⁶)	Inhibition Type 1 IC ₅₀ (nM) (% Inh. At 3.10 ⁻⁷ 3.10 ⁻⁶)	Inhibition Type 3 IC ₅₀ (nM) (% Inh. At 3.10 ⁻⁷ 3.10 ⁻⁶)	Androgenic and Antiandrogenic Activity Shionogi	ZR-75-1 Activity	% Inhibition Androgen Receptor	% Inhibition Progesterone Receptor	% Inhibition Glucocorticoid Receptor	% Inhibition Estrogen Receptor		
EM-1151	ND	(76 95)							Basal E-7 E-6 DHT E-7 E-6 IC ₅₀ (nM)	Basal E2 E-8 E-6 3E-8 E-6	E-6 E-6 E-6 E-6 E-6 E-6	E-6 E-6 E-6 E-6 E-6 E-6	E-6 E-6 E-6 E-6 E-6 E-6	E-6 E-6 E-6 E-6 E-6 E-6		
EM-922	ND	66 ± 9			[27]				0 -25 -13 -48	ND ND 0 0	ND ND 0 0	ND ND 0 0	ND ND 0 0	ND ND 0 0		
CS-204	ND	94			[23]				0 -17 -25 -13	0 0 0 -25	0 0 0 -25	0 0 0 -25	0 0 0 -25	0 0 0 -25		
EM-1261	ND	(92 96)			[61]				0 -31 -11 -123	ND ND 0 0	ND ND 0 0	ND ND 0 0	ND ND 0 0	ND ND 0 0		
EM-1277	ND	(82 97)			[49]				9 -16 11 -22	ND ND 0 0	ND ND 0 0	ND ND 0 0	ND ND 0 0	ND ND 0 0		
EM-1299	ND	(73 99)			[49]				5 10 0 -27	ND ND 0 0	ND ND 0 0	ND ND 0 0	ND ND 0 0	ND ND 0 0		
SA-208-59	ND	(72 88)							ND ND ND ND	ND ND ND ND	ND ND ND ND	ND ND ND ND	ND ND ND ND	ND ND ND ND		
EM-925		(46 81)		[13]					11 -4 15 -7							
EM-1057		(57 90)							16 -2 -20 -64							
EM-1135		(67 95)							7 -17 -29 -90							

SUBSTITUTE SHEET (RULE 26)

- 112 -

Table 2' (Cont'd)

Name	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
	Oral Bioavailability AUC 0-7h (ng/mLh)	Inhibition Type V IC ₅₀ (nM) (% inh. At 3.10 ⁻⁷ 3.10 ⁻⁶)	Reversibility (% of control)	Inhibition Type 1 IC ₅₀ (nM) (% inh. At 3.10 ⁻⁷ 3.10 ⁻⁶)	Inhibition Type 2 IC ₅₀ (nM) (% inh. At 3.10 ⁻⁷ 3.10 ⁻⁶)	Inhibition Type 3 IC ₅₀ (nM) (% inh. At 3.10 ⁻⁷ 3.10 ⁻⁶)	Inhibition Type 1 IC ₅₀ (nM) (% inh. At 3.10 ⁻⁷ 3.10 ⁻⁶)	Inhibition Type 3 IC ₅₀ (nM) (% inh. At 3.10 ⁻⁷ 3.10 ⁻⁶)	Androgenic and Antandrogenic Activity Shown	Basal E-7 E-6 IC ₅₀ (nM)	Basal E ₂ E-8 E-6 3E-9 E-6	ZR-75-1 Activity	% Inhibition Androgen Receptor E-7 E-5 E-8 E-6	% Inhibition Progesterone Receptor E-7 E-5 E-8 E-6	% Inhibition Glucocorticoid Receptor E-7 E-5 E-8 E-6	% Inhibition Estrogen Receptor E-7 E-5 E-8 E-6
EM-1155-CS		(49 90)							0 -12 -7 -93							
EM-1192		(73 91)							-15 -17 -48 -98							
CS-239		(20 62)							20 0 11 -19							
EM-1257		(96 97)							0 -37 -8 -49							
EM-1260		(8 57)							-3 -27 -10 -43							
EM-1262		(93 97)							-1 -29 4 -47							
EM-1272-CS		(66 93)							-7 -26 -6 -13							
EM-1313									-7 -40 2 -51							
EM-1314									-2 -41 6 -53							
EM-1349-CS		(61 93)							-6 -35 -21 -71							

SUBSTITUTE SHEET (RULE 26)


- 113 -

Table 2' (Cont'd)

Name	1	2	3	4	5	6	7	8	9		10	11	12	13	14	15	16
									Androgenic and Antiandrogenic Activity (Shiog)								
Oral Bioavailability AUC 0-7h (ng/mL.h)	Inhibition Type V IC ₅₀ (nM) (% inh. At (3.10 ⁻⁷ 3.10 ⁻⁶)	Reversibility (%) of control)	Inhibition Type 1 IC ₅₀ (nM) (% inh. At 3.10 ⁻⁶ M)	Inhibition Type 2 IC ₅₀ (nM) (% inh. At 3.10 ⁻⁶ M)	Inhibition Type 3 IC ₅₀ (nM) (% inh. At 3.10 ⁻⁶ M)	Inhibition Type 1 IC ₅₀ (nM) (% inh. At 3.10 ⁻⁶ M)	Inhibition Type 3 IC ₅₀ (nM) (% inh. At 3.10 ⁻⁶ M)	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6
Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6		
																Basal E-7 E-6	Basal E-7 E-6
Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6		
																Basal E-7 E-6	Basal E-7 E-6
Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6		
																Basal E-7 E-6	Basal E-7 E-6
Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6		
																Basal E-7 E-6	Basal E-7 E-6
Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6		
																Basal E-7 E-6	Basal E-7 E-6
Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6		
																Basal E-7 E-6	Basal E-7 E-6
Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6		
																Basal E-7 E-6	Basal E-7 E-6
Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6		
																Basal E-7 E-6	Basal E-7 E-6
Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6		
																Basal E-7 E-6	Basal E-7 E-6
Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6		
																Basal E-7 E-6	Basal E-7 E-6
Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6		
																Basal E-7 E-6	Basal E-7 E-6
Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6		
																Basal E-7 E-6	Basal E-7 E-6
Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6		
																Basal E-7 E-6	Basal E-7 E-6
Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6	Basal E-7 E-6		
																Basal E-7 E-6	Basal E-7 E-6

SUBSTITUTE SHEET (RULE 26)

Table 3



Name	Example	Δ	R ¹	R ⁶	R ^{16a}	Y
EM-1201-CS	16	⁶ Δ	H	CH ₃	H	OCOC ₄ H ₈ Cl
EM-1202	16	⁶ Δ	H	CH ₃	H	OCOC ₅ H ₁₀ F
EM-1196-CS	16	⁶ Δ	H	CH ₃	H	OCOC ₄ H ₈ F
EM-1078	16	⁶ Δ	H	CH ₃	H	OCO(CH ₂) ₂ CH ₃
EM-1172-CS	16	⁶ Δ	H	CH ₃	H	OCOC ₅ H ₁₀ Cl
CS-237	16	¹ Δ , ⁶ Δ	H	CH ₃	H	OAc
EM-1091	16	⁶ Δ	H	CH ₃	H	OCOC ₂ H ₅
CS-259	16	⁶ Δ	H	CH ₃	H	OCO(CH ₂) ₅ Br
CS-260	16	⁶ Δ	H	CH ₃	H	OCO(CH ₂) ₄ CH ₃
EM-1205-CS	16	⁶ Δ	H	CH ₃	Br	H
EM-1154-CS	16	⁶ Δ	α -CH ₃	CH ₃	H	OCOCycloC ₅ H ₉
EM-1143-CS	16	⁶ Δ	α -CH ₃	CH ₃	H	OCOCH(CH ₃) ₂
EM-1098-CS	16	⁶ Δ	H	CH ₃	H	OCOCH ₂ Φ
EM-1108-CS	16	⁶ Δ	H	CH ₃	H	OCO(CH ₂) ₃ CH ₃
EM-1146	16	⁶ Δ	H	CH ₃	H	OCOCH ₂ Φ OCOC(C
CS-240	16	⁶ Δ	α -CH ₃	CH ₃	H	OAc

SUBSTITUTE SHEET (RULE 26)

- 115 -

Table 3 (Cont'd)

EM-1142-CS	16	$^6\Delta$	α -CH ₃	CH ₃	H	OCOC ₅ H ₁₁
CS-1Q98	16	$^6\Delta$	H	CH ₃	H	OAc
EM-1117-CS	Not reported	$^6\Delta$	α -CH ₃	CH ₃	H	OCOC ₆ H ₁₁
EM-1121-CS	Not reported	$^6\Delta$	α -CH ₃	CH ₃	H	OCOC ₄ H ₉
EM-1418-CS	Not reported	$^6\Delta$	H	CH ₃	H	OCOCH ₂ ϕ OMe(o)
EM-1293	Not reported	$1,6\Delta$	H	CH ₃	H	OCO-iso-C ₃ H ₇
EM-1144-CS	Not reported	$^6\Delta$	α -CH ₃	CH ₃	H	OCO-CH ₂ ϕ
EM-1295-CS	Not reported	$1,6\Delta$	H	CH ₃	H	OCOC ₂ H ₅
EM-1296	Not reported	$1,6\Delta$	H	CH ₃	H	OCOC ₃ H ₇

SUBSTITUTE SHEET (RULE 26)

- 116 -

Table 3' (Cont'd)

Name	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
	Oral Bioavailability AUC 0-7h (ng/mLh)	Inhibition Type V 17 β -HSD IC ₅₀ (nM) (% inh. At 3.10 ⁻⁷ 3.10 ⁻⁶)	Reversibility (%) of control	Inhibition Type 1 17 β -HSD Activity IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 2 17 β -HSD Activity IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 3 17 β -HSD Activity IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 4 3 α -HSD Activity IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 5 3 α -HSD Activity IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Androgenic and Antiestrogenic Activity Shown Basal E-7 E-6 E-7 E-6 [IC ₅₀ (nM)]	ZR-75-1 Activity Basal E2 E-8 E-6 3E-8 E-	% Inhibition Androgen Receptor (10 ⁻⁷ 10 ⁻⁵ 10 ⁻⁸ 10 ⁻⁶)	% Inhibition Progesterone Receptor (10 ⁻⁷ 10 ⁻⁵ 10 ⁻⁸ 10 ⁻⁶)	% Inhibition Glucocorticoid Receptor (10 ⁻⁷ 10 ⁻⁵ 10 ⁻⁸ 10 ⁻⁶)	% Inhibition Estrogen Receptor (10 ⁻⁷ 10 ⁻⁵ 10 ⁻⁸ 10 ⁻⁶)		
EM-1201-CS	ND	2.6			[24]				-29 -36	-99 -110	ND	ND	7 45	8 73	2 90	0 0
EM-1202	ND	3.4			[21]				-28 -37	-88 -109	ND	ND	4 30	7 64	10 86	0 0
EM-1196-CS	ND	6.5±0.5	32		[48]				-30 -32	-98 -109	ND	ND	0 37	1 44	7 79	0 0
EM-1078	ND	3.8±0.6			[15]				5 45	-79 -72	ND	ND	7 83	0 53	20 94	5 0
EM-1172-CS	ND	6.4±1.1			[13]				-12 -29	-84 -114	ND	ND	0 22	5 73	10 87	0 0
CS-237	ND	921							-22 -29	-51 -106	ND	ND	0 11	0 0	7 69	0 0
EM-1091	ND	1121			[38]				-25 -21	-88 -105	ND	ND	1 34	2 47	13 78	2 0
CS-259	ND	430.4			[63]				-25 -25	-48 -108	ND	ND	2 12	3 68	0 17	2 0
CS-260	ND	330.3			[66]				-29 -31	-80 -109	ND	ND	4 21	7 74	2 72	1 0
EM-1208-CS	ND	29.5			[45]				-15 -38	-16 -107	ND	ND	6 15	1 9	1 19	0 0

SUBSTITUTE SHEET (RULE 26)

- 117 -

Table 3' (Cont'd)

Name	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
	Oral Bioavailability AUC 0-7h (ng/mL.h)	Inhibition Type V IC ₅₀ (nM) (% inh. At (3.10 ⁻⁷ 3.10 ⁻⁶)	Reversibility (% of control)	Inhibition Type 1 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 2 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 3 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 4 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 5 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Androgenic and Antandrogenic Activity Shown Basal E-7 E-6 DHT E-7 E-6 [IC ₅₀ (nM)]	2R-7S-1 Activity Basal E ₂ E-6 E-6 3E-8 E-6	% Inhibition Androgen Receptor (E-7 E-5) E-6 E-6	% Inhibition Progesterone Receptor (E-7 E-5) E-6 E-6	% Inhibition Glucocorticoid Receptor (E-7 E-5) E-6 E-6	% Inhibition Estrogen Receptor (E-7 E-5) E-6 E-6		
EM-1154-CS	ND	24.2							0 -22 -23 -107 [184]	ND	ND	1 5 2 35 0 30 10 13				
EM-1143-CS	ND	38.6							-13 -17 -19 -95 [300]	ND	ND	0 2 0 24 0 9 0 0				
EM-1098-CS	ND	14.6			[56]				0 -17 -13 -100 [19]	0 0 -34 -4	1 3 0 66 0 24 0 0					
EM-1108-CS	ND	8.9			[70]				-28 -14 -92 -104 [151]	ND	ND	4 42 0 55 4 73 0 0				
EM-1146	ND	29.7							13 -11 9 -19 [151]	ND	ND	0 0 1 24 4 30 0 0				
CS-240	ND	28.5±2.7							-12 -32 -41 -106 [151]	ND	ND	1 9 0 9 0 13 0 1				
EM-1142-CS	ND	(78 95)							-15 -32 -40 -102 [151]	ND	ND	0 6 10 74 0 19 3 3				
CS-198	ND	38.5±10.7			[13]				-27 -33 -84 -128 [8223]	-10 -12 -23 -4	4 23 0 44 1 73 0 0					
EM-1117-CS	ND	(72 95)			[75]				-39 -3 -93							
EM-1121-CS	ND	(82 94)			[83]				-8 -23 -53 -109							


SUBSTITUTE SHEET (RULE 26)

- 118 -

Table 3' (Cont'd)

Name	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
	Oral Bioavailability (ng/mLh)	Inhibition Type V IC ₅₀ (nM) (% inh. At 3.10 ⁻⁷ 3.10 ⁻⁶)	Reversibility (% of control)	Inhibition Type 1 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁷ 3.10 ⁻⁶)	Inhibition Type 2 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁷ 3.10 ⁻⁶)	Inhibition Type 3 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁷ 3.10 ⁻⁶)	Inhibition Type 1 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁷ 3.10 ⁻⁶)	Inhibition Type 3 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁷ 3.10 ⁻⁶)	Androgenic and Antandrogenic Activity Shown	DHT E-7 E-8 IC ₅₀ (nM)	Basal E ₂ E-8 E-8 3E-8 E	ZR-75-1 Activity	% Inhibition Androgen Receptor *E-7 E-5 E-8 E-8	% Inhibition Progesterone Receptor *E-7 E-5 E-8 E-8	% Inhibition Glucocorticoid Receptor *E-7 E-5 E-8 E-8	% Inhibition Estrogen Receptor *E-7 E-5 E-8 E-8
EM-1144-CS		(36 89)							0 21 -13 -55							
EM-141B-CS	ND			[69]					-7 -34 -18 -71							
EM-1293	ND	(94 94)			[67]				-37 -53 -38 -111							
EM-1295-CS		(93 95)			[46]				-48 -50 -81 -112							
EM-1296		(94 95)			[27]				-41 -39 -102 -111							

Table 4



Name	Example	R ²	R ³	R ⁴	R ⁶	R ⁹	X	Y	Z
EM-1404	28	H	-CONH ₂	H	H	H	CH ₃	CH ₃	H
EM-1403	28	H	-CON(CH ₃) ₂	H	H	H	CH ₃	CH ₃	H
EM-1401	28	H	-COOH	H	H	H	CH ₃	CH ₃	H
EM-1394	31	H	-OCH ₃	H	=O	H	CH ₃	CH ₃	H
EM-1424-CS	29	CONH ₂	-O(CH ₂) ₂ OCH ₃	H	H	H	CH ₃	CH ₃	H
EM-1413-CS	29	CON(CH ₃) ₂	-O(CH ₂) ₂ OCH ₃	H	H	H	CH ₃	CH ₃	H
EM-1402-CS	29	COOCH ₃	-O(CH ₂) ₂ OCH ₃	H	H	H	CH ₃	CH ₃	H
EM-1396	30	CN	-O(CH ₂) ₂ OCH ₃	H	H	H	CH ₃	CH ₃	H
EM-1393-CS	24	F	-O(CH ₂) ₂ OCH ₃	H	H	H	CH ₃	CH ₃	H
EM-1131	19	NO ₂	-OH	H	H	H	H	CH ₃	H
EM-1125-CS	19	NO ₂	-OH	H	H	H	CH ₃	CH ₃	H
EM-1408-CS	31	H	-O(CH ₂) ₂ OCH ₃	H	=O	H	CH ₃	CH ₃	H
EM-1407-CS	32	-CH=N-O-		H	H	H	CH ₃	CH ₃	H
EM-1126	19	NO ₂	-OH	H	H	H	CH ₃	H	H
EM-1118	19	NO ₂	-O(CH ₂) ₂ OCH ₃	H	H	H	H	H	H
EM-1124	19	NO ₂	-OH	H	H	H	H	H	H

SUBSTITUTE SHEET (RULE 26)

Table 4 (Cont'd)

Name	Example	R ²	R ³	R ⁴	R ⁶	R ⁹	X	Y	Z
CS-224	18	H	-H	H	H	H	CH ₃	CH ₃	H
EM-1157-CS	26	H	-F	H	H	H	CH ₃	CH ₃	H
EM-1365-CS	27	H	-OSO ₂ CH ₃	H	H	H	CH ₃	CH ₃	H
EM-1364-CS	27	H	-OSO ₂ C ₂ H ₅	H	H	H	CH ₃	CH ₃	H
EM-1392-CS	23	Cl	-OSO ₂ CH ₃	Cl	H	H	CH ₃	CH ₃	H
EM-1391-CS	23	Cl	-OH	Cl	H	H	CH ₃	CH ₃	H
EM-1371-CS	22	Cl	-O(CH ₂) ₂ OCH ₃	H	H	H	CH ₃	CH ₃	H
EM-1368-CS	21	H	-O(CH ₂) ₂ OCH ₃	H	H	H	CH ₃	CH ₃	H
EM-1405	29	COOH	-O(CH ₂) ₂ OCH ₃	H	H	H	CH ₃	CH ₃	H
EM-1386	31	H	-OCH ₃	H	=O	OH	CH ₃	CH ₃	H
EM-1388	28	H	-COOCH ₃	H	H	H	CH ₃	CH ₃	H
EM-1370	21	H	-OCH ₃	H	H	H	CH ₃	CH ₃	H
EM-1369	21	H	-OC ₂ H ₅	H	H	H	CH ₃	CH ₃	H
EM-1389-CS	21	H	-O(CH ₂) ₂ N(CH ₃)	H	H	H	CH ₃	CH ₃	H
EM-1412-CS	33	CH ₃	-OCH ₃	H	H	H	CH ₃	CH ₃	H
EM-1390-CS	21	H	-O(CH ₂) ₂ cycloN-	H	H	H	CH ₃	CH ₃	H
EM-1385-CS	23	Br	-OCH ₃	Br	H	H	CH ₃	CH ₃	H
EM-1366-CS	27	H	-OSO ₂ C ₆ H ₅	H	H	H	CH ₃	CH ₃	H
EM-1025	18	H	-H	H	H	H	CH ₃	H	H
EM-1170-CS	26	H	-F	H	H	H	H	H	H
CS-242	25	H	CH ₃ SC ₂ H ₄ O-	H	H	H	H	H	H
EM-919	Not reported	H	HO-	H	H	H	H	H	H
EM-916	18	H	-H	H	H	H	H	H	H
PB-132-140	35	H	HO-	H	H	H	H	nil	nil
PB-132-146	35	H	HO-	H	H	H	H	COO	H
PB-132-152	35	H	HO-	H	H	H	H	CH ₂	H
PB-132-142	35	H	HO-	H	H	H	H	H	CH ₃
EM-1438	33	CF ₃	-O(CH ₂) ₂ OCH ₃	H	H	H	CH ₃	CH ₃	H

Table 4 (Cont'd)

Name	Example	R ²	R ³	R ⁴	R ⁶	R ⁹	X	Y	Z
EM-1382-CS	23	Br	HO-	Br	H	H	CH ₃	CH ₃	H
EM-1372	Not reported	H	-O(CH ₂) ₃ CH ₃	H	H	H	CH ₃	CH ₃	H
EM-1373	Not reported	H	-O(CH ₂) ₂ OC ₂ H ₅	H	H	H	CH ₃	CH ₃	H
EM-1398	Not reported	H	ϕ CH ₂ OCO-	H	H	H	CH ₃	CH ₃	H
EM-1409	Not reported	CF ₃	-OCH ₃	H	H	H	CH ₃	CH ₃	H
EM-1406-CS	Not reported	-CON(CH ₃) ₂	-O(CH ₂) ₂ OCH ₃	H	=O	H	CH ₃	CH ₃	H
EM-1413-CS	Not reported	-CON(CH ₃) ₂	-O(CH ₂) ₂ OCH ₃	H	H	H	CH ₃	CH ₃	H
EM-1416	Not reported	H	-OH	H	H	H	C ₂ H ₅	C ₂ H ₅	H
EM-1419	Not reported	H	-OH	H	H	H	C ₂ H ₅	C ₂ H ₅	H
EM-01607-C	Not reported	H	-OH	H	H	H	CH ₃	CH ₃	H
EM-1608-D	Not reported	H	-OH	H	=O	H	CH ₃	CH ₃	H
EM-01645	Not reported	-CN	-OH	H	H	H	CH ₃	CH ₃	H
EM-01646	Not reported	H	-CN	H	H	H	CH ₃	CH ₃	H
EM-01660	Not reported	-CONH ₂	-OH	H	H	H	CH ₃	CH ₃	H
EM-01661-B	Not reported	-CON(CH ₃) ₂	-OH	H	H	H	CH ₃	CH ₃	H
EM-01662	Not reported	-CO ₂ CH ₃	-OH	H	H	H	CH ₃	CH ₃	H
EM-01667C	Not reported	-Cl	-OH	H	H	H	CH ₃	CH ₃	H
EM-01668	Not reported	-CO ₂ H	-OH	H	H	H	CH ₃	CH ₃	H
EM-1692	Not reported	-I	-OH	H	H	H	CH ₃	CH ₃	H
EM-1695	Not reported	H	-CN	H	H	H	H	H	H
EM-01807-B	Not reported	-CN	-OCH ₃	H	H	H	CH ₃	-CH ₃	H
EM-01905-B	Not reported	-CF ₃	-OH	H	H	H	CH ₃	CH ₃	H
EM-2016-D	Not reported	-CN	-OC ₂ H ₅	H	H	H	CH ₃	CH ₃	H

Name	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
	Oral Bioavailability AUC 0-7h (ng.h/mL)	Inhibition Type V IC ₅₀ (nM) (% Inh. At 3.10 ⁻⁷ 3.10 ⁻⁶)	Reversibility (% of control)	Inhibition Type 1 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 2 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 3 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 1 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 3 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Androgenic and Antiandrogenic Activity Shown† DHT E-7 E-6 [IC ₅₀ (nM)]	ZR-75-1 Activity Basal E ₂ E-8 E-6 3E-8 E- E-5	% Inhibition Androgen Receptor E-7 E-6 E-8 E-5	% Inhibition Progesterone Receptor E-7 E-6 E-8 E-5	% Inhibition Glucocorticoid Receptor E-7 E-6 E-8 E-5	% Inhibition Estrogen Receptor E-7 E-6 E-8 E-5		
EM-1404	364±197	3.2±1.5		>>> 10 ⁿ	>>> 10 ⁿ	>>> 10 ⁿ	>>> 10 ⁿ	>>> 10 ⁿ	0 0 (-1000)	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0						
EM-1403		7.2±1.6							19 0 0 -54	ND ND 0 0 0 0 0 0 0 0 0 0 0 0 0 0						
EM-1401	1629±181	4±1.5	31	>>> 10 ⁿ	[74]	>>> 10 ⁿ	[74]	>>> 10 ⁿ	2 0 (>1000)	ND ND 0 0 0 0 0 0 0 0 0 0 0 0 0 0						
EM-1394	1764 ± 69	9	23	>>> 10 ⁿ	>>> 10 ⁿ	>>> 10 ⁿ	>>> 10 ⁿ	>>> 10 ⁿ	4 -12 0 -23	ND ND 0 0 0 0 0 0 0 0 0 0 0 0 0 0						
EM-1424	369 ± 70	9.5	17	>>> 10 ⁿ	>>> 10 ⁿ	>>> 10 ⁿ	>>> 10 ⁿ	>>> 10 ⁿ	0 -17 -22 -58	0 0 -11 -2 2 2 1 0 0 0 0 0 0 0 0 0						
EM-1413-CS	ND	17	37		>>> 10 ⁿ				0 0 -17 -44	ND ND						
EM-1402-CS	214 ± 36 ± (EM-1405 576 ± 93)	12	25	>>> 10 ⁿ	>>> 10 ⁿ	>>> 10 ⁿ	>>> 10 ⁿ	>>> 10 ⁿ	0 -9 -13 -87	0 -10 0 -61 0 0 2 4 4 7 1 0						
EM-1396	196 ± 53	13	28	>>> 10 ⁿ	>>> 10 ⁿ	>>> 10 ⁿ	>>> 10 ⁿ	>>> 10 ⁿ	0 -15 -16 -29	0 0 +12 -1 0 2 0 0 0 0 1 3 2						

Table 4' (Cont'd)

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
Name	Oral Bioavailability AUC 0-7h (ng·h/mL)	Inhibition Type V IC ₅₀ (nM) (% Inh. At 3.10 ⁻⁷ 3.10 ⁻⁶)	Reversibility (% of control)	Inhibition Type 1 IC ₅₀ (nM) (% Inh. at 3.10 ⁻⁷ M)	Inhibition Type 2 IC ₅₀ (nM) (% Inh. at 3.10 ⁻⁶ M)	Inhibition Type 3 IC ₅₀ (nM) (% Inh. at 3.10 ⁻⁶ M)	Inhibition Type 4 IC ₅₀ (nM) (% Inh. at 3.10 ⁻⁶ M)	Inhibition Type 5 IC ₅₀ (nM) (% Inh. at 3.10 ⁻⁶ M)	Androgenic and Antiestrogenic Activity Shown Basal E-7 E-8 DHT E-7 E-8 [IC ₅₀ (nM)]	ZR-75-1 Activity Basal E ₂ E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3E-8 E- E-8 E-9 3						

Table 4' (Cont'd)

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
Name	Oral Bioavailability AUC 0-7h (ng/mL)	Inhibition Type V IC ₅₀ (nM) (% Inh. At 3.10 ⁻⁷ 3.10 ⁻⁸)	Reversibility (% of control)	Inhibition Type 1 IC ₅₀ (nM) (% Inh. At 3.10 ⁻⁷ 3.10 ⁻⁸)	Inhibition Type 2 IC ₅₀ (nM) (% Inh. At 3.10 ⁻⁷ 3.10 ⁻⁸)	Inhibition Type 3 IC ₅₀ (nM) (% Inh. At 3.10 ⁻⁷ 3.10 ⁻⁸)	Inhibition Type 1 IC ₅₀ (nM) (% Inh. At 3.10 ⁻⁷ 3.10 ⁻⁸)	Inhibition Type 3 IC ₅₀ (nM) (% Inh. At 3.10 ⁻⁷ 3.10 ⁻⁸)	Androgenic and Antiestrogenic Activity (nM)	Basal E-7 E-8 DHT E-7 E-8 [IC ₅₀ (nM)]	ZR-75-1 Activity Basal E ₂ E-8 E-9 3E-8 E-9	% Inhibition Androgen Receptor (E-7 E-8 E-9 E-10)	% Inhibition Progesterone Receptor (E-7 E-8 E-9 E-10)	% Inhibition Glucocorticoid Receptor (E-7 E-8 E-9 E-10)	% Inhibition Estrogen Receptor (E-7 E-8 E-9 E-10)	
EM-1157-CS	40 ± 7	4 10	28	>>> 10 ⁶	>>> 10 ⁶	>>> 10 ⁶	>>> 10 ⁶	>>> 10 ⁶	16 -12 0 -19	ND	ND	0 0 0 0	2 5 1 0	0 0 0 0	0 0 0 0	
EM-1363-CS	ND	12	49	>>> 10 ⁶	>>> 10 ⁶	>>> 10 ⁶	>>> 10 ⁶	>>> 10 ⁶	4 -28 -17 -53	-17 0 -17 -48	0 0 0 0	0 2 0 0	2 0 5 2	0 0 0 0	0 0 0 0	
EM-1364-CS	ND	17			[73]				0 -16 -11 -59	0 +36 -12 -37	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	
EM-1392-CS	302 ± 49	19	38		>>> 10 ⁶				7 -35 0 -75	ND	ND	0 0 0 0	2 0 2 0	0 8 0 0	0 0 0 0	
EM-1391-CS	28 ± 3.4	19	49		>>> 10 ⁶				0 -13 0 -19	ND	ND	0 0 0 0	1 0 1 0	2 0 0 0	0 0 0 0	
EM-1371-CS	64 ± 21	19 20	40		>>> 10 ⁶				58 92 0 -76	0 +137 0 0 0	0 0 0 0	0 1 0 3	1 0 2 1	0 0 0 0	0 0 0 0	
EM-1368-CS	ND	21			[73]				8 -22 0 -44	0 +15 0 -28	0 0 0 0	0 0 0 3	3 0 0 0	0 0 0 0	0 0 0 0	
EM-1405	ND	23	53		>>> 10 ⁶				0 0 0 0	ND	ND	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	
EM-1366	5595 ± 789	25	54		>>> 10 ⁶				5 -17 0 -27	0 -12 0 -16	0 0 0 0	0 0 0 0	0 0 0 3	0 0 0 3	0 0 0 0	

Table 4' (Cont'd)

Name	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
	Oral Bioavailability AUC 0-7h (ng·h/mL)	Inhibition Type V IC ₅₀ (nM) (% Inh. At 3.10 ⁻⁷ 3.10 ⁻⁶)	Reversibility (% of control)	Inhibition Type 1 IC ₅₀ (nM) (% Inh. at 3.10 ⁻⁶ M)	Inhibition Type 2 IC ₅₀ (nM) (% Inh. at 3.10 ⁻⁶ M)	Inhibition Type 3 IC ₅₀ (nM) (% Inh. at 3.10 ⁻⁶ M)	Inhibition Type 1 IC ₅₀ (nM) (% Inh. at 3.10 ⁻⁶ M)	Inhibition Type 3 IC ₅₀ (nM) (% Inh. at 3.10 ⁻⁶ M)	Androgenic and Antiandrogenic Activity Shown Basal E-7 E-6 DHT E-7 E-6 [IC ₅₀ (nM)]	ZR-75-1 Activity Basal E ₂ E-8 E-6 3E-8 E- E-8 E-6	% Inhibition Androgen Receptor E-7 E-5 E-8 E-6	% Inhibition Progesterone Receptor E-7 E-5 E-8 E-6	% Inhibition Glucocorticoid Receptor E-7 E-5 E-8 E-6	% Inhibition Estrogen Receptor E-7 E-5 E-8 E-6		
EM-1368	136 ± 33	25	52		>>> 10 ⁶				-18 -23 0 -84	ND	ND	ND	0 0 2 3 2 0 0 0	0 0 2 3 2 0 0 0	0 0 2 3 2 0 0 0	
EM-1370	ND	41			[33]				12 -11 0 -28	0 +24	0 0 3 2 0 0 3 0 0 2	0 0 3 2 0 0 3 0 0 2	0 0 3 2 0 0 3 0 0 2	0 0 3 2 0 0 3 0 0 2		
EM-1369	ND	46			[62]				0 0 0 -24	0 +84	0 +18 -1	0 1 1 3 1 2 2 0	0 1 1 3 1 2 2 0	0 1 1 3 1 2 2 0		
EM-1389-CS	169 ± 2	25	40		>>> 10 ⁶				0 -41 -94 -103	ND	ND	ND	0 0 3 0 0 3 0 0 3 0 0	0 0 3 0 0 3 0 0 3 0 0	0 0 3 0 0 3 0 0 3 0 0	
EM-1412-CS	ND	54	71		>>> 10 ⁶				0 -11 0 -60	ND	ND	ND	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
EM-1390-CS	401 ± 5	48	50		>>> 10 ⁶				-18 -43 -36 -119	ND	ND	ND	0 0 0 0 2 2 0 0 0 0 0	0 0 2 2 0 2 0 5 2 4	0 0 2 2 0 2 0 5 2 4	0 0 2 2 0 2 0 5 2 4
EM-1385-CS	301 ± 36	51	60		>>> 10 ⁶				-11 -28 0 -61	ND	ND	ND	0 0 2 2 0 2 0 5 2 4	0 0 2 2 0 2 0 5 2 4	0 0 2 2 0 2 0 5 2 4	
EM-1366-CS	ND	54			[62]				0 0 -13 -67	0 0 +19 -4	6 0 0 0 0 0 1 3 6 3	6 0 0 0 0 0 1 3 6 3	6 0 0 0 0 0 1 3 6 3	6 0 0 0 0 0 1 3 6 3		
EM-1025	ND	6.1±0.7 4.3±0.7			[64]				5 0 -14 -25	20 201 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0						

- 126 -

Table 4' (Cont'd)

Name	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16						
	Oral Bioavailability AUC 0-7h (ng/mL)	Inhibition Type V IC50 (nM) (% inh. At (3.10 ⁻⁷ 3.10 ⁻⁴)	Reversibility (% of control)	Inhibition Type 1 IC50 (nM) (% inh. at 3.10 ⁻⁴ M)	Inhibition Type 2 IC50 (nM) (% inh. at 3.10 ⁻⁴ M)	Inhibition Type 3 IC50 (nM) (% inh. at 3.10 ⁻⁴ M)	Inhibition Type 1 IC50 (nM) (% inh. at 3.10 ⁻⁴ M)	Inhibition Type 3 IC50 (nM) (% inh. at 3.10 ⁻⁴ M)	Basal E-7 E-8	Androgenic and Antiandrogenic Activity (Shionogi) DHT E-7 E-8 [IC50 (nM)]	Basal E2 E-7 E-8 3E-8 E-	2R-75-1 Activity	% Inhibition Androgen Receptor (E-7 E-8 E-8 E-8	% Inhibition Progesterone Receptor (E-7 E-8 E-8 E-8	% Inhibition Glucocorticoid Receptor (E-7 E-8 E-8 E-8	% Inhibition Estrogen Receptor (E-7 E-8 E-8 E-8						
EM-1170CS	ND	721			[84]				12	-27	15	-38	ND	ND	0	1	24	4	3	0	0	
CS-242	0	6.6±0.9							0	-32	9	-66	ND	ND	0	0	0	0	0	0	0	
EM-919	4.8 ± 3	1021.4			[86]				+73	-17	+38	-95	0	-20	0	6*	68*	0*	33*	07*	90*	
EM-916	ND	10.3±0.8			[88]				+17	-1	+2	-46	0	0	0	12*	70*	0*	13*	0*	13*	
PB-132-140	ND	4925							30	-18	16	0	15	71	0	ND	ND	ND	ND	ND	ND	
PB-132-146	ND	7223			[75]				29	0	14	-40	0	91	0	ND	ND	ND	ND	ND	ND	
PB-132-152	ND	10729			[50]				39	0	14	-19	39	90	-11	ND	ND	ND	ND	ND	ND	
PB-132-142	ND	19±1.5			[69]				25	-17	0	-13	38	94	0	ND	ND	ND	ND	ND	ND	
EM-1438	ND	(90.6 95.2)			[72]				10	-14	0	-53	ND	ND	0	10	0	0	1	0	4	0

SUBSTITUTE SHEET (RULE 26)

- 127 -

Table 4' (Cont'd)

Name	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
	Oral Bioavailability AUC 0-7h (ng.h/mL)	Inhibition Type V IC ₅₀ (nM) (% inh. At (3.10 ⁻⁷ 3.10 ⁻⁶)	Reversibility (% of control)	Inhibition Type 1 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶)	Inhibition Type 2 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶)	Inhibition Type 3 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶)	Inhibition Type 1 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶)	Inhibition Type 3 IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶)	Androgenic and Antiandrogenic Activity Shown Basal E-7 E-8 DHT E-7 E-8 IC ₅₀ (nM)	ZN-75-1 Activity Basal E2 E-8 E-8 3E-9 E-	% Inhibition Androgen Receptor (E-7 E-8 E-7 E-8)	% Inhibition Progesterone Receptor (E-7 E-8 E-7 E-8)	% Inhibition Glucocorticoid Receptor (E-7 E-8 E-7 E-8)	% Inhibition Estrogen Receptor (E-7 E-8 E-7 E-8)		
EM-1382-CS	ND	(74 86)			[70]				0 0 0 0	0 0 0 0	ND ND	0 0	2 2	0 2	4 0	3 3
EM-1372	12 ± 7	(39 81)			[65]				-13 -35	-13 -35						
EM-1373	32 ± 7	(77 88)			[69]				-5 -31	-4 -42						
EM-1396	ND	(70 89)			[64]				13 -10	0 -37						
EM-1409	36 ± 13	171 ± 70			[4]				5 -23	-5 -105						
EM-1406-CS	ND	(84 94)			[65]				-3 11	-18 -13						
EM-1413-CS	ND				[69]				-1 -24	-18 -44						
EM-1416	ND				[76]				28 -4	26 -41						
EM-1419	ND				[74]				16 -29	2 -64						

SUBSTITUTE SHEET (RULE 26)

Table 4' (Cont'd)


Name	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
	Oral Bioavailability AUC 0-7h (ng/mL)	Inhibition Type V IC ₅₀ (nM) (% Inh. At 3.10 ⁻⁷ 3.10 ⁻⁶)	Reversibility (% of control)	Inhibition Type 1 IC ₅₀ (nM) (% Inh. At 2.10 ⁻⁶ M)	Inhibition Type 2 IC ₅₀ (nM) (% Inh. At 2.10 ⁻⁶ M)	Inhibition Type 3 IC ₅₀ (nM) (% Inh. At 2.10 ⁻⁶ M)	Inhibition Type 4 IC ₅₀ (nM) (% Inh. At 2.10 ⁻⁶ M)	Inhibition Type 5 IC ₅₀ (nM) (% Inh. At 2.10 ⁻⁶ M)	Androgenic and Antiandrogenic Activity (nmol) DHT E-7 E-6	ZR-75-1 Activity E-8 E-6 3E-6 E-7	% Inhibition Androgen Receptor E-8 E-6 E-7 E-5	% Inhibition Progesterone Receptor E-8 E-6 E-7 E-5	% Inhibition Glucocorticoid Receptor E-8 E-6 E-7 E-5	% Inhibition Estrogen Receptor E-8 E-6 E-7 E-5		
EM-01607-D	ND															
EM-01608-D	ND	3.6 ± 0.5			[58]											
EM-01643	52 ± 3	4.5 ± 0.3			[38]				-5 -35 -6 -10							
EM-01646	ND				[42]				-4 -42 8 -74							
EM-01660	ND	5.6 ± 0.4			[59]				-4 -31 -20 -51							
EM-01661-B	ND	19.2 ± 1			[55]				0 -13 3 -15							
EM-01662	ND	35 ± 5			[70]				0 -27 -11 -51							
EM-01663-C	152 ± 18				[83]				6 -3 9 -42							
EM-01668	ND	(81 90)			[63]				-3 26 11 2							

Table 4' (Cont'd)

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
Name	Oral Bioavailability AUC 0-7h (ng/mL)	Inhibition Type V 17 β -HSD IC ₅₀ (nM) (% inh. At 3.10 ⁻⁷ 3.10 ⁻⁶)	Reversibility (% of control)	Inhibition Type 1 17 β -HSD Activity IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 2 17 β -HSD Activity IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 3 17 β -HSD Activity IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 4 3 α -HSD Activity IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 3 3 α -HSD Activity IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Androgenic and Antiandrogenic Activity Shown: Basal E ₂ E ₂ E ₂ E ₂ E ₂ (IC ₅₀ (nM))	ZR-75-1 Activity Basal E ₂ E ₂ E ₂ 3E ₂ E ₂	% Inhibition Androgen Receptor E ₂ E ₂ E ₂ E ₂ E ₂ E ₂	% Inhibition Progesterone Receptor E ₂ E ₂ E ₂ E ₂ E ₂ E ₂	% Inhibition Glucocorticoid Receptor E ₂ E ₂ E ₂ E ₂ E ₂ E ₂	% Inhibition Estrogen Receptor E ₂ E ₂ E ₂ E ₂ E ₂ E ₂		
EM-1692	ND	(88 95)			[25]				8 -12 3 -78							
EM-1695	ND	(94 97)			[85]				6 -18 -27 -98							
EM-21807-B	449 \pm 115				[39]				4 -12 -7 -12							
EM-1808-B	388 \pm 71				[0]				2 -30 -14 -58							
EM-21905-B	ND				[66]				0 -16 -5 -24							
EM-2016-D	ND															

- 130 -

Table 5



Name	Example	X	R	Unsaturation	n	b	c
EM-1122-CS	17	O	CH ₃	1Δ	1	H	H
CS-254	17	O	H	nil	2	H	H
EM-980	17	O	CH ₃	nil	1	H	H
CS-201	17	O	H	nil	1	H	H
EM-1086	17	S	H	nil	1	H	H
EM-1266-CS	Not reported	O	H	1Δ	1	CH ₃	CH ₃
EM-1267-CS	Not reported	O	H	nil	1	CH ₃	CH ₃
EM-1265	Not reported	O	CH ₃	1Δ	1	CH ₃	CH ₃
EM-1269	Not reported	O	CH ₃	nil	1	CH ₃	CH ₃

SUBSTITUTE SHEET (RULE 26)

Table 5' (Cont'd)

Name	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
	Oral Bioavailability AUC 0-7h (ng/mLh)	Inhibition Type V IC ₅₀ (nM) (% Inh. At 3.10 ⁻⁷ 3.10 ⁻⁶)	Reversibility (% of control)	Inhibition Type 1 IC ₅₀ (nM) (% Inh. at 3.10 ⁻⁶ M)	Inhibition Type 2 IC ₅₀ (nM) (% Inh. at 3.10 ⁻⁶ M)	Inhibition Type 3 IC ₅₀ (nM) (% Inh. at 3.10 ⁻⁶ M)	Inhibition Type 1 IC ₅₀ (nM) (% Inh. at 3.10 ⁻⁶ M)	Inhibition Type 3 IC ₅₀ (nM) (% Inh. at 3.10 ⁻⁶ M)	Androgenic and Antiestrogenic Activity Shionogi DHT E-7 E-6 [IC ₅₀ (nM)]	2R-75-1 Activity Basal E ₂ E-6 E-8 3E-8 E-7	% Inhibition Androgen Receptor (E-7 E-5 E-8 E-6)	% Inhibition Progesterone Receptor (E-7 E-5 E-8 E-6)	% Inhibition Glucocorticoid Receptor (E-7 E-5 E-8 E-6)	% Inhibition Estrogen Receptor (E-7 E-5 E-8 E-6)		
EM-1122- CS	ND	(80 95)			[90]				0 -11 -14 -74 [447]	ND ND	1 8 0 3 0 0 2 0					
CS-254	ND	20±2							0 7 -5 -7	ND ND	0 0 0 0 3 0 2 1					
EM-980	ND	27.8±10			[68]				0 -34 9 58 0 0 -19 3		5 1 0 0 0 0 0 0					
CS-201	ND	31.4±5.4			[70]				-26 -37 -23 7 0 0 15 0 0		0 0 0 0 0 0 0 0					
CS-205	ND	83±18			[31]				-26 -37 -74 -112 0 0 25 1 15 0 7 0 0 2 2							
EM-1266- CS	ND	26			[81]				0 -22 -12 -10	ND ND	0 0 1 0 0 0 3 6					
EM-1267- CS	ND	29			[43]				0 -24 -12 -25	ND ND	0 0 0 0 3 3 1 3 4					
EM-1268	ND	(83 95)			[77]				0 0 -11 -80							

- 132 -

Table 5' (Cont'd)

Name	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
	Oral Bioavailability AUC 0-7h (ng/mLh)	Inhibition Type V 17β-HSD IC ₅₀ (nM) (% inh. At 3.10 ⁻⁷ 3.10 ⁻⁶)	Reversibility (% of control)	Inhibition Type 1 17β-HSD Activity IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 2 17β-HSD Activity IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 3 17β-HSD Activity IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 1 3α-HSD Activity IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Inhibition Type 3 3α-HSD Activity IC ₅₀ (nM) (% inh. at 3.10 ⁻⁶ M)	Androgenic and Antandrogenic Activity (nmol) Basal E-7 E-8 DHT E-7 E-8 (IC ₅₀ (nM))		ZR-75-1 Activity Basal E-7 E-8 E-9 E-10 E-11 E-12	% Inhibition Androgen Receptor (E-7 E-8 E-9 E-10 E-11 E-12)	% Inhibition Progesterone Receptor (E-7 E-8 E-9 E-10 E-11 E-12)	% Inhibition Glucocorticoid Receptor (E-7 E-8 E-9 E-10 E-11 E-12)	% Inhibition Estrogen Receptor (E-7 E-8 E-9 E-10 E-11 E-12)	
EM-1269	ND	(74 93)			[57]				0 0 -10 -59							

SUBSTITUTE SHEET (RULE 26)

LEGENDS TO TABLES

5 In column 1, the oral bioavailability of preferred type 5 inhibitors, expressed in ng/mL.h, was determined as described below in "Other Tests, A- *In Vivo* Assays of Bioavailability of Human Type 5 17 β -HSD Inhibitors". Higher number are desirable. ND means that a determination was not done.

10 In column 2, the inhibition of human type 5 17 β -hydroxysteroid dehydrogenase activity expressed by the concentration which produce 50% of inhibition (IC₅₀ in nM) is reported (centered numbers). The manner in which IC₅₀ was determined is described in "Efficacy of the Preferred Inhibitors". Lower numbers for IC₅₀ are desirable. When IC₅₀ was not determined, the percentage of inhibition is reported in parentheses at 3.10⁻⁷M (left number) and 3.10⁻⁶M (right number).

20 In column 3, the reversibility of the inhibition of type 5 17 β -hydroxysteroid dehydrogenase activity expressed in percentage of control is reported. The manner in which the reversibility is determined is described in "Efficacy of Preferred Inhibitors: V. Reversibility of Human Type 5 17 β -HSD Inhibitory Activity". Lower number is desirable. Blank means that a determination was not done.

25 In column 4, the inhibition of human type 1 17 β -hydroxysteroid dehydrogenase activity expressed by the concentration which produce 50% of inhibition of enzymatic activity (IC₅₀ in nM) is reported. The manner in which IC₅₀ was determined is described in "Efficacy of Preferred Inhibitors: VI. Enzymatic assay for types 1, 2, and 3 17 β -HSD and types 1 and 3 3 α -HSD". Higher numbers of IC₅₀ are desirable. Blank means that a determination was not done. The % of inhibition at the concentration of 3.10⁻⁶M determined in preliminary screening test is reported in square brackets.

35 In column 5, the inhibition of human type 2 17 β -hydroxysteroid dehydrogenase activity expressed by the concentration which produce 50% of inhibition of enzymatic activity (IC₅₀ in nM) is reported. The manner in which IC₅₀ was determined is described in "Efficacy of Preferred Inhibitors: VI. Enzymatic assay for types 1, 2, and 3 17 β -HSD and types 1 and 3 3 α -HSD". Higher numbers of IC₅₀ are desirable. Blank means that a determination was not done. The % of inhibition at the concentration of 3.10⁻⁶M determined in preliminary screening test is reported in square brackets.

5 In column 6, the inhibition of human type 3 17 β -hydroxysteroid dehydrogenase activity expressed by the concentration which produce 50% of inhibition of enzymatic activity (IC₅₀ in nM) is reported. The manner in which IC₅₀ was determined is described in "Efficacy of Preferred Inhibitors: VI. Enzymatic assay for types 1, 2, and 3 17 β -HSD and types 1 and 3 3 α -HSD". Lower numbers of IC₅₀ are desirable. Blank means that a determination was not done. The % of inhibition at the concentration of 3.10⁻⁶M determined in preliminary screening test is reported in square braquets.

15 In column 7, the inhibition of human type 1 3 α -hydroxysteroid dehydrogenase activity expressed by the concentration which produce 50% of inhibition of enzymatic activity (IC₅₀ in nM) is reported. The manner in which IC₅₀ was determined is described in "Efficacy of Preferred Inhibitors: VI. Enzymatic assay for types 1, 2, and 3 17 β -HSD and types 1 and 3 3 α -HSD". Higher numbers of IC₅₀ are desirable. Blank means that a determination was not done. The % of inhibition at the concentration of 3.10⁻⁶M determined in preliminary screening test is reported in square braquets.

25 In column 8, the inhibition of human type 3 3 α -hydroxysteroid dehydrogenase activity expressed by the concentration which produce 50% of inhibition of enzymatic activity (IC₅₀ in nM) is reported. The manner in which IC₅₀ was determined is described in "Efficacy of Preferred Inhibitors: VI. Enzymatic assay for types 1, 2, and 3 17 β -HSD and types 1 and 3 3 α -HSD". Higher numbers of IC₅₀ are desirable. Blank means that a determination was not done. The % of inhibition at the concentration of 3.10⁻⁶M determined in preliminary screening test is reported in square braquets.

35 In column 9, the androgenic activity of preferred type 5 inhibitors expressed as the percentage of stimulation of proliferation of Shionogi cells at concentrations of 10⁻⁷ M (left number) and 10⁻⁶ M (right number) of inhibitor. The manner in which the stimulation is determined is described in "Other Tests; B- Androgenic/Antiandrogenic Activity". Lower numbers are desirable. ND means that a determination was not done.

40 In column 10, the antiandrogenic activity of preferred type 5 inhibitors expressed by the concentration which produce 50% of inhibition (IC₅₀ in nM) of DHT-induced proliferation of Shionogi cells is reported (bracketed

- 135 -

centered numbers). The percentage of inhibition of DHT-induced proliferation of Shionogi cells at concentrations of 10^{-7} M (left number) and 10^{-6} M (right number) of inhibitor is also reported. For example, EM-1403 in Table 4', column 10, the number -54 means that at a concentration of 10^{-6} M, the stimulation of DHT-induced proliferation of Shionogi cells was 54% reduced. The manner in which the inhibition is determined is described in "Other Tests; B- Androgenic/Antiandrogenic Activity". Lower numbers are desirable. ND means that a determination was not done.

In column 11, the estrogenic activity of preferred type 5 inhibitors expressed as the percentage of stimulation of the proliferation of ZR-75-1 cells at concentrations of 10^{-7} M (left number) and 10^{-6} M (right number) of inhibitor. The manner in which the stimulation is determined is described in "Other Tests; C- Estrogenic/Antiestrogenic activity" Lower numbers are desirable. ND means that a determination was not done.

In column 12, the antiestrogenic activity of preferred type 5 inhibitors expressed as percentage of inhibition of E_2 -induced proliferation of ZR-75-1 cells at a concentrations of 10^{-7} M (left number) and 10^{-6} (right number) of inhibitor is reported. For example, EM-1402-CS in Table 4', column 12, the number -61 means that at a concentration of 10^{-6} M, the stimulation of E_2 -induced proliferation of ZR-75-1 cells was 61% reduced. The manner in which the inhibition is determined is described in "Other Tests; C- Estrogenic/Antiestrogenic Activity". Lower numbers are desirable. ND means that a determination was not done.

In column 13, the binding on androgen receptor expressed as percentage of inhibition of the binding of [3 H]R1881 at the concentration of 10^{-8} M (stared number at 10^{-7} M) (left number) and 10^{-6} M (stared number at 10^{-5} M) (right number) of inhibitor is reported. The manner in which the percentage of inhibition is determined is described in "Other Tests; D- Androgen Receptor (AR) Assays". Lower numbers are desirable.

In column 14, the binding on progesterone receptor expressed as percentage of inhibition of the binding of [3 H]R5020 at the concentration of 10^{-8} M (stared number at 10^{-7} M) (left number) and 10^{-6} M (stared number at 10^{-5} M) (right number) of inhibitor is reported. The manner in which the percentage of inhibition is determined is described in "Other Tests; E- Progesterone Receptor Assay". Lower numbers are desirable.

In column 15, the binding on glucocorticoid receptor expressed as percentage of inhibition of the binding of [$6,7\text{-}^3\text{H}^*(\text{N})$]-dexamethasone at

- 136 -

the concentration of 10^{-8}M (stared number at 10^{-7}M) (left number) and 10^{-6}M (stared number at 10^{-5}M) (right number) of inhibitor is reported. The manner in which the percentage of inhibition is determined is described in "Other Tests; F- Glucocorticoid Receptor Assay".

5

In column 16, the binding on estrogen receptor expressed as percentage of inhibition of the binding of $[^3\text{H}]\text{E}_2$ at the concentration of 10^{-8}M (stared number 10^{-7}) (left number) and 10^{-6}M (stared number 10^{-5}) (right number) of inhibition is reported. The manner in which the percentage of inhibition is determined is described in "Other Tests; G- Estrogen Receptor (ER) Assay".

10

EFFICACY OF THE PREFERRED INHIBITORS

A The preferred inhibitors of the invention are tested for their type 5 17 β -HSD inhibitory activity by the following method

5

I) Cloning of type 5 17 β -HSD cDNA

Using a oligoprimers pair (5'-GGA-AAT-CGT-GAC-AGG-GAA-TGG-ATT-CCA-AAC-AG-3', 5'-GGA-ATT-CTT-TAT-TGT-ATT-TCT-GGC-CTA-TGG-AGT-GAG-3') derived from human aldoketoreductase (Qin et al., J. Steroid Biochem. Molec. Biol. 46: 673-679, 1993) and polymerase chain reaction (PCR), we have amplified from a human placental λ gt11 cDNA library (Clontech Laboratories Inc., Palo Alto, CA) a cDNA fragment that was used as probe to screen again a human placental λ gt11 cDNA to get the full length cDNA clone. The amplified cDNA fragment was purified on agarose gel and labeled with [α ³²P]dCTP (Amersham Corp.) using the random primer labeling kit from Pharmacia Inc. PCR amplification reaction medium contained 50 mM KCl, 10 mM Tris-HCl, pH 8.3, 0.1% gelatin, 1 mM MgCl₂, 250 μ M dNTP, 0.25 μ M oligonucleotide primers, and 200 ng of DNA prepared from human placental λ gt11 cDNA library. The aqueous phase was overlaid with 75 μ L of mineral oil to avoid evaporation. The mixture was heated at 98°C for 5 min, following the temperature reduction to 72°C, 1 unit of Taq DNA polymerase was added. Using a DNA Thermal Cycler (Perkin-Elmer Corp.), 30 cycles of amplification were carried out using a step program (94°C, 1 min; 60°C, 1 min; and 72 °C, 1 min)/cycle.

Approximately 5×10^5 recombinant phage plaques were screened with 1.5×10^6 cpm/ml of the probe. Prehybridization was performed for 4 h at 42°C in 50% formamide, 5X Denhardt's solution (1 X Denhardt's being 0.02% polyvinyl pyrrolidone, 0.02 Ficoll, 0.02 bovine serum albumin), 5 X SSPE (1 X SSPE being 0.18M NaCl, 10 mM NaH₂PO₄, pH 7.4, 1 mM EDTA), 0.1% SDS, and 100 μ g/ml yeast tRNA. The probe was denatured by heating at 100°C for 5 min, before being added to the hybridization solution at 42°C overnight. Filters were then washed twice at room temperature in 2 X SSC (1 X SSC being 0.015 M NaCl, 0.15M sodium citrate, pH 7.0), 0.1% SDS, and twice in 0.1 X SSC, 0.1% SDS at 60°C. Positive recombinant plaques were purified by replating twice and grown in liquid culture. Phage DNA were isolated by centrifugation for 90 min at 105,000 X g, and DNA was then isolated by phenol extraction and precipitation with isopropanol (Karen et al. 1987; In: Current Protocols in Molecular Biology (F.M. Ausubel, R. Brent, E. Kingston, D.D. Moore, T.G.

Seidman, T.A. Smith and K. Struhl, eds), Wiley & Sons, New York, pp. 1.13.1-1.13.6).

5 II) Construction of expression vector, and nucleotide sequence determination

10 The phage DNA were digested with EcoRI restriction enzymes and the resulting cDNA fragments were inserted into the EcoRI site downstream to the cytomegalovirus (CMV) promoter of the pCMV vector (kindly provided by Dr. Matthew, Cold Spring Harbor, N.Y., USA). Recombinant pCMV plasmids were amplified in Escherichia Coli DH5 α competent cells, and were isolated by alkaline lysis procedure (Maniatis et al., In: Molecular cloning: a laboratory manual, Cold Spring Harbor Laboratory., 1982). Sequencing of double-stranded plasmid DNA was performed according to the dideoxy chain termination method (Sanger et al., PNAS 74: 5453-5467, 1977) using a T7 DNA polymerase sequencing kit (Pharmacia LKB Biotechnology). To avoid errors, all sequences were determined by sequencing both strands of the DNA. Oligonucleotide primers were synthesized in our laboratory with a 394 DNA/RNA synthesizer (Applied Biosystem).

20 The pCMV vector contain 576 nucleotides of the pCMV promoter (followed by 432 bp of small t intron (fragment 4713-4570) and poly adenylation signal (2825-2536) of SV40 , followed by 1989 bp of the Pvu II(628) -AatII (2617) fragment from pUC 19 vector (New England Biolabs) that contains an E.Coli origin of replication and an ampicillin resistance gene for propagation in E.Coli.

30 III) Cells overexpressing 17 β -HSDs in transformed embryonal kidney (293) cells

 A. Transient transfection

35 Transfection was performed by the calcium phosphate procedure (Kingston et al., In: Current Protocols in Molecular Biology (Ausubel et al., eds), pp. 9.1.1-9.1.9, John Wiley & Sons, Inc., New York, 1987) using 1 to 10 μ g of recombinant plasmid DNA per 10⁶ cells. The total amount of DNA is keep at 10 μ g of plasmid DNA per 10⁶ by completing with pCMV plasmid without insert. The cells were initially plated at 10⁴ cells/cm² in Falcon culture flasks and grown in Dulbecco's modified Eagle's medium containing 10% (vol/vol) fetal bovine serum (Hyclone, Logan, UT) under a humidified atmosphere of air/CO₂ (95/5 %) at 37°C supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 100 IU penicillin/ml, and 100 μ g streptomycin sulfate/ml.

B. Stable transfection

Cells were cultured in 6-wells falcon flasks to approximately 3 10⁵ cells/well in DMEM. Five µg of pCMV-neo plasmid that expresses type 5 17β-HSD and Neomycin resistant gene, were transfected into 293 cells using lipofectin transfection kit (Life Technologies, Burlington, ON). pCMV-neo vector were constructed by inserting 2685 bp of a BamH1-BamH1 DNA fragment that expresses a neomycin resistance gene isolated from the pMAMneo vector (Clontech Laboratories, Palo Alto, CA) at the BamH1 site of the pCMV vector. After 6h incubation at 37°C, the transfection medium was removed and 2 ml of DMEM were added. Cells were further cultured for 48h then transferred into a 10 cm petri dishes and cultured in DMEM containing 700µg/ml of G-418 (Life Technologies, Burlington, ON), in order to inhibit the growth of non-transfected cells. Medium containing G-418 was changed every two days until resistant colonies were observed. Resistant clones that incorporated Neomycin resistant gene were tested for 17β-HSD activity. The most active clone was cultured and kept frozen at -70°C for further inhibition study.

IV) Assay of enzymatic activity

Determination of activity was performed as described (Luu-The et al., Mol. Endocrinol. 4: 268-275, 1990; Lachance et al., J. Biol. Chem. 265: 20469-20475, 1990; Luu-The et al., DNA & Cell Biol. 14: 511-518, 1995).

Briefly, 0.1 µM of the indicated ¹⁴C-labeled substrate (Dupont Inc. (Canada), namely, DHEA, 4-androstene-3,17-dione (Δ⁴), in absence or presence of increasing concentration of preferred inhibitor of the invention, was added to freshly changed culture medium in a 6-well culture plate. After incubation for 1 h, the steroids were extracted twice with 2 ml of ether. The organic phase were pooled and evaporated to dryness. The steroids were solubilized in 50 µl of dichloromethane, applied to Silica gel 60 thin layer chromatography (TLC) plate (Merck, Darmstadt, Germany) then separated by migration in the toluene-acetone (4:1) solvent system. Substrates and metabolites were identified by comparison with reference steroids and revealed by autoradiography and quantitated using the Phosphorimager System (Molecular Dynamics, Sunnyvale, CA). Transfection could be also performed with HeLa, SW-13, 293, COS-1 cells, the preferred cell line is 293 cells.

- 140 -

V. Reversibility of Human Type 5 17 β -HSD Inhibitory Activity

The reversibility assay was performed as described above for the standard type 5 17 β -HSD enzymatic assay, except that before adding the ¹⁴C-labeled substrate, the cells were preincubated with 0.3 μ M of the indicated inhibitor for 1 h, (or the indicated time interval), followed by two washes with phosphate saline buffer (PBS).

VI. Enzymatic assay for types 1, 2, and 3 17 β -HSD and types 1 and 3 3 α -HSD

Enzyme sources. 293 cells transiently transfected with expression vectors encoding types 1, 2 and 3 17 β -HSD (Luu-The et al., J. Steroid Biochem. Molec. Biol., 55: 581-587, 1995), types 1 and 2 5 α -reductase (Luu-The et al., J. Invest. Dermatol., 102: 221-226, 1994) and types 1 and 3 3 α -HSD (Dufort et al. Biochem. Biophys. Res. Commun. 228: 474-479, 1996), using the calcium phosphate procedure (Kingston et al., In: Current Protocols in Molecular Biology. Edited by E.M. Ausbel, R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith, K. Struhl. John Wiley & Sons, New York, pp. 9.1.1-9.1.9, 1991; Luu-The et al., J. Invest. Dermatol., 102: 221-226, 1994). For assays using cell subfractions, cells were sonicated in 50 mM sodium phosphate buffer (pH 7.4), containing 20% glycerol and 1 mM EDTA and centrifuged at 10 000 xg for 30 min before centrifugation for 100 000 x g for 1 h to separate the mitochondrial and microsomal fractions, respectively. The cytosol fractions (100 000 x g supernatant) was used to determine type 1 activity while the microsomal fraction (pellet at 100 000 x g) was used for measurement of types 2 and 3 17 β -HSD activities.

Incubation. The enzymatic reaction was carried out at 37°C in 1 ml of 50 mM sodium phosphate buffer, pH 7.4, containing 20% glycerol, 1 mM EDTA, and 2 mM cofactors (NADPH or NAD⁺) for 1 h in the presence of 0.1 μ M ¹⁴C-labeled substrate: estrone and 4-dione for types 1 and 2 17 β -HSD, respectively, testosterone for type 2 17 β -HSD as well as types 1 and 2 5 α -reductases, DHT for types 1 and 3 3 α -HSD activities, and the indicated concentration of inhibitor.

Extraction of metabolites, migration on TLC and quantification were as described above for the assay of type 5 17 β -HSD.

OTHER TESTS

A- *In Vivo* Assays of Bioavailability of Human Type 5 17 β -HSD Inhibitors

1) Principle

The assays of the bioavailability of 17 β -HSD Type 5 inhibitors were performed in male Sprague Dawley rats by measuring the plasma concentrations of the compounds after single oral administration of the compounds. The measurements at various time intervals were for values greater than or equal to 1.0 ng/mL and less than or equal to 50 ng/mL.

a) Animals and treatment

Male Sprague-Dawley rats [CrI:CD(SD)Br] weighing 275-350 g were obtained from Charles-River Canada Inc. and housed 2 per cage during the acclimation period and individually during the study period. The animals were maintained under a regimen of 12 hours light: 12 hours dark (lights on at 08:00). Animals received certified Rodent feed (Lab Diet # 5002, pellets) and tap water *ad libitum*. Rats were fasted (access to water only) starting on the evening prior to dosing.

Each compound to be tested was administered to three animals as a suspension in 0.4% methylcellulose by oral gavage at a dose of 0.5 mg/rat (1.0 ml/rat). Four to eight new compounds were tested each day and one group of animals received megestrol acetate (MGA) under the same conditions on each dosing day as a reference. One blood sample of ~0.7 ml was collected from the jugular vein of rats under Isoflurane-induced anesthesia at 1, 2, 3, 4, and 7 hours post-gavage. Blood samples were immediately transferred into a refrigerated 0.75 ml Microtainer containing EDTA and kept in an ice-water bath until centrifugation at 3000 rpm for 10 minutes. Plasma separation was performed rapidly (less than 50 minutes) after blood collection. One aliquot of 0.25 ml of plasma was then transferred into a borosilicate tube (13 x 100) and was rapidly frozen on dry-ice. Plasma samples were kept at -80°C until measurement of plasma concentration of the inhibitor(s) by LCMS/MS.

- 142 -

2) LCMS measurements**a) *Apparatus***

1. Vacuum manifold
2. Turbo Vap LV evaporator
3. Mass spectrometer API III or API-300 (PE/Sciex) with associated peripherals
4. Automatic Injector
5. HPLC pump
6. Infusion pump
7. Calibrated pipets

b) *Reagents and Solutions*

1. Methanol, HPLC grade
2. Water, Ultrapure (Super Q)
3. Ethanol, reagent grade
4. N-butyl chloride, HPLC grade
5. Acetone, HPLC grade
6. Male rat plasma (EDTA)
7. 17 β -HSD type 5 inhibitors in reference standard ethanol solution approximately 100 μ g/mL
8. EM 248 Internal Standard reference standard (solution of 50 ng/mL)
9. Mass calibrator solution Polypropylene Glycol (PE/Sciex)

c) *Mass Spectrometer Conditions*

Detector: Mass spectrometer API-300 (PE/Sciex)
Interface: Turbo Ion spray inlet (split 1/5)
Auxiliary flow: 4.5L/minute (nitrogen)
Nebulizer Flow: 11
Curtain Gas Flow: 11
Probe Temperature: 460 °C
Pressure: Approximately 3×10^{-5} Torr
CAD gas thickness: 3
Count Control: 1
Mobile Phase: Gradient of Methanol with 1 mm Ammonium formate and Water with 1 mm Ammonium formate
Flow Rate: 1 mL/minute

- 143 -

d) Mass Spectrometer Analysis Parameters for EM-1118

Dwell time: 150 msec
Pause time: 30 msec
Duration: 4 minute
MRM mode for
EM-1118 analysis : 444.2 and 398.3
Injection: 10 μ L
Data handling: "API Standard Software" update version.

e) Preparation of Standard Solutions

Stock solutions for each type 5 inhibitor were prepared in methanol and, when not in use, the methanol solutions were stored at -20°C. Calibration curve standard solutions for each compound were prepared in male rat plasma as illustrated in Table 1.

A solution of internal standard in methanol containing EM-248 at 50 ng/mL, was prepared from stock standard solutions of EM-248 stored at -20°C.

Concentration of inhibitor 17 β -HSD	Volume of solution	Volume of plasma
Std 50 ng/mL	90 μ L of 1 μ g/mL	1.71 mL
Std 20 ng/mL	0.8 mL of 50 ng/mL	1.2 mL
Std 10 ng/mL	0.9 mL of 20 ng/mL	0.9 mL
Std 5 ng/mL	0.8 mL of 10 ng/mL	0.8 mL
Std 2 ng/mL	0.6 mL of 5 ng/mL	0.9 mL
Std 1 ng/mL	0.5 mL of 2 ng/mL	0.5 mL
Std 0	N/A	0.5 mL
Blank	N/A	0.5 mL

f) Extraction Procedure for Type 5 Inhibitors From Rat Plasma

Aliquots of rat plasma (0.250 mL) were transferred to 13 x 100 mm borosilicate tubes. Water (1.0 mL) and internal standard solution (0.1 mL) were added to each sample and vortexed for 2 min. A mixture of N-butyl chloride and acetone (v:v, 7:3) (3 mL) was added to each sample and vortexed for 2 min. This step was repeated and the combined organic phases were evaporated to dryness under nitrogen in a Turbo Vap evaporator at 35° C. The residue was reconstituted with 1 mL of methanol and evaporated in a Turbo Vap evaporator at 35°C. The final extract was reconstituted into 0.1 mL of methanol/water (v:v, 75:25) and then transferred into a conical vial for injection into the mass spectrometer.

g) Assay

The assay procedure was performed by analyzing, in duplicate, rat plasma samples spiked at six different Type 5 inhibitor concentrations (1, 2, 5, 10, 20 and 50 ng/mL). As example, the results of EM-1118 are presented in Figure 1. The lower limit of quantitation (LOQ) was established at 1.0 ng/mL. Values lower than 1.0 ng/mL were expressed as below limit of quantification (BLQ).

h) Linearity

The assay procedures for EM-1118 were found to be linear over the 1.0 to 50 ng/mL range. Weighted (1/X) linear regression analysis gave a correlation (r^2) of 0.991.

i) Calculation of AUC Values

For all compounds studied, the area under the plasma concentration versus time curve (AUC) from time 0 to 7 hours post-dosing was determined. AUC₀₋₇ values were calculated by the linear trapezoidal method (model-independent) for each rat and data were expressed as mean AUC₀₋₇±SEM (n=3).

B- Androgenic/Antiandrogenic Activity

Androgenic/antiandrogenic activity of some preferred compounds has been measured using the Shionogi mouse mammary carcinoma cells.

Materials

Minimal essential culture medium (MEM), non-essential amino acids, and fetal calf serum were purchased from Flow Laboratories. In order to remove endogenous steroids, serum was incubated overnight at 4 °C with 1% activated charcoal (Norit A, Fisher) and 0.1% Dextran T-70 (Pharmacia). A 2-h supplementary adsorption was performed at 25°C in order to further remove protein-bound steroids. Serum was also inactivated by a 20-min incubation at 56°C.

5 α -dihydrotestosterone (DHT) was obtained from Steraloids. The antiandrogen hydroxyflutamide (OH-FLU) was kindly supplied by Drs. T.L. Nagabuschan and R. Neri (Schering Corporation, Kenilworth, U.S.A.).

Cell dispersion, culture and cloning

Shionogi male mice bearing androgen-sensitive mammary tumors were obtained from Drs. Keishi Matsumoto, Osaka, Japan, and Yvonne Lefebvre, Ottawa, Canada. For primary culture, tumors were excised and washed in ice-cold sterile 25 mM Hepes buffer (137 mM NaCl; 5 mM KCl; 0.7 mM Na₂HPO₄; 10 mM glucose, pH 7.2). After mincing with scissors, the tumor minces were digested for 2 h at 37°C in Hepes buffer containing 3.8 mg/ml collagenase (Clostridium, Boehringer), 1.5 mg/ml hyaluronidase II (Sigma), and 3% bovine serum albumin fraction V (Schwartz-Mann). Dispersed cells were collected by centrifugation (500 x g for 10 min), washed twice by suspension in minimal essential medium (MEM) containing 5% dextran-coated charcoal-treated fetal calf serum (DCC-FCS), 1% non-essential amino acids, 10 IU/ml penicillin, 50 μ g/ml streptomycin, and 100 nM dihydrotestosterone (DHT) (Steraloids).

Cells were plated in the same medium at a density of 75 000 cells/ml in 75 cm² flasks under an atmosphere of 5% carbon dioxide in air at 37°C. The medium was changed weekly. The steroids and antisteroids were dissolved in ethanol and kept in stock solutions chosen to yield final ethanol concentrations less than 0.01% in the culture medium. Such a concentration of ethanol does not affect cell growth.

Cells were subcultured at near-confidence by gentle digestion in a solution of 0.1% pancreatin (Flow Laboratories) in Hepes buffer containing 3 mM ethylenediaminetetraacetic acid (EDTA) (pH 7.2). Cells were pelleted by centrifugation, resuspended in culture medium, counted in a Coulter counter, and replated as described above. Soft agar cloning was performed as described (Stanley et al., Cell 10: 35-44, 1977) in the presence of 100 nM DHT.

- 146 -

Measurement of Cell Growth and Sensitivity to Steroids and Antisteroids

Cells were plated in 24-well plates at a density of 20 000 cells/well. The indicated increasing concentrations of agents were added to triplicate dishes, and cells were grown for 10-12 days with changes of medium every 3-4 days. Cell number was measured by direct counting in a Coulter counter.

Calculations and Statistical Analysis

ED₅₀ values of action of DHT and glucocorticoids were calculated according to a least-square regression as described (Rodbard, Endocrinology 94: 1427-1431, 1974). Statistical significance was calculated according to a multiple-range test (Kramer, Biometrics 12: 307-310, 1956).

C- Estrogenic/Antiestrogenic Activity

Estrogenic/antiestrogenic activity of some preferred compounds has been measured using the ZR-71-1 human breast cancer cell line as described in more detail below.

Maintenance of Stock Cultures

ZR-75-1 cells (83rd passage) were obtained from the American Type Culture Collection (Rockville, MD) and routinely cultured in phenol red free RPMI 1640 supplemented with 1 nM estradiol (E₂), 2 mM L glutamine, 1 mM sodium pyruvate, 15 mM N-2-hydroxyethyl piperazine-N'-2-ethanesulfonic acid, 100 IU penicillin/ml, 100 µg streptomycin/ml, and 10% (v/v) fetal bovine serum (Hyclone, Logan, UT) under a humidified atmosphere of 95% air, 5% CO₂, at 37 °C. All media and medium supplements were purchased from Sigma. Cells were subcultured weekly by treatment with a pancreatic solution containing EDTA (0.2 g/L). The cell cultures used for the experiments herein described were between passages 89 and 94.

Measurements of Cell Proliferation

Cells in their logarithmic growth phase were harvested, briefly centrifuged, and resuspended in RPMI 1640. Cells were then plated in triplicate in LIMBRO 24-well plastic culture plates (2 cm²/well). Since plating density influences the effect of hormones on ZR-75-1 cell growth, cells were plated at a density of 1 × 10⁴ cells/well. After 72 h, medium was replaced with fresh medium containing the inhibitor at the concentration of 3.10⁻⁷ and 10⁻⁶ M in absence or presence of 0.1 M estradiol (E₂). Control cultures received the ethanol vehicle only. Cells were then allowed to grow at 37 °C for 10 days with medium changes (of identical

- 147 -

composition) every 2 days. In absence of inhibitors, in 0.1M estradiol (E₂)-containing medium, ZR-75-1 cells have doubling time of about 48 h.

After E₂ and/or antiestrogen treatment, cells were harvested by addition of 0.5 ml of a pancreatin solution (Sigma) for 5-10 min at 37 °C before addition of 0.5 ml of RPMI 1640 containing 5% dextran coated charcoal-free bovine serum in order to block enzymatic action. Cell number (0.10 ml aliquot) was determined by measurement of DNA content as previously described (Simard et al., Endocrinology 126: 3223-3231, 1990).

D- Androgen Receptor (AR) Assays

Tissue Preparation

Male Sprague-Dawley rats (CrI: CD(SD)Br) weighing 200-300g were obtained from Charles-River Inc. (St-Constant, Québec, Canada). The rats were gonadectomized under general anesthesia (Isoflurane) and killed by cervical dislocation 24 hours later. The ventral prostates were rapidly removed, dissected free from adhering tissue and frozen on dry-ice. Prostates were kept at -80°C until assay.

All subsequent steps were performed at 0-4°C. Prostates were homogenized in 5 vol (wt/vol) of buffer A (25 mM Tris-HCl, 1.5 mM EDTA disodium salt, 10 mM α -monothioglycerol, 10% glycerol, and 10 mM sodium molybdate, pH 7.4), using a Polytron PT-10 homogenizer (Brinkman Instruments, Canada) at a setting of 5 for three periods of 10 sec, with intervals of 10 sec for cooling. The homogenate was then centrifuged at 105,000 x g for 60 min in a Beckman L5-65 ultracentrifuge (Fullerton, CA). The protein concentration of the cytosol fraction was measured according to the method of Bradford (Anal. Biochem. 72: 248-254, 1976), using bovine serum albumin as standard.

Androgen Receptor Assay

Androgen binding was measured using the hydroxylapatite assay (HAP). In brief, the radioactive steroid [³H]R1881 solubilized in ethanol was diluted into buffer A. Aliquots of prostate cytosol preparation (0.1 ml) were then incubated with 8 nM [³H]R1881 (0.1 ml, ~200,000 cpm) in the presence or absence of the indicated concentrations of unlabeled compounds (0.1 ml, prepared in buffer A containing 10% ethanol) for 16-18 h at 0-4°C. Triamcinolone acetonide (150 nM) was added in order to mask progesterone receptors. Unbound steroids were separated by incubation for 40 min at 0-4°C with 0.3 ml HAP prepared in buffer P (50

- 148 -

mM, Tris-HCl, 10 mM KH_2PO_4 , pH 7.4) as follows: 10 g HAP were washed with buffer P until the supernatant reached a pH of 7.4 and then following centrifugation and decantation of the supernatant, 37.5 ml of buffer P were added. After incubation with HAP and 10 minutes of centrifugation at 1,000 x g, the pellet was washed 3 times with 1 ml buffer P. Thereafter, the radioactivity was extracted from the pellet by incubation at room temperature for 60 minutes with 1 ml EtOH. After centrifugation, the supernatant was decanted into a scintillation vial and the pellet was extracted again with ethanol. Thereafter, 10 ml Formula-989 scintillation liquid was added to pooled supernatant and the radioactivity was measured in a Beckman counter.

Calculations

The results were reported as the percentage of inhibition of the binding of [^3H]R1881 at the concentrations of 10^{-8} and 10^{-6} M of the inhibitor.

E- Progesterone Receptor Assay

Chemicals

[17 α -methyl- ^3H]-promegestone (R5020) (84 Ci/mmol) and the corresponding unlabeled compound were purchased from New England Nuclear (Lachine, Québec, Canada). All other chemicals were of analytical grade.

Stock solutions of the unlabeled steroids were kept at 4°C in ethanol. The desired steroid solutions were then prepared by appropriate dilution in buffer B (10 mM Tris-HCl, 1.5 mM EDTA, 10 mM α -monothioglycerol, pH 7.4) containing 30% ethanol.

Tissue preparation

Female Sprague-Dawley rats weighing 200-300g were obtained from Charles-River Inc. (St-Constant, Québec, Canada). The rats were gonadectomized under general anesthesia (Isoflurane) and killed by cervical dislocation 24 hours later. The uteri are rapidly removed, dissected free from adhering tissue and frozen on dry-ice. Tissues were kept at -80°C until use.

Cytosol preparation

All procedures were performed at 4°C. Tissues were pulverized frozen in dry ice with a Thermovac pulverizer. The samples were then homogenized in 10 vol (w/v) of buffer A (25 mM Tris-HCl, 1.5 mM EDTA, 10 mM α -monothioglycerol, 10% glycerol, 10 mM sodium

molybdate, pH 7.4) using a Polytron PT-10 homogenizer (Brinkmann Instruments, Canada) at a setting of 5 for two periods of 10 sec, with intervals of 10 sec for cooling. The homogenate was then centrifuged at 105,000 x g for 90 min. The supernatant was used immediately for assay.

Binding Assays

Progesterone binding was measured using the dextran-coated charcoal adsorption technique. Incubations were performed at 0-4°C. for 16-18 h using 100 µl of cytosol, 100 µl of [³H]-R5020 (5 nM final, which contained 1,000 nM of dexamethasone in order to mask the glucocorticoid receptors) and 100 µl of unlabeled compounds at the indicated concentrations. Each concentration was done in triplicate. Assay was ended with 300 µl of DCC (1% Norit A and 0.1% Dextran T-70 in Buffer B). After 10 min of incubation, tubes were centrifuged at 2,000 x g for 10 min. and decanted in vials with 6 ml of BCS liquid scintillation (New England Nuclear, Dupont). The radioactivity was measured in a Beckman counter at a counting efficiency of 35%.

Calculations

The results were reported as the percentage of the inhibition of the binding of [³H]R5020 at the concentrations of 10⁻⁸ and 10⁻⁶M of the inhibitors.

F- Glucocorticoid Receptor Assay

Chemicals

[6,7-³H(N)]-Dexamethasone (39 Ci/mmol) was purchased from New England Nuclear (Lachine, Québec, Canada) while unlabeled dexametasone was obtained from Steraloids (Wilton, NH). All other chemicals were of analytical grade.

Stock solutions of the unlabeled steroids were kept at 4°C in ethanol. The desired steroid solutions were then prepared by appropriate dilution in buffer B (10 mM Tris-HCl, 1.5 mM EDTA, 10 mM α-monothioglycerol, pH 7.4) containing 30% ethanol.

Tissue preparation

Male Sprague-Dawley rats weighing 200-300g were obtained from Charles-River Inc. (St-Constant, Québec, Canada). The rats were killed by cervical dislocation and the liver were rapidly removed, dissected free from adhering tissue and frozen on dry-ice. Tissues were kept at -80°C until use.

- 150 -

Cytosol preparation

All procedures were performed at 4°C. Tissues were minced and homogenized in 10 vol (w/v) of buffer A (25 mM Tris-HCl, 1.5 mM EDTA, 10 mM α -monothioglycerol, 10% glycerol, 10 mM sodium molybdate, pH 7.4) using a Polytron PT-10 homogenizer (Brinkmann Instruments, Canada) at a setting of 5 for two periods of 10 sec, with intervals of 10 sec for cooling. The homogenate was then centrifuged at 105,000 x g for 90 min. The supernatant was used immediately for assay.

Binding Assays

Glucocorticoid binding was measured using the dextran-coated charcoal adsorption technique. Incubations were performed at 0-4°C. for 16-18 h using 100 μ l of cytosol, 100 μ l of [3 H]-Dexamethasone (5 nM final) and 100 μ l of unlabeled compounds at the indicated concentrations. Each concentration was done in triplicate. Assay was ended with 300 μ l of DCC (2.5% Norit A and 0.25% Dextran T-70 in Buffer B). After 10 min of incubation, tubes were centrifuged at 2,000 x g for 10 min. and decanted in vials with 6 ml of BCS liquid scintillation (New England Nuclear, Dupont). The radioactivity was measured in a Beckman counter at a counting efficiency of 35%.

Calculations

The results were reported as the percentage of the inhibition of the binding of [3 H]-dexamethasone at the concentrations of 10^{-8} and 10^{-6} M of the inhibitor.

G- Estrogen Receptor (ER) Assay

Tissue Preparation

Female Sprague-Dawley rats (CrI: CD(SD)Br) weighing 200-300g were obtained from Charles-River Inc. (St-Constant, Québec, Canada). The rats were gonadectomized under general anesthesia (Isoflurane) and killed by cervical dislocation 24 hours later. The uteri were rapidly removed, dissected free from adhering tissue and frozen on dry-ice. Uteri were kept at -80°C until assay.

All subsequent steps were performed at 0-4°C. Uteri were homogenized in 10 vol (wt/vol) of buffer A (25 mM Tris-HCl, 1.5 mM EDTA disodium salt, 10 mM α -monothioglycerol, 10% glycerol, and 10 mM sodium molybdate, pH 7.4), using a Polytron PT-10 homogenizer (Brinkman Instruments, Canada) at a setting of 5 for three periods of 10 sec, with

- 151 -

intervals of 10 sec for cooling. The homogenate was then centrifuged at 105,000 x g for 60 min in a Beckman L5-65 ultracentrifuge (Fullerton, CA). The protein concentration of the cytosol fraction was measured according to the method of Bradford (Anal. Biochem. 72: 248-254, 1976), using bovine serum albumin as standard.

Estrogen binding was measured using the dextran-coated charcoal adsorption technique as described previously (Asselin et al., Endocrinology, 101: 666-671, 1977; Asselin and Labrie, J. Steroid Biochem., 9: 1079-1082, 1978). Briefly, [^3H]E₂ solubilized in ethanol were diluted into buffer A. Aliquots of uterine cytosol preparation (0.1 ml) were incubated with 5 nM [^3H]E₂ (~200,000 cpm, 0.1 ml) in the presence or absence of the indicated concentrations of unlabeled compounds (0.1 ml, prepared in buffer A containing 10% ethanol) for 3 h at room temperature. Unbound steroids were then separated by incubation for 15 min at 0-4°C with 0.3 ml 0.5% Norit-A and 0.05% Dextran T-70 in buffer B (1.5 mM EDTA disodium salt, 10 mM monothioglycerol, and 10 mM Tris-HCl, pH 7.4) and centrifuged at 3,000 x g for 15 min. Aliquots of the supernatant (0.3 ml) were removed for radioactivity measurement. After the addition of 10 ml Formula-989 scintillation liquid (New England Nuclear-DuPont), the radioactivity was measured in a Beckman counter at a counting efficiency of 62%.


Calculations

The results were reported as the percentage of inhibition of the binding of E₂ at the concentrations of 10⁻⁸ and 10⁻⁶ M of the inhibitor.


- 152 -

Primary criteria in selecting preferred inhibitors include bioavailability ,
desirable inhibition of type 5 17β -hydroxysteroid dehydrogenase, extent
of undesirable inhibition on type 2 17β -hydroxysteroid dehydrogenase
and androgenicity. It is believed that the methyl groups in 5' position in
EM 1394 and analogous compounds promote selectivity of type 5
inhibition (versus undesirable type 2 inhibition). Of the compounds in the
foregoing tables, the most preferred and their molecular structures are set
forth below:


EM-1291




EM-1195-CS



CS-243




CS-245




- 153 -

EM-1183




EM-1097




5

EM-1273-CS




EM-1401




10

EM-1404




- 154 -

CS-237




EM-1078




5


EM-1196-CS



EM-1394




EM-1424




- 155 -

EM-1157-CS




EM-1125




5

EM-1402-CS




EM-1396




10

EM-1181




- 156 -

EM-1159




EM-1165



5


EM-1122-CS



**PREFERRED INHIBITORS OF TYPE 3
17 β -HYDROXYSTEROID DEHYDROGENASE**

Natural androsterone provides inhibition of type 3 17 β -hydroxysteroid dehydrogenase with a IC_{50} = 200 nM. *In vitro* testing has shown the following compounds to also be capable of inhibiting the type 3-catalyzed conversion of 4-dione to testosterone:

Table 6




Name	R	% of Inhibition of the Type 3 17 β -HSD Activity *	
		3.10 ⁻⁷ M	3.10 ⁻⁶ M
EM-1071	-O(CH ₂) ₂ OC ₂ H ₅	73	91
EM-1065	-S(CH ₂) ₂ SCH ₃	63	94
EM-1066	-OCH ₂ SCH ₃	63	93
EM-1064	-SCH ₂ OCH ₃	62	92
EM-1074	-O(CH ₂) ₃ CH ₃	62	92
EM-1073	-O(CH ₂) ₂ OCH ₃	51	87
EM-1070	-OCH ₂ OCH ₃	57	90

* The inhibition of human type 3 17 β -hydroxysteroid dehydrogenase activity, expressed as the percentage of inhibition of enzymatic activity at 3.10⁻⁷ M (left column) and 3.10⁻⁶ M (right column), is reported. The manner in which the percentage of inhibition was obtained is described in "Efficacy of types 1, 2, and 3 17 β -HSD and types 1 and 3 3 α -HSD supra ". Higher numbers are desirable.

- 158 -

or

Table 7



5

Name	n	Inhibition of the Type 3 17 β -HSD Activity*
		IC ₅₀ (nM)
CS-213	1	31 \pm 4
EM-1324-CS	2	31 \pm 4

* The inhibition of human type 3 17 β -hydroxysteroid dehydrogenase activity, expressed by the concentration which produce 50% of inhibition of enzymatic activity (IC₅₀ is nM), is reported. The manner in which IC₅₀ was determined is described in "Efficacy of types 1, 2, and 3 17 β -HSD and types 1 and 3 3 α -HSD". Lower numbers of IC₅₀ are desirable.

10

EXAMPLES OF SYNTHESIS OF PREFERRED INHIBITORS

The IR spectra herein were taken on a Perkin-Elmer 1600 Series FT-IR spectrophotometer. Proton NMR spectra were recorded on a Bruker AC-F 300 instrument. The following abbreviations have been used: s, singlet; d, doublet; dd, doublet of doublet; t, triplet; q, quadruplet; and m, multiplet. The chemical shifts (δ) were referenced to chloroform (7.26 ppm for ^1H and 77.00 ppm for ^{13}C) and were expressed in ppm. Optical rotations were measured at room temperature on a Jasco DIP 360 polarimeter. Mass spectra (MS) were obtained on a V.G. Micromass 16F machine. Thin-layer chromatography (TLC) was performed on 0.25 mm Kieselgel 60F254 plates (E. Merck, Darmstadt, FRG). For flash chromatography, Merck-Kieselgel 60 (230-400 mesh A.S.T.M.) was used. Unless otherwise noted, starting material and reactant were obtained commercially and were used as such or purified by standard means. All solvents and reactants purified and dried were stored under argon. Anhydrous reactions were performed under an inert atmosphere, the set-up assembled and cooled under argon. Organic solutions were dried over magnesium sulfate, evaporated on a rotatory evaporator and under reduced pressure. Starting materials and reagents were available from Aldrich Chemical Company, Inc. (Milwaukee, Wisconsin)

LIST OF ABBREVIATIONS


DHP	3,4-dihydro-2H-pyran
EDTA	Ethylenediaminetetraacetic acid
HPLC	High pressure liquid chromatography
PTSA	p-toluenesulfonic acid
THF	Tetrahydrofuran
THP	Tetrahydropyranyl
TMS	Tetramethylsilyl

Example 1


Synthesis of 6-methyl 4,6-pregnadien/1,4,6-pregnatrien--
17-ol-3,20-dione alkananoates/benzoates

These syntheses are described in Schemes 1 and 2.

Scheme 1



Scheme 2



Example 1A**6-methyl-1,4,6-Pregnatrien-17 α -ol-3,20-dione acetate (2; EM-910):**

Megestrol acetate (2.5 g; 6.7 mmol) and DDQ (5.07 g; 22 mmol) in dioxane (30 mL) were refluxed for 2 h. Solvent was removed and the mixture in EtOAc was washed with saturated NaHCO₃ solution (3 times). Solvent was dried (MgSO₄) and evaporated to give the product.

Purification on silica gel column (hexanes/acetone) gave the trienone (2.1 g) in 90% yield; IR (KBr, cm⁻¹) 2953, 2895, 1729, 1709, 1658, 1646, 1610, 1365, 1264, 1247, 887. ¹H NMR (CDCl₃) δ 0.69 (s, 3 H, H-C18), 1.13 (s, 3 H, H-C19), 1.87(s, 3H, 6-CH₃), 2.0(s, 3H) 2.02(s, 3H), 2.89-2.98 (m,1H), 5.79 (s, 1 H), 6.22 (s, 1 H), 6.20-6.24 (m, 1 H, 2-H), 7.04 (d, 1 H, 1-H, J= 10 Hz); ¹³C NMR (CDCl₃) δ 203.7, 186.4, 170.6, 163.2, 153.4, 134.5, 131.8, 127.7, 121.6, 96.2, 49.1, 47.9, 47.1, 41.1, 37.7, 31.1 30.3, 26.4, 23.2, 21.5, 20.5 19.2, 14.4.

Example 1B

6-methyl-4,6-Pregnadien-17 α -ol-3,20-dione (3): Megestrol acetate (11.2 g) was dissolved in 200 mL of boiling MeOH and to this , was added 2N NaOH (20 mL). The mixture was refluxed for 5 h. Approx. 100 mL of MeOH was removed, and water (50 mL) was added and the suspension was cooled to 0 °C to give a solid, which was filtered and washed with water (9.6 g, 96%); IR (KBr, cm⁻¹) 3493, 2942, 2767, 1702, 1658, 1646, 1623, 1575. ¹H NMR (CDCl₃) δ 0.75 (s, 3 H, H-C18), 1.06 (s, 3 H, H-C19), 1.81(s, 3H, 6-CH₃), 2.25(s, 3H), 2.96 (s,1H), 5.83 (s, 1 H), 5.95 (s, 1H); ¹³C NMR (CDCl₃) δ 211.3, 200.0, 164.4, 138.5, 131.1, 121.0, 89.5, 50.3, 48.7, 47.9, 36.9, 36.1, 34.0 33.5, 30.2, 27.7, 23.3, 20.1, 19.8 16.3, 15.2.

Example 1C

6-methyl-4,6-Pregnadien-17 α -ol-3,20-dione akanoates/benzoates (4): Esterification was conducted by following the method A or B, C, D, E.

Condition A; Using Trifluoromethanesulfonic Anhydride: To a concentrated solution of the organic acid (1.1 eq.) in CH₂Cl₂ (1 mol/L), was added trifluoromethanesulfonic anhydride (1.2 eq.) at room temperature. After 15 min, the mixed anhydride was added to a solution of megestrol 3 in CH₂Cl₂ (1 mol/L) at 0 °C. The mixture was stirred for 1 h at 0 °C followed by 1 h at room temperature. Saturated solution of NaHCO₃ was added and the aq. layer was extracted with CH₂Cl₂ (3 times). The combined organic layer was dried and evaporated to give the dark brown oil, which was purified on a silica gel column using hexanes/acetone as an eluent to give pure product (yields range from 40 to 80 %)

Condition B; Using Trifluoroacetic Anhydride: Acid (5.61 mmol) was added to trifluoroacetic anhydride (5.33 mmol) in CH_2Cl_2 (5 mL) at room temperature and the solution was stirred for 3 h. The resulting solution was transferred to compound 3 (0.56 mmol) in CH_2Cl_2 (5 mL) at room temperature and the reaction was followed by TLC. The reaction mixture was diluted with CH_2Cl_2 (50 mL) and the organic solution was washed with saturated NaHCO_3 solution and then with saturated NaCl solution, dried (MgSO_4). Evaporation of solvents gave the crude product which was purified by column chromatography using hexanes/acetone as an eluent to give the pure product.

Condition C; Using Acid chloride or Acid anhydride and p-Toluenesulfonic acid: To a solution of megestrol 3 in CH_2Cl_2 , was added p-toluenesulfonic acid (1 eq.) followed by acid chloride/acid anhydride (2 to 3 eq.). The reaction mixture was stirred for 8 to 10 h depending upon the alkyl chains. The mixture was poured in ice water and extracted with CH_2Cl_2 . The organic layer was washed with saturated NaHCO_3 , dried, and solvents removed to give the product which was purified by column chromatography using hexanes/acetone as an eluent.

Condition D; Using Acid chloride or Acid anhydride and phosphoric acid: To a solution of megestrol 3 in CH_2Cl_2 , was added 85 % aq phosphoric acid (1 eq.) followed by acid chloride/acid anhydride (2 to 3 eq.). The reaction mixture was stirred for 8 to 10 h depending upon the alkyl chains. The mixture was poured in ice water and extracted with CH_2Cl_2 . The organic layer was washed with saturated NaHCO_3 , dried, and solvents removed to give the product which was purified by column chromatography using hexanes/acetone as an eluent.

Condition E; Using Acid anhydride and Scandium Trifluoromethanesulfonate: To compound 3 (1.12 mmol), was added propionic acid (47 mmol) and scandium trifluoromethanesulfonate (1 mol %; 5 mg) under argon and left for 3 h while stirring. The mixture was diluted with EtOAc and washed twice with saturated NaHCO_3 solution. Organic solvents were evaporated to give the product which was purified by column chromatography using hexanes/EtOAc as a solvent system to give pure product.

Example 1D

The followings are non-limiting examples of physicochemical characteristics of inhibitors of Example 1.

5 EM-917 (4; R=n-C₅H₁₁); Yield, 74 %; IR (NaCl, cm⁻¹) 2950, 2870, 1731, 1661, 1626, 1580, 1458, 1352, 1249, 1159, 1110; ¹H NMR (CDCl₃) δ 0.69 (s, 3H, H-C18), 0.86 (t, 3H, H-C6', J=7 Hz), 1.07 (s, 3H, H-C19), 1.82 (s, 3H, 6-CH₃), 2.02 (s, 3H, H-C21), 2.31 (t, 2H, H-C2', J=7 Hz), 2.44-2.56 (m, 2H), 2.92-3.01(m, 1H), 5.85 (s, 1H), 5.94 (s, 1H); ¹³C NMR (CDCl₃) δ 203.9, 199.8, 173.3, 164.0, 137.9, 131.4, 121.3, 96.2, 50.3, 49.1, 47.6, 37.1, 36.1, 34.4, 34.1, 33.6, 31.3, 31.2, 30.4, 26.4, 24.5, 23.3, 22.3, 20.3, 19.9, 16.4, 14.3, 13.9.

10 EM-923 (4; R=n-C₄H₉); Yield, 82 %; IR (NaCl, cm⁻¹) 2951, 2872, 1731, 1660, 1626, 1580, 1458, 1387, 1351, 1263, 1160, 1110; ¹H NMR (CDCl₃) δ 0.71 (s, 3H, H-C18), 0.90 (t, 3H, H-C5', J=7 Hz), 1.08 (s, 3H, H-C19), 1.84 (s, 3H, 6-CH₃), 2.03 (s, 3H, H-C21), 2.20-2.27(m, 1H), 2.38 (t, 2H, H-C2', J=7 Hz), 2.40-2.59 (m, 2H), 2.94-3.03 (m, 1H), 5.86 (s, 1H), 5.95 (s, 1H); ¹³C NMR (CDCl₃) δ 203.9, 199.8, 173.3, 164.0, 137.9, 131.4, 121.2, 96.1, 50.3, 49.1, 47.5, 37.1, 36.1, 34.2, 34.1, 33.6, 31.1, 30.4, 26.8, 26.4, 23.3, 22.2, 20.3, 16.4, 14.3, 13.6.

20 EM-928 (4; R=CH(CH₃)₂); Yield, 58 %; IR (NaCl, cm⁻¹) 2947, 2874, 1731, 1660, 1626, 1580, 1469, 1387, 1351, 1272, 1215, 1197, 1154, 1111, 1084, 1060; ¹H NMR (CDCl₃) δ 0.71 (s, 3H, H-C18), 1.08 (s, 3H, H-C19), 1.18 (t, 6H, 2'-CH₃, J=7 Hz), 1.83 (s, 3H, 6-CH₃), 2.01(s, 3H, H-C21), 2.45-2.60(m, 3H), 2.93-3.02 (m, 1H), 5.86 (s, 1H), 5.94 (s, 1H); ¹³C NMR (CDCl₃) δ 203.8, 199.8, 176.2, 164.0, 137.9, 131.4, 121.3, 96.0, 50.3, 49.2, 47.7, 37.1, 36.1, 34.2, 34.1, 33.6, 31.2, 30.4, 26.3, 23.3, 20.3, 19.9, 18.8, 18.6, 16.4, 14.4.

25 EM-948 (4; R=CH₂Cypent); Yield, 68 %; IR (NaCl, cm⁻¹) 2947, 2867, 1731, 1681, 1626, 1579, 1455, 1352, 1262, 1160; ¹H NMR (CDCl₃) δ 0.66 (s, 3H, H-C18), 1.00 (s, 3H, H-C19), 1.79 (s, 3H, 6-CH₃), 1.98 (s, 3H, H-C21), 2.29 (t, 2H, H-C2', J=8 Hz), 2.38-2.54 (m, 2H), 2.89-2.97 (m, 1H), 5.84 (s, 1H), 5.92 (s, 1H); ¹³C NMR (CDCl₃) δ 203.9, 199.8, 173.4, 164.0, 137.9, 131.4, 121.3, 96.1, 50.3, 49.1, 47.5, 39.6, 37.1, 36.1, 34.1, 33.7, 33.6, 32.4, 32.3, 31.1, 30.8, 30.4, 26.4, 25.1, 23.3, 20.3, 19.9, 15.3, 14.3.

35 EM-949 (4; R=CH₂Ph); Yield, 47 %; IR (NaCl, cm⁻¹) 2946, 2870, 1730, 1658, 1625, 1579, 1454, 1351, 1264, 1141; ¹H NMR (CDCl₃) δ 0.67 (s, 3H, H-C18), 1.07 (s, 3H, H-C19), 1.86 (s, 3H, 6-CH₃), 1.90 (s, 3H, H-C21), 2.00-2.04(m, 1H), 2.17-2.19 (m, 1H), 2.43-2.64 (m, 2H), 2.90-2.98 (m, 1H), 3.65 (s, 2H, H-C2'), 5.90 (s, 2H), 7.22-7.33 (m, 5H, Ar); ¹³C NMR (CDCl₃) δ 203.6, 199.9, 170.8, 164.0, 137.9, 133.4, 131.4, 129.3, 128.7, 127.3, 121.3, 96.8, 50.4, 48.9, 47.7, 41.9, 37.1, 36.1, 34.2, 33.5, 31.0, 30.2, 26.2, 23.2, 20.3, 19.9, 16.4, 14.3.

EM-950 (4; R=Cypent); Yield, 49 %; IR (NaCl, cm^{-1}) ;2948, 2869, 1726, 1660, 1625, 1578, 1475, 1351, 1271, 1193, 1155, 1110; ^1H NMR (CDCl_3) δ 0.72 (s, 3H, H-C18), , 1.09 (s, 3H, H-C19), 1.85 (s, 3H, 6- CH_3), 2.03 (s, 3H, H-C21), 2.21-2.24(m, 1H), 2.41-2.63 (m, 2H), 2.72-2.79 (m, 1H, H-C2'), 2.94-3.03 (m, 1H), 5.88 (s, 1H), 5.95 (s, 1H) ; ^{13}C NMR (CDCl_3) δ 203.9, 199.8, 175.9, 164.0, 138.0, 131.4, 121.3, 96.0, 50.3, 49.2, 47.6, 44.0, 37.1, 36.1, 34.1, 33.6, 31.2, 30.5, 29.7, 29.6, 26.3 ,25.7, 25.6, 23.4, 20.3, 19.9, 16.4, 14.3 .

EM-978 (4; R=Cyhex); Yield, 48 %; IR (NaCl, cm^{-1}) 2935, 2857, 1726, 1660, 1625, 1579, 1449, 1351, 1316, 1247, 1159; ^1H NMR (CDCl_3) δ 0.71 (s, 3H, H-C18), , 1.09 (s, 3H, H-C19), 1.85 (s, 3H, 6- CH_3), 2.01 (s, 3H, H-C21), 2.24-2.37(m, 2H), 2.42-2.64 (m, 2H), 2.94-3.03 (m, 1H), 5.88 (s, 1H), 5.95 (s, 1H) ; ^{13}C NMR (CDCl_3) δ 203.8, 199.8, 175.3, 164.0, 138.0, 131.4, 121.3, 95.9, 50.3, 49.2, 47.6, 43.2, 37.1, 36.1, 34.0, 33.6, 31.3, 30.5, 28.8, 28.7, 26.3, 25.6, 25.3, 23.4, 20.3, 19.9, 16.4, 14.4 .

EM-979 (4; R=t-Bu); Yield, 82 %; IR (NaCl, cm^{-1}) 2949, 2872, 1724, 1660, 1626, 1580, 1152; ^1H NMR (CDCl_3) δ 0.71 (s, 3H, H-C18), 1.09 (s, 3H, H-C19), 1.22 (s, 9H, 2'- CH_3), 1.84 (s, 3H, 6- CH_3), 2.01 (s, 3H, H-C21), 2.21-2.25(m, 1H), 2.42-2.62 (m, 2H), 2.95-3.04 (m, 1H), 5.87 (s, 1H), 5.94 (s, 1H) ; ^{13}C NMR (CDCl_3) δ 203.7, 199.8, 177.5, 164.0, 137.9, 131.4, 121.3, 95.9, 50.4, 49.4, 47.8, 39.0, 37.1, 36.1, 34.0, 33.6, 31.4, 30.4, 26.9, 26.2, 23.3, 20.3, 19.9, 16.4, 14.3 .

EM-996 (4; R=(CH_2)₅Br); Yield, 43 %; IR (NaCl, cm^{-1}) 2946, 2868, 1731, 1660, 1626, 1579, 1457, 1387, 1352, 1260, 1194, 1123, 1110; ^1H NMR (CDCl_3) δ 0.70 (s, 3H, H-C18), 1.07 (s, 3H, H-C19), 1.83 (s, 3H, 6- CH_3), 2.03 (s, 3H, H-C21), 2.35 (t, 2H, H-C2', $J=7$ Hz), 2.93-3.02(m, 1H), 3.37 (t, 2H, H-C6', $J=7$ Hz), 5.85 (s, 1H), 5.94 (s, 1H); ^{13}C NMR (CDCl_3) δ 203.8, 199.8, 172.9, 164.0, 137.8, 131.4, 121.2, 96.2, 50.2, 49.0, 47.5, 37.0, 36.0, 34.1, 34.0, 33.5, 33.3, 32.2, 31.1, 30.4, 27.6, 26.5, 23.9, 23.2, 20.2, 19.8, 16.3, 14.3 .

EM-1003 (4; R=(CH_2)₃Br); Yield, 13 %; IR (NaCl, cm^{-1}) 2947, 1731, 1659, 1625, 1579, 1444, 1124; ^1H NMR (CDCl_3) δ 0.74 (s, 3H, H-C18), 1.01 (s, 3H, H-C19), 1.85 (s, 3H, 6- CH_3), 2.07 (s, 3H, H-C21), 2.55 (t, 2H, H-C2', $J=5$ Hz), 2.96-3.05(m, 1H), 3.47 (t, 2H, H-C6', $J=7$ Hz), 5.89 (s, 1H), 5.96 (s, 1H); ^{13}C NMR (CDCl_3) δ 203.6, 199.7, 172.0, 163.9, 137.7, 131.3, 121.2, 96.4, 50.1, 48.9, 47.5, 37.0, 36.0, 33.9, 33.5, 32.5, 32.4, 31.0, 30.4, 27.2, 26.5, 23.2, 20.2, 19.8, 16.3, 14.2 .

EM-1029 (4; R=(CH_2)₄Cl); Yield, 30 %; IR (NaCl, cm^{-1}) 2947, 2871, 1730, 1659, 1625, 1579, 1458, 1445, 1353, 1271, 1059; ^1H NMR (CDCl_3) δ 0.67 (s,

5 3H, H-C18), 1.04 (s, 3H, H-C19), 1.79 (s, 3H, 6-CH₃), 2.00 (s, 3H, H-C21), 2.16-2.23 (m, 1H), 2.34 (t, 2H, H-C2', J=7 Hz), 2.89-2.98 (m, 1H), 3.49 (t, 2H, H-C5', J=7 Hz), 5.81 (s, 1H), 5.91 (s, 1H); ¹³C NMR (CDCl₃) δ 203.6, 199.6, 172.5, 163.9, 137.8, 131.2, 121.0, 96.2, 50.1, 48.9, 47.4, 44.2, 36.9, 35.9, 33.9, 33.4, 31.6, 30.9, 30.3, 26.4, 23.1, 21.9, 20.1, 19.7, 16.2, 14.1.

10 EM-1044 (4; R=CH₂PhCl(p)); Yield, 38 %; IR (KBr, cm⁻¹) 2948, 1734, 1656, 1625, 1578, 1492, 1459, 1352, 1262, 1154, 1089, 1017; ¹H NMR (CDCl₃) δ 0.67 (s, 3H, H-C18), 1.07 (s, 3H, H-C19), 1.86 (s, 3H, 6-CH₃), 1.92 (s, 3H, H-C21), 2.15-2.22 (m, 1H), 2.41-2.67 (m, 2H), 2.88-2.96 (m, 1H), 3.61 (s, 2H, H-C2'), 5.89 (s, 2H), 7.18 (d, 2H, J=8.3 Hz), 7.27 (d, 2H, J=8.3 Hz); ¹³C NMR (CDCl₃) δ 203.6, 199.9, 170.3, 164.0, 137.7, 133.4, 131.8, 131.5, 130.7, 128.8, 121.3, 96.9, 50.4, 48.9, 47.8, 41.1, 37.1, 36.1, 34.1, 33.6, 31.0, 30.3, 26.4, 23.1, 20.3, 19.9, 16.4, 14.3.

15 EM-1049 (4; R=CH₂PhOMe(p)); Yield, 40 %; IR (KBr, cm⁻¹) 2947, 2871, 1729, 1657, 1625, 1578, 1513, 1459, 1352, 1302, 1249, 1151, 1035; ¹H NMR (CDCl₃) δ 0.64 (s, 3H, H-C18), 1.05 (s, 3H, H-C19), 1.83 (s, 3H, 6-CH₃), 1.87 (s, 3H, H-C21), 1.96-2.08 (m, 1H), 2.13-2.20 (m, 1H), 2.39-2.62 (m, 2H), 2.85-2.93 (m, 1H), 3.56 (s, 2H, H-C2'), 3.72 (s, 3H, p-OCH₃), 5.86 (s, 1H), 5.89 (s, 1H), 6.83 (d, 2H, J=8.5 Hz), 7.18 (d, 2H, J=8.5 Hz); ¹³C NMR (CDCl₃) δ 203.8, 199.9, 171.1, 164.1, 158.9, 137.9, 131.4, 130.3, 125.4, 121.3, 114.0, 96.7, 55.3, 50.3, 48.9, 47.7, 40.9, 37.1, 36.1, 34.1, 33.6, 31.0, 30.2, 26.2, 23.2, 20.3, 19.9, 16.4, 14.3.

25 EM-1107 (4; R=CH₂PhOCO-t-Bu(p)); Yield, 38 %; IR (NaCl, cm⁻¹) 2972, 2872, 1731, 1659, 1625, 1579, 1508, 1263, 1202, 1118; ¹H NMR (CDCl₃) δ 0.67 (s, 3H, H-C18), 1.07 (s, 3H, H-C19), 1.33 (s, 9H, tert-Butyl), 1.85 (s, 3H, 6-CH₃), 1.91 (s, 3H, H-C21), 3.64 (s, 2H, H-C2'), 5.88 (s, 1H), 5.93 (s, 1H), 6.97-7.0 (m, 2H), 7.25-7.28 (m, 2H); ¹³C NMR (CDCl₃) δ 203.7, 200.0, 177.0, 170.6, 164.1, 150.4, 138.0, 131.4, 130.6, 130.2, 121.8, 121.3, 96.9, 50.3, 49.0, 47.7, 41.2, 39.1, 37.1, 36.1, 34.0, 33.6, 30.9, 30.2, 27.1, 26.3, 23.2, 20.2, 19.9, 16.4, 14.3.

35 CS-251 (4; R=(CH₂)₃COCH₃); Yield, 26 %; IR (NaCl, cm⁻¹) 2949, 2873, 1732, 1660, 1626, 1580, 1463, 1356, 1258, 1060; ¹H NMR (CDCl₃) δ 0.63 (s, 3H, H-C18), 1.00 (s, 3H, H-C19), 1.77 (s, 3H, 6-CH₃), 1.96 (s, 3H, H-C6'), 2.05 (s, 3H, H-C21), 2.29 (t, 2H, J=7 Hz), 2.43 (t, 2H, J=7 Hz), 5.77 (s, 1H), 5.87 (s, 1H); ¹³C NMR (CDCl₃) δ 207.5, 203.6, 199.6, 172.5, 163.8, 137.7, 131.1, 120.9, 96.0, 50.0, 48.8, 47.4, 42.0, 36.8, 35.8, 33.8, 33.4, 33.1, 30.8, 30.2, 29.7, 26.3, 23.1, 20.0, 19.6, 18.4, 16.1, 14.1.

40

CS-256 (4; R=CH₂PhF(p)); Yield, 32 %; IR (KBr, cm⁻¹) 2948, 2872, 1734, 1657, 1625, 1578, 1510, 1458, 1352, 1264, 1224, 1152 ; ¹H NMR (CDCl₃) δ 0.65 (s, 3H, H-C18), 1.05 (s, 3H, H-C19), 1.84 (s, 3H, 6-CH₃), 1.88 (s, 3H, H-C21), 1.96-2.02 (m, 1 H), 2.13-2.21(m, 1H), 2.38-2.49 (m, 2H), 2.87-2.95 (m, 1H), 3.59 (s, 2H, H-C2'), 5.86 (s, 1H), 5.89 (s, 1 H), 6.93-6.99 (m, 2H), 7.18-7.82 (m, 2H); ¹³C NMR (CDCl₃) δ 203.6, 199.9, 170.6, 164.0, 163.7, 160.5, 137.8, 131.4, 130.9, 130.8, 129.12, 129.07, 121.3, 115.7, 115.4, 96.9, 50.4, 48.9, 47.7, 40.9, 37.0, 36.1, 34.1, 33.6, 31.0, 30.2, 26.3, 23.1, 20.3, 19.9, 16.4, 14.3 .

Example 2

Synthesis of 1 α -alkyl-6-methyl-4,6-pregnadien-17 α -ol-3,20-dione alkanoates/benzoates

These syntheses are described in Scheme 2

Example 2A

1 α -alkyl-6-methyl-4,6-Pregnadien-17 α -ol-3,20-dione acetate (5): The following example is a representative: To trienone 2 (500 mg; 1.33 mmol) in THF (30 mL), were added CuBr (12 mg; 0.08 mmol), trimethylaluminum (2.6 mL; 5.2 mmol) and chlorotrimethylsilane (0.659 mL; 5.2 mmol) under argon. The reaction mixture was stirred for 1 h. Excess of reagents was destroyed by the slow addition of MeOH at 0 °C. The mixture was extracted with CH₂Cl₂, dried and solvents removed. Purification on silica gel column using hexanes/EtOAc as an eluent gave the 1 α -methyl compound, EM-952 (466 mg) in 90 % yield; IR (KBr, cm⁻¹) 2972, 2892, 1734, 1715, 1661, 1625, 1368, 1259; ¹H NMR (CDCl₃) δ 0.66 (s, 3 H, 18-CH₃), 0.93 (d, 3H, 1-CH₃, J=7 Hz), 1.12 (s, 3 H, 19-CH₃), 1.88 (s, 3H, 6-CH₃), 1.99 (s, 3H), 2.05 (s, 3H), 2.78-2.97 (m, 2H), 5.81 (s, 1 H), 5.89 (s, 1H); ¹³C NMR (CDCl₃) δ 203.6, 199.2, 170.5, 160.3, 137.8, 131.8, 120.5, 96.3, 49.0, 47.3, 44.6, 41.1, 39.2, 36.8, 35.6, 30.99, 30.2, 26.2, 23.2, 21.5, 19.7, 19.6, 18.9, 14.8, 14.2.

Example 2B

1 α -alkyl-6-methyl-4,6-Pregnadien-17 α -ol-3,20-dione (6): The following example is a representative: To 1 α -Methyldienone 5 (517 mg; 1.3 mmol) in MeOH (30 mL), was added aq NaOH (52 mg in 1 mL of water and the mixture was refluxed for 1 h. The mixture was diluted with brine and extracted with CH₂Cl₂ (3x50 mL), dried, and solvents were removed under reduced pressure to the 17 α -hydroxy compound 6 (430 mg) in 93 % yield; IR (KBr, cm⁻¹) 3445, 2972, 2892, 1703, 1647, 1622, 1576, 1259; ¹H NMR (CDCl₃) δ 0.75 (s, 3 H, H-C18), 0.91 (d, 3H, 1-CH₃, J=7 Hz), 1.14 (s, 3 H, H-C19), 1.81 (s, 3H, 6-CH₃), 2.25 (s, 3H COCH₃), 2.69-2.88 (m, 2H), 3.0 (s, 1H), 5.83 (s, 1 H), 5.93 (s, 1H); ¹³C NMR (CDCl₃) δ 211.3, 199.6, 160.9, 138.5, 131.8, 120.5, 89.6, 48.9, 48.2, 44.8, 42.1, 39.2, 36.8, 35.7, 33.5, 30.2, 27.7, 23.3, 19.8, 19.6, 18.9, 15.3, 14.8.

Example 2C

**1 α -alkyl-6-methyl-4,6-Pregnadien-17 α -ol-3,20-dione
aklanoates/benzoates (7):**

Esterification was conducted by following the method A or B, C, D, E of
Example 1.

Example 2D

The following is a non-limiting example of physicochemical
characteristics of inhibitors of Example 2.

EM-1022 (7; R=Cypent); Yield 54%; IR (CDCl₃) 1733, 1717, 1652, 1623, 1576
cm⁻¹; ¹H NMR (CDCl₃) δ 0.69 (s, 3 H), 0.95 (d, 3 H, $J=7$ Hz), 1.15 (s, 3 H),
1.82 (s, 3 H), 2.00 (s, 3 H), 2.71-3.00 (m, 3 H), 5.84 (s, 1 H), 5.91 (s, 1 H); 2
(s, 3 H), ¹³C NMR (CDCl₃) δ 203.8, 199.3, 175.9, 160.4, 137.9, 131.9, 120.6,
95.9, 49.3, 47.6, 44.7, 43.7, 42, 39.2, 36.9, 35.7, 31.2, 30.4, 29.7, 29.5, 26.2, 25.7,
25.6, 23.3, 19.9, 19.7, 19, 14.8, 14.3.

EM-1059 (7; R=CH₂Ph); Yield 74%; IR (CDCl₃) 1731, 1651, 1576 cm⁻¹; ¹H
NMR (CDCl₃) δ 0.59 (s, 3 H), 0.92 (d, 3 H, $J=7$ Hz), 1.08 (s, 3 H), 1.79 (s, 3
H), 1.84 (s, 3 H), 2.85 (m, 2 H), 3.59 (s, 2 H), 5.81 (s, 2 H) 7.19 (m, 5 H); ¹³C
NMR (CDCl₃) δ 203.6, 199.3, 170.7, 160.5, 137.9, 133.4, 131.9, 129.3, 128.6,
127.2, 120.6, 96.7, 49.1, 47.8, 44.7, 42.1, 41.8, 39.2, 39.9, 35.9, 35.8, 30.8, 30.1,
26.1, 23.1, 19.9, 19.7, 19, 14.9, 14.2.

CS-209 (7; R=CH(CH₃)₂); Yield 33%; IR (CDCl₃) 1731, 1659, 1624, 1577 cm⁻¹;
¹H NMR (CDCl₃) δ 0.72 (s, 3H), 0.98 (d, 3 H, $J=7$ Hz), 1.18 (s, 3 H), 1.18
(d, 3 H, $J=7$ Hz), 1.20 (d, 3 H, $J=7$ Hz), 1.85 (s, 3 H), 2.03 (s, 3 H), 2.56-2.66
(m, 1 H), 2.85-3.05 (m, 2 H), 5.88 (s, 1 H), 5.94 (s, 1 H); ¹³C NMR (CDCl₃) δ
203.7, 199.4, 176.3, 160.4, 137.9, 132, 120.6, 95.9, 49.3, 47.7, 44.8, 42, 39.2,
36.7, 35.7, 34, 31.2, 30.4, 26.2, 23.3, 19.9, 19.7, 19, 18.7, 18.6, 14.9, 14.3.

CS-243 (7; R=CH₂CH₃); Yield 67%; IR (CDCl₃) 1732, 1716, 1659, 1625, 1577
cm⁻¹; ¹H NMR (CDCl₃) δ 0.68 (s, 3H), 0.94 (d, 3 H, $J=7$ Hz), 1.12 (t, 3H,
 $J=5.8$ Hz), 1.14 (s, 3 H), 1.81 (s, 3 H), 2 (s, 3 H), 2.80-2.90 (m, 2 H), 5.83 (s, 1
H), 5.91 (s, 1 H); ¹³C NMR (CDCl₃) δ 203.8, 199.4, 173.9, 160.5, 137.9, 132,
120.7, 96, 49.1, 47.5, 44.6, 41.9, 39.1, 36.9, 35.6, 31, 30.2, 27.7, 26.2, 23.2, 19.8,
19.6, 18.9, 14.8, 14.2, 8.9.

CS-245 (7; R=(CH₂)₂CH₃); Yield 70%; IR (CDCl₃) 1731, 1715, 1660, 1625,
1577 cm⁻¹; ¹H NMR (CDCl₃) δ 0.67 (s, 3 H), 0.91 (t, 3 H, $J=7$ Hz), 0.94 (d, 3
H, $J=7$ Hz), 1.14 (s, 3 H), 1.81 (s, 3 H), 1.99 (s, 3 H), 2.29 (t, 2 H, $J=7$ Hz),

- 170 -

2.80-2.90 (m, 2 H), 5.82 (s, 1 H), 5.9 (s, 1 H); ^{13}C NMR (CDCl_3) δ 203.7, 199.3, 173.1, 160.4, 137.9, 131.9, 120.6, 96, 49.1, 47.5, 44.6, 42, 39.2, 36.9, 36.2, 35.7, 31, 30.3, 26.2, 23.2, 19.8, 19.6, 18.9, 18.2, 14.8, 14.2, 13.6.

Example 3

6-methyl-4,6-Pregnadien-17 α -ol-3,20-dione 4'-carbomethoxybutyrate

(EM-1007): To a solution of megestrol 3 (400 mg; 1.17 mmol) in CH₂Cl₂,
5 was added p-toluenesulfonic acid (90 mg; 0.47 mmol.) followed by

glutaryl chloride (2.1 g; 12.5 mmol) at 20 °C. After addition, the reaction
mixture was stirred for 7.5 h. The mixture was cooled to 0 °C and

quenched with excess of MeOH. After 10 min, the mixture was poured in
brine and extracted with CH₂Cl₂. The organic layer was washed with
10 saturated NaHCO₃, dried, and solvents removed to give the product

which was purified by column chromatography using hexanes/ acetone:

80/20 as an eluent to give EM-1007 (161 mg) in 30 % yield; IR (NaCl, cm⁻¹)

2949, 2873, 1732, 1860, 1626, 1580, 1443, 1363, 1260, 1198, 1144; ¹H NMR

(CDCl₃) δ 0.72 (s, 3H, H-C18), 1.09 (s, 3H, H-C19), 1.85 (s, 3H, 6-CH₃), 1.96
15 (t, 2H, H-C4', J=7 Hz), 2.06 (s, 3H, H-C21), 2.21-2.27 (m, 1H), 2.39 (t, 2H,
H-C2', J=7 Hz), 2.95-3.04(m, 1H), 3.67 (s, 3H, 5'-OCH₃), 5.88 (s, 1H), 5.95 (s,
1H); ¹³C NMR (CDCl₃) δ 203.6, 199.6, 173.0, 172.3, 163.9, 137.8, 131.2, 121.0,

96.2, 51.4, 50.0, 48.8, 47.4, 36.9, 35.9, 33.8, 33.4, 33.2, 32.7, 30.9, 30.2, 26.3,
23.1, 20.1, 19.7, 16.2, 14.1 .

- 172 -

Example 4

5 **6-methyl-17 α -pentyloxy-4,6-Pregnadien-3,20-dione (EM-1127):** Powered potassium hydroxide (263 mg; 4.7 mmol) was added to DMSO (4 mL) under argon. After 5 min, megestrol (3) (400 mg; 1.17 mmol) was added followed by 1-iodopentane (305 μ l; 2.3 mmol). The reaction mixture was stirred for 1 h and water (20 mL) was added, and extracted with CH₂Cl₂ (3x20 ml). The organic layer was washed with brine (20 mL), dried, and solvents removed to give the crude product which was purified on silica
10 gel column using hexanes/EtOAc as eluent to give pure product (33 mg) in 7 % yield: IR (NaCl, cm⁻¹) 2932, 2868, 1706, 1662, 1625, 1579; ¹H NMR (CDCl₃) δ 0.63 (s, 3 H, H-C18), 0.88 (t, 3H, J=6.9 Hz), 1.06 (s, 3 H, H-C19), 1.82(s, 3H, 6-CH₃), 2.11(s, 3H, COCH₃), 2.42-2.56 (m, 3H), 2.91 (app. q, 1H), 3.34 (app. q, 1H), 5.85 (s, 1 H), 5.95 (s, 1H); ¹³C NMR (CDCl₃) δ 211.2,
15 200.1, 164.5, 138.7, 131.0, 121.0, 95.9, 64.4, 50.1, 48.5, 48.1, 37.2, 36.1, 33.9, 33.6, 30.7, 29.9, 28.3, 26.5, 23.5, 23.1, 22.5, 20.4, 19.8, 16.3, 14.7, 14.0.


Example 5

16 α -substituted 4,6-androstadien-3,17-dione derivatives

5 These syntheses are described in Scheme 3.

Scheme 3

10



Example 5A

General method for 16 α -substituted 4,6-androstadien-3,17-dione (13)
16 α -substituted 5-androsten-3,17-dione 3-ethyleneketal (11) Under argon atmosphere, a solution of 5-androsten-3,17-dione 3-ethyleneketal 10 in anhydrous THF (3.3% W/V) was cooled at 0 °C and treated with a 1.0 M solution of lithium bis(trimethylsilyl)amide in THF (1.0 equiv) and HMPA (2.0 equiv). The solution was stirred 20 min at room temperature, cooled at -78 °C, and treated with 1.2 equiv of alkyl iodide. The reaction mixture was allowed to reach room temperature and stirred overnight (for R= isobutyl). For smaller R group (e.g.: R=Pr), the reaction was allowed to reach -40 °C and stirred 3 h. The reaction was quenched with saturated ammonium chloride and diluted with ethyl acetate. The organic phase was washed with brine, dried over magnesium sulfate, filtered, and evaporated. The crude mixture was purified by flash chromatography (hexanes to hexanes-acetone 19-1) to provide compound 11 (e.g., R=isobutyl, 8%): ¹H NMR (300 MHz, CDCl₃) δ 0.88 (d, J=6.3 Hz, 3H), 0.92 (s, 3H), 0.92 (d, J=6.1 Hz, 3H), 1.05 (s, 3H), 1.08-1.84 (m, 17H), 2.11 (m, 2H), 2.46 (m, 1H), 2.58 (m, 1H), 3.95 (m, 4H), 5.37 (m, 1H).

16 α -substituted 4-androsten-3,17-dione (12). Under argon atmosphere, a solution of compound 11 and *p*-toluenesulfonic acid (0.11 equiv) in acetone (1.0% W/V) was refluxed for 2.5 h. The crude mixture was warmed to room temperature, diluted with distilled water, and evaporated (acetone). The aqueous phase was extracted with dichloromethane. The organic phase was washed two times with saturated sodium bicarbonate and brine, dried over magnesium sulfate, filtered, and evaporated. The crude mixture was purified by flash chromatography (hexanes-acetone 49-1 to hexanes-acetone 19-1) to provide compound 12 (e.g., R=isobutyl, 81%): ¹H NMR (300 MHz, CDCl₃) δ 0.88 (d, J=6.5 Hz, 3H), 0.92 (d, J=6.5 Hz, 3H), 0.96 (s, 3H), 1.21 (s, 3H), 0.98-2.02 (m, 16H), 2.38 (m, 5H), 5.75 (s, 1H).

16 α -substituted 4,6-androstadien-3,17-dione (13). Under argon atmosphere, a solution of compound 12 and chloranil (4.8 equiv) in anhydrous *tert*-butanol (2.6% W/V) was refluxed for 3 h. The reaction mixture was cooled at room temperature and the suspension was filtered to remove excess of chloranil and then evaporated. The crude mixture was diluted with dichloromethane and the obtained solution was washed 3 times with distilled water, 4 times with 5% sodium hydroxide, and 4 times with distilled water. The organic phase was dried over magnesium sulfate, filtered, and evaporated. The crude mixture was purified by 2 flash chromatographies (hexanes to hexanes-acetone 9-1; and hexanes-ethyl acetate 97-3 to hexanes-ethyl acetate 17-3) to provide compound 13

- 175 -

5

(e.g., EM-1273-CS, R=isobutyl, 29%): IR (CHCl₃) 3010, 2957, 2871, 1733, 1656, 1619, 1467 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 0.89 (d, J=6.5 Hz, 3H), 0.93 (d, J=6.4 Hz, 3H), 1.01 (s, 3H), 1.14 (s, 3H), 1.05-2.05 (m, 13H), 2.34-2.58 (m, 4H), 5.70 (s, 1H), 6.18 (m, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 14.45, 16.32, 19.92, 21.35, 23.44, 26.57, 27.45, 31.52, 33.87, 36.13, 36.97, 40.02, 43.06, 46.56, 48.88, 50.86, 124.16, 128.76, 138.37, 162.91, 199.30, 221.43.


- 176 -

Example 6

16-Symmetrical-disubstituted 4,6-androstadien-3,17-dione
and 4,6-estradien-3,17-dione derivatives

5

Scheme 4



Example 6A

General method for 16-symmetrical-disubstituted 4,6-androstadien-3,17-dione and 4,6-estradien-3,17-dione (17)

- 5 16-symmetrical-disubstituted 5-androsten-3,17-dione 3-ethyleneketal (15). Under argon atmosphere, a solution of 5-androsten-3,17-dione 3-ethyleneketal (14) in anhydrous THF (2.4% W/V) was treated with sodium hydride in 60% dispersion in mineral oil (10 equiv) and alkyl dihalide (1.5 equiv) or alkyl halide (10 equiv) and refluxed for 20 h. The reaction mixture was cooled at room temperature and quenched with ethanol, and then the solvents were evaporated. The crude mixture was diluted with dichloromethane and washed with saturated ammonium chloride and brine. The organic phase was dried over magnesium sulfate, filtered, and evaporated. The crude compound 16 (e.g. $R^1=CH_3$, $R^2=-(CH_2)_4-$) was directly used for the next step: 1H NMR (300 MHz, $CDCl_3$) δ 0.88 (s, m, 3H), 1.05 (s, 3H), 1.0-2.2 (m, 24H), 2.58 (m, 1H), 3.95 (m, 4H), 5.37 (m, 1H). When alkyl halide was used, compounds 15 were purified by flash chromatography.
- 10
- 15
- 20 16-symmetrical-disubstituted 4-androsten-3,17-dione (16). The same procedure for compound 12 was used, starting from compound 15. The crude mixture was purified by flash chromatography (hexanes-acetone 19-1 to hexanes-acetone 4-1) to provide compound 16 (e.g. EM-844, $R^1=CH_3$, $R^2=-(CH_2)_4-$, 74%). A sample was recrystallized from hexanes-acetone 4-1: IR (KBr) 2950, 2925, 2858, 1730, 1674, 1617, 1448 cm^{-1} ; 1H NMR (300 MHz, $CDCl_3$) δ 0.89 (s, 3H), 1.18 (s, 3H), 0.93-2.04 (m, 19H), 2.26-2.44 (m, 4H), 5.70 (s, 1H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 14.03, 17.36, 20.31, 25.37, 25.93, 30.93, 31.89, 32.58, 33.89, 34.71, 35.65, 38.18, 38.66, 39.21, 39.93, 48.00, 48.54, 53.94, 56.15, 124.06, 170.39, 199.22, 225.41.
- 25
- 30 16-symmetrical-disubstituted 4,6-androstadien-3,17-dione (17). A solution of compound 16 in acetic anhydride (12.4 equiv) and pyridine (1.1 equiv) was treated with acetyl chloride (13.0 equiv), refluxed for 3 h, cooled at room temperature, and stirred overnight. The reaction mixture was evaporated and coevaporated 2 times with ethanol and 1 time with toluene. The crude dienol acetate was dissolved in wet DMF (97%). The solution was treated with N-bromosuccinimide (1.03 equiv), stirred for 45 min, treated with lithium carbonate (2.4 equiv) and lithium bromide (1.02 equiv), and heated at 100 °C for 3 h. The reaction mixture was cooled at room temperature, treated with saturated ammonium chloride, and extracted 3 times with ethyl acetate. The combined organic phase was dried over magnesium sulfate, filtered, and evaporated. The crude mixture was purified by flash chromatography (hexanes to hexanes-
- 35
- 40

acetone 19-1) and recrystallization (hexanes-acetone 49-1) to provide compound 17 (e.g. CS-195, $R^1=CH_3$, $R^2=-(CH_2)_4-$, 61%): IR ($CHCl_3$) 2947, 2872, 1731, 1657, 1619 cm^{-1} ; 1H RMN (300 MHz, $CDCl_3$) δ 0.98 (s, 3H), 1.14 (s, 3H), 1.2-2.05 (m, 18H), 2.35-2.65 (m, 3H), 5.70 (s, 1H), 6.17 (m, 2H); ^{13}C RMN (75 MHz, $CDCl_3$) δ 14.04, 16.33, 20.00, 25.38, 25.93, 31.86, 33.87, 36.17, 36.65, 37.73, 39.20, 39.98, 46.57, 48.84, 50.91, 56.24, 124.12, 128.70, 138.68, 163.00, 199.32, 224.69.

Example 6B

16-symmetrical-disubstituted 1,4,6-androstatrien-3,17-dione (18). Under argon atmosphere, a solution of compound 17 and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (1.7 equiv) in toluene (4.3% W/V) was refluxed for 5 h. The reaction mixture was cooled at room temperature, diluted with ethyl acetate, and washed with saturated sodium carbonate and brine. The organic phase was dried over magnesium sulfate, filtered, and evaporated. The crude mixture was purified by flash chromatography (hexanes to hexanes-acetone 19-1) and triturated in hexanes to provide compound 18 (e.g. EM-1039, $R^1=CH_3$, $R^2=-(CH_2)_4-$, 52%): IR ($CHCl_3$) 2946, 1732, 1652, 1603 cm^{-1} ; 1H NMR (300 MHz, $CDCl_3$) δ 1.01 (s, 3H), 1.23 (s, 3H), 1.29-2.04 (m, 16H), 2.45 (m, 1H), 6.03 (m, 2H), 6.29 (m, 2H), 7.06 (d, $J=10.1$ Hz, 1H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 14.14, 20.76, 21.22, 25.37, 25.93, 31.84, 37.20, 37.70, 39.18, 39.99, 41.18, 46.75, 48.40, 48.58, 56.22, 124.28, 128.34, 128.49, 135.99, 152.41, 161.78, 186.13, 224.32.

Example 6C

1 α -methyl-16-symmetrical-disubstituted 4,6-androstadien-3,17-dione (19). Under argon atmosphere, a solution of compound 18 and cuprous bromide (0.01 equiv) in anhydrous THF (15% W/V) was treated with a 2.0 M solution of trimethylaluminum in toluene (1.1 equiv) and stirred 1 h at room temperature. The reaction mixture was hydrolyzed with water and the solid filtered off and washed. The crude mixture was purified by flash chromatography (hexanes-acetone 19-1) to provide compound 19 (e.g. EM-1077, $R^1=CH_3$, $R^2=-(CH_2)_4-$, 55%): IR ($CHCl_3$) 3014, 2948, 2873, 1731, 1651, 1618, 1253 cm^{-1} ; 1H NMR (300 MHz, $CDCl_3$) δ 0.95 (d, $J=6.8$ Hz, 3H), 0.99 (s, 3H), 1.23 (s, 3H), 1.25-2.05 (m, 16H), 2.19-2.38 (m, 3H), 2.85 and 2.91 (dd, $J=5.4$ and 17.8 Hz, 1H), 5.71 (s, 1H), 6.17 (m, 2H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 14.10, 14.85, 19.02, 19.47, 25.40, 25.96, 31.84, 35.82, 36.63, 37.77, 39.23, 39.32, 40.02, 42.38, 45.47, 46.79, 49.00, 56.22, 123.70, 129.54, 138.41, 159.77, 198.95, 224.71.

Example 6D**16-symmetrical-disubstituted 4-androsten-3,17-dione-6-methylene (22)**

A solution of 16-symmetrical-disubstituted 4-androsten-3,17-dione (16), sodium acetate (4.4 equiv), diethoxymethane (89 equiv), and phosphorus oxychloride (15 equiv) in chloroform (3.3% W/V) was refluxed for 1 h. The reaction mixture was cooled at rt, quenched slowly with saturated sodium carbonate, and diluted in chloroform. The organic phase was washed with distilled water and brine. The crude mixture was purified by flash chromatography (hexanes-ethyl acetate 9-1 to hexanes-ethyl acetate 4-1) and recrystallization (acetone-hexanes 1-19) to provide compound XI (e.g. EM-921, R¹=CH₃, R²=(CH₂)₅-, 59%): IR (KBr) 2931, 2857, 1726, 1673, 1596, 1444, 1267, 1227 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 0.91 (s, 3H), 1.11 (s, 3H), 1.14-2.08 (m, 22H), 2.35-2.50 (m, 2H), 2.58 and 2.26 (dd, J=3.3 and 12.9 Hz, 1H), 4.98 (d, J=1.9 Hz, 1H), 5.09 (d, J=2.0 Hz, 1H), 5.92 (s, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 14.29, 17.10, 20.24, 22.40, 22.55, 25.42, 31.87, 31.92, 33.00, 33.79, 34.77, 35.10, 36.65, 39.02, 39.18, 48.25, 48.56, 50.47, 52.80, 114.44, 121.91, 145.54, 168.43, 199.61, 223.84.

Example 6E**16-symmetrical-disubstituted 4,6-androstadien-3,17-dione-6-methyl (23)**

A solution of 16-symmetrical-disubstituted 4-androsten-3,17-dione-6-methylene (22) in benzene (0.67% W/V) was treated with acetic anhydride (15 equiv) and a solution of p-toluenesulfonic acid (5 equiv) in benzene (8.4% W/V), and refluxed for 3.5 h. The reaction mixture was cooled at rt, quenched with distilled water, and diluted with benzene. The organic phase was washed 1 time with distilled water, 2 times with 5% sodium bicarbonate, and 4 times with brine. The organic phase was dried over magnesium sulfate, filtered, and evaporated. The crude mixture was purified by flash chromatography (hexanes-ethyl acetate 9-1 to hexanes-ethyl acetate 4-1) and recrystallization (acetone-hexanes 1-19) to provide compound 23 (e.g. EM-925, R¹=CH₃, R²=(CH₂)₅-, 60%): IR (KBr) 2926, 2858, 1726, 1662, 1629, 1582, 1444, 1268 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 0.97 (s, 3H), 1.11 (s, 3H), 1.20-2.62 (m, 26H), 5.89 (s, 1H), 6.06 (s, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 14.31, 16.39, 19.89, 19.98, 22.46, 22.58, 25.40, 31.81, 32.01, 32.53, 33.61, 34.02, 36.22, 36.63, 46.13, 49.27, 50.59, 51.13, 121.45, 131.85, 136.56, 163.88, 199.82, 223.45.

Example 7

5 **16-symmetrical-disubstituted 1,4-androstadien-3,17-dione (21).** The
The reflux period was 20 h instead of 5 h. The crude mixture was purified
by 2 flash chromatographies (hexanes to hexanes-acetone 9-1) to provide
compound 21 (e.g. EM 1123, R¹=CH₃, R²=(CH₂)₄-, 74%). A sample was
recrystallized in acetone-hexanes (1-49): IR (CHCl₃) 3014, 2946, 2871, 1730,
10 1661, 1622, 1603 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 0.96 (s, 3H), 1.26 (s,
3H), 1.14-2.05 (m, 19H), 2.35-2.60 (m, 2H), 6.09 (s, 1H), 6.23 and 6.26 (dd,
J=2.0 and 10.2 Hz), 7.05 (d, J=10.2 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ
14.16, 18.72, 22.14, 25.38, 25.94, 31.81, 32.50, 32.59, 34.71, 38.37, 39.23, 39.98,
43.49, 48.16, 52.45, 56.13, 124.13, 127.72, 155.34, 168.37, 186.22, 225.19.


Example 8

16-asymmetrical-disubstituted 6-methyl-4,6-androstadien-3,17-dione (27)

5

These syntheses are described in Scheme 5.

Scheme 5



10

Example 8A**General method for 16-asymmetrical-disubstituted 4,6-androstadien-3,17-dione (27)**

5 16-monosubstituted 5-androsten-3,17-dione 3-ethyleneketal (24). Under argon atmosphere, a solution of 5-androsten-3,17-dione 3-ethyleneketal (10) in anhydrous THF (4.6% W/V) was cooled at -20 °C, treated with a 1.0 M solution of lithium bis(trimethylsilyl)amide in THF (1.0 equiv), warmed to room temperature for 15 min, cooled at -78 °C, and treated with alkyl iodide (1.05 equiv). The reaction mixture was warmed to room temperature, stirred for 2 h, quenched with saturated ammonium chloride, and evaporated (THF). The aqueous phase was extracted with dichloromethane. The combined organic phase was washed with brine, dried over magnesium sulfate, filtered, and evaporated. The crude mixture was purified by flash chromatography (hexanes-acetone 99-1 to hexanes-acetone 19-1) to provide compound 24 (e.g. R¹=CH₃, 7:3 16 α /16 β ratio, 69%): ¹H NMR (300 MHz, CDCl₃) δ 0.84 (s, 0.9H), 0.91 (s, 2.1H), 1.04 (s, 3H), 1.09 (d, J=6.5 Hz, 2.1H), 1.20 (d, J=7.0 Hz, 0.9 H), 1.25-1.86 (m, 13H), 2.05-2.16 (m, 3H), 2.56 (m, 2H), 3.95(m, 4H), 5.36 (m, 1H).

20 16-asymmetrical-disubstituted 5-androsten-3,17-dione 3-ethyleneketal (25). Under argon atmosphere, a solution of compound 24 in anhydrous THF (4.0% W/V) was cooled at -40 °C, treated with 0.5 M solution of potassium bis(trimethylsilyl)amide in toluene (1.2 equiv), warmed to room temperature for 15 min, cooled at -78 °C, and treated with 1.5 equiv of alkyl iodide. The reaction mixture was allowed to reach room temperature, refluxed for 2 h, and cooled at room temperature. The reaction mixture was quenched with saturated ammonium chloride, evaporated (THF), and extracted with dichloromethane. The combined organic phase was washed with brine, dried over magnesium sulfate, filtered, and evaporated. The crude mixture was purified by flash chromatography (hexanes-acetone 99-1 to hexanes-acetone 19-1) to provide compound 25 (e.g. R¹=CH₃, R²=isobutyl, 56%): ¹H NMR (300 MHz, CDCl₃) δ 0.85 (d, J=6.6 Hz, 3H), 0.90 (d, J=6.6 Hz, 3H), 0.93 (s, 3H), 1.05 (s, 3H), 1.15 (s, 3H), 1.27-2.16 (m, 19H), 2.56 (m, 1H), 3.95 (m, 4H), 5.37 (m, 1H).

40 16-asymmetrical-disubstituted 4-androsten-3,17-dione (26). The same procedure for compound 12 was used, starting from compound 25. The crude mixture was purified by flash chromatography (hexanes-acetone 49-1 to hexanes-acetone 19-1) to provide compound 26 (e.g. EM-1133, R¹=CH₃, R²=isobutyl, 96%): IR (KBr) 2951, 2869, 1734, 1676, 1616, 1454 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 0.86 (d, J=6.6 Hz, 3H), 0.90 (d, J=6.6 Hz,

3H), 0.96 (s, 3H), 1.17 (s, 3H), 1.21 (s, 3H), 1.02-2.07 (m, 16H), 2.31-2.49 (m, 4H), 5.75 (s, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 15.06, 17.30, 20.13, 24.64, 24.88, 25.15, 25.96, 30.85, 32.05, 32.55, 33.89, 34.65, 35.12, 35.61, 38.66, 46.27, 47.74, 48.21, 48.90, 54.02, 124.06, 170.40, 199.31, 224.70.

5
10
15
16-asymmetrical-disubstituted 4,6-androstadien-3,17-dione (27). The same procedure for compound 13 was used, starting from compound 26. The crude mixture was purified by flash chromatography (hexanes-acetone 49-1 to hexanes-acetone 19-1) to provide compound 27 (e.g. EM-1134, $\text{R}^1=\text{CH}_3$, $\text{R}^2=\text{isobutyl}$, 57%): IR (KBr) 2954, 2870, 1735, 1665, 1618, 1584, 1466 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 0.88 (d, $J=6.7$ Hz, 3H), 0.91 (d, $J=6.6$ Hz, 3H), 1.01 (s, 3H), 1.14 (s, 3H), 1.20 (s, 3H), 1.22-2.65 (m, 16H), 5.71 (s, 1H), 6.18 (m, 2H); ^{13}C NMR (75 MHz, CDCl_3) δ 15.10, 16.29, 19.82, 24.56, 24.89, 25.15, 25.97, 31.99, 33.78, 33.87, 34.80, 36.15, 36.59, 45.77, 46.27, 48.98, 50.92, 124.07, 128.77, 138.70, 163.05, 199.34, 224.32.

Example 8B


20
25
30
35
16 α -alkylhalide-16 β -alkyl 4,6-androstadien-3,17-dione (27b). Under argon atmosphere, a solution of 16 α -hydroxyalkyl-16 β -alkyl 4,6-androstadien-3,17-dione (27a) and triphenylphosphine (1.2 equiv) in dichloromethane (10% W/V) was cooled at 0 °C and treated with N-chlorosuccinimide (or N-bromosuccinimide) (1.2 equiv). The reaction mixture was warmed to room temperature for 30 min and diluted with dichloromethane. The organic phase was washed with brine, dried over magnesium sulfate, filtered, and evaporated. The crude mixture was purified by 2 flash chromatographies (hexanes-ethyl acetate 9-1 to hexanes-ethyl acetate 7-3; and dichloromethane to dichloromethane-ethyl acetate 9-1) to provide compound 27b (e.g. EM-1135, $\text{R}^1=\text{CH}_3$, $\text{R}^2=(\text{CH}_2)_3\text{Cl}$, 51%): IR (CHCl_3) 3010, 2946, 2873, 1733, 1657, 1619 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 1.02 (s, 3H), 1.14 (s, 3H), 1.21 (s, 3H), 1.26-2.11 (m, 14H), 2.35-2.65 (m, 3H), 3.49 (m, 2H), 5.71 (s, 1H), 6.17 (m, 2H); ^{13}C NMR (75 MHz, CDCl_3) δ 14.91, 16.32, 19.80, 25.16, 27.97, 31.78, 33.80, 33.89, 34.83, 35.25, 36.16, 36.60, 45.19, 46.01, 48.10, 49.36, 50.89, 124.21, 128.89, 138.43, 162.92, 199.40, 223.36.

Example 9

17 α -acyloxy-6-methyl-4,6-androstadien-3-one-17 β -carboxamide (34)

5 These syntheses are described in Scheme 6.

Scheme 6



Example 9A

General method for 17 α -acyloxy-6-methyl-4,6-androstadien-3-one-17 β -carboxamide (34)

5 **4-androsten-17 α -ol-3-one-17 β -carboxylic acid methyl ester (29).** A solution of 4-pregnen-17,21-diol-3,20-dione (28) (6.93 g, 0.0200 mol) in methanol (500 mL) was treated with a 0.075 M periodic acid (300 mL, 0.0225 mol) and 2.5 M sulfuric acid (70 mL, 0.175 mol) and stirred 3 h. The reaction mixture was evaporated (methanol) and filtered. The crude mixture was dried to afford 4-androsten-17 α -ol-3-one-17 β -carboxylic acid (6.50 g). A solution of the carboxylic acid (4.56 g, 0.0137 mol) and 6 drops of concentrated sulfuric acid in methanol (250 mL) was refluxed for 30 h. The reaction mixture was cooled to room temperature, evaporated, diluted with ethyl acetate, dichloromethane, and water, and treated with sodium bicarbonate. The mixture was extracted 3 times with ethyl acetate. The combined organic phase was washed with brine, dried over magnesium sulfate, filtered, and evaporated. The crude mixture was purified by flash chromatography (hexanes to hexanes-ethyl acetate 3-2) to provide the methyl ester 29 (4.12 g, 87%): ¹H NMR (300 MHz, CDCl₃) δ 0.72 (s, 3H), 1.18 (s, 3H), 0.94-1.89 (m, 13H), 2.01 (m, 1H), 2.36 (m, 4H), 2.65 (m, 1H), 2.85 (s, 1H), 3.75 (s, 3H), 5.72 (s, 1H).

Example 9B

25 **6-methylene-4-androsten-17 α -ol-3-one-17 β -carboxylic acid methyl ester (30).** A suspension of sodium acetate (6.65 g, 0.081 mol), diethoxymethane (201 mL, 1.62 mol) and phosphorus oxychloride (25 mL, 0.27 mol) in chloroform (250 mL) was refluxed for 1 h, treated with a solution of compound 29 (6.02 g, 0.018 mol) in chloroform (50 mL), and refluxed for 2 h. The reaction mixture was cooled at room temperature, diluted with water, and extracted with dichloromethane. The combined organic phase was stirred in the presence of sodium carbonate for 1 h, decanted, washed with water and brine, dried over magnesium sulfate, filtered, and evaporated. The crude mixture was purified by flash chromatography (hexanes to hexanes-ethyl acetate 1-1) to provide the methyl ester 30 (3.60 g, 56%): ¹H NMR (300 MHz, CDCl₃) δ 0.71 (s, 3H), 1.08 (s, 3H), 1.13-2.08 (m, 13H), 2.45 (m, 3H), 2.67 (m, 1H), 2.85 (m, 1H), 3.76 and 3.77 (2s, 2.2 and 0.8H), 4.93 (d, J =1.9 Hz, 1H), 5.05 (d, J =1.6 Hz, 1H), 5.90 (s, 1H).

Example 9C

17 α -acetoxyl-6-methyl-4,6-androstadien-3-one-17 β -carboxylic acid methyl ester (31). The same procedure for compound 23 was used, starting from compound 30. The crude mixture was purified by flash chromatography (hexanes to hexanes-ethyl acetate 7-3) to provide compound 31 (EM-1010, 75%): IR (KBr) 2967, 2871, 1742, 1668, 1628, 1584, 1458, 1366, 1260, 1245 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 0.77 (s, 3H), 1.09 (s, 3H), 1.23-2.02 (m, 11H), 1.84 (broad s, 3H), 2.04 (s, 3H), 2.24 (m, 1H), 2.42-2.65 (m, 2H), 2.98 (m, 1H), 3.71 (s, 3H), 5.87 (s, 1H), 5.96 (s, 1H); ¹³C NMR (75 MHz, CDCl₃) 14.43, 16.38, 19.86, 20.15, 21.05, 23.36, 30.35, 31.90, 33.61, 34.08, 36.12, 37.23, 48.01, 48.40, 50.36, 52.08, 90.58, 121.22, 131.37, 138.02, 164.12, 170.25, 170.41, 199.88.

Example 9D

6-methyl-4,6-androstadien-17 α -ol-3-one-17 β -carboxylic acid (32). A solution of compound 31 (3.00 g, 7.50 mmol) in methanol (225 mL) and 10% potassium carbonate (62 mL, 0.045 mol) was refluxed for 21 h. The crude mixture was cooled at room temperature, evaporated (methanol), acidified with 10% hydrochloric acid, and diluted with water. The precipitate was filtered, washed with water, and dried. The filtrate was extracted with dichloromethane. The organic phase was washed 3 times with brine, dried over magnesium sulfate, filtered, and evaporated. A solution of the combined solids in methanol-dichloromethane 1-1 (300 mL) was treated with 10% hydrochloric acid (60 mL), stirred for 3 h, and evaporated (methanol and dichloromethane). The aqueous phase was extracted 3 times with dichloromethane. The combined organic phase was washed 4 times with brine, dried over magnesium sulfate, filtered, and evaporated to provide carboxylic acid 32 (2.05 g, 80%): ¹H NMR (CDCl₃, CD₃OD) δ 0.68 (s, 3H), 0.95 (s, 3H), 1.05-1.88 (m, 13H), 1.68 (s, 3H), 2.09 (m, 1H), 2.55 (m, 1H), 5.69 (s, 1H), 5.89 (s, 1H).

Example 9E

6-methyl-4,6-androstadien-17 α -ol-3-one-17 β -carboxamide (33). A solution of compound 32 and 1,3-bis(trimethylsilyl)urea (1.5 equiv) in dichloromethane-pyridine 8-1 (5.7% W/V) was refluxed for 21 h. The reaction mixture was cooled at room temperature, filtered, evaporated (dichloromethane), dissolved in dichloromethane, filtered, and evaporated. A solution of the silylated α -hydroxycarboxylic acid in chloroform-dimethylformamide 99-1 (5.1% W/V) was cooled at 0 °C, treated with oxalyl chloride (1.2 equiv), stirred for 1 h, and warmed to room temperature for 30 min. The reaction mixture was cooled at 0 °C, treated with pyridine (4 equiv), and amine (3 equiv), stirred for 1 h, and warmed to room temperature for 3 h. The reaction mixture was diluted

- 187 -

with water and extracted with ethyl acetate. The combined organic phase was washed with 10% hydrochloric acid and brine, dried over magnesium sulfate, filtered, and evaporated. A solution of the crude mixture in methanol-acetone 1-1 (10 mL) was treated with 10% hydrochloric acid (2 mL) and stirred for 3 h. The reaction mixture was evaporated and extracted 3 times with ethyl acetate. The combined organic phase was washed 2 times with brine, dried over magnesium sulfate, filtered, and evaporated. The crude mixture was purified by flash chromatography (hexanes to hexanes-ethyl acetate 2-1) to provide compound 33 (e.g. R¹=Me, R²=Et, 41%): ¹H NMR (300 MHz, CDCl₃) δ 0.83 (broad s, 3H), 1.09 (s, 3H), 1.13 (t, J=7.0 Hz, 3H), 1.22-2.23 (m, 12H), 1.84 (s, 3H), 2.45-2.63 (m, 3H), 3.08 (m, 5H), 3.80 (m, 1H), 5.86 (s, 1H), 5.98 (s, 1H).

Example 9F


17α-acyloxy-6-methyl-4,6-androstadien-3-one-17β-carboxamide (34). A solution of compound 33 and *p*-toluenesulfonic acid (0.14 equiv) in acid chloride (4.7% W/V) was stirred 10 h at room temperature. The reaction mixture was quenched with methanol and water, stirred for 30 min, and extracted with ethyl acetate. The combined organic phase was washed with saturated sodium bicarbonate and brine, dried over magnesium sulfate, filtered, and evaporated. The crude mixture was purified by 2 flash chromatographies (hexanes to hexanes-ethyl acetate 3-2 and dichloromethane to dichloromethane-acetone 49-1) to provide compound 34 (e.g. EM-1181-CS, R¹=Me, R²=Et, R³=(CH₂)₃Cl, 50%): IR (KBr) 2944, 2871, 1738, 1659, 1640, 1631, 1580 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 0.84 (s, 3H), 1.10 (m, 6H), 1.25-2.25 (m, 14H), 1.85 (s, 3H), 2.40-2.63 (m, 4H), 2.89 and 2.99 (2s, 0.7 and 2.3H), 3.43 (m, 3H), 3.62 (t, J=6.1 Hz, 2H), 5.88 (s, 1H), 5.98 (s, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 11.49, 14.70, 16.32, 19.85, 20.54, 22.91, 27.12, 30.99, 32.93, 33.57, 33.99, 34.10, 35.44, 36.02, 37.28, 43.87, 45.18, 48.51, 48.91, 50.04, 94.76, 121.15, 131.28, 138.10, 164.07, 167.31, 170.78, 199.87.

Example 10

17 β -acyl-17 α -acyloxy-6-methyl-4,6-androstadien-3-one

5 These syntheses are described in Scheme 7.

Scheme 7



General method for 17 β -acyl-17 α -acyloxy-6-methyl 4,6-androstadien-3-one (40)

Example 10A

5

10

15

5-androsten-17 α -ol-3-one-17 β -carboxylic acid 3-ethyleneketal methyl ester (35). A solution of 4-androsten-17 α -ol-3-one-17 β -carboxylic acid methyl ester (29) (5.16 g, 0.0154 mol) and ethylene glycol (2.87 g, 0.0463 mol) in benzene (500 mL) was refluxed with a Dean-Stark apparatus for 1 h, treated with *p*-toluenesulfonic acid (100 mg, 0.53 mmol), and refluxed for 6.5 h. The reaction mixture was cooled to room temperature, diluted with ethyl acetate, washed with saturated sodium bicarbonate, and 2 times with water, dried over magnesium sulfate, filtered, and evaporated. The crude mixture was purified by flash chromatography (hexanes to hexanes-ethyl acetate 7-3) to provide the ketal 35 (5.12 g, 85%): ¹H NMR (300 MHz, CDCl₃) δ 0.70 (s, 3H), 1.03 (s, 3H), 1.08-1.82 (m, 15H), 2.01 (m, 1H), 2.10 and 2.15 (dd, *J*=2.6 and 14.2 Hz, 1H), 2.61 (m, 2H), 2.78 (s, 1H), 3.75 (s, 3H), 3.94 (m, 4H), 5.35 (m, 1H).

20

Example 10B

25

30

17 α -(2'-tetrahydro-2'H-pyranyloxy)-5-androsten-3-one-17 β -carboxylic acid 3-ethyleneketal methyl ester (36). A solution of compound 35 (4.94 g, 0.0126 mol) in 3,4-dihydro-2H-pyran (100 mL) was cooled at 0 °C, treated with *p*-toluenesulfonic acid (300 mg, 1.6 mmol), and stirred for 5 h. The reaction mixture was diluted with ethyl acetate, washed with saturated sodium bicarbonate and 2 times with water, dried over magnesium sulfate, filtered, and evaporated. The crude mixture was purified by flash chromatography (hexanes to hexanes-ethyl acetate 21-4) to quantitatively provide the diketal 36 (6.10 g): ¹H NMR (300 MHz, CDCl₃) δ 0.66 (s, 1.1H), 0.67 (s, 1.9 H), 1.01 (s 3H), 1.09-2.15 (m, 22H), 2.47 (m, 3H), 3.37 (m, 0.7H), 3.51 (m, 1.3H), 3.65 (s, 1.7H), 3.69 (s, 1.3H), 3.93 (m, 4H), 4.56 (m, 0.6H), 4.77 (m, 0.4H), 5.34 (m, 1H).

35

Example 10C

40

17 α -(2'-tetrahydro-2'H-pyranyloxy)-5-androsten-3-one-17 β -carboxylic acid 3-ethyleneketal (37). Compound 36 (3.73 g, 0.00786 mol) was treated with 1 N potassium *tert*-butoxide in dimethyl sulfoxide (118 mL). The reaction mixture was stirred 4 h at room temperature, diluted with water, acidified to pH 2, and extracted 3 times with ethyl acetate. The combined organic phase was washed with brine and water, dried over magnesium sulfate, filtered, and evaporated. The crude mixture was purified by flash chromatography (hexanes to ethyl acetate) to provide the carboxylic acid

37 (2.50 g, 69%): ^1H NMR (300 MHz, CDCl_3) δ 0.76 (s, 2.0H), 0.80 (s, 1.0H), 0.82-2.15 (m, 22H), 1.03 (s, 3H), 2.38-2.58 (m, 3H), 3.4-3.6 (2m, 2H), 3.95 (m, 4H), 4.68 (m, 1H), 5.35 (m, 1H).

5 Example 10D

17 β -acyl-4-androsten-17 α -ol-3-one (38). Under argon atmosphere, a solution of compound 37 in dry benzene (3.0% W/V) was cooled at 0 °C, treated with an organolithium solution (7.0 equiv), and stirred 20 h at room temperature. The reaction mixture was cooled to 0 °C, quenched with saturated ammonium chloride, diluted with water, and extracted 3 times with ethyl acetate. The combined organic phase was washed with brine, dried over magnesium sulfate, filtered, and evaporated. The crude mixture was dissolved in methanol-acetone 1-1 (2% W/V), treated with 2.5 M hydrochloric acid, and refluxed for 1 h. The reaction mixture was cooled at room temperature, evaporated (solvents), diluted in water, and extracted 3 times with ethyl acetate. The combined organic phase was washed with brine and water, dried over magnesium sulfate, filtered, and evaporated. The crude mixture was purified by flash chromatography (hexanes to hexanes-ethyl acetate 3-1) to provide compound 38 (e.g. R¹=Bn, 42%): ^1H NMR (300 MHz, CDCl_3) δ 0.74 (s, 3H), 0.96-1.88 (m, 13H), 1.17 (s, 3H), 2.02 (m, 1H), 2.35 (m, 4H), 2.76 (m, 2H), 3.77 (d, J =16.5 Hz, 1H), 4.07 (d, J =16.4 Hz, 1H), 5.72 (s, 1H), 7.16-7.33 (m, 5H).

25 Example 10E

17 β -acyl-6-methylene-4-androsten-17 α -ol-3-one (39). A solution of compound 38, paraformaldehyde (5.4 equiv), and N-methylanilinium trifluoroacetate (4.8 equiv) in THF (2.9% W/V) was refluxed for 2.5 h. The reaction mixture was cooled at room temperature, treated with 2.5 M hydrochloric acid, stirred for 15 min, and extracted 3 times with ethyl acetate. The combined organic phase was washed with water, saturated sodium bicarbonate, and brine, dried over magnesium sulfate, filtered, and evaporated. The crude mixture was purified by flash chromatography (hexanes to hexanes-ethyl acetate 4-1) to provide compound 39 (e.g. R¹=Bn, 33%): ^1H NMR (300 MHz, CDCl_3) δ 0.75 (s, 3H), 1.09 (s, 3H), 1.15-2.08 (m, 13H), 2.45 (m, 3H), 2.78 (m, 2H), 3.78 (d, J =16.3 Hz, 1H), 4.07 (d, J =16.3 Hz, 1H), 4.94 (s, 1H), 5.06 (s, 1H), 5.91 (s, 1H), 7.17-7.34 (m, 5H).

Example 10F

17 β -acyl-17 α -acyloxy-6-methyl-4,6-androstadien-3-one (40). The same procedure for compound 23 was used, starting from compound 39. The crude mixture was purified by 2 flash chromatographies (dichloromethane to dichloromethane-acetone 99-1 and hexanes to hexanes-ethyl acetate 17-3) to provide compound 40 (e.g. EM-1106, R¹=Bn, R²=CH₃, 45%): IR (KBr) 2943, 2857, 1736, 1718, 1656, 1628, 1579, 1266, 1236; ¹H NMR (300 MHz, CDCl₃) δ 0.72 (s, 3H), 1.09 (s, 3H), 1.26-2.25 (m, 12H), 1.86 (s, 3H), 2.14 (s, 3H), 2.43-2.64 (m, 2H), 3.06 (m, 1H), 3.68 (m, 2H), 5.89 (s, 1H), 5.97 (s, 1H), 7.16-7.33 (m, 5H); ¹³C NMR (75 MHz, CDCl₃) δ 14.52, 16.39, 19.94, 20.35, 21.35, 23.30, 30.76, 31.21, 33.64, 34.07, 36.12, 37.11, 45.02, 47.91, 49.06, 50.23, 96.42, 121.29, 126.85, 128.32, 129.94, 131.49, 133.88, 137.93, 164.08, 170.76, 199.97, 203.41.

Example 11


17 α -acyloxy-6-methyl-4,6-androstadien-3-one-17 β -carboxyester

5

These syntheses are described in Scheme 8.

Scheme 8

10



Example 11A

4-androsten-17 α -ol-3-one-17 β -carboxyester (41). The same procedure for compound 29 was used and provide compound 41 (e.g., compound 41, R¹=CH₃).

5

Example 11B

6-methylene-4-androsten-17 α -ol-3-one-17 β -carboxester (42). The same procedure for compound 30 was used and provide compound 42 (e.g. compound 42, R¹=CH₃).

10

Example 11C

17 α -acyl-6-methyl-4,6-androstadien-17 α -ol-3-one-17 β -carboxester (43). The same procedure for compound 31 was used and provide compound 43 (e.g. compound 43, R¹,R²=CH₃).


- 194 -

Example 12

15 α -substituted 4,6-androstadien-3,17-dione derivatives

5 These synthesis are described in Scheme 9.

Scheme 9



10

Example 12A

5,15-androstadien-3,17-dione 3-ethyleneketal (**44**). Under argon atmosphere, a solution of 5-androsten-3,17-dione 3-ethyleneketal **10** (4.95 g, 0.0150 mol) in anhydrous THF (150 mL) was cooled at 0 °C and treated with 1.0 M solution of lithium bis(trimethylsilyl)amide in THF (18 mL, 0.018 mol). The solution was stirred 20 min at room temperature, cooled at -78 °C, and treated with chlorotrimethylsilane (2.24 mL, 0.0176 mol). The reaction was allowed to warm to room temperature, then evaporated. The residue was diluted with dichloromethane, washed two times with water and brine, dried over magnesium sulfate, filtered, and evaporated. A solution of the crude silylenol ether in a dichloromethane-acetonitrile 2-5 (140 mL) was treated with palladium acetate (4.04 g, 0.0180 mol) and refluxed for 30 min. The reaction mixture was cooled to room temperature and evaporated. The black residue was purified by flash chromatography (hexanes-ethyl acetate 4-1) to provide the enone **44** (3.49 g, 71%): ¹H NMR (300 MHz, CDCl₃) δ 1.085 (s, 3H), 1.09 (s, 3H), 1.21-1.93 (m, 11H), 2.15 (dd, J=2.7 and J=14.1 Hz, 1H), 2.26-2.34 (m, 2H), 2.58 (d, J=14.1 Hz, 1H), 3.95 (m, 4H), 5.40 (d, J=5.1 Hz, 1H), 6.04 (dd, J=3.2 and J=6 Hz, 1H), 7.50 (d, J=5.8 Hz, 1H).

Example 12B

17 α -substituted allyl 5,15-androstadien-17 β -ol-3-one 3-ethyleneketal (**45**). Under argon atmosphere, a solution of compound **44** in anhydrous THF (10% W/V) was cooled at 0 °C, treated with a solution of substituted allylmagnesium bromide or chloride in THF or ether (3 equiv) and stirred 3 h. The reaction mixture was quenched with saturated ammonium chloride and diluted with ethyl acetate. The organic phase was washed with brine, dried over magnesium sulfate, filtered, and evaporated. The crude residue was purified by flash chromatography (hexanes-ethyl acetate 9-1 to hexanes-ethyl acetate 4-1) to provide compound **45** (e.g., R¹, R², R³, R⁴, R⁵=H, 70%): ¹H NMR (300 MHz, CDCl₃) δ 0.92 (s, 3H), 1.06 (s, 3H), 1.11-1.81 (m, 11H), 1.95 (d, J=9.3 Hz, 1H), 2.10-2.21 (m, 3H), 2.30-2.36 (m, 1H), 2.57 (d, J=5 Hz, 1H), 3.95 (m, 4H), 5.10-5.16 (m, 2H), 5.36 (broad d, J=5 Hz, 1H), 5.61 (dd, J=3.1 and 5.7 Hz, 1H), 5.83 (d, J=5.8 Hz, 1H), 5.84-5.94 (m, 1H).

Example 12C

15 α -substituted allyl-5-androsten-3,17-dione 3-ethyleneketal (46).

Under argon atmosphere, a solution of compound 45 in dry THF (10% W/V) was cooled at 0 °C, treated with potassium hydride in 35% dispersion in mineral oil (2 equiv), and stirred 30 min. Then, the resulting suspension was treated with 18-crown-6 ether (1.5 equiv), allowed to reach room temperature, and stirred 2 h. The black mixture was quenched with saturated ammonium chloride then diluted with ethyl acetate. The organic phase was washed with brine, dried over magnesium sulfate, filtered, and concentrated. The oily residue was purified by flash chromatography (hexanes-ethyl acetate 4-1) to provide compound 46 (e.g., R¹, R², R³, R⁴, R⁵=H, 71%): ¹H NMR (300 MHz, CDCl₃) δ 0.94 (s, 3H), 1.06 (s, 3H), 1.1-1.5 (m, 5H), 1.5-2.0 (m, 11H), 2.14 (d, *J*=14.1 Hz, 1H), 2.19-2.29 (m, 2H), 2.62 (dd, *J*=8.3 and 19.3 Hz, 2H), 3.95 (m, 4H), 4.66 (d, *J*=16 Hz, 2H), 5.35 (s, 2H).

Example 12D

15 α -substituted allyl 4-androsten-3,17-dione (47). The same procedure for compound 12 was used, starting from compound 46. The crude mixture was purified by flash chromatography (hexanes-ethyl acetate 9-1 to hexanes-ethyl acetate 4-1) to provide compound 47 (e.g., EM-1284, R¹, R², R³, R⁴, R⁵=H, 85%): IR (CHCl₃) 3020, 2954, 1733, 1664, 1617, 1275, 1230 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 0.97 (s, 3H), 1.21 (s, 3H), 0.99-1.60 (m, 4H), 1.60-2.05 (m, 10H), 2.05-2.50 (m, 4H), 2.65 (dd, *J*=8.7 and 16.2 Hz, 2H), 5.03 (m, 2H), 5.67-5.73 (m, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 15.30, 17.62, 20.26, 31.09, 32.40, 32.57, 33.91, 35.79, 35.88, 36.59, 38.73, 40.17, 42.42, 49.94, 53.91, 54.36, 116.78, 123.72, 135.93, 169.93, 199.15, 219.08.

Example 13E

15 α -substituted allyl 4,6-androstadien-3,17-dione (48). The same procedure for compound 13 was used, starting from compound 47. The crude residue was purified by 2 flash chromatographies (hexanes-acetone 9-1 and hexanes-ethyl acetate 17-3) to provide compound 48 (e.g., EM-1261, R¹, R², R³, R⁴, R⁵=H, 61%): IR (CHCl₃) 3013, 2943, 2865, 1734, 1655, 1619, 1229 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 1.02 (s, 3H), 1.12 (s, 3H), 1.30-1.55 (m, 4H), 1.64-2.20 (m, 6H), 2.30-2.80 (m, 6H), 5.03-5.08 (m, 2H), 5.65-5.85 (m, 2H), 6.17 (dd, *J*=2.7 and 10.0 Hz, 1H), 6.42 (dd, *J*=1.8 and 10.0 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 15.41, 16.31, 19.79, 31.12, 33.85, 33.95, 35.29, 36.03, 38.40, 39.96, 42.25, 50.57, 52.61, 117.31, 123.97, 128.29, 135.19, 139.01, 162.35, 199.12, 218.20.


Example 13

(E)-16-monosubstituted methylene 4,6-androstadien-3,17-dione

5

These syntheses are described in Scheme 10.

Scheme 10



Example 13A

16-monosubstituted hydroxymethyl 5-androsten-3,17-dione 3-ethyleneketal (49). Under argon atmosphere, a solution of 5-androsten-3,17-dione 3-ethyleneketal (**10**) in anhydrous THF (3.3% W/V) was cooled at 0 °C and treated with a 1.0 M solution of lithium bis(trimethylsilyl)amide in THF (1.0 equiv) and HMPA (2.0 equiv). The solution was stirred 20 min at room temperature, cooled at -78 °C, and treated with 1.2 equiv of aldehyde. The reaction mixture was allowed to reach room temperature and stirred over 3 h. The reaction was quenched with saturated ammonium chloride and diluted with ethyl acetate. The organic phase was washed with brine, dried over magnesium sulfate, filtered, and evaporated. The crude mixture was used to carry out the next step without further purification (e.g., R²=isopropyl, quantitative yield): ¹H NMR (300 MHz, CDCl₃) δ 0.89-0.99 (m, 9H), 1.01-2.00 (m, 14H), 2.2-2.6 (m, 6H), 3.5-4.0 (m, 5H), 5.72 (m, 2H).

Example 13B

(E)-16-monosubstituted methylene 4-androsten-3,17-dione (50). The same procedure for compound **12** was used, starting from compound **49**. The crude mixture was purified by flash chromatography (hexanes-ethyl acetate 97-3 to hexanes-ethyl acetate 17-3) to provide compound **50** (e.g., R²=isopropyl, 19%): ¹H NMR (300 MHz, CDCl₃) δ 0.88 (s, 3H), 0.99 (d, J=6.6 Hz, 3H), 1.00 (d, J=6.6 Hz, 3H), 1.18 (s, 3H), 1.1-1.5 (m, 5H), 1.6-1.8 (m, 3H), 1.8-2.1 (m, 4H), 2.2-2.6 (m, 6H), 5.70 (s, 1H), 6.38 (m, 1H).

Example 13C


(E)-16-monosubstituted methylene 4,6-androstadien-3,17-dione (51). The same procedure for compound **13** was used, starting from compound **50**. The crude mixture was purified by 2 flash chromatographies (hexanes-ethyl acetate 19-1 to hexanes-ethyl acetate 7-3) to provide compound **51** (e.g., EM-1353, R²=isopropyl, 60%): IR (CHCl₃) 2961, 2868, 1722, 1656, 1619, 1465, 1374, 1269, 1209, 914, 733 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 0.98 (s, 3H), 1.05 (d, J=6.4 Hz, 3H), 1.07 (d, J=5.9 Hz, 3H), 1.16 (s, 3H), 1.25-1.55 (m, 4H), 1.71-1.80 (m, 2H), 1.94-2.05 (m, 2H), 2.18-2.28 (m, 1H), 2.40-2.65 (m, 4H), 2.74 and 2.79 (dd, J=6.5 and 15.2 Hz, 1H), 5.71 (s, 1H), 6.19 (s, 2H), 6.49 (m, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 14.26, 16.29, 19.97, 21.79, 25.74, 29.19, 31.21, 33.73, 33.83, 36.13, 36.56, 46.39, 48.50, 50.74, 124.13, 128.76, 133.68, 138.44, 144.27, 162.88, 199.25, 208.08.

Example 14

4,6-androstadien-3,17-dione-16-spirobicyclo [3'.1'.0'] hexane

5 These syntheses are described in Scheme 11.

Scheme 11



10

Example 14A

5-androsten-3,17-dione-16-spirobicyclo[3'.1'.0']-hexane 3-ethyleneketal (52). Under argon atmosphere, a solution of 5-androsten-3,17-dione 3-ethyleneketal (10) (3.96 g, 0.0120 mol), potassium tertbutylate (0.70g, 0.059 mol) and 4-pentynyltriphenylphosphonium iodide (2.90 g, 0.0635 mol) in dry toluene (3% W/V) was heated at 100 °C for 1 h. The reaction mixture was cooled at room temperature, poured into ice-water and extracted several times with ethyl acetate. The combined organic phase was washed with water and brine, dried over magnesium sulfate, filtered, and evaporated. The obtained solid was purified by flash chromatography (hexanes-ethyl acetate 9-1 to hexanes-ethyl acetate 4-1) to provide spirobicycloketal 52 (0.95 g, 20%): ¹H NMR (300 MHz, CDCl₃) δ 0.94 (s, 3H), 1.06 (s, 3H), 1.15-2.04 (m, 22H), 2.16 (dd, J=2.7 and J=14.1 Hz, 1H), 2.57 (m, 2H), 3.96 (m, 4H), 5.38 (s, 1H).

Example 14B

4-androsten-3,17-dione-16-spirobicyclo[3'.1'.0']-hexane (53). The same procedure for compound 12 was used, starting from compound 52. The crude mixture was purified by flash chromatography (hexanes-ethyl acetate 9-1) to provide spirobicycloenone 53 (50%): ¹H NMR (300 MHz, CDCl₃) δ 0.95 (s, 3H), 1.18 (s, 3H), 1.02-2.10 (m, 22H), 2.25-2.45 (m, 3H), 5.8 (s, 1H).

Example 14C


4,6-androstadien-3,17-dione-16-spirobicyclo[3'.1'.0']-hexane (EM-1299). The same procedure for compound 13 was used, starting from compound 53. The crude mixture was purified by flash chromatography (hexanes-ethyl acetate 9-1 to hexanes-ethyl acetate 4-1) to provide spirobicyclodienone EM-1299 (51%): IR (CHCl₃) 3008, 2943, 2878, 1730, 1643, 1611 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.01 (s, 3H), 1.14 (s, 3H), 1.15-1.80 (m, 13H), 1.84-2.15 (m, 5H), 2.38-2.54 (m, 3H), 5.70 (s, 1H), 6.14-6.24 (m, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 14.51, 16.32, 19.92, 23.12, 23.24, 25.77, 31.21, 33.83, 35.35, 36.16, 36.28, 47.54, 48.58, 50.87, 124.12, 128.70, 138.65, 163.01, 199.31, 218.66.

Example 15

15 α , 16 α , (E-ring)-4,6-androstadien-3,7-dione derivatives

5 These syntheses are described in Scheme 12.

Scheme 12



Example 15A

15 α -[1-(3-hydroxypropyl)]-5-androsten-17 β -ol-3-one 3-ethyleneketal (54). Under argon atmosphere, a solution of compound 46 (1.20 g, 3.24 mmol) in dry THF (6 mL) was cooled at 0 °C and treated with a 0.5 M solution of 9-BBN in THF (20 mL, 10 mmol). The reaction mixture was allowed to warm to room temperature and stirred overnight. The reaction mixture was cooled at 0 °C and treated with few drops of methanol, 3 N sodium hydroxide (5 mL) and 30% hydrogen peroxide (5 mL). The reaction mixture was vigorously stirred 2 h and neutralized with 10% hydrochloric acid. After evaporating of the solvent, the aqueous phase was extracted with dichloromethane. The organic phase was washed with brine, dried over magnesium sulfate, filtered, and evaporated. The crude mixture was purified by flash chromatography (dichloromethane-ethyl acetate 9-1 to dichloromethane-ethyl acetate 4-1) to provide the diol 54 (0.97 g, 77%): ¹H NMR (300 MHz, CDCl₃) δ 0.78 (s, 3H), 1.04 (s, 3H), 1.07-1.89 (m, 19H), 2.11 (dd, J =2.6 and 14 Hz, 2H), 2.55 (d, J =14.1 Hz, 1H), 3.60 (m, 3H), 3.92 (m, 4H), 5.32 (s, 1H).

Example 15B

15 α -[1-(3-tosyloxypropyl)]-5-androsten-17 β -ol-3-one 3-ethyleneketal (55). Under argon atmosphere, a solution of compound 54 (558 mg, 1.43 mmol) in dry pyridine (5 mL) was cooled at 0 °C, treated with p-toluenesulfonyl chloride (328 mg, 1.72 mmol), and stirred 5 h. The reaction mixture was diluted with ethyl acetate and washed with 10% hydrochloric acid and brine. The organic phase was dried over magnesium sulfate, filtered, and evaporated. The crude mixture was purified by flash chromatography (hexanes-ethyl acetate 9-1) to give the hydroxytosylate 55 (389 mg, 50%): ¹H NMR (300 MHz, CDCl₃) 0.74 (s, 3H), 1.04 (s, 3H), 1.06-1.76 (m, 19H), 2.12 (dd, J \approx 2 and 15 Hz, 2H), 2.45 (s, 3H), 2.55 (d, J =15 Hz, 1H), 3.58 (t, J \approx 8 Hz, 1H), 3.92-4.12 (m, 4H), 5.29 (s, 1H), 7.34 (d, J =8.4 Hz, 2H), 7.75 (d, J =8.2 Hz, 2H).

Example 15C

15 α -[1-(3-tosyloxypropyl)]-5-androsten-3,17-dione 3-ethyleneketal (56). Under argon atmosphere, a solution of compound 55 (258 mg, 0.474 mmol) in dry dichloromethane (10 mL) was treated with 4-methylmorpholine N-oxide (82 mg, 0.70 mmol) and molecular sieves 4Å, stirred 30 min, treated with a catalytic amount of tetrapropylammonium perruthenate (5 mg) and stirred 2 h. Filtrating and evaporating of the reaction mixture afforded a black residue which was purified by flash chromatography (hexanes-ethyl acetate 7-3) to provide the ketotosylate 56 (129 mg, 50%): ¹H NMR (300 MHz, CDCl₃) δ 0.74 (s, 3H), 1.05 (s 3H), 1.08-

2.16 (m, 20H), 2.45 (s, 3H), 2.54-2.66 (m, 2H), 3.90-4.00 (m, 4H), 4.03 (t, $J=6.4$ Hz, 2H), 5.30 (s, 1H), 7.35 (d, $J=8.4$ Hz, 2H), 7.79 (d, $J=8.2$ Hz, 2H).

Example 15D

15 α ,16 α -(1,3-propylene)-5-androsten-3,17-dione 3-ethyleneketal (57).

Under argon atmosphere, a solution of compound 56 in dry THF (10 mL) was cooled at 0 °C and treated with 1 M solution of lithium bis(trimethylsilyl)amide in THF (0.50 mL, 0.50 mmol) and HMPA (57.5 μ L, 0.330 mmol). The reaction mixture was stirred 10 min, quenched with saturated ammonium chloride, evaporated (THF) and extracted with dichloromethane. The organic phase was washed with brine, dried over magnesium sulfate, filtered, and evaporated. The crude mixture was purified by flash chromatography (hexanes-ethyl acetate 4-1 to hexanes-ethyl acetate 7-3) to provide the pentacyclic ketone 57 (96 mg, 78%): ^1H NMR (300 MHz, CDCl_3) δ 0.95 (t, $J=10.4$ Hz, 1H), 1.02 (s, 3H), 1.07 (s, 3H), 1.13-1.88 (m, 17H), 2.12 (dd, $J=2.6$ and 14.2 Hz, 2H), 2.55 (m, 2H), 2.99 (m, 1H), 3.95 (m, 4H), 5.3 (s, 1H).

Example 15E

15 α ,16 α -(1,3-propylene)-4-androsten-3,17-dione (58). The same procedure for compound 12 was used, starting from compound 57. The crude mixture was purified by flash chromatography (hexanes-ethyl acetate 4-1) to provide pentacyclic enone 58 (~100%): ^1H NMR (300 MHz, CDCl_3) δ 0.85 (t, $J=10.6$ Hz, 1H), 0.94-1.02 (m, 1H), 1.05 (s, 3H), 1.22 (s, 3H), 1.24-1.87 (m, 14H), 2.06 (m, 2H), 2.31-2.48 (m, 3H), 2.58 (m, 1H), 3.01 (m, 1H), 5.30 (s, 1H).

Example 15F

15 α ,16 α -(1,3-propylene)-4,6-androstadien-3,17-dione (59). The same procedure for compound 13 was used, starting from compound 58. The crude mixture was purified by 2 flash chromatographies (hexanes-acetone 9-1 and hexanes-ethyl acetate 97-3 to hexanes-ethyl acetate 17-3) to provide the pentacyclic dienone 59 (60%). The ^1H NMR spectrum shows the presence of pentacyclic enone 58 in 10%: ^1H NMR (300 MHz, CDCl_3) δ 1.04 (t, $J=\approx 10$ Hz, 1H), 1.09 (s, 3H), 1.13 (s, 3H), 1.22-1.86 (m, 12H), 1.99 (m, 1H), 2.16-2.60 (m, 3H), 2.72 (q, $J=8.2$ Hz, 1H), 3.05 (m, 1H), 5.70 (s, 1H), 6.18 (dd, $J=9.8$ and 2.5 Hz, 1H), 6.32 (d, $J=10$ Hz, 1H).


Example 16

6,17a,β-dimethyl/1α,6,17aβ-trimethyl-D-Homo-4,6-androstadien/1,4,6-androstatrien-17α-ol-3, 17-dione alkananoate

5

These syntheses are described in Scheme 13.

Scheme 13



10

Example 16A

6, 17a β -dimethyl-D-Homo-4,6-androstadien-17 α -ol-3,17-dione (60): The following example is a representative: Megestrol (44.1 g; 129 mmol) was dissolved in THF (550 mL). Sodium hydride (10.2 g; 3.2 eq.) was added portion-wise at 0 °C. After addition, the mixture was stirred for 9 h at room temperature and cooled to 0 °C, and water (300 mL) was added slowly. Approximately THF (300 mL) was evaporated under vacuum and another 300 mL of water was added. The suspension was cooled to 0 °C. Solid was filtered and washed with water. Solid, thus obtained was triturated with boiling MeOH (150 mL) and cooled to room temperature. This gave pure product which was filtered and washed with MeOH, and dried (36.4 g; 82 % yield).

Example 16B

6,17a β -dimethyl-D-Homo-1,4,6-androstatrien-17 α -ol-3,17-dione (61): Compound 60 (5 g; 14.7 mmol) and DDQ (10 g; 3 eq) in dioxane (60 mL) were refluxed for 3 h. Solvent was removed and the mixture in EtOAc was washed with saturated NaHCO₃ solution (3 times). Solvent was dried (MgSO₄) and evaporated to give the product. Purification on silica gel column (hexanes/acetone) gave the trienone 61 (3.7 g) in 76% yield.

Example 16C

1 α ,6,17a β -trimethyl-D-Homo-4,6-androstadien-17 α -ol-3,17-dione (63): This compound was prepared by following the methods, described above.

Example 16D

6, 17a β -dimethyl/1 α ,6,17a β -trimethyl-D-Homo-4,6-androstadien-17 α -ol-3,17-dione alkanoate (64): The alcohols were esterified by using the conditions A, B, C, D or E.

Example 16E

The followings are non-limiting examples of physicochemical characteristics of inhibitors of Example 16.

EM-1078 (64, R'=H, R=(CH₂)₂CH₃); Yield, 66 %; IR (KBr, cm⁻¹) 2948, 2871, 1735, 1660, 1624, 1577, 1458, 1375, 1317, 1269, 1188, 1099; ¹H NMR (CDCl₃) δ 0.80 (s, 3H, H-C18), 0.96 (t, 3H, H-C4', J=7 Hz), 1.06 (s, 3H, H-C19), 1.34 (s, 3H, 17a-CH₃), 1.87 (s, 3H, 6-CH₃), 2.01-2.06 (m, 2H), 2.32 (t, 2H, H-C2', J=7 Hz), 5.89 (s, 1H), 6.13 (s, 1H); ¹³C NMR (CDCl₃) δ 208.0, 200.0, 172.5, 163.7, 136.5, 131.8, 121.0, 87.6, 49.5, 45.4, 40.4, 37.3, 36.3, 36.1, 33.7, 33.4, 31.8, 26.1, 20.2, 19.8, 18.3, 16.2, 13.6, 13.0.

EM-1091 (64, R'=H, R=CH₂CH₃); Yield, 53 %; IR (KBr, cm⁻¹) 2944, 1734, 1664, 1625, 1581, 1444, 1352, 1273, 1194, 1098; ¹H NMR (CDCl₃) δ 0.77 (s, 3H, H-C18), 1.01 (s, 3H, H-C19), 1.12 (t, 3H, H-C3', J=7 Hz), 1.30 (s, 3H, 17a-CH₃), 1.83 (s, 3H, 6-CH₃), 2.34 (q, 2H, H-C2', J=7 Hz), 5.84 (s, 1H), 6.10 (s, 1H); ¹³C NMR (CDCl₃) δ 207.8, 199.8, 173.2, 163.5, 136.4, 131.9, 121.4, 121.2, 87.7, 49.7, 45.5, 40.6, 37.4, 36.2, 33.9, 33.6, 31.9, 27.9, 26.1, 20.2, 19.9, 16.3, 13.7, 13.1, 9.0.

EM-1098 (64, R'=H, R=CH₂Ph); Yield, 37 %; IR (KBr, cm⁻¹) 2946, 2869, 1735, 1657, 1624, 1578, 1456, 1268, 1127, 1098; ¹H NMR (CDCl₃) δ 0.72 (s, 3H, H-C18), 1.01 (s, 3H, H-C19), 1.30 (s, 3H, 17a-CH₃), 1.90 (s, 3H, 6-CH₃), 3.65 (s, 2H, H-C2'), 5.93 (s, 1H), 6.00 (s, 1H), 7.26 (s, 5H, Aromatics); ¹³C NMR (CDCl₃) δ 207.5, 199.9, 169.7, 165.6, 136.5, 131.6, 129.3, 128.6, 127.2, 121.0, 88.2, 49.6, 45.5, 42.0, 39.9, 37.2, 37.1, 36.1, 33.9, 33.5, 31.8, 25.8, 20.1, 20.2, 19.9, 19.2, 13.6, 14.0.

EM-1146 (64, R'=H, R=CH₂PhOCO-t-Bu(p)); Yield, 14 %; IR (KBr, cm⁻¹) 2955, 2871, 1736, 1660, 1624, 1582, 1508, 1458, 1393, 1270, 1202, 1166, 1117; ¹H NMR (CDCl₃) δ 0.69 (s, 3H, H-C18), 1.05 (s, 3H, H-C19), 1.31 (s, 3H, 17a-CH₃), 1.34 (s, 9H, t-Butyl), 1.88 (s, 3H, 6-CH₃), 3.64 (s, 2H, H-C2'), 5.90 (s, 1H), 6.10 (s, 1H), 6.97 (d, 2H, J=8.3 Hz), 7.28 (d, 2H, J=8.3 Hz); ¹³C NMR (CDCl₃) δ 207.7, 199.9, 177.0, 169.7, 163.6, 150.5, 136.7, 131.7, 130.5, 130.4, 121.9, 121.2, 88.4, 49.8, 45.6, 41.4, 40.2, 39.1, 37.4, 37.2, 36.2, 33.8, 33.6, 31.8, 27.1, 25.9, 20.2, 19.9, 16.3, 13.7, 13.1.

CS-259 (64, R'=H, R=(CH₂)₅Br); Yield, 32 %; IR (KBr, cm⁻¹) 2943, 2869, 1734, 1660, 1624, 1579, 1458, 1375, 1270, 1194, 1099; ¹H NMR (CDCl₃) δ 0.81 (s, 3H, H-C18), 1.06 (s, 3H, H-C19), 1.34 (s, 3H, 17a-CH₃), 1.87 (s, 3H, 6-CH₃), 1.89-2.07 (m, 1H), 2.38 (t, 2H, H-C2', J=7 Hz), 3.40 (t, 2H, H-C6', J=7 Hz), 5.89 (s, 1H), 6.13 (s, 1H); ¹³C NMR (CDCl₃) δ 207.8, 199.8, 172.2, 163.5, 136.4, 131.8, 121.0, 87.8, 49.5, 45.3, 40.4, 37.3, 36.1, 34.1, 33.7, 33.4, 32.1, 31.8, 27.5, 26.0, 23.8, 20.2, 19.8, 16.1, 13.6, 13.0.

CS-260 (64, R'=H, R=(CH₂)₄CH₃); Yield, 41 %; IR (KBr, cm⁻¹) 2953, 2870, 1735, 1660, 1624, 1579, 1458, 1375, 1317, 1270, 1098; ¹H NMR (CDCl₃) δ 0.79 (s, 3H, H-C18), 0.87 (t, 3H, H-C6'), 1.06 (s, 3H, H-C19), 1.32 (s, 3H, 17a-CH₃), 1.86 (s, 3H, 6-CH₃), 2.00-2.06 (m, 2H), 2.33 (t, 2H, H-C2', J=7 Hz), 5.88 (s, 1H), 6.12 (s, 1H); ¹³C NMR (CDCl₃) δ 208.0, 199.9, 172.7, 163.6, 136.5, 131.9, 121.2, 87.7, 49.7, 45.5, 40.5, 37.4, 36.2, 34.4, 33.8, 33.5, 31.9, 31.3, 26.1, 24.5, 22.3, 20.2, 19.9, 16.2, 13.9, 13.7, 13.1.

5 CS-237 (64, R¹=H, □1, R=CH₃); Yield 67%; IR (CDCl₃) 1735, 1652, 1609, 1582 cm⁻¹; ¹H NMR (CDCl₃) δ 0.79 (s, 3 H), 1.1 (s, 3 H), 1.29 (s, 3 H), 1.89 (s, 3 H), 2.02 (s, 3 H), 2.41-2.50 (m, 1 H), 5.96 (s, 1 H), 6.17 (s, 1 H), 6.24 (d, 1 H, J=10 Hz), 7.06 (d, 1 H, J=10 Hz); ¹³C NMR (CDCl₃) δ 207.6, 186.3, 169.9, 162.7, 153.1, 132.7, 132.3, 127.8, 121.5, 87.7, 77.4, 77, 76.6, 47.2, 45, 41.1, 40.7, 38, 37.2, 31.7, 26.1, 21.3, 21.1, 20.2, 19.5, 13.6, 13.

10 CS-240 (64, R=CH₃); Yield 70%; IR (CDCl₃) 1737, 1651, 1622, 1578 cm⁻¹; ¹H NMR (CDCl₃) δ 0.78 (s, 3 H), 0.96 (d, 3 H, J=7 Hz), 1.12 (s, 3 H), 1.31 (s, 3 H), 1.84 (s, 3 H), 2.01 (s, 3 H), 2.80-2.90 (dd, 1 H, J=5.1, 17.5 Hz), 5.85 (s, 1 H), 6.1 (s, 1 H); ¹³C NMR (CDCl₃) δ 207.8, 199.4, 169.9, 159.9, 136.5, 132.5, 120.6, 87.9, 45.5, 44, 42, 40.6, 39.3, 37.4, 37.3, 35.5, 31.8, 26, 21.2, 20.2, 19.3, 18.8, 14.8, 13.7, 13.

15 EM-1117 (64, R=Cyhex); Yield 38%; IR (CDCl₃) 1731, 1703, 1658, 1619, 1578 cm⁻¹; ¹H NMR (CDCl₃) δ 0.80 (s, 3 H), 0.99 (d, 3 H, J=7 Hz), 1.14 (s, 3 H), 1.31 (s, 3 H), 1.87 (s, 3 H), 5.89 (s, 1 H), 6.1 (s, 1 H); ¹³C NMR (CDCl₃) δ 208.1, 199.7, 174.7, 160.2, 136.7, 132.5, 120.6, 87.4, 45.7, 44.2, 43, 42.8, 42.1, 40.9, 39.4, 37.4, 35.6, 32, 29.7, 28.9, 28.8, 28.7, 26.2, 25.6, 25.3, 25.2, 20.3, 19.4, 18.9, 14.9, 13.8, 13.2.

25 EM-1121 (64, R=(CH₂)₃CH₃); Yield 70%; IR (CDCl₃) 1735, 1657, 1622, 1578 cm⁻¹; ¹H NMR (CDCl₃) δ 0.77 (s, 3 H), 0.85 (t, 3 H, J=7 Hz), 0.94 (d, 3 H, J=7 Hz), 0.87 (s, 3 H), 1.11 (s, 3 H), 1.83 (s, 3 H), 2.33 (t, 2 H, J=7.4 Hz), 2.47 (m, 1 H), 2.80-2.88 (dd, 1 H, J=5.3, 17.8 Hz), 5.84 (s, 1 H), 6.09 (s, 1 H); ¹³C NMR (CDCl₃) δ 207.9, 199.4, 172.7, 160, 136.5, 132.4, 120.5, 87.6, 45.5, 44, 42, 40.7, 39.2, 37.4, 37.3, 35.5, 34, 31.9, 26.7, 26, 22.1, 20.2, 19.3, 18.8, 14.8, 13.7, 13.6, 13.

30 EM-1142 (64, R=(CH₂)₄CH₃); Yield 39%; IR (CDCl₃) 1735, 1657, 1621, 1578 cm⁻¹; ¹H NMR (CDCl₃) δ 0.80 (s, 3 H), 0.87 (t, 3 H, J=7 Hz), 0.98 (d, 3 H, J=7 Hz), 1.15 (s, 3 H), 1.33 (s, 3 H), 1.87 (s, 3 H), 2.84-2.91 (dd, 1 H, J=5.1, 17.6 Hz), 5.89 (s, 1 H), 6.11 (s, 1 H); ¹³C NMR (CDCl₃) δ 208.10, 199.6, 172.8, 160.1, 136.6, 132.5, 120.6, 87.7, 45.6, 44.2, 42.1, 40.8, 39.4, 37.5, 37.6, 34.4, 33.8, 32, 31.2, 26.1, 24.4, 22.3, 20.3, 19.4, 18.9, 14.9, 13.9, 13.2.

40 EM-1143 (64, R=CH(CH₃)₂); Yield 34%; IR (CDCl₃) 1733, 1657, 1622, 1578 cm⁻¹; ¹H NMR (CDCl₃) δ 0.80 (s, 3 H), 0.96 (d, 3 H, J=7 Hz), 1.14 (s, 3 H), 1.17 (d, 3 H, J=7 Hz), 1.18 (d, 3 H, J=7 Hz), 1.31 (s, 3 H), 1.86 (s, 3 H), 2.84-2.92 (dd, 1 H, J=5.1, 17.6 Hz), 5.87 (s, 1 H), 6.1 (s, 1 H); ¹³C NMR (CDCl₃) δ 207.8, 199.5, 175.8, 160, 136.5, 132.6, 120.7, 87.5, 61.9, 45.8, 44.2, 42.1, 40.9, 39.4, 37.4, 35.6, 34.1, 32, 26.2, 20.3, 19.4, 18.9, 18.7, 14.9, 14.1, 13.8, 13.1.

5 EM-1144 (64, R=CH₂Ph); Yield 34%; IR (CDCl₃) 1734, 1654, 1623, 1578 cm⁻¹; ¹H NMR (CDCl₃) δ 0.72 (s, 3 H), 0.99 (d, 3 H, J=7 Hz), 1.06 (s, 3 H), 1.29 (s, 3 H), 1.89 (s, 3 H), 2.83-2.90 (dd, 1 H, J=5, 17.4 Hz), 3.66 (s, 2 H), 5.91 (s, 1 H), 5.96 (s, 1 H); ¹³C NMR (CDCl₃) δ 207.6, 199.5, 169.7, 160, 136.6, 133.6, 132.2, 129.4, 128.7, 127.2, 120.5, 88.1, 45.7, 44, 42, 40.1, 39.2, 37.2, 37.1, 35.6, 31.8, 25.8, 20.2, 19.3, 18.8, 14.9, 13.7, 13.


10 EM - 1154 (64, R=Cypent); Yield 30%; IR (CDCl₃) 1731, 1657, 1622, 1578 cm⁻¹; ¹H NMR (CDCl₃) δ 0.79 (s, 3 H), 0.97 (d, 3 H, J=7 Hz), 1.14 (s, 3 H), 1.31 (s, 3 H), 1.86 (s, 3 H), 2.79-2.84 (m, 2 H), 5.87 (s, 1 H), 6.1 (s, 1 H); ¹³C NMR (CDCl₃) δ 208.1, 199.5, 175.5, 160, 136.6, 132.6, 120.7, 87.5, 45.7, 44.2, 43.8, 42.1, 40.9, 39.4, 37.4, 37.3, 35.6, 32, 29.9, 29.6, 26.2, 25.8, 25.7, 20.3, 19.4, 18.9, 14.9, 13.8, 13.1.

Example 17

Synthesis of 4-aza-androstan-3-one-spiro γ/δ -lactone derivatives

5 These syntheses are described in Scheme 14.

Scheme 14



Example 17A**General Procedure for 66a and 66c:**

A flask was charged with $\text{HC}\equiv\text{C}(\text{CH}_2)_n\text{OTHP}$ ($n=2$ or 3) (41.5 mmol) and dry THF (300 mL) under argon, and cooled to -50°C in a cold bath. To this solution, was added $n\text{-BuLi}$ (1.6 M, 41.4 mmol) via a syringe slowly, and the solution was allowed to warm up to 0°C over a course of 2 h. Then, the solution was cooled to -78°C , and the ketone 65a (10.4 mmol) was added as a solid. The reaction mixture was stirred and allowed to warm up to room temperature over a course of 3 h, and stirred for additional 2 h at room temperature. Saturated aqueous NH_4Cl solution (50 mL) was added. The resulting two phase was separated, and water phase was extracted with CH_2Cl_2 (2 x 100 mL). The combined solvents were removed and the residue was extracted with CH_2Cl_2 (2 x 150 mL). Solution was washed with brine and dried over MgSO_4 . Solvent was removed on a rotary evaporator. The purification of the residue by flash column gave the product as a white solid.

17 β -Hydroxy-17 α -[4'-(2"-tetrahydro-2"H-pyranyloxy)butyn-1'-yl]-4-aza-5 α -androstan-3-one (66a): Yield, 73%; IR (KBr, cm^{-1}) 3520-3210 (br), 2906, 2838, 1642; ^1H NMR (CDCl_3) δ 0.81 (s, 3H, 18- CH_3), 0.88 (s, 3H, 19- CH_3), 2.52 (dd, 2H, $J=4.8, 11.2$ Hz), 2.61 (t, 2H, $J=7.7$ Hz), 3.01 (dd, 1H, $J=3.2, 12.2$ Hz), 3.48-3.56 (m, 2H), 3.78-3.86 (m, 2H), 4.64 (t, 1H, $J=3.1$ Hz), 6.14 (br, s, 1H); ^{13}C NMR (CDCl_3) 172.4, 98.6, 84.6, 83.1, 79.6, 65.8, 62.0, 60.7, 50.9, 49.9, 35.7, 35.6, 33.3, 32.6, 30.5, 29.6, 29.2, 29.0, 28.5, 27.2, 25.4, 22.9, 20.8, 20.3, 19.3, 12.8, 11.3.

17 β -Hydroxy-17 α -[5'-(2"-tetrahydro-2"H-pyranyloxy)pentyn-1'-yl]-4-aza-5 α -androstan-3-one (66c): Yield, 70%; IR (KBr, cm^{-1}) 3242, 3136, 2906, 2842, 1642; ^1H NMR (CDCl_3) δ 0.78 (s, 3H, 18- CH_3), 0.86 (s, 3H, 19- CH_3), 2.28-2.58 (m, 3H), 3.0 (dd, 1H, $J=3.4, 12.3$ Hz), 3.39-3.47 (m, 2H), 3.74-3.84 (m, 2H), 4.55 (br s, 1H), 6.44 (s, 1H); ^{13}C NMR (CDCl_3 , ppm) δ 172.3, 98.7, 85.3, 84.0, 79.5, 65.8, 62.1, 60.7, 50.9, 49.8, 46.9, 38.9, 35.6, 33.3, 32.5, 30.5, 29.3, 29.0, 28.9, 28.5, 27.1, 25.3, 22.9, 20.8, 19.4, 15.6, 12.8, 11.3.

Example 17B

17 β -Hydroxy-17 α -[4'-(2"-tetrahydro-2"H-pyranyloxy)butyn-1'-yl]-4-methyl-4-aza-5 α -androstan-3-one (66b): A flask was charged with $\text{HC}\equiv\text{C}(\text{CH}_2)_2\text{OTHP}$ (3.05g, 19.8 mmol) and anhydrous THF (200 mL) under argon, and cooled to -50°C in a cold bath. To this solution was added $n\text{-BuLi}$ (1.6 M, 19.8 mmol) and the solution was allowed to warm up to 0°C over a course of 2 h. Then, the solution was cooled to -78°C , and ketone 65b in dry THF (100 mL) was added via a cannula. The

reaction mixture was stirred under argon and allowed to warm up to room temperature over a course of 3 h, and stirred for additional 2 h at room temperature. Saturated aqueous NH_4Cl solution (50 mL) was added. The resulting two phase was separated, and water phase was extracted with CH_2Cl_2 (2 x 100 mL). The combined solvents were removed and the residue was extracted with CH_2Cl_2 (2 x 150 mL). Solution was washed with brine and dried over MgSO_4 . Solvent was removed on a rotary evaporator. The purification of the residue by a flash column gave the product as a white solid (3.18 g, 7.12 mmol, 72%); IR (KBr, cm^{-1}) 3530-3130 (br), 2920, 2850, 1620; ^1H NMR (CDCl_3) δ 0.84 (s, 3H, 18- CH_3), 0.90 (s, 19- CH_3), 2.54 (t, 2H, $J=7.1$ Hz), 2.93 (s, 3H), 3.54 (dd, 1H, $J=3.3, 12.9$ Hz), 3.51-3.59 (m, 2H), 3.78-3.89 (m, 2H), 4.11-4.64 (m, 1H); ^{13}C NMR (CDCl_3 , ppm) δ 172.1, 98.2, 84.1, 83.1, 79.4, 65.9, 65.2, 62.1, 60.9, 60.7, 53.8, 50.7, 49.8, 46.5, 38.3, 35.6, 35.4, 33.1, 31.3, 29.4, 28.3, 27.5, 26.8, 25.7, 21.4, 20.9, 20.6, 12.7, 11.4.

Example 17C

General procedure for 67a - 67c: Compound 66 (5 mmol) was dissolved in methanol (100 mL) and amberlyst-15 (0.4 g) was added. The reaction mixture was stirred for 2 to 3 h (monitored by TLC) at room temperature and filtered. Solvent was removed on a rotary evaporator, and purification of the residue by flash column gave product as a white solid.

17 β -Hydroxy-17 α -[4'-hydroxybutyn-1'-yl]-4-aza-5 α -androstan-3-one (67a): Yield, 87%; IR (KBr, cm^{-1}) 3490-3108 (br), 2910, 2832, 1636; ^1H NMR (CDCl_3) δ 0.80 (s, 3H, 18- CH_3), 0.86 (s, 3H, 19- CH_3), 2.45 (t, 2H, $J=6.9$ Hz), 3.02 (dd, 1H, $J=3.4, 12.1$ Hz), 3.67 (t, 2H, $J=6.8$ Hz), 6.23 (br, s, 1H); ^{13}C NMR (CDCl_3 , ppm) δ 172.6, 85.6, 82.7, 79.3, 60.8, 60.6, 50.8, 49.7, 49.2, 46.8, 38.8, 35.6, 33.1, 32.6, 29.0, 28.4, 27.0, 23.1, 22.9, 20.7, 12.8, 11.2.

17 β -Hydroxy-17 α -[4'-hydroxybutyn-1'-yl]-4-methyl-4-aza-5 α -androstan-3-one (67b): Yield, 91%; IR (KBr, cm^{-1}) 3540-3120, 2904, 2836, 1624; ^1H NMR (CDCl_3) δ 0.83 (s, 3H, 18- CH_3), 0.89 (s, 3H, 19- CH_3), 2.43-2.51 (m, 4H), 2.92 (s, 3H), 3.35 (dd, 1H, $J=3.4, 12.5$ Hz), 3.69 (t, 2H, $J=6.2$ Hz); ^{13}C NMR (CDCl_3 , ppm) δ 171.1, 85.6, 82.8, 79.4, 65.7, 60.9, 60.7, 51.6, 49.9, 46.9, 38.9, 36.4, 34.9, 32.8, 29.7, 29.6, 29.2, 29.0, 25.2, 23.2, 22.9, 20.8, 12.9, 12.4

17 β -Hydroxy-17 α -{5'-hydroxypentyn-1'-yl}-4-aza-5 α -androstan-3-one (67c): Yield, 84%; IR (KBr, cm⁻¹) 3530-3082, 2902, 2842, 1618; ¹H NMR (CDCl₃) δ 0.83 (s, 3H, 18-CH₃), 0.89 (s, 3H, 19-CH₃), 2.24(t, 2H, J=6.9 Hz), 2.29 (dd, 2H, J= 4.7, 5.5 Hz), 2.95 (dd, 1H, J=3.8, 12.6 Hz), 3.59 (t, 2H, J=6.3 Hz), 6.26 (br, s 1H); ¹³C NMR (CDCl₃, ppm) δ 173.0, 84.9, 83.9, 79.2, 60.7, 60.4, 50.7, 49.7, 46.7, 38.7, 35.4, 32.9, 31.1, 28.9, 28.8, 28.1, 26.7, 22.8, 20.6, 15.1, 12.7, 11.1.

Example 17D

General procedure for 68a - 68c: A flask was charged with compound 67 (5 mmol), 10 mmol % of Pd/C, CH₃OH (30 mL), ethyl acetate (120 mL) and stir bar, and then the compound was hydrogenated using a balloon. The reaction mixture was stirred at room temperature for 3 h and filtered. Solvent was removed on a rotary evaporator, and purification of the residue by flash column gave product as a white solid.

17 β -Hydroxy-17 α -{4'-hydroxybutan-1'-yl}-4-aza-5 α -androstan-3-one (68a): Yield, 65%; ¹H NMR (CDCl₃) δ 0.87 (s, 3H, 18-CH₃), 0.91 (s, 3H, 19-CH₃), 2.39-2.44(m, 2H), 3.04 (dd, 1H, J=4.2, 11.9 Hz), 3.67 (t, 2H, J=5.8 Hz), 5.93 (br, s 1H).

17 β -Hydroxy-17 α -{4'-hydroxybutan-1'-yl}-4-methyl-4-aza-5 α -androstan-3-one (68b): Yield, 81%; ¹H NMR (CDCl₃) δ 0.87 (s, 3H, 18-CH₃), 0.89 (s, 3H, 19-CH₃), 2.41-2.46(m, 2H), 2.92 (s, 3H), 3.02 (dd, 1H, J=3.5, 12.5 Hz), 3.68-7.26 (br, s, 2H).

17 β -Hydroxy-17 α -{5'-hydroxypentan-1'-yl}-4-aza-5 α -androstan-3-one (68c): Yield, 76%; IR (thin film, cm⁻¹) 1663 (s); ¹H NMR (CDCl₃) δ 0.87 (s, 3H, 18-CH₃), 0.92 (s, 3H, 19-CH₃), 2.41-2.46 (m, 2H), 3.08 (dd, 1H, J=4.8, 11.5 Hz), 3.62 (br, s, 2H), 5.48 (br, s, 1H); ¹³C NMR (CDCl₃) δ 172.3, 83.2, 62.8, 60.8, 51.2, 50.1, 46.6, 36.6, 35.9, 35.8, 34.3, 33.4, 32.7, 31.4, 29.4, 28.6, 27.3, 26.6, 23.6, 23.3, 20.9, 14.5, 11.4.

Example 17E

General procedure for 69a and 69b: Alcohol 68 (5 mmol) was dissolved in 150 mL of acetone and the solution was cooled to 0 °C in an ice bath. Jones' reagent (0.5 M, 12.5 mmol) was added dropwise. After addition, the mixture was stirred for 30 min at 0 °C. Then 100 mL of water was added and product was extracted with CH₂Cl₂ (3 x 150 mL). The combined organic layer was washed with saturated aqueous NaHCO₃ solution, water and brine, and then dried over MgSO₄. Solvents were

removed on a rotary evaporator and the purification of the residue by flash column gave product as a white solid.

4-aza-5 α -androstan-3-one-17(R)-spiro-2'-(6'-oxo)tetrahydropyran) (69a):

Yield, 58%; IR (thin film, cm⁻¹) 1725 (s), 1663 (s). ¹H NMR (CDCl₃) δ 0.92 (s, 3H, 18-CH₃), 0.98 (s, 3H, 19-CH₃), 5.53 (s, 1H, br, NH); ¹³C NMR (CDCl₃) δ 172.2, 171.9, 93.0, 59.5, 51.0, 49.3, 47.1, 35.7, 35.4, 33.8, 33.4, 31.7, 29.3, 29.2, 28.5, 27.8, 27.1, 23.6, 20.6, 15.8, 14.4, 11.3. Anal. Calcd for C₂₂H₃₃NO₃: C 73.50; H 9.25, N 3.90. Found: C 73.23; H 9.29, N 3.78.

4-methyl-4-aza-5 α -androstan-3-one-17(R)-spiro-2'-(6'-

oxo)tetrahydropyran) (69b): Yield, 64%; IR (thin film, cm⁻¹) 1727 (s), 1641 (s); ¹H NMR (CDCl₃) δ 0.89 (s, 3H, 18-CH₃), 0.97 (s, 3H, 19-CH₃), 2.91 (s, 3H, NMe); ¹³C NMR (CDCl₃, ppm) δ 171.9, 170.6, 93.0, 65.6, 51.7, 49.3, 47.0, 36.4, 34.7, 33.9, 32.9, 31.8, 29.9, 29.4, 29.0, 27.8, 25.2, 23.6, 20.6, 15.8, 14.4, 12.3. Anal. Calcd for C₂₃H₃₅NO₃: C 73.96; H 9.44, N 3.75. Found: C 73.85; H 9.59, N 3.50.

Example 17F

General procedure for 71a and 71b: A flask was charged with 69 (1.11 mmol), DDQ (1.11 mmol) and anhydrous dioxane (8 mL).

Bis(trimethylsilyl) trifluoroacetamide (BSTFA) (4.56 mmol) was added via a syringe. The reaction mixture was stirred at room temperature under argon for 18 h, and then refluxed for 8 h. The mixture was poured into CH₂Cl₂ (80 mL), and the solution was washed with saturated NaHCO₃ (2 x 50 mL) and Brine. The organic layer was dried over MgSO₄. Solvents were removed on a rotary evaporator and the residue purified by a flash column to give product as a white solid.

4-aza-5 α -androst-1-en-3-one-17(R)-spiro-2'-(6'-oxo)tetrahydropyran

(71a): Yield, 52%; IR (thin film, cm⁻¹) 1715 (s), 1674 (s), 1599 (m). ¹H NMR (CDCl₃) δ 0.95 (s, 3H, 18-CH₃), 0.96 (s, 3H, 19-CH₃), 5.76 (d, 1H, J=10.0 Hz, CH=CH), 6.67 (br, s, 1H, NH), 6.76 (d, 1H, J=10.0 Hz, CH=CH); ¹³C NMR (CDCl₃) δ 172.0, 166.9, 151.0, 123.0, 92.9, 59.6, 49.3, 47.4, 47.2, 39.3, 35.6, 33.8, 31.7, 29.4, 29.1, 27.8, 25.6, 23.7, 20.7, 15.7, 14.5, 11.9.

4-methyl-4-aza-5 α -androst-1-en-3-one-17(R)-spiro-2'-(6'-

oxo)tetrahydropyran (71b): Yield, 25%; IR (thin film, cm⁻¹) 1725 (s), 1661 (s), 1604 (m); ¹H NMR (CDCl₃) δ 0.92 (s, 3H, 18-CH₃), 0.98 (s, 3H, 19-CH₃), 2.93 (s, 3H, NMe), 5.83 (d, 1H, J=9.9 Hz, CH=CH), 6.67 (d, 1H, J=9.9 Hz, CH=CH); ¹³C NMR (CDCl₃) δ 171.9, 165.5, 148.5, 123.2, 92.9, 63.7, 49.2,

- 214 -

47.6, 47.1, 39.5, 35.0, 33.9, 31.7, 29.6, 29.4, 27.8, 27.6, 24.3, 23.6, 20.7, 15.7, 14.5, 12.1.

Example 17G

5 **17 β -Hydroxy-17 α -[4'-carboxybutan-1'-yl]-4-methyl-4-aza-5 α -androstan-3-one (70):** Alcohol 68c (1.82 g, 5.00 mmol) was dissolved in 100 mL of acetone and the solution was cooled to 0 °C in an ice bath. Jones' reagent (0.5 M, 25.0 mL, 12.5 mmol) was added dropwise. Then saturated aqueous NaHCO₃ (150 mL) and ethyl acetate (100 mL) were added and
10 the mixture was stirred vigorously for overnight. Two phases were separated and the water phase was acidified using 1 M HCl. The acidic solution was extracted with CH₂Cl₂ (3 x 120 mL). The combined organic layer were washed with water and brine, and then dried over MgSO₄. Removal of solvents gave the product as a white solid (1.25 g, 3.20 mmol, 64%); IR (thin film, cm⁻¹) 1704 (s), 1632 (s); ¹H NMR (pyridine-d₅) δ 1.22 (s, 3H, 18-CH₃), 1.45 (s, 3H, 19-CH₃), 8.41 (s, 1H, NH); ¹³C NMR (pyridine-d₅) δ 176.1, 171.4, 82.6, 60.9, 51.5, 50.5, 47.2, 37.5, 36.2, 35.9, 35.2, 34.5, 34.0, 32.1, 29.9, 29.4, 27.5, 26.8, 24.2, 21.3, 15.4, 11.4.

Example 17H


20 **Preparation of the lactone 72:** To acid 70 (100 mg, 0.258 mol) in 20 mL of CH₂Cl₂ was added oxalyl chloride (1.2 eq, 42 mL) at 0 °C under argon, and the reaction mixture was stirred for 1 h. After 1h, no more acid was detected on the TLC. Then, pyridine (4 eq, 50 mL) was added and the
25 mixture was stirred for 48 h at room temperature. The product was extracted with ethyl acetate, dried over MgSO₂ and purified by a flash column using CH₂Cl₂/MeOH (gradient, 2 to 8 %) as an eluent to give the lactone 72 as a white solid (43 mg, 45%); IR (thin film, cm⁻¹) 1714 (s), 1660 (s); ¹H NMR (CDCl₃, ppm) δ 0.88 (s, 3H, 18-CH₃), 0.96 (s, 3H, 19-CH₃), 6.57 (s, 1H, NH); ¹³C NMR (CDCl₃, ppm) δ 175.6, 172.8, 60.7, 51.2, 48.8, 36.1, 35.6, 33.6, 33.3, 30.9, 30.6, 29.7, 28.5, 27.1, 24.2, 24.1, 23.1, 22.6, 20.6, 15.3, 14.1, 11.4.

Example 18

Syntheses of unsubstituted-A-ring-1,3,5(10)-estratrien-17-spiro- δ -lactone derivatives

These syntheses are described in Scheme 15.

Scheme 15

a: Tf₂O pyridineb: HCOOH, PPh₃, Pd(OAc)₂, Et₃N

c: tetrahydro-2-(butynyloxy)-2-H-pyran, THF, n-BuLi, 0 °C

d: H₂, 10% Pd on charcoal

e: p-TSA, methanol, room temperature

f: 1) Jones' reagent, acetone; 2) isopropyl alcohol

g: n-BuLi, diisopropylamine, THF, CH₃I, room temperature

Example 18A

Synthesis of 3-deoxygenated-estrone (74). At 0 °C, 1.0 g (3.7 mmol) of estrone (73) was dissolved in 50 mL of dry pyridine and 1.24 mL (7.4 mmol) of trifluoroacetic anhydride (Tf₂O) was added slowly to the solution. After 1 h, the crude solution was poured into a cold aqueous solution of CuSO₄ (1M) and the organic phase washed with the same solution until the blue color disappear. Next, the solution was extracted with EtOAc and the organic phase washed with water, and dried over MgSO₄. After evaporation of the solvent, the crude estrone-triflate was dissolved in 50 mL of dry DMF. To the resulting mixture, we added 1.54 mL (11 mmol) of Et₃N, 0.41 mL (11 mmol) of HCOOH, 0.143 mg (0.55 mmol) of PPh₃, and 30.8 mg (0.14 mmol) of Pd(OAc)₂. After 3 h at room temperature, the solution was quenched with aqueous HCl (5%) and extracted with CH₂Cl₂. The organic phase was washed with water, dried over MgSO₄, and solvents evaporated to dryness. The crude compound was purified by flash chromatography with hexanes/EtOAc (9:1) as eluent to give 615 mg (65% two steps) of 1,3,5(10)-estratrien-17-one (74). White solid; IR ν (film): 1738 (C=O); ¹H NMR (CDCl₃) δ 0.94 (s, 3H, 18-CH₃), 2.94 (m, 2H, 6-CH₂), 7.16 (m, 3H, 1-CH, 2-CH, 3-CH), 7.32 (d, J=5.9 Hz, 1H, 4-CH); ¹³C NMR (CDCl₃) δ 13.76 (C-18), 21.51 (C-15), 25.61 (C-11), 26.42 (C-7), 29.29 (C-6), 31.56 (C-12), 35.77 (C-16), 38.04 (C-8), 44.40 (C-9), 47.88 (C-13), 50.49 (C-14), 125.22 (C-3), 125.73 (C-2 and C-1), 128.98 (C-4), 136.37 (C-5), 139.62 (C-10), 220.63 (C-17).

Example 18B

Synthesis of alcohol 75. To a solution of tetrahydro-2-(butynyloxy)-2H-pyran (0.94 mL, 5.9 mmol) in 30 mL of dry THF was added at 0 °C, 3.53 mL of *n*-BuLi 1.6 M (5.7 mmol), and the mixture was stirred for 40 min. A solution of 3-deoxygenated-estrone (74) (500 mg, 1.96 mmol) in 10 mL of THF was then added dropwise at -78 °C and the mixture stirred for 11 h. After this time, a solution of aqueous NaHCO₃ (5%) was added and aqueous phase was extracted with EtOAc. Organic layer was washed with brine, and dried over MgSO₄. After evaporation of solvent, the crude compound was purified by flash chromatography with hexane/EtOAc (9:1) as eluent to give 566 mg (68%) of 17 β -hydroxy-17 α -[4'-(tetrahydro-2''H-pyranyl)oxy] butynyl]-1,3,5(10)-estratrien (75). Colorless oil; IR ν (film): 3438 (OH, alcohol), 2233 very weak (C \equiv C); ¹H NMR (CDCl₃) δ 0.88 (s, 3H, 18-CH₃), 2.57 (t, J=7.0 Hz, 2H, C \equiv CCH₂), 2.87 (m, 2H, 6-CH₂), 3.55 and 3.86 (2m, 4H, CH₂O of side chain and CH₂O of THP), 4.68 (s_{app}, 1H, CH of THP), 7.13 (m, 3H, 1-CH, 2-CH, 3-CH), 7.31 (d, J=6.7 Hz, 1H, 4-CH); ¹³C NMR (CDCl₃) δ 12.72 (C-18), 19.21 (C-4'' of THP), 20.30 (C-3'), 22.76 (C-15), 25.37 (C-5'' of THP), 26.18 (C-11), 27.13 (C-7), 29.49 (C-6), 30.48 (C-3'' of THP), 32.87 (C-12), 38.98 (C-16), 39.14 (C-8), 43.07 (C-9), 47.07 (C-13), 49.53 (C-14),

61.95 (C-2" of THP), 65.78 (C-4'), 79.81 (C-17), 83.07 (C-2'), 84.68 (C-1'), 98.58 (C-1" of THP), 125.25 (C-3), 125.47 (C-2), 125.51 (C-1), 128.91 (C-4), 136.62 (C-5), 140.22 (C-10).

Example 18C

Synthesis of lactone 77

a) Reduction of triple bond (75 -> 78a). To a solution of compound 75 (650 mg, 1.6 mmol) in EtOAc was added 40 mg of palladium on activated charcoal (10%), and the mixture was stirred at room temperature overnight under an hydrogen atmosphere. After this time, it was filtered through celite, washed with EtOAc, and evaporated to dryness to give the compound 78a as a white foam.

b) Hydrolysis of THP group (78a -> 78b). The crude alcohol 78a was dissolved in 60 mL of methanol and 20 mg of *p*-TSA was added. After 2 h at room temperature, water was added to the mixture, the methanol was evaporated, and the resulting mixture extracted with EtOAc. The organic phase was washed with water and dried over MgSO₄. Then the solvent was evaporated to dryness to give 455 mg of crude diol 78b.

c) Jones' oxidation with lactonization (78b -> 77) The crude diol 78b (450 mg) was dissolved in 30 mL of acetone and 0.9 mL of Jones' reagent (2.7M) was added dropwise at 0 °C. After the addition was completed, the mixture was stirred at room temperature for 2 h. Then 2 mL of isopropyl alcohol was added and the resulting green solution was evaporated to dryness. The solid was dissolved in water and EtOAc, and the mixture extracted with EtOAc. Organic layer was washed with brine and dried over MgSO₄. After evaporation of solvent, the crude compound was purified by flash chromatography with hexanes/EtOAc (8:2) as eluent to give 392 mg (65%, three steps) of 1,3,5(10)-estratrien-17(R)-spiro-2'-(6'-oxo)tetrahydropyran (77). White solid; IR ν (KBr): 1732 (C=O, lactone); ¹H NMR (CDCl₃) δ 1.03 (s, 3H, 18-CH₃), 2.88 (m, 2H, 6-CH₂), 7.12 (m, 3H, 1-CH, 2-CH, 3-CH), 7.29 (d, *J*=5.8 Hz, 1H, 4-CH); ¹³C NMR (CDCl₃) δ 14.03 (C-18), 15.59 (C-2'), 23.22 (C-15), 25.54 (C-11), 27.13 (C-1'), 27.63 (C-7), 29.17 (C-6 and C-3'), 31.69 (C-12), 33.67 (C-16), 38.56 (C-8), 43.83 (C-9), 46.92 (C-13), 48.64 (C-14), 92.93 (C-17), 124.92 (C-3), 125.39 (C-1 and C-2), 128.70 (C-1), 136.18 (C-10), 139.56 (C-5), 171.70 (C-4'); EI-HRMS: calcd for C₂₂H₂₈O₂ 324.20892, found 324.20702.

Example 18D

Synthesis of lactones 76a and 76b. A mixture of 127 μ L (1.0 mmol) of diisopropylamine, 0.5 mL (0.80 mmol) of *n*-BuLi (1.6M) and 5 mL of dry THF was stirred at 0 °C for 30 min. The solution was cooled at -78 °C, and 75 mg (0.233 mmol) of lactone 77 in 10 mL of dry THF was added dropwise. After 1 h, 90 μ L of CH₃I was added and the mixture stirred overnight and let warm to room temperature. Then, the solution was quenched with water and extracted with EtOAc. The organic phase was washed with water and dried over MgSO₄. After evaporation of the solvent, the crude compound was purified by flash chromatography with hexanes/EtOAc (95:5) as eluent to give 28 mg (36%, two steps) of mono-methylated lactone 76a and 33 mg (40%, two steps) of dimethylated lactone 76b.

1,3,5(10)-estratrien-17(R)-spiro-2'-(5'-methyl-6'-oxo)tetrahydropyran (76a). [major isomer only]. White solid; IR ν (film): 1734 (C=O, lactone); ¹H NMR (CDCl₃) δ 1.02 (s, 3H, 18-CH₃), 1.25 (d, *J*=6.8 Hz, 3H, CHCH₃), 2.56 (m, 1H, CHCH₃), 2.87 (m, 2H, 6-CH₂), 7.12 (m, 3H, 1-CH, 2-CH, 3-CH), 7.29 (d, *J*=6.1 Hz, 1H, 4-CH); ¹³C NMR (CDCl₃) δ 14.34 (C-18), 17.26 (CHCH₃), 23.52 (C-15), 24.44 (C-2'), 26.78 (C-11), 27.28 (C-1'), 27.40 (C-7), 29.41 (C-6), 32.01 (C-12), 33.51 (C-3'), 34.00 (C-16), 38.84 (C-8), 44.14 (C-9), 47.21 (C-13), 48.76 (C-14), 92.75 (C-17), 125.22 (C-3), 125.56 (C-1 and C-2), 128.97 (C-4), 135.51 (C-10), 139.87 (C-5), 175.84 (C-4').


1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (76b). White solid; IR ν (film): 1724 (C=O, lactone); ¹H NMR (CDCl₃) δ 1.02 (s, 3H, 18-CH₃), 1.28 (s, 6H, 2 x CH₃), 2.88 (m, 2H, 6-CH₂), 7.13 (m, 3H, 1-CH, 2-CH, 3CH), 7.30 (d, *J*=6.2 Hz, 1H, 4-CH); ¹³C NMR (CDCl₃) δ 14.41 (C-18), 23.29 (C-15), 25.59 (C-1'), 25.84 (C-11), 27.39 (C-7), 27.54 and 27.76 (2x CH₃), 29.42 (C-6), 31.51 (C-12), 32.02 (C-16), 34.82 (C-2'), 37.79 (C-3'), 38.87 (C-8), 44.15 (C-9), 47.25 (C-13), 48.84 (C-14), 93.55 (C-17), 125.21 (C-3), 125.52 (C-2), 125.56 (C-1), 128.99 (C-4), 135.52 (C-10), 139.87 (C-5), 177.82 (C-4').

Example 19

Synthesis of 2-nitro-1,3,5(10)-estratrien-17-spiro- δ -lactone derivatives

5 These syntheses are described in Scheme 16.

Scheme 16



Example 19A

3-hydroxy-2-nitro-1,3,5(10)-estratrien-17-one (79a). The titled compound was prepared as described by Stubenrauch and Knuppen[2]. The procedure is described below.

Estrone (37, 18.004 g, 66.6 mmol) was dissolved in boiling acetic acid (540 mL) and allowed to cool down to 50°C. The nitrating mixture was prepared from 70% nitric acid (4.5 mL, 70 mmol), water (10 mL) and a few crystal of sodium nitrite, warmed up to 50 °C and added dropwise to the solution of estrone with stirring. After stirring overnight at room temperature, the yellow precipitate was filtered by suction and recrystallized from 92% aqueous acetic acid. 4-nitro derivative (6.800 g, 32%) was thus obtained as a pale yellow solid. IR (ν) 3227 (OH), 2931, 2864, 1723 (C=O), 1626, 1584, 1523, 1458, 1404, 1374, 1295, 1264, 1245, 1211, 1169, 1085, 1062, 1027, 954, 930, 908, 881, 823, 796, 719, 654, 588, 556, 530, 494 cm^{-1} ; ^1H NMR (Pyridine- d_5) δ 0.85 (3H, s, 18'-CH₃), 2.85 (2H, d, 6'-CH₂), 5.00 (1H, s, OH), 7.11 (1H, d, $J=8.7$ Hz, 2'-CH), 7.26 (1H, d, $J=8.7$ Hz, 1'-CH); ^{13}C NMR (Pyridine- d_5) δ 13.8 (C-18), 21.6 (C-15), 24.4 (C-11), 25.7 (C-7), 26.2 (C-12), 32.0 (C-6), 35.9 (C-16), 37.7 (C-8), 44.0 (C-14), 47.9 (C-13), 50.1 (C-9), 115.4 (C-2), 128.4 (C-1), 129.0 (C-10), 131.8 (C-5), 148.4 (C-3), 219.2 (C-17).

The reaction filtrate from above was evaporated under reduced pressure and the residue was recrystallized from EtOH/H₂O 8.5:1.5. A brown solid (7.854 g) was obtained which was further purified by flash chromatography on SiO₂ column (EtOAc/hexanes, gradient 8-20%) to give pure compound 79a (6.284 g, 30%) as a yellow solid. IR (ν): 3300 (OH), 2933, 2864, 1737 (C=O), 1630, 1562, 1522, 1480, 1431, 1372, 1311, 1252, 1216, 1146, 1084, 1054, 1035, 1008, 905, 832, 762, 722, 662, 600, 520 cm^{-1} . ^1H NMR (Pyridine- d_5) δ 0.85 (3H, s, 18'-CH₃), 2.76 (2H, d, 6'-CH₂), 4.99 (1H, s, OH), 6.98 (1H, s, 4'-CH), 7.96 (1H, s, 1'-CH). ^{13}C NMR (Pyridine- d_5) δ 13.8 (C-18), 21.7 (C-15), 25.8 (C-11), 26.1 (C-7), 29.6 (C-12), 31.9 (C-6), 35.9 (C-16), 37.8 (C-8), 43.5 (C-14), 47.9 (C-13), 50.3 (C-9), 119.8 (C-4), 122.2 (C-1), 132.8 (C-10), 147.8 (C-2), 152.6 (C-3), 219.1 (C-17).

Example 19B

3-(tert-butyldimethylsilyloxy)-2-nitro-1,3,5(10)-estratrien-17-one (79b).

A solution of 2-nitro-estrone (79a, 1.118g, 3.55 mmole), imidazole (0.670g, 9.84 mmole) and TBDMSCl (0.781g, 5.18 mmole) in dry DMF (50 mL) was stirred under Ar(g) overnight. The mixture was then poured onto ice/ water (80) mL. The white precipitate was filtered, washed with water and then dried in vacuo to give (79b) as a yellowish powder (1.447 g, 95%). $[\alpha]_D^{25} +123.9^\circ$ (c 1.03, CHCl₃); IR (NaCl) 2933, 2860, 1736 (s, C=O),

1617, 1561, 1518, 1492, 1408, 1351, 1291, 1256, 1054, 909, 832, 790, 697 cm^{-1} ;
 ^1H NMR δ 0.24 (6H, s, $\text{Si}(\text{CH}_3)_2$), 0.92 (3H, s, 18- CH_3), 1.01 (9H, s,
 $\text{SiC}(\text{CH}_3)_3$), 1.40-1.78 (6H, m), 1.90-2.35 (5H, m), 2.37-2.60 (2H, m), 2.90
(2H, m, 6- CH_2), 6.67 (1H, s, 4-CH), 7.76 (1H, s, 1-CH); ^{13}C NMR δ 220.2,
147.2, 143.8, 139.6, 133.3, 122.6, 122.1, 50.3, 47.9, 43.6, 37.8, 35.8, 31.3, 29.4,
26.1, 25.7, 25.6, 21.5, 18.2, 13.8, -4.4.

Example 19C

3-(tert-butyl dimethylsilyloxy)-17 β -hydroxy-2-nitro-17 α -(4'-(2''-
tetrahydro-2''H-pyranyloxy)-butynyl)-1,3,5(10)-estratriene (80). To a
stirred solution of tetrahydro-2-(butynyloxy)-2H-pyran (1.71 mL, 10.91
mmole) in dry THF (75 mL) under Ar (g) at -35 $^\circ\text{C}$ was dropwise added
(MeLi 1.4M in ether 7.80 mL, 10.92 mmole). The solution was stirred for
45 min. after which was added at -35 $^\circ\text{C}$ a solution of ketone 79b (1.294 g,
3.01 mmole) in dry THF (20 mL). After 75 min. ice (20 g) and saturated
aqueous NaHCO_3 (70 mL) were added to the reaction mixture and the
aqueous phase was extracted with EtOAc. The combined organic layers
were washed with brine, dried with magnesium sulfate, filtered and then
concentrated in vacuo. The crude yellow oil was purified on SiO_2 (40 g,
2:8 EtOAc/hexanes) to give compound 80 as a yellow foam (1.617 g, 92%).
 $[\alpha]_D^{25}$ -57.5 $^\circ$ (c 0.72, CHCl_3); IR (NaCl) 3423 (broad, OH), 2936, 2870, 2366,
1654, 1630, 1578, 1560, 1527, 1481, 1458, 1438, 1313, 1268, 1121, 1080, 1032,
899, 869, 761, 669 cm^{-1} ; ^1H NMR δ 0.23 (6H, s, $\text{Si}(\text{CH}_3)_2$), 0.87 (3H, s, 18-
 CH_3), 1.00 (9H, s, $\text{SiC}(\text{CH}_3)_3$), 1.20-2.35 (20H, m), 2.55 (2H, t, $J=6.9\text{Hz}$,
 CCCH_2), 2.84 (2H, m, 6- CH_2), 3.55 (2H, m, CH_2O of chain), 3.85 (2H, m,
 CH_2O of THP), 4.65 (1H, m, CH of THP), 6.65 (1H, s, 4-CH), 7.76 (1H, s, 1-
CH); ^{13}C NMR δ 147.0, 144.2, 139.5, 133.9, 122.6, 122.0, 98.8, 84.5, 83.4,
79.8, 65.8, 62.2, 49.4, 47.1, 43.2, 38.9, 32.6, 30.6, 29.6, 26.7, 26.2, 25.6, 25.4,
22.8, 20.4, 19.4, 18.2, 12.7, -4.4.

Example 19D

3-(tert-butyl dimethylsilyloxy)-17 β -hydroxy-2-nitro-17 α -(4'-(2''-
tetrahydro-2''H-pyranyloxy)-butyl)-1,3,5(10)-estratriene (81). A solution
of compound 80 (2.00g, 3.42 mmol) and 5% Pd/ CaCO_3 (400 mg) in dry
MeOH (400 mL) was stirred under H_2 (g) atmosphere (balloon) for 1 h.
The mixture was then filtered through celite and the filtrate rotary
evaporated. The residue was purified on silica gel (2:8 EtOAc/hexanes)
to give compound 81 as a white foamy solid (1.483 g, 74%). $[\alpha]_D^{25}$ +31.3 $^\circ$
(c 0.90, CHCl_3); IR (NaCl) 3458 (broad, OH), 2935, 2860, 1616, 1563, 1518
(NO_2), 1491, 1408, 1348 (NO_2), 1291, 1256, 1119, 1070, 1023, 925, 893, 832,
784, 672 cm^{-1} ; ^1H NMR δ 0.23 (6H, s, $\text{Si}(\text{CH}_3)_2$), 0.91 (3H, s, 18- CH_3), 1.00
(9H, s, $\text{SiC}(\text{CH}_3)_3$), 1.20-2.38 (26H, m), (2.85 (2H, m, 6- CH_2), 3.48 (2H, m,

CH₂O of chain), 3.83 (2H, m, CH₂O of THP), 4.59 (1H, m, CH of THP), 6.65 (1H, s, 4-CH), 7.75 (1H, s, 1-CH); ¹³C NMR δ 146.9, 144.1, 139.4, 134.0, 122.4, 121.9, 98.9, 83.2, 67.6, 67.6, 62.4, 62.4, 49.3, 46.6, 36.3, 34.1, 31.3, 30.7, 30.3, 29.5, 26.9, 26.0, 25.5, 25.4, 23.3, 20.4, 19.6, 18.1, 14.3, -4.4.

Example 19E

17α-(4'-hydroxybutyl)-3,17β-dihydroxy-2-nitro-1,3,5(10)-estratriene (82).

A solution of compound 81 (300 mg, 0.510 mmol) in 5% HCl in MeOH (10 mL) was stirred at room temperature and under argon atmosphere for 12 h. The reaction mixture was then poured into NaHCO₃/ice and MeOH was evaporated under reduced pressure. The aqueous phase was extracted with EtOAc and the combined organic layers were washed with brine, dried over MgSO₄, filtered and evaporated to dryness. This gave a crude yellow foam (198 mg, 100%). Purification by flash chromatography (column loaded with CH₂Cl₂ and then eluted with EtOAc/CH₂Cl₂ 2:8, 4:6, 1:1, 6:4, 9:1) gave compound 82 as a yellow solid (127.0 mg, 64%). R_f 0.21 (8:2 EtOAc/Hexanes); M.p. 184-6 °C; [α]_D²⁶ +58.8° (c. 1.00, CHCl₃); IR (ν) 3335, 2934, 2865, 1735, 1719, 1654, 1630, 1576, 1522, 1479, 1434, 1373, 1305, 1266, 1169, 1112, 1067, 1033, 1000, 896, 874, 762, 659 cm⁻¹; ¹H NMR δ 0.90 (3H, s), 3.69 (2H, d, J=5.7 Hz), 6.84 (1H, s), 7.98 (1H, s), 10.42 (1H, s); ¹³C NMR δ 14.3, 19.8, 23.3, 26.1, 26.8, 29.8, 31.2, 33.3, 34.3, 36.1, 39.0, 43.2, 46.5, 49.4, 61.7, 62.8, 83.4, 118.8, 121.4, 131.6, 133.7, 149.2, 152.8.

Example 19F

2-Nitro-1,3,5(10)-estraetriene-3-ol-17(R)-spiro-2'-(6'-oxo)tetrahydropyran (EM-1124). To a stirred solution of compound 82 (128 mg, 0.33mmole) in dry acetone (25 mL) at 0 °C was slowly added a first 1.1 equivalent of Jones' reagent (1.25 M, 0.29 mL, 0.80 mmol). The orange solution was then stirred for 0.5 h then a second equivalent was added. The dark solution was stirred for a further 0.5 h then quenched with isopropanol (green precipitate formed). the mixture was stirred for 10 min. then filtered through celite and the filtrate rotary evaporated. The residue was taken in EtOAc then washed with aq. sat. NaHCO₃, H₂O, brine, dried (MgSO₄), filtered, rotovaped. The crude solid was purified by flash chromatography on SiO₂ (3:7 EtOAc/Hexanes) to give EM-1124 (108 mg, 85%) as a yellow solid. M.p. 213 °C; [α]_D²⁵ +90.0° (c 0.70, CHCl₃); IR (NaCl) 3198, 2934, 2876, 2245, 1720 (s, C=O, lactone), 1630, 1577, 1522, 1480, 1434, 1378, 1314, 1267, 1234, 1199, 1169, 1151, 1120, 1070, 1036, 1024, 992, 914, 851, 759, 732, 662, 585 cm⁻¹; ¹H NMR δ 1.02 (3H, s, 18-CH₃), 1.20-2.23 (16H, m), 2.25-2.65 (3H, m), 2.90 (2H, m, 6-CH₂), 6.85 (1H, s, 4-CH), 7.97 (1H, s, 1-CH), 10.41 (1H, s, OH phenol); ¹³C NMR δ 171.9, 152.8, 148.9, 133.3, 131.7, 121.5, 118.9, 93.0, 48.8, 47.1, 43.1, 38.4, 33.9, 31.6, 29.7, 29.4, 27.9, 26.8, 25.8, 23.4, 15.8, 14.2.

Example 19G

2-Nitro-1,3,5(10)-estratrien-3-ol-17(R)-spiro-2'-(5'-methyl-6'-oxo)tetrahydropyran (EM-1126, EM-1131). LDA was prepared as follows: To a stirred solution of diisopropylamine (92 μ L, 71 mg, 0.70 mmol) in dry THF (5 mL) at -78 °C under Ar(g) was added n-BuLi (1.2 M/Hexane, 580 μ L, 0.68 mmol) and the solution was then stirred at 0 °C for 25 min. then cooled down to -78 °C. A solution of EM-1124 (66 mg, 0.17 mmol) in dry THF (5 mL) was added and the resulting dark orange solution was then stirred for 30 min. Dry HMPA (2 mL) was added and after 15 min., MeI (107 μ L, 243 mg, 1.71 mmol). The solution was then stirred for a further 4 h. The reaction was quenched with aqueous saturated NH₄Cl and extracted with EtOAc. The organic phase was washed with 1 M aqueous CuSO₄ (4X), H₂O, aqueous 1M Na₂SO₃, brine, dried (MgSO₄), filtered then rotary evaporated to give a crude solid (103 mg). Purification by flash chromatography on SiO₂ (1:9 \rightarrow 2:8 EtOAc/Hexanes) provided first EM-1126 (11 mg, 16%) closely followed by EM-1131 (34 mg, 34%) both as yellow solids. EM-1126: M.p. 204-6 °C; [α]_D²⁵ +73.4° (c 1.67, CDCl₃); IR ν 3422 (br, OH), 2937, 2874, 1725 (vs, CO), 1630, 1577, 1525, 1479, 1458, 1432, 1378, 1311, 1269, 1249, 1205, 1188, 1150, 1118, 1088, 1071, 1007, 990, 934, 896, 760, 731, 668, 585, 495 cm⁻¹; ¹H NMR δ 1.03 (3H, s), 1.30 (3H, d, J=7.1 Hz), 1.31-1.77 (10H, m), 1.89-2.03 (5H, m), 2.15 (1H, td, J=7.1 Hz, J'=5.0 Hz), 2.30-2.50 (2H, m), 2.90 (2H, dd, J=8.3 Hz,

$J=4.9$ Hz), 6.85, (1H, s), 7.98 (1H, s), 10.43 (1H, s, OH); ^{13}C NMR δ 174.8, 152.9, 149.0, 133.4, 131.7, 121.5, 118.9, 93.4, 48.7, 47.1, 43.1, 38.5, 36.2, 34.6, 31.6, 29.7, 28.6, 26.9, 25.9, 25.2, 23.4, 17.4, 14.4.

5 EM-1131 (5'-epimer of EM-1126, real configuration not determined): M.p. 206-8 °C; $[\alpha]^{25}_{\text{D}} +62.6^\circ$ (c 0.68, CDCl_3); IR ν 3422 (br, OH), 3192, 2934, 2876, 2858, 2824, 1721 (vs, CO), 1631, 1578, 1522, 1482, 1458, 1436, 1377, 1314, 1271, 1237, 1204, 1173, 1120, 1103, 1082, 1051, 1019, 1002, 933, 901, 877, 860, 759, 663, 638, 600, 495 cm^{-1} ; ^1H NMR δ 1.01 (3H, s), 1.24 (3H, d, $J=7.0$ Hz), 1.31-1.80 (10H, m), 1.89-2.20 (6H, m), 2.35 (1H, br s), 2.55 (1H, sextuplet, $J=7.5$ Hz), 2.89 (2H, t, $J=5.2$ Hz), 6.84 (1H, s), 7.96 (1H, s), 10.41 (H, s, OH); ^{13}C NMR δ 175.8, 152.8, 148.9, 133.3, 131.6, 121.4, 118.8, 92.5, 77.4, 77.0, 76.6, 48.5, 47.0, 43.0, 38.4, 33.8, 33.4, 31.6, 29.7, 27.16, 26.7, 25.8, 24.3, 23.6, 17.2, 14.3.

15 Example 19H

2-Nitro-1,3,5(10)-estratrien-3-ol-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (EM-1125). LDA was prepared as follows: To a stirred solution of diisopropylamine (206 μL , 159 mg, 1.57 mmol) in dry THF (12 mL) at -78 °C under Ar(g) was added n-BuLi (1.2 M/Hexane, 1.28 mL, 1.53 mmol) and the solution was then stirred at 0 °C for 20 min. then cooled down to -78 °C. A solution of a mixture of EM-1126 and EM-1131 (153 mg, 0.38 mmol) in dry THF (10 mL) was added and the resulting dark orange solution was then stirred for 20 min. Dry HMPA (4.7 mL) was added and after 15 min., MeI (238 μL , 544 mg, 3.83 mmol). The solution was then stirred for 5 min. then was warmed up to -30 °C and stirred for a further 1 h. The reaction was quenched with aqueous saturated NH_4Cl and extracted with EtOAc. The organic phase was washed with brine (6X), aqueous 1M Na_2SO_3 , brine, dried (MgSO_4), filtered then rotary evaporated to give a crude liquid. Purification by flash chromatography on SiO_2 (1:9 \rightarrow 2:8 EtOAc/Hexanes) provided EM-1125 (82 mg, 52%) as a yellow solid. M.p. 195-7 °C; $[\alpha]^{25}_{\text{D}} +72.8^\circ$ (c 1.61, CDCl_3); IR ν 3421 (br, OH), 3194, 2954, 2927, 2873, 1718 (vs, CO), 1631, 1578, 1523, 1476, 1458, 1438, 1386, 1312, 1298, 1271, 1204, 1151, 1118, 1059, 1032, 1016, 931, 898, 872, 855, 758, 663, 595 cm^{-1} ; ^1H NMR δ 1.02 (3H, s), 1.28 (6H, s), 1.32-1.77 (10H, m), 1.85-2.15 (6H, m), 2.36 (1H, br s), 2.89 (2H, dd, $J=8.2$ Hz, $J'=4.9$ Hz), 6.85 (1H, s), 7.97 (1H, s), 10.42 (H, s, OH); ^{13}C NMR δ 177.7, 152.8, 149.0, 133.3, 131.7, 121.5, 118.9, 93.4, 48.6, 47.1, 43.1, 38.5, 37.8, 34.7, 31.6, 31.5, 29.7, 27.7(4), 27.6(8), 26.7, 25.9, 25.5, 23.3, 14.4.

Example 19I

2-Nitro-3-methylthioethoxy-1,3,5(10)-estratrien-17(R)-spiro-2'-(6'-oxo) tetrahydropyran (EM-1118). To a solution of EM-1124 (40 mg, 0.117 mmol) in anhydrous acetonitrile (20 mL) at room temperature under Ar(g) was added K₂CO₃ (16 mg, 0.117 mmol) and chloroethylmethyl sulfide (39mg, 35 mL, 0.350 mmol). The solution was refluxing for 44 h. The acetonitrile solution was evaporated to dryness and ethyl acetate (40 mL) was then added. The organic phase was washed with water, brine and dried with MgSO₄ to gave crude product (49 mg). Purification by flash chromatography on silica gel (SiO₂, 3 g) using ethyl acetate/hexanes (2:8) as eluent gave EM-1118 (35 mg, 70%). IR (ν) 2921, 1727, 1608, 1576, 1499, 1466, 1438, 1382, 1348, 1330, 1310, 1280, 1236, 1187, 1159, 1100, 1067, 1036, 992, 931, 914, 860, 818, 731 cm⁻¹; ¹H NMR (CDCl₃) δ 1.01 (3H, s), 1.25-2.57 (19H, m), 2.20 (3H, s) 2.85 (4H, t, J=6.88 Hz), 4.12 (2H, t, J=6.74 Hz), 6.62 (1H, d, J=2.49 Hz), 6.71 (1H, dd, J₁=2.58 Hz J₂=5.89 Hz), 7.19 (1H, d, J=8.54 Hz); ¹³C NMR(CDCl₃) δ 14.8, 15.9, 16.2, 23.5, 26.1, 27.5, 28.0, 29.5, 29.7, 32.0, 33.1, 34.0, 39.1, 43.7, 47.3, 48.9, 67.4, 93.3, 112.1, 114.6, 126.3, 132.6, 137.9, 156.5, 172.1.


Example 20

Synthesis of 3-hydroxy-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo) tetrahydropyran (89)

5

This synthesis is described in Scheme 17

Scheme 17



3-t-butyldimethylsilyloxy-1,3,5(10)-Estratrien-17-one (83). The ether was prepared from estrone (37) following the method described Pelletier et al. (Steroids 59: 536-547, 1994).

3-t-butyldimethylsilyloxy-17 β -hydroxy-17 α -[4'-(2"-tetrahydro-2"H-pyranyl)butyn-1'-yl]-1,3,5(10)-estratriene (84). To a solution of $\text{HC}\equiv\text{C}(\text{CH}_2)_2\text{OTHP}$ (18.3 mL, 117 mmol) in dry THF (600 mL) at 0 °C, was added dropwise n-butyllithium (43.7 mL, 109 mmol) and the mixture was stirred for 90 min. The mixture was cooled to -78 °C and a solution of TBDMS-estrone 37 (15 g, 39 mmol) in THF (500 mL) was added dropwise. Then, the reaction mixture was allowed to come to room temperature and left stirring for a period of 15 h. Solvents were evaporated to the half volume and 200 mL of water was added. The mixture was extracted with EtOAc (3 x 200 mL), the organic layer was washed with brine, dried (MgSO_4) and evaporated to dryness. The residue was purified over silica gel column chromatography with hexanes/EtOAc (9/1) as an eluent to furnish 15.1 g (72%) of the product; IR (NaCl cm^{-1}) 3432, 2934, 2858, 1607, 1495, 1287, 1256, 1033, 958, 839; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 7.12 (d, 1H, $J=8.4$ Hz), 6.62 (dd, 1H, $J=2.4, 8.4$ Hz), 6.54 (d, 1H, $J=2.2$ Hz), 4.66 (br.s., 1H), 3.89-3.79 (m, 2H), 3.56-3.50 (m, 2H), 2.79 (br.s., 2H), 2.56 (t, 2H, $J=7.0$ Hz), 2.35-2.17 (m, 3H), 2.07-1.23 (m, 17H), 0.98 (s, 9H), 0.87 (s, 3H, 18-Me), 0.19 (s, 6H); $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 153.3, 137.8, 133.0, 126.1, 119.9, 117.1, 98.7, 84.7, 83.2, 80.0, 65.8, 62.1, 49.5, 47.2, 43.7, 39.4, 39.0, 32.9, 30.6, 29.7, 27.3, 26.4, 25.7, 25.4, 22.8, 20.3, 19.3, 18.1, 12.8, -4.4.

3-t-butyldimethylsilyloxy 17 β -Hydroxy-17 α -[4'-(2"-tetrahydro-2"H-pyranyl)butan-1'-yl]-1,3,5(10)-estratriene (85). 5% Palladium on activated carbon (1.5 g, 10% wt) was added to a solution of the alkyne 84 (15.1 g, 28 mmol) in EtOAc (500 mL) at room temperature. The flask was purged with H_2 three times (vacuum followed by H_2) and left stirring under 1 atm pressure of H_2 . The reaction was followed by TLC. After a period of 3 h, the mixture was filtered over a plug of celite and the solvent was removed under reduced pressure. The crude product was used in the next step without further purification; IR (NaCl, cm^{-1}) 3474, 2935, 2858, 1607, 1570, 1496, 1471, 1286, 1257, 1156, 1137, 1119, 1033, 954, 839, 780; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 7.12 (d, 1H, $J=8.4$ Hz), 6.62 (dd, 1H, $J=2.1, 8.4$ Hz), 6.55 (s, 1H), 4.59 (br.s., 1H), 3.92-3.73 (m, 2H), 3.55-3.38 (m, 2H), 2.82-2.77 (m, 2H), 2.30-1.33 (m, 26H), 0.97 (s, 9H), 0.90 (s, 3H, 18-Me), 0.18 (s, 6H); $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 153.27, 137.81, 133.08, 126.02, 119.87, 117.06, (98.90, 98.84), 83.38, 67.61, 62.33, 49.50, 46.67, 43.81, 39.58, 36.35, 34.28, 31.60, 30.75, 30.36, 29.62, 27.51, 26.26, 25.67, 25.47, 23.37, 20.45, 19.66, 18.12, 14.35, -4.43.

3-t-butyltrimethylsilyloxy 17 β -hydroxy-17 α -(4'-hydroxybutan-1'-yl)-1,3,5(10)-estratriene (86). To a solution of the THP ether 85 (15.1 g, 28 mmol) in MeOH (400 mL), was added *p*-toluenesulfonic acid monohydrate (150 mg, 0.8 mmol) and the reaction was stirred over a period of 5 h. A saturated solution of NaHCO₃ (100 mL) was added and volume of solvent was reduced to half on a rotary evaporator. The mixture was extracted with CH₂Cl₂, the organic phase was washed with brine, dried (MgSO₄) and evaporated to dryness. The crude product was used in the next step without purification; IR (NaCl, cm⁻¹) 3356, 2931, 2858, 1608, 1496, 1471, 1286, 1256, 954, 839, 780; ¹H NMR (300 MHz, CDCl₃) δ 7.12 (d, 1H, *J*=8.5 Hz), 6.61 (dd, 1H, *J*=2.5, 8.5 Hz), 6.55 (s, 1H), 3.69 (br.d, 2H, *J*=5.2 Hz), 2.82-2.78 (m, 2H), 2.35-2.26 (m, 1H), 2.20-1.94 (m, 2H), 1.90-1.81 (m, 1H), 1.62-1.22 (m, 17H), 0.98 (s, 9H), 0.90 (s, 3H, 18-Me), 0.19 (s, 6H); ¹³C NMR (75 MHz, CDCl₃) δ 153.27, 137.81, 133.05, 126.02, 119.89, 117.09, 83.59, 62.56, 49.50, 46.69, 48.81, 39.58, 35.98, 34.32, 33.20, 31.61, 29.62, 27.51, 26.26, 25.68, 23.37, 19.74, 18.14, 14.36, -4.40.

3-t-butyltrimethylsilyloxy-1,3,5(10)-estratrien-17(R)-spiro-2'-(6'-oxo) tetrahydropyran (87). To a solution of the diol 86 (12.5 g, 27 mmol) in acetone (500 mL) at 0°C, was added dropwise of a 2.7 M solution of Jones reagent (15.1 mL, 41 mmol). The reaction was stirred for 30 min. 2-Propanol (100 mL) was added, followed by of a saturated solution of NaHCO₃ (200 mL). The volume of solvents was reduced to half by evaporation and the mixture was extracted with EtOAc. The organic phase was washed with brine, dried (MgSO₄) and concentrated under reduced pressure. The residue was purified a silica gel column chromatography with hexanes/acetone (6/1) to afford 8.6 g of the lactone. (68% yield for 3 steps); IR (NaCl, cm⁻¹): 2960, 2930, 2857, 1732, 1607, 1496, 1284, 1264, 1244, 1037, 958, 840; ¹H NMR (300 MHz, CDCl₃) δ 7.11 (d, 1H, *J*=8.4 Hz), 6.61 (dd, 1H, *J*=2.3, 8.4 Hz), 6.56 (s, 1H), 2.85-2.79 (m, 2H), 2.58-2.39 (m, 2H), 2.38-2.25 (m, 1H), 2.21-2.10 (m, 1H), 2.03-1.27 (m, 15H), 1.02 (s, 3H, 18-Me), 0.97 (s, 9H), 0.18 (s, 6H); ¹³C NMR (75 MHz, CDCl₃) δ 172.00, 153.36, 137.63, 132.62, 126.02, 119.92, 117.19, 93.25, 48.88, 47.26, 43.68, 39.05, 33.98, 31.96, 29.50, 29.48, 27.94, 27.46, 25.98, 25.67, 23.48, 18.12, 15.87, 14.30, -4.43.

3-t-butyltrimethylsilyloxy-1,3,5(10)-estratrien-17(R)-spiro-2'-(5'-5'-dimethyl-6'-oxo) tetrahydropyran(88). In a dry 1L flask under argon, was dissolved the lactone 87 (8.6 g, 19 mmol) in dry THF (300 mL), and cooled to 0°C. A 1M solution of LiHMDS (47.3 mL, 47.3 mmol) was added dropwise. The mixture was stirred 15 min at 0°C and cooled to -78°C and then methyl iodide (5.9 mL, 79 mmol) was added. The reaction was stirred 1 h at this temperature and then allowed to warm to room temperature over a period of 2 h. A saturated solution of NH₄Cl (200 mL) was added

and the mixture was extracted with EtOAc. The organic layer was washed with a saturated solution of $\text{Na}_2\text{S}_2\text{O}_3$, brine, dried (MgSO_4) and concentrated under reduced pressure. The residue was purified by column chromatography with hexanes/acetone (5/1) as an eluent to afford 7.4 g (81%) of the dimethyl compound; IR (NaCl, cm^{-1}) 2954, 2930, 2858, 1725, 1496, 1287, 1258, 1150, 1137, 956, 840; ^1H NMR (300 MHz, CDCl_3) δ 7.11 (d, 1H, $J=8.5\text{Hz}$), 6.62 (dd, 1H, $J=2.4, 8.5\text{Hz}$), 6.55 (d, 1H, $J=2.1\text{Hz}$), 2.81-2.78 (m, 2H), 2.36-2.28 (m, 1H), 2.20-1.38 (m, 16H), 1.28 (s, 3H), 1.27 (s, 3H), 1.02 (s, 3H, 18-Me), 0.97 (s, 9H), 0.18 (s, 6H); ^{13}C NMR (75 MHz, CDCl_3) δ 177.79, 153.33, 137.62, 132.62, 125.99, 119.90, 117.14, 93.66, 48.67, 47.24, 43.65, 39.06, 37.74, 34.79, 31.96, 31.56, 29.50, 27.73, 27.61, 27.42, 26.01, 25.65, 25.55, 23.26, 18.11, 14.42, -4.43.

1,3,5(10)-estratrien-3-ol-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)

tetrahydropyran (89): To a solution of the silyl ether 88 (7.1 g, 14.7 mmol) in THF (300 mL) at 0°C , was added dropwise a 1M solution of TBAF (17.6 mL, 17.6 mmol) and the reaction was stirred for 15 min. Ice water (200 mL) was added to precipitate the compound. The flask was placed on a rotary evaporator to reduce the volume of THF, and then placed on an ice bath. The precipitate was collected by filtration, washed with cold water and dried in an oven (30°C) over a period of 24 h to furnish 5.4 g (100%) of the 3-OH compound; IR (NaCl, cm^{-1}): 3357, 2932, 2871, 1695, 1287, 1158; ^1H NMR (300 MHz, CDCl_3) δ 7.14 (d, 1H, $J=8.4\text{Hz}$), 6.63 (dd, 1H, $J=2.6, 8.4\text{Hz}$), 6.55 (d, 1H, $J=2.6\text{Hz}$), 4.62 (br.s, 1H, OH), 2.81-2.79 (m, 2H), 2.38-2.29 (m, 1H), 2.20-1.81 (m, 5H), 1.76-1.31 (m, 11H), 1.29 (s, 3H), 1.28 (s, 3H), 1.01 (s, 3H, 18-Me); ^{13}C NMR (75 MHz, CDCl_3) δ 178.06, 153.52, 138.08, 132.19, 126.42, 115.26, 112.74, 93.80, 48.69, 47.29, 43.65, 39.14, 37.81, 34.84, 31.98, 31.61, 29.53, 27.76, 27.64, 27.39, 26.12, 25.59, 23.29, 14.43.

Example 21


Synthesis of 3-hydroxy-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran-3-derivatives

5

These syntheses are described in Scheme 18.

Scheme 18

10



Example 21A

Synthesis of 3-ethoxy-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)-tetrahydropyran (EM-1369). To a solution of lactone 89 (50 mg, 0.136 mmol) in anhydrous THF (10 ml) and under argon was added K₂CO₃ (26 mg, 0.190 mmol), 18-crown-6 (14 mg, 0.054 mmol) and bromoethane (303 µl, 4.08 mmol). The solution was refluxed for 24h. Then water (10 ml) was added and the product was extracted with ethyl acetate (2 x 20 ml), washed with brine, and dried with MgSO₄. After evaporation of solvent, the crude product was purified by flash chromatography on silica gel using ethyl acetate / hexanes (1:9) as eluent to give the pure EM-1369. White solid; 59% yield; IR (film NaCl) ν 2930, 2872, 1732, 1608, 1573, 1500, 1477, 1455, 1385, 1309, 1236, 1149, 1137, 1114, 1051, 1017; ¹H NMR (300 MHz, CDCl₃) δ 1.02 (s, 3H, 18-CH₃), 1.28 (2s, 6H, 2 x CH₃), 1.30 to 2.36 (m, 17H), 1.39 (t, *J* = 7.0 Hz, 3H, CH₃CH₂O), 2.84 (m, 2H, 6-CH₂), 4.00 (q, *J* = 7.0 Hz, 2H, CH₃CH₂O), 6.62 (d, *J* = 2.5 Hz, 1H, 4-CH), 6.70 (dd, *J*₁ = 2.5 Hz and *J*₂ = 8.5 Hz, 1H, 2-CH), 7.19 (d, *J* = 8.5 Hz, 1H, 1-CH); ¹³C NMR (75 MHz, CDCl₃) δ 14.44, 14.91, 23.30, 25.61, 26.11, 27.48, 27.66, 27.77, 29.73, 31.63, 32.01, 34.85, 37.80, 39.17, 43.69, 47.30, 48.71, 63.31, 93.70, 112.05, 114.50, 126.21, 132.10, 137.76, 156.88, 177.85; HRMS calculated for C₂₆H₃₇O₃ (M⁺ + H): 397.27426, found: 397.27520.

Example 21B

Typical procedure for the synthesis of EM-1368-CS, EM-1389-CS, and EM-1390-CS. To a solution of lactone 89 (0.20 mmol) in anhydrous acetonitrile (20 ml) and under argon was added K₂CO₃ (0.20 mmol). The appropriate electrophile (16.0 mmol) (chloroethylmethylether, 2-dimethylaminoethylchloride-HCl, and 1-(2-chloro-ethyl)-piperidine-HCl). The solution was refluxed for 56h. The acetonitrile was evaporated to dryness and ethyl acetate (40 ml) was then added. The organic phase was washed with water, brine, and dried with MgSO₄ to gave the crude products which were purified by flash chromatography on silica gel using, as eluent, ethyl acetate / hexanes (1:9) for EM-1368CS and CH₂Cl₂ / Et₃N (95.5:0.5) for EM-1389CS and EM-1390CS.

3-Methoxyethoxy-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)-tetrahydropyran (EM-1368-CS). White solid; 74% yield; IR (film NaCl) ν 2930, 2873, 1722, 1609, 1574, 1499, 1455, 1385, 1309, 1237, 1201, 1135, 1064, 1032, 1017; ¹H NMR (300 MHz, CDCl₃) δ 1.02 (s, 3H, 18-CH₃), 1.28 (2s, 6H, 2 x CH₃), 1.30 to 2.35 (m, 17H), 2.85 (m, 2H, 6-CH₂), 3.44 (s, 3H, OCH₃), 3.73 (t, *J* = 4.7 Hz, 2H, CH₃OCH₂CH₂O), 4.09 (t, *J* = 4.7 Hz, 2H, CH₃OCH₂CH₂O), 6.66 (d, *J* = 2.5 Hz, 1H, 4-CH), 6.73 (dd, *J*₁ = 2.5 Hz

- 232 -

and $J_2 = 8.6$ Hz, 1H, 2-CH), 7.19 (d, $J = 8.6$ Hz, 1H, 1-CH); ^{13}C NMR (75 MHz, CDCl_3) δ 14.44, 23.29, 25.61, 26.09, 27.45, 27.66, 27.76, 29.71, 31.62, 31.99, 34.85, 37.79, 39.14, 43.67, 47.29, 48.70, 59.16, 67.20, 71.12, 93.70, 112.16, 114.67, 126.21, 132.49, 137.78, 156.72, 177.85; HRMS calculated for $\text{C}_{27}\text{H}_{39}\text{O}_4$ ($\text{M}^+ + \text{H}$): 427.28482, found: 427.28690.

3-(N,N-dimethylaminoethyl)-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)-tetrahydropyran (EM-1389-CS). White solid; 40% yield; IR (film NaCl) ν 2936, 2871, 2819, 2770, 1723, 1609, 1575, 1499, 1456, 1385, 1309, 1290, 1256, 1238, 1202, 1149, 1032; ^1H NMR (300 MHz, CDCl_3) δ 1.01 (s, 3H, 18- CH_3), 1.28 (2s, 6H, 2 \times CH_3), 1.30 to 2.20 (m, 17H), 2.33 (s, 6H, $(\text{CH}_3)_2\text{N}$), 2.71 (t, $J = 5.8$ Hz, 2H, $\text{NCH}_2\text{CH}_2\text{O}$), 2.83 (m, 2H, 6- CH_2), 4.04 (t, $J = 5.8$ Hz, 2H, $\text{NCH}_2\text{CH}_2\text{O}$), 6.65 (d, $J = 2.4$ Hz, 1H, 4-CH), 6.73 (dd, $J_1 = 2.7$ Hz and $J_2 = 8.6$ Hz, 1H, 2-CH), 7.19 (d, $J = 8.6$ Hz, 1H, 1-CH); ^{13}C NMR (75 MHz, CDCl_3) δ 14.45, 23.30, 25.62, 26.11, 27.46, 27.67, 27.77, 29.73, 31.64, 32.01, 34.86, 37.79, 39.16, 43.70, 45.87, 47.30, 48.72, 58.35, 65.92, 93.71, 112.13, 114.59, 126.21, 132.34, 137.79, 156.79, 177.85; HRMS calculated for $\text{C}_{28}\text{H}_{42}\text{O}_3\text{N}$ ($\text{M}^+ + \text{H}$): 440.31647, found: 440.31520.

3-(N-piperidyl-ethyl)-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)-tetrahydropyran (EM-1390-CS)
White solid; 69% yield; IR (film NaCl) ν 2933, 2871, 2783, 1724, 1609, 1574, 1499, 1455, 1385, 1308, 1290, 1256, 1236, 1202, 1148, 1136, 1033; ^1H NMR (300 MHz, CDCl_3) δ 1.01 (s, 3H, 18- CH_3), 1.28 (2s, 6H, 2 \times CH_3), 1.30 to 2.40 (m, 17H), 2.50 (m, 4H, $(\text{CH}_2)_2\text{N}$), 2.76 (t, $J = 6.2$ Hz, 2H, $\text{NCH}_2\text{CH}_2\text{O}$), 2.84 (m, 2H, 6- CH_2), 4.08 (t, $J = 6.2$ Hz, 2H, $\text{NCH}_2\text{CH}_2\text{O}$), 6.63 (d, $J = 2.6$ Hz, 1H, 4-CH), 6.71 (dd, $J_1 = 2.6$ Hz and $J_2 = 8.6$ Hz, 1H, 2-CH), 7.18 (d, $J = 8.6$ Hz, 1H, 1-CH); ^{13}C NMR (75 MHz, CDCl_3) δ 14.46, 23.31, 24.18, 25.63, 25.92, 26.13, 27.47, 27.68, 27.79, 29.74, 31.65, 32.02, 34.87, 37.81, 39.17, 43.71, 47.32, 48.73, 55.00, 57.98, 65.83, 93.70, 112.14, 114.60, 126.23, 132.32, 137.81, 156.72, 177.87; HRMS calculated for $\text{C}_{31}\text{H}_{46}\text{O}_3\text{N}$ ($\text{M}^+ + \text{H}$): 480.34778, found: 480.34550.


- 233 -

Example 22

Synthesis of 2-chloro-1,3,5(10)-estratrien-17-spiro- δ -lactone derivatives

5 These syntheses are described in Scheme 19.

Scheme 19



a. PhSeCl, CHCl₃ b. NCS, CHCl₃ c. Cs₂CO₃, CH₃OCH₂CH₂Cl, CH₃CN, NaI

10

Example 22A

3-Hydroxy-2-phenylselenenyl-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo) tetrahydropyran (90). A solution of 3-hydroxy-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (89) (406 mg, 1.10 mmol) and phenylselenenyl chloride (253 mg, 1.32 mmol) in dry CHCl₃ (24 mL) under Ar (g) was stirred at 0 °C for 1 h then at room temperature overnight. The resulting yellow solution was poured onto ice/H₂O then extracted with CH₂Cl₂ (3x). The combined organic phase was dried (cotton plug) then rotary evaporated to give a crude foamy solid. Purification by flash chromatography (SiO₂) using 1:9 EtOAc/Hexanes as eluent gave compound 90 (353 mg, 61%) with the 4-isomer (86 mg, 15%). Compound 90: [α]_D²⁵ +77.7 ° (c 1.14, CHCl₃); IR ν 3366, 3050, 2965, 2928, 2869, 1709, 1603, 1576, 1550, 1458, 1438, 1384, 1349, 1310, 1294, 1262, 1202, 1157, 1141, 1114, 1065, 1017, 984, 892, 845, 736, 689, 665, 593, 555, 498, 460 cm⁻¹; ¹H NMR(CDCl₃) δ 1.02 (3H, s), 1.27(9) (3H, s), 1.28(4) (3H, s), 1.27-1.80 (11H, m), 1.88-2.28 (6H, m), 2.87 (2H, t, J = 4.8 Hz), 6.24 (1H, s, OH), 6.80 (1H, s), 7.21 (5H, br s), 7.52 (1H, s); ¹³C NMR(CDCl₃) δ 14.4, 23.3, 25.5, 26.1, 27.2, 27.6, 27.7, 29.5, 31.5, 31.8, 34.7, 37.7, 38.9, 43.4, 47.2, 48.6, 93.6, 111.6, 114.7, 126.5, 129.2(6), 129.3(4), 131.2, 133.3, 134.7, 141.4, 154.4, 177.8.

Example 22B

2-Chloro-3-hydroxy-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo) tetrahydropyran (91). A solution of compound 90 (347 mg, 0.66 mmol) and N-chlorosuccinimide (177 mg, 1.33 mmol) in dry CHCl₃ (30 mL) under Ar(g) at 0 °C were stirred for 30 min. The solution was poured onto ice/H₂O then was extracted with CH₂Cl₂ (3x). The combined organic phase was dried (cotton plug) then rotary evaporated to give a crude solid. Purification by flash chromatography (SiO₂) using 1:9 EtOAc/Hexanes as eluent gave compound 91 (104 mg, 39%) as a white solid. ¹H NMR (CDCl₃) δ 1.01 (3H, s), 1.28 (6H, s), 1.25-1.75 (11H, m), 1.85-2.28 (6H, m), 2.80 (2H, dd, J' = 8.7 Hz, J'' = 3.9 Hz), 5.39 (1H, br s, OH), 6.73 (1H, s), 7.19 (1H, s); ¹³C NMR(CDCl₃) δ 14.4, 23.3, 25.6, 26.1, 27.2, 27.7, 27.8, 29.1, 31.6, 31.9, 34.8, 37.8, 38.8, 43.5, 47.3, 48.6, 93.6, 116.0, 117.1, 125.6, 133.5, 137.2, 149.0, 177.8.

Example 22C

2-Chloro-3-methoxyethoxy-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo) tetrahydropyran (EM-1371). A mixture of compound 91 (95 mg, 0.24 mmol), Cs₂CO₃ (230 mg, 0.70 mmol) 2-chloroethylmethyl ether (1.72 mL, 1.78 g, 18.86 mmol) and NaI (4 mg, 0.02 mmol) in acetonitrile (45 mL) were refluxed for 4 h. The solvent was rotary evaporated and the residue was taken into H₂O/CH₂Cl₂. The aqueous

- 235 -

phase was extracted with CH_2Cl_2 (3x). The combined organic phase was dried (MgSO_4), filtered then rotary evaporated. The crude solid was purified by flash chromatography (SiO_2) using 1:9 to 2:8 EtOAc/Hexanes as eluent to give **EM-1371** (73 mg, 67%) as a white solid. IR ν 2982, 2963, 2927, 2880, 1718, 1654, 1598, 1499, 1458, 1397, 1387, 1364, 1323, 1307, 1286, 1259, 1247, 1210, 1151, 1125, 1059, 1032, 1018, 987, 928, 885, 866, 738, 669 cm^{-1} ; ^1H NMR (CDCl_3) δ 1.02 (3H, s), 1.28 (6H, s), 1.29-1.75 (11H, m), 1.85-2.35 (6H, m), 2.80 (2H, br t, $J=5.0$ Hz), 3.48 (3H, s), 3.78 (2H, t, $J=5.2$ Hz), 4.14 (2H, t, $J=5.2$ Hz), 6.66 (1H, s), 7.25 (1H, s); ^{13}C NMR (CDCl_3) δ 14.4, 23.2, 25.5, 26.0, 27.2, 27.6, 27.7, 29.3, 31.5, 31.9, 34.7, 37.7, 38.7, 43.4, 47.2, 48.5, 59.3, 68.9, 70.8, 93.5, 114.5, 120.3, 127.0, 133.7, 136.1, 152.1, 177.7.

- 236 -


Example 23

**3-hydroxy-2,4-dihalo-1,3,5(10)-estratrien-
17-spiro-(dimethyl- δ -lactone) derivatives**

5

These syntheses are described in Scheme 20.

Scheme 20



10

- 237 -

Example 23A

2,4-dihalo-3-hydroxy-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (92). Under argon atmosphere, a solution of 3-hydroxy-1,3,5(10)-estratriene-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (89) and N-halosuccinimide (2 equiv) in anhydrous chloroform (1.3% W/V) was stirred at room temperature for 1.5 h. The reaction mixture was diluted with dichloromethane, washed with brine, dried over magnesium sulfate, filtered, and evaporated. The crude mixture was purified by flash chromatography (hexanes-ethyl acetate 32-1 to hexanes-ethyl acetate 9-1) to provide compound 92 (e.g., EM-1382-CS, X=Br, 62%): IR (NaCl) 3197, 2936, 2872, 1694, 1466, 1387, 1297, 1154 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.01 (s, 3H), 1.29 (s, 6H), 1.35-2.35 (m, 17H), 2.65 (m, 1H), 2.88 (dd, J=6.1 and 18.0 Hz, 1H), 5.83 (s, 1H), 7.40 (s, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 14.35, 23.25, 25.55, 26.29, 27.39, 27.69, 27.76, 30.98, 31.58, 31.77, 34.76, 37.80, 38.12, 43.59, 47.11, 48.50, 93.44, 106.36, 113.21, 128.45, 135.23, 136.51, 147.17, 177.75.

Example 23B

3-substituted-2,4-dihalo-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (93)

Method A: Under argon atmosphere, a solution of compound 92, anhydrous potassium carbonate (1.2 equiv) and alkyl iodide (2.0 equiv) in dimethylformamide (3.3% W/V) was stirred at 30 °C for 1 h. The reaction mixture was cooled at room temperature, quenched with saturated ammonium chloride, and extracted with ethyl acetate. The organic phase was quenched with brine, dried over magnesium sulfate, filtered, and evaporated. The crude mixture was purified by flash chromatography (hexanes-ethyl acetate 49-1 to hexanes-ethyl acetate 19-1) to provide compound 93 (e.g., EM-1385-CS, X=Br, R=Me, 78%): IR (NaCl) 2935, 2870, 1720, 1462, 1384, 1298, 1150 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.01 (s, 3H), 1.29 (s, 6H), 1.30-2.35 (m, 17H), 2.68 (m, 1H), 2.88 (dd, J=5.6 and 18.2 Hz, 1H), 3.86 (s, 3H), 7.45 (s, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 14.36, 23.28, 25.59, 26.24, 27.45, 27.72, 27.80, 31.07, 31.62, 31.84, 34.79, 37.84, 37.99, 43.87, 47.11, 48.63, 60.38, 93.45, 114.48, 121.45, 129.07, 137.31, 139.26, 151.96, 177.75.

- 238 -

Method B: Under argon atmosphere, a solution of compound 92, triphenylphosphine (6 equiv) and alcohol (6 equiv) in THF (1.5% W/V) was cooled at 0 °C and treated with diethyl azodicarboxylate (6 equiv). The solution was warmed at room temperature, stirred for 2 h, and evaporated. The crude mixture was purified by flash chromatography (hexanes-ethyl acetate 19-1) to provide compound 93 (e.g., EM-1387, X=Br, R=allyl, 72%): IR (neat) 2937, 2871, 1722, 1453, 1386 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.01 (s, 3H), 1.28 (s, 6H), 1.30-2.35 (m, 17H), 2.68 (m, 1H), 2.88 (dd, J=5.8 and 18.0 Hz, 1H), 4.50 (d, J=5.6 Hz, 2H), 5.30 (dd, J=1.3 and 10.3 Hz, 1H), 5.46 (dd, J=1.3 and 17.0 Hz, 1H), 6.18 (m, 1H), 7.45 (s, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 14.35, 23.26, 25.56, 26.20, 27.42, 27.69, 27.77, 31.09, 31.59, 31.81, 34.76, 37.81, 37.93, 43.84, 47.08, 48.60, 73.79, 93.42, 114.76, 118.41, 121.73, 129.04, 133.20, 137.24, 139.21, 150.86, 177.72.

- 239 -


Example 24

Synthesis of 2-fluoro-1,3,5(10)-estratrien-
17-dimethyl- δ -lactone derivatives

5

These syntheses are described in Scheme 21.

Scheme 21



a. K_2CO_3 , NaI, $CH_3OCH_2CH_2Cl$, CH_3CN , Δ b. $Na_2S_2O_4$, NaOH, acetone, H_2O c. $BF_3 \cdot OEt_2$, $t-BuONO$,
d. $HCC(CH_2)_2OTHP$, MeLi e. H_2 , Pd/CaCO₃, MeOH f. PTSA, MeOH g. Jones' reagent h. LiHMDS,

10

- 240 -

Example 24A

2-Nitro-3-methyloxyethyloxy-1,3,5(10)-estratrien-17-one (94). A mixture of compound 79a (905 mg, 2.87 mmol), K₂CO₃ (793 mg, 5.74 mmol), 2-chloroethylmethyl ether (17 mL, 18 g, 189 mmol) and NaI (43 mg, 0.29 mmol) in acetonitrile (60 mL) were refluxed for 24 h. The solvent was rotary evaporated and the residue was taken into H₂O/EtOAc. The aqueous phase was extracted with EtOAc (3x). The combined organic phase was washed with brine, dried (MgSO₄), filtered then rotary evaporated. The crude solid was purified by flash chromatography (SiO₂) using 1:9 to 2:8 EtOAc/Hexanes as eluent to give recovery of the starting material (416 mg, 46%) and the title compound (520 mg, 49%) as a yellow solid. $[\alpha]_D^{25} +135.8^\circ$ (c 1.28, CHCl₃); IR ν 3448 (w), 2930, 2890, 1737 (CO), 1617, 1568, 1518, 1498, 1454, 1409, 1373, 1351, 1339, 1287, 1194, 1129, 1070, 1031, 1006, 960, 916, 895, 874, 833, 795, 758, 733, 669, 594, 588 cm⁻¹; ¹H NMR (CDCl₃) δ 0.91 (3H, s), 1.42-1.66 (6H, m), 1.95-2.42 (6H, m), 2.51 (1H, dd, $J=18.9$ Hz, $J'=8.9$ Hz), 2.92 (2H, br t, $J=9.5$ Hz), 3.45 (3H, s), 3.78 (2H, t, $J=5.1$ Hz), 4.20 (2H, t, $J=4.8$ Hz), 6.80 (1H, s), 7.79 (1H, s); ¹³C NMR (CDCl₃) δ 13.8, 21.5, 25.7, 26.0, 29.7, 31.3, 35.7, 37.8, 43.5, 47.8, 50.2, 59.4, 69.7, 70.7, 115.4, 122.9, 132.9, 137.9, 144.1, 150.4, 220.1.

Example 24B

2-Amino-3-methyloxyethyloxy-1,3,5(10)-estratrien-17-one (95). To a refluxing solution of compound 94 (506 mg, 1.35 mmol) in acetone (120 mL), H₂O (24 mL) and aqueous 1 M NaOH (24 mL, 24.0 mmol) was portionwise added with care solid Na₂S₂O₄ (3.89 g, 18.97 mmol). The reflux was continued for 2 h then the acetone was removed under vacuum. More H₂O (50 mL) was added and the aqueous phase was extracted with CH₂Cl₂ (4x). The organic phase was dried (MgSO₄), filtered then rotary evaporated. The crude solid was purified by flash chromatography (SiO₂) using 3:7 to 1:1 EtOAc/Hexanes as eluent to give compound 95 (228 mg, 49%) as a foamy solid. ¹H NMR (CDCl₃) δ 0.88 (3H, s), 1.37-2.78 (14 H, m), 3.41 (3H, s), 3.71 (2H, t, $J=5.0$ Hz), 4.09 (2H, 2.9 Hz), 6.52 (1H, s), 6.65 (1H, s).

Example 24C

2-Fluoro-3-methyloxyethyloxy-1,3,5(10)-estratrien-17-one (96). To neat BF₃·Et₂O (126 μ L, 141 mg, 1.00 mmol) at -15 °C under Ar (g) was added a solution of compound 95 (228 mg, 0.66 mmol) in dry CH₂Cl₂ (4 mL) followed by the dropwise addition t-butyl nitrite (95 μ L, 82 mg, 0.80 mmol). This solution was stirred at -15 °C for 10 min then at 0 °C for 1.5 h. Pentane (16 mL) was added to the cold solution and a red gummy solid precipitated. The solvent was decanted and the residue was rinsed with cold Et₂O (5 mL). The residue was dried under vacuum to give a

foamy orange-red solid. This solid was heated under vacuum with a heatgun for 5 min. The residue was purified by flash chromatography (SiO₂) using 3:7 to 1:1 EtOAc/Hexanes as eluent to give compound 96 (32 mg, 14%) as a solid. ¹H NMR (CDCl₃) δ 0.90 (3H, s), 1.25-1.64 (m, 6H), 1.92-2.29 (6H, m), 2.50 (1H, dd, J=18.9 Hz, 8.9 Hz), 2.82 (2H, dd, J=8.4 Hz, J'=3.5 Hz), 3.45 (3H, s), 3.75 (2H, t, J=4.7 Hz), 4.15 (2H, t, J=4.5 Hz), 6.71 (1H, d, J=8.7 Hz), 6.98 (1H, d, J=13.2 Hz); ¹³C NMR(CDCl₃) δ 13.8, 21.5, 25.9, 26.5, 29.0, 29.7, 31.5, 35.8, 38.0, 43.9, 47.9, 50.3, 59.2, 69.2, 71.0, 113.1 (d, J=18.7 Hz), 116.1, 132.6 (d, J=87.0 Hz), 144.5, 149.5, 152.7, 220.6.

Example 24D

2-Fluoro-17β-hydroxy-3-methyloxyethyloxy-17α-(4'-(2''-tetrahydro-2''H-pyranyloxy)-butynyl)-1,3,5(10)-estratriene (97). To a stirred solution of 2-(3-butynyloxy)tetrahydro-2H-pyran (58 μL, 57 mg, 0.37 mmol) in dry THF (4 mL) at -30 °C under Ar(g) was dropwise added MeLi (1.4 M in Et₂O, 5.39 mL, 7.55 mmol). The solution was stirred at room temperature for 25 min. then cooled down to -30 °C. A solution of compound 96 (32 mg, 0.09 mmol) in dry THF (4 mL) was added and the solution was stirred for a further 1 h. The solution was quenched with ice and aqueous sat. NaHCO₃ and extracted with EtOAc. The organic layer was washed with brine, dried (MgSO₄), filtered then rotary evaporated to give compound 97 as a crude oil (73 mg). This compound was used without further purification.

Example 24E

2-Fluoro-17β-hydroxy-3-methyloxyethyloxy-17α-(4'-(2''-tetrahydro-2''H-pyranyloxy)-butyl)-1,3,5(10)-estratriene (98). A mixture of crude compound 97 (73 mg, ~0.09 mmol) and 5% Pd/CaCO₃ (35 mg) in MeOH (10 mL) was stirred under H₂(g) (balloon) at room temperature for 2 h. The mixture was filtered through celite and the solvent evaporated under vacuum to give compound 98 (52 mg) as a crude oil. This compound was used without further purification.

Example 24F

2-Fluoro-17β-hydroxy-3-methyloxyethyloxy-17α-(4'-hydroxybutyl)-1,3,5(10)-estratriene (99). Crude compound 98 (52 mg, ~0.09 mmol) and PTSA monohydrate (7 mg, 0.04 mmol) were stirred in MeOH (5 mL) at room temperature for 3 h. The solvent was reduced to about 1-2 mL, EtOAc was added, and the organic phase was washed with cold aqueous saturated NaHCO₃, H₂O, brine and was dried (MgSO₄), filtered and then evaporated to give compound 99 (42 mg) as a crude solid. This compound was used without further purification.

Example 24G

2-Fluoro-3-methoxyethoxy-1,3,5(10)-estratrien-17(R)-spiro-2'-(6'-oxo) tetrahydropyran (100). To a stirred solution of crude compound 99 (42 mg, ~0.09 mmol) in acetone (6 mL) at 0 °C was added 1.25 M H₂CrO₄ (Jones' reagent, 326 µL, 0.4 mmol). The solution was stirred for 20 min. then more 1.25 M H₂CrO₄ (Jones' reagent, 326 µL, 0.4 mmol) was added. After 20 min, iso-propanol (1 mL) was added and the solution was stirred for a further 10 min. The precipitated formed was decanted and washed with acetone (4x). The acetone volume was reduced to about 2 mL and was then poured onto cold aqueous saturated NaHCO₃ with the help of EtOAc. The organic phase was washed with H₂O, brine, dried (MgSO₄), filtered and then evaporated to give compound 100 (33 mg) as a crude solid. This compound was used without further purification. ¹H NMR (CDCl₃) δ 1.01 (3H, s), 1.24-2.60 (19H, m), 2.78 (2H, br s), 3.45 (3H, s), 3.74 (2H, dd, J=5.0 Hz, J'=4.5 Hz), 4.14 (2H, dd, J=5.0 Hz, J'=4.5 Hz), 6.69 (1H, d, J=8.7 Hz), 6.97 (1H, d, J=13.2 Hz); ¹³C NMR (CDCl₃) δ 14.3, 15.9, 23.4, 26.0, 27.4, 27.9, 29.0, 29.5, 31.9, 34.0, 38.7, 43.6, 47.2, 48.8, 59.2, 69.2, 71.0, 93.2, 113.1 (d, J=18.6 Hz), 116.1, 132.0, 133.3, 144.4, 151.1 (d, J_{CF}=243.4 Hz), 172.0.

Example 24H


2-Fluoro-3-methoxyethoxy-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo) tetrahydropyran (EM-1393). To a stirred solution of compound 100 (33 mg, ~0.08 mmol) in dry THF (3 mL) at 0 °C under Ar(g) was dropwise added HMDSLi (1.0 M in THF, 198 µL, 0.20 mmol). After 25 min, the solution was cooled down to -60 °C and MeI (99 µL, 225 mg, 1.58 mmol) was added. The solution temperature was allowed to slowly rise from -60 to 0 °C over 40 min. The reaction was quenched with aqueous NH₄Cl, extracted with EtOAc (4x), dried (MgSO₄), filtered and then evaporated. The crude compound was purified on silica gel using 1:9 EtOAc/Hexanes as eluent to give EM-1393 (8 mg, 19% yield from compound 96, 5 steps) as a solid. IR (ν) 2924, 2871, 2832, 1722 (CO), 1620, 1586, 1513, 1454, 1384, 1357, 1306, 1290, 1268, 1201, 1149, 1133, 1116, 1032, 1018, 931, 874, 810, 789, 722 cm⁻¹; ¹H NMR (CDCl₃) δ 1.02 (3H, s), 1.28(0) (3H, s), 1.28(3) (3H, s), 1.29-2.30 (17H, m), 2.80 (2H, br s), 3.45 (3H, s), 3.75 (2H, t, J=4.8 Hz), 4.15 (2H, dd, J=5.0 Hz, J'=4.6 Hz), 6.69 (1H, d, J=8.6 Hz), 6.98 (1H, d, J=13.2 Hz); ¹³C NMR (CDCl₃) δ 14.4, 23.3, 25.6, 26.1, 27.4, 27.6, 27.8, 29.1, 29.7, 31.6, 34.9, 37.8, 38.8, 43.6, 47.3, 48.6, 59.2, 69.2, 71.0, 93.6, 113.1 (d, J=17.7 Hz), 116.1, 132.1, 133.4, 144.4, 151.1 (d, J=248.6 Hz), 177.8.

- 243 -

Example 25**Synthesis of 3-methylthioethoxy-1,3,5(10)-estratrien- δ -lactone**

5

These syntheses are described in Scheme 22.

Scheme 22

10

a. K_2CO_3 , $ClCH_2CH_2SCH_3$, DMF, reflux

Example 25A


3-Methylthioethoxy-1,3,5(10)-estratrien-17(R)-spiro-2'-(6'-oxo) tetrahydropyran (CS-242). To a solution of 1,3,5(10)-estratrien-3-ol-17(R)-spiro-2'-(6'-oxo)tetrahydropyran (EM-919, 40 mg, 0.117 mmol) in anhydrous acetonitrile (20 mL) at room temperature under Ar(g) was added K₂CO₃ (16 mg, 0.117 mmol) and chloroethylmethyl sulfide (39mg, 35 mL, 0.350 mmol). The solution was refluxing for 44h. The acetonitrile solution was evaporated to dryness and ethyl acetate (40 mL) was then added. The organic phase was washed with water, brine and dried with MgSO₄ to gave crude product (49 mg). Purification by flash chromatography on silica gel (SiO₂, 3 g) using ethyl acetate/hexanes (2:8) as eluent gave desired product (35 mg, 70%). IR (ν) 2921, 1727, 1608, 1576, 1499, 1466, 1438, 1382, 1348, 1330, 1310, 1280, 1236, 1187, 1159, 1100, 1067, 1036, 992, 931, 914, 860, 818, 731 cm⁻¹; ¹H NMR(CDCl₃) δ 1.01 (3H, s), 1.25-2.57 (19H, m), 2.20 (3H, s) 2.85 (4H, t, J=6.88Hz), 4.12 (2H, t, J=6.74Hz), 6.62 (1H, d, J=2.49Hz), 6.71 (1H, dd, J₁=2.58Hz J₂=5.89 Hz), 7.19 (1H, d, J=8.54 Hz); ¹³C NMR(CDCl₃) δ 14.8, 15.9, 16.2, 23.5, 26.1, 27.5, 28.0, 29.5, 29.7, 32.0, 33.1, 34.0, 39.1, 43.7, 47.3, 48.9, 67.4, 93.3, 112.1, 114.6, 126.3, 132.6, 137.9, 156.5, 172.1 ppm. HRMS: FAB M/S [M]⁺ calculated for C₂₅H₃₅O₃S: 415.23068, found 415.23250.

Example 26

Synthesis of 3-fluoro-1,3,5(10) estratrien-17-spiro(dimethyl- δ -lactone) derivatives

These syntheses are described in Scheme 22.

Scheme 22



a. $\text{BF}_3 \cdot \text{OEt}_2$, tBuONO , CH_2Cl_2 then Δ b. $\text{HCC}(\text{CH}_2)_2\text{OTHP}$, MeLi c. H_2 , Pd/CaCO_3 , MeOH
d. PTSA , MeOH e. Jones' reagent f. LDA , MeI

Example 26A

2-Amino-1,3,5(10)-estratriene (101). The title compound was synthesized from estrone according to the procedure reported by Morrow and Hofer (J. Med. Chem. 9, 249-51, 1966).

Example 26B

3-Fluoro-1,3,5(10)-estratriene (102). 3-Fluoroestrone was synthesized from 2-aminoestrone by adapting the procedure reported by Doyle and Bryker (J. Org. Chem. 44, 1572-1574, 1979) for the synthesis of arenediaxonium tetrafluoroborate salts from aromatic amines. The procedure is as followed: To neat stirred boron trifluoride etherate (642 μ L, 719 mg, 5.07 mmol) at -15 °C under Ar (g) was added a solution of 3-aminoestrone (101) (910 mg, 3.38 mmol) in dry CH_2Cl_2 (10 mL). After 15 min, a solution of t-butyl nitrite (482 μ L, 418 mg, 4.05 mmol) in dry CH_2Cl_2 (5 mL) was dropwise added. The now dark brown solution was stirred at -15 °C for 15 min, then at 0 °C for 30 min. Pentane was added to the solution and a gummy solid precipitated. The solvent was decanted and the residue was dried under vacuum to give a crude light brown solid. The neat solid was heated under vacuum at 70-80 °C in an oil bath for 15 min to give a crude orange solid. Purification by flash chromatography on SiO_2 using 1:9 EtOAc/Hexanes gave 3-fluoroestrone (102) as a white solid (437 mg, 47 %). M.p. 178 °C; $[\alpha]_D^{25} +152.0^\circ$ (c 1.03, CDCl_3); IR (ν) 3044, 3039, 2928, 1740 (CO), 1611, 1585, 1495, 1474, 1458, 1428, 1405, 1377, 1340, 1272, 1245, 1230, 1212, 1148, 1094, 1084, 1053, 1008, 908, 889, 817, 784, 718, 704, 642, 620, 580, 564, 467 cm^{-1} ; ^1H NMR (CDCl_3) δ 0.92 (3H, s), 1.37-1.70 (6H, m), 1.93-2.44 (6H, m), 2.52 (1H, dd, $J=18.8$ Hz, $J'=9.0$ Hz), 2.91 (2H, dd, $J=8.4$ Hz, $J'=3.8$ Hz), 6.82 (2H, dq, $J=8.3$ Hz, $J'=2.8$ Hz), 7.23 (1H, dd, $J=8.5$ Hz, $J'=5.8$ Hz); ^{13}C NMR (CDCl_3) δ 13.8, 21.6, 25.9, 26.3, 29.5, 31.5, 35.9, 38.1, 44.0, 47.9, 50.4, 112.5 (d, $J=21.6$ Hz), 115.1 (d, $J=19.7$ Hz), 126.8 (d, $J=7.5$ Hz), 135.3, 138.7, 161.0 (d, $J=244.3$ Hz), 220.7.

Example 26C

3-Fluoro-17 β -hydroxy-17 α -(4'-(2"-tetrahydro-2"H-pyranyloxy-1'-butynyl)-1,3,5(10)-estratriene (103). To a stirred solution of 2-(3-butynyloxy)tetrahydro-2H-pyran (1.21 mL, 1.199 g, 7.77 mmol) in dry THF (45 mL) at -30 °C under Ar(g) was dropwise added MeLi (1.4 M in Et_2O , 5.39 mL, 7.55 mmol). After 30 min., a solution of 3-fluoroestrone (102) in dry THF was added and the solution was stirred for a further 2 h. The solution was quenched with ice and aqueous sat NaHCO_3 and extracted with EtOAc. The organic layer was washed with H_2O , brine, dried (MgSO_4), filtered then rotary evaporated to give a crude orange oil. Purification by flash chromatography on silica gel using EtOAc/Hexanes (1:9 \rightarrow 2:8 \rightarrow 3:7) gave pure compound 103 (789 mg, 83 %) as a solid.

- 247 -

[α] $^{25}_D$ -4.7° (c 1.14, CDCl₃); IR (ν) 3432 (br, OH), 2937, 2870, 1611, 1589, 1495, 1458, 1438, 1420, 1380, 1354, 1285, 1233, 1201, 1183, 1122, 1073, 1032, 970, 911, 870, 846, 815, 783, 728, 692, 563, 466 cm⁻¹; ¹H NMR (CDCl₃) δ 0.87 (3H, s), 1.25-2.05 (17H, m), 2.22-2.36 (3H, m), 2.56 (2H, t, J=7.0 Hz), 2.84 (2H, br t, J=4.8 Hz), 3.49-3.59 (2H, m), 3.79-3.88 (2H, m), 4.66 (1H, br s), 6.80 (2H, dq, J=9.8 Hz, J'=2.8 Hz), 7.24 (1H, dd, J=8.4 Hz, J'=5.8 Hz); ¹³C NMR (CDCl₃) δ 12.7, 19.1, 20.2, 22.7, 25.3, 26.3, 26.9, 29.5, 30.4, 32.7, 38.9, 39.1, 43.5, 46.9, 49.3, 61.8, 65.7, 79.6, 82.9, 84.6, 98.4, 112.1 (d, J=20.9 Hz), 114.9 (d, J=20.6 Hz), 126.6 (d, J=8.5 Hz), 135.7, 138.7 (d, J=6.7 Hz), 160.7 (d, J=244.8 Hz).

Example 26D

3-Fluoro-17β-hydroxyl-17α-(4'-(2"-tetrahydro-2"H-pyranyloxy-1'-butyl)-1,3,5(10)-estratriene (104). A suspension of compound 103 (720 mg, 1.69 mmol) and 5% Pd/CaCO₃ (123 mg) in MeOH (40 mL) was stirred under H₂(g) atmosphere (balloon) at room temperature for 2h. The mixture was filtered through celite and the solvent rotary evaporated to give compound 104 (692 mg, 95%) as a solid. This compound was used without further purification for the next step. [α] $^{25}_D$ +28.8° (c 0.59, CDCl₃); IR (ν) 3464 (br w, OH), 2938, 2870, 1611, 1588, 1494, 1453, 1440, 1380, 1271, 1252, 1234, 1200, 1142, 1119, 1076, 1024, 989, 971, 930, 910, 868, 815, 782, 731 cm⁻¹; ¹H NMR (CDCl₃) δ 0.91 (3H, s), 1.31-2.35 (20H, m), 2.84 (2H, br t, J=4.8 Hz), 3.43-3.52 (2H, m), 3.78-3.88 (2H, m), 6.80 (2H, dq, J=8.3 Hz, J'=2.7 Hz), 7.23 (1H, dd, J=8.4 Hz, J'=6.1 Hz) ppm; ¹³C NMR (CDCl₃) δ 14.4, 19.7, 20.5, 23.4, 25.5, 26.3, 27.3, 29.7, 30.4, 30.8, 31.6, 34.3, 36.4, 39.2, 39.4, 43.8, 46.7, 62.4, 67.7, 83.4, 98.4 (d, J=4.5 Hz), 112.3 (d, J=21.0 Hz), 115.0 (d, J=20.3 Hz), 126.7 (d, J=8.1 Hz), 136.0, 138.9 (d, J=6.6 Hz), 160.9 (d, J=244.1 Hz).

Example 26E

3-Fluoro-17β-hydroxyl-17α-(4'-hydroxybutyl)-1,3,5(10)-estratriene (105). A solution of compound 104 (692 mg, 1.61 mmol), PTSA monohydrate (31 mg, 0.16 mmol) in MeOH was stirred overnight at room temperature. The volume of solvent was reduced to about 10 mL and EtOAc (125 mL) was added. This solution was washed with aqueous saturated NaHCO₃, H₂O, brine, dried (MgSO₄), filtered then rotary evaporated to give a crude solid. Purification on silica gel (3:7 to 1:1 EtOAc/Hexanes) gave compound 105 (469 mg, 84%) as a solid. [α] $^{25}_D$ +42.6° (c 1.07, CDCl₃); IR (ν) 3362 (br s, OH), 2933, 2866, 1740 (w), 1611, 1589, 1495, 1458, 1420, 1376, 1303, 1271, 1236, 1144, 1036, 1008, 931, 912, 870, 816, 783, 728, 562, 468 cm⁻¹; ¹H NMR (CDCl₃) δ 0.91 (3H, s), 1.25-1.65 (17H, m), 1.85-2.35 (4H, m), 2.85 (2H, br t, J=4.6 Hz), 3.70 (2H, br t, J=5.9 Hz), 6.81 (2H, dq, J=8.4 Hz,

- 248 -

$J'=1.1$ Hz), 7.22 (1H, dd, $J=8.4$ Hz, $J'=6.0$ Hz); ^{13}C NMR (CDCl_3) δ 14.3, 19.8, 23.4, 26.3, 27.3, 29.6, 31.6, 33.3, 34.4, 36.1, 39.4, 43.8, 46.7, 49.5, 62.7, 83.5, 112.3 (d, $J=19.9$ Hz), 115.1 (d, $J=20.5$ Hz), 126.7 (d, $J=8.1$ Hz), 135.9, 138.9 (d, $J=6.9$ Hz), 160.9 (d, $J=243.8$ Hz).

Example 26F

3-Fluoro-1,3,5(10)-estratrien-17(R)-spiro-2'-(6'-oxo)tetrahydropyran (EM-1170). To a stirred solution of compound 105 (410 mg, 1.18 mmol) in acetone (40 mL) at 0 °C was added Jones' reagent (1.25 M, 1.04 mL, 1.30 mmol). The solution was stirred for 15 min. then more Jones' reagent (1.25 M, 1.04 mL, 1.30 mmol) was added. After 50 min., the excess reagent was quenched with isopropanol and the solution was stirred for a further 10 min. The precipitate was filtered through celite and the acetone rotary evaporated. The residue was taken in EtOAc and the solution was washed with aqueous saturated NaHCO_3 , H_2O , brine, dried (MgSO_4), filtered, then rotary evaporated to give a crude solid. Purification on silica gel (2:8 \rightarrow 3:7 EtOAc/Hexanes) gave EM-1170 (298 mg, 72 %) as a solid. $[\alpha]_D^{25} +47.0^\circ$ (c 1.09, CDCl_3); IR (ν) 3435, 3040, 2955, 2933, 2906, 2879, 2836, 2815, 1885, 1736 (CO), 1611, 1586, 1494, 1467, 1435, 1419, 1383, 1366, 1356, 1328, 1312, 1290, 1263, 1232, 1182, 1140, 1103, 1067, 1026, 990, 964, 933, 912, 861, 822, 782, 718, 670, 636, 584, 563, 536, 508 cm^{-1} ; ^1H NMR (CDCl_3) δ 1.02 (3H, s), 1.23-2.58 (19H, m), 2.85 (2H, br t, $J=5.2$ Hz), 6.80 (2H, dq, $J=8.4$ Hz, $J'=2.7$), 7.23 (1H, dd, $J=8.4$ Hz, $J'=6.0$ Hz); ^{13}C NMR (CDCl_3) δ 14.2, 15.7, 23.4, 25.9, 27.1, 27.8, 29.4, 31.8, 33.8, 38.7, 43.5, 47.1, 48.7, 93.1, 112.2 (d, $J=20.5$ Hz), 114.9 (d, $J=20.1$ Hz), 126.6 (d, $J=8.5$ Hz), 135.4, 138.6 (d, $J=6.7$ Hz), 160.8 (d, $J=243.8$ Hz), 171.9.

Example 26G

3-Fluoro-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (EM-1157). LDA was prepared as follows. To a stirred solution of diisopropylamine (501 μL , 386 mg, 3.82 mmol) in dry THF (20 mL) at -78°C under Ar(g) was dropwise added $n\text{-BuLi}$ (1.6 M in Hexane, 2.38 mL, 3.82 mmol). The solution was stirred at room temperature for 30 min then was cooled down to -78°C for the addition of a solution of EM-1170 (218 mg, 0.64 mmol) in dry THF (15 mL). The solution was then stirred at room temperature for 1h. then cooled down to -78°C . MeI (476 μL , 1.084g, 0.64 mmol) was added and the solution was stirred at -78°C for 5 h and was allowed to rise to room temperature overnight. The reaction was quenched with ice/ H_2O , extracted with EtOAc, washed with aqueous saturated NH_4Cl , 1M aqueous Na_2SO_3 , H_2O , brine, dried (MgSO_4), filtered then rotary evaporated to give a crude solid. Purification on silica gel (1:9 EtOAc/Hexanes) gave EM-1157 (40 mg, 17 %) as a solid. $[\alpha]_D^{25} +43.3^\circ$ (c 1.09, CHCl_3); IR (ν) 3430, 2969, 2941,

- 249 -


5

2867, 1734(CO), 1492, 1458, 1387, 1306, 1235, 1201, 1148, 1132, 1062, 1032, 1017, 979, 915, 874, 818, 785, 727, 597, 580, 567, 530, 508 cm⁻¹; ¹H NMR (CDCl₃) δ 1.02 (3H, s), 1.28 (3H, s), 1.28 (3H, s), 1.29-1.74 (10H, m), 1.83-2.36 (7H, m), 2.85 (2H, t, J=5.1 Hz), 6.80 (2H, dq, J=8.6 Hz, J'=2.7 Hz), 7.22 (1H, dd, J=8.6 Hz, J'=6.2 Hz); ¹³C NMR (CDCl₃) δ 14.4, 23.3, 25.6, 26.1, 27.2, 27.7, 27.8, 29.5, 31.6, 31.9, 34.8, 37.8, 38.9, 43.7, 47.2, 48.7, 93.6, 112.3 (d, J=19.9 Hz), 115.1 (d, J=19.5 Hz), 126.7 (d, J=8.4 Hz), 135.5, 138.7 (d, J=6.8 Hz), 160.9 (d, J=244.2 Hz), 177.8.

Example 27
3-sulfonyl derivatives of 1,3,5(10)-estatrien-
17-spiro-(dimethyl δ -lactone)

5 These syntheses are described in Scheme 23.

Scheme 23



Example 27A


3-alkylsulfonyloxy-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (106). A solution of compound 89 in dichloromethane (3.0% W/V) was treated with alkylsulfonyl chloride (1.1 equiv) and triethylamine (1.5 equiv), and stirred for 2 h. The reaction mixture was quenched with distilled water and diluted with dichloromethane. The organic phase was washed with brine and 5% sodium bicarbonate, dried over magnesium sulfate, filtered, and evaporated. The crude mixture was purified by flash chromatography (hexanes-ethyl acetate 49-1 to hexanes-ethyl acetate 9-1) and trituration (hexanes-acetone 19-1) to provide compound 106 (e.g., EM-1364-CS, R=Et, 90%): IR (CHCl₃) ν 3025, 2944, 2874, 1708, 1605, 1492, 1366, 1213, 1136 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.02 (s, 3H), 1.28 (s, 3H), 1.29 (s, 3H), 1.30-1.80 (m, 13H), 1.80-2.05 (m, 5H), 2.18 (m, 1H), 2.34 (m, 1H), 2.88 (m, 2H), 3.26 (q, J=14.8 Hz, 2H), 6.99-7.05 (m, 2H), 7.30 (d, J=8.5 Hz, 1H); ¹³C NMR (75 Hz, CDCl₃) δ 8.23, 14.41, 23.29, 25.58, 25.92, 27.67, 27.76, 29.46, 31.61, 31.93, 34.79, 37.80, 38.68, 43.81, 44.89, 47.20, 48.72, 93.53, 118.89, 121.90, 126.77, 138.84, 139.13, 146.99, 177.76.

Example 28
3-carbonyl substituted 1,3,5(10)-estratrien-17-spiro-(dimethyl- δ -lactone)

These syntheses are described in Scheme 24.

5

Scheme 24



Example 28A

3-trifluoromethanesulfonyloxy-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (107). Under argon atmosphere, a solution of compound 89 (500 mg, 1.35 mmol), 2,6-lutidine (0.355 mL, 3.05 mmol) and 4-dimethylaminopyridine (33 mg, 0.27 mmol) in dry dichloromethane (25 mL) was cooled at 0 °C, treated with trifluoromethanesulfonic anhydride (0.308 mL, 1.83 mmol) and stirred for 45 min. The reaction mixture was quenched with water and extracted with dichloromethane. The organic phase was washed with 2% hydrochloric acid, saturated sodium bicarbonate and water, dried over magnesium sulfate, filtered, and evaporated. The crude oil was purified by flash chromatography (hexanes-ethyl acetate 49-1 to hexanes-ethyl acetate 4-1) to provide trifluoromethanesulfonate 107 (EM-1399) (540 mg, 80%): IR (CHCl₃) 2957, 2872, 1711, 1490, 1426, 1248, 1214, 1141, 926, 846, 621 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.03 (s, 3H), 1.28 (s, 3H), 1.29 (s, 3H), 1.35-2.40 (m, 17H), 2.88 (m, 2H), 6.98 (s, 1H), 7.02 (d, J=8 Hz, 1H), 7.33 (d, J=8.7 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 14.32, 23.22, 25.48, 25.80, 26.89, 27.57, 27.68, 29.37, 31.49, 31.80, 34.69, 37.72, 38.46, 43.66, 47.10, 48.59, 93.43, 116.54, 118.08, 120.80, 121.07, 127.05, 139.31, 140.43, 147.46, 177.70.

Example 28B

3-carboxy-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (EM-1401). Method A: A mixture of compound 107 (560 mg, 1.12 mmol), potassium acetate (440 mg, 4.48 mmol), palladium acetate (12.6 mg, 0.056 mmol), and 1,1'-bis(diphenylphosphino)ferrocene (125 mg, 0.255 mmol) in dimethyl sulfoxide (20 mL) was purged with carbon monoxide for 20 min and stirred over under a carbon monoxide balloon at 80 °C over a 3 h period. The reaction mixture was diluted with 0.5 N hydrochloric acid and extracted with dichloromethane. The organic phase was washed with water, dried over magnesium sulfate, filtered, and evaporated. The reaction mixture was purified by flash chromatography (dichloromethane-methanol 19-1 to dichloromethane-methanol 4-1) to provide the carboxylic acid EM-1401 (300 mg, 68%): IR (KBr) 2937, 2872, 1718, 1676, 1388, 1314, 1230, 1180, 1160 cm⁻¹; ¹H NMR (300 MHz, CDCl₃ + CD₃OD) δ 0.75 (s, 3H), 1.01 (s, 6H), 1.10-2.17 (m, 17H), 2.65 (m, 2H), 7.09 (d, J=8.1 Hz, 1H), 7.48 (s, 1H), 7.51 (d, J=8.5 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃ + CD₃OD) δ 13.71, 22.75, 24.98, 25.27, 26.65, 26.87, 28.76, 30.84, 31.46, 34.21, 37.33, 38.22, 43.84, 46.74, 93.92, 124.84, 126.52, 127.32, 129.91, 136.31, 144.94, 168.70, 178.97.

Example 28C

3-alkoxycarbonyl-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (108). A mixture of compound 107, triethylamine (3.25 equiv), palladium acetate (0.07 equiv), 1,3-bis(diphenylphosphino)propane (0.06 equiv), and alcohol (1.5 equiv to large excess) in DMF (10% W/V) was purged with carbon monoxide for 20 min and stirred under a carbon monoxide balloon at 90 °C over a 16 h period. The reaction mixture was cooled at room temperature, diluted with water and extracted with dichloromethane. The organic phase was washed with brine, dried over magnesium sulfate, filtered, and evaporated. The reaction mixture was purified by 3 flash chromatographies (2 times with benzene-acetone 4-1 and hexanes-ethyl acetate 7-3) to provide compound 108 (e.g., EM-1398, R=benzyl, 70%): IR (CHCl₃) 2938, 1716, 1293, 1262, 1177, 1152, 1130, 1109, 732 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.02 (s, 3H), 1.28 (s, 3H), 1.29 (s, 3H), 1.34-1.41 (m, 17H), 2.91 (m, 2H), 5.35 (s, 2H), 7.33-7.45 (m, 6H), 7.79 (s, 1H), 7.83 (d, J=8.1 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 14.39, 23.28, 25.55, 25.74, 27.14, 27.64, 27.75, 29.25, 31.56, 31.93, 34.75, 37.77, 38.56, 44.34, 47.16, 48.82, 66.42, 93.50, 125.34, 126.90, 127.45, 128.05, 128.10, 128.52, 130.23, 136.22, 136.81, 145.49, 166.55, 177.75.

Example 28D

3-carboxy-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (EM-1401). Method B: A mixture of compound 108 (350 mg, 0.72 mmol) and 10% palladium on activated carbon (50 mg) in ethyl acetate (40 mL) was stirred under an hydrogen balloon over a 3 h period. The reaction mixture was filtered on celite and evaporated. The crude mixture was purified by flash chromatography (dichloromethane-THF 19-1 to dichloromethane-THF 3-1) to provide the carboxylic acid EM-1401 (240 mg, 84%). A sample was recrystallized in methanol-THF (the characterization was described previously).

Example 28E

3-carboxamido-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (109). Under argon atmosphere, a solution of EM-1401 and pyridine (15 equiv) in dry dichloromethane (1.6% W/V) was cooled at 0 °C, treated with oxalyl chloride (6 equiv) and stirred for 0.5 h. The reaction mixture was allowed to reach room temperature and stirred over a 4 h period. The reaction mixture was evaporated, dissolved in dry THF (1.6% W/V), cooled at 0 °C, treated with 10 equiv of amine and stirred for 15 min. The reaction mixture was quenched with water, extracted with dichloromethane, dried over magnesium sulfate, filtered, and evaporated. The crude mixture was purified by flash

- 255 -

5 chromatography (hexanes-acetone 19-1 to hexanes-acetone 3-2) to provide compound 109 (e.g., EM-1404, $R^1=R^2=H$, 65%): IR ($CHCl_3$) 3433, 3350, 2941, 2873, 1702, 1664, 1611, 1388, 1310, 1159 cm^{-1} ; 1H NMR (300 MHz, $CDCl_3 + CD_3OD$) δ 0.73 (s, 3H), 0.99 (s, 6H), 1.10-2.16 (m, 17H), 2.64 (m, 2H), 7.08 (d, $J=8.0$ Hz, 1H), 7.30 (s, 1H), 7.32 (d, $J\approx 9$ Hz, 1H); ^{13}C NMR (75 MHz, $CDCl_3 + CD_3OD$) δ 13.69, 22.72, 24.96, 25.27, 26.64, 26.84, 28.78, 29.09, 30.81, 31.44, 34.19, 37.31, 38.27, 43.72, 46.74, 93.92, 124.20, 124.93, 127.70, 130.00, 136.45, 143.88, 170.63, 178.96.

- 256 -


Example 29

Synthesis of 2-carboxy/alkoxycarbonyl/carboxamide-3-alkoxy-1,3,5(10)-estratrien-17spiro-(dimethyl- δ -lactone) derivatives

5

These syntheses are described in Scheme 25.

Scheme 25



10

2-formyl-1,3,5(10)-estratrien-3-ol-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (110). Lactone 89 (1.0 g, 2.72 mmol) was dissolved in dry 1,2-dichloroethane (9 mL) under argon atmosphere. SnCl₄ (0.16 mL, 1.37 mmol) and Bu₃N (0.52 mL, 2.18 mmol) were added successively. The mixture was stirred at room temperature for 20 min. Formaldehyde (0.23 g, 7.84 mmol) was added and the mixture was stirred at reflux for 6h. The reaction mixture was poured into aq acid (pH=2) and, was extracted with CH₂Cl₂. The organic layers were washed with brine solution, dried (Na₂SO₄) filtered and concentrated in vacuo. The crude product was purified by flash chromatography on silica gel, eluting with (95:5 to 80:20) hexanes-acetone to yield 0.74 g (69 %) of the product; IR (NaCl cm⁻¹): 3164, 2937, 2872, 1716, 1652, 1571, 1487, 1466, 1386, 1298, 1152, 1017, 914, 731; ¹H NMR (CDCl₃) 1.00 (s, 3H), 1.26 (s, 6H) 1.23-2.40 (m, 17H), 2.80-2.90 (m, 2H), 6.66 (s, 1H), 7.39 (s, 1H), 9.79 (s, 1H), 10.77 (s, 1H); ¹³C NMR (CDCl₃) δ 14.3, 23.2, 25.4, 25.9, 26.8, 27.6, 27.7, 30.0, 31.4, 31.6, 34.6, 37.7, 38.6, 42.9, 47.0, 48.5, 93.4, 116.9, 118.9, 130.3, 132.2, 147.8, 159.2, 177.7, 196.0.

2-formyl-3-(2"-methoxyethyloxy)-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (111). To a solution of aldehyde 110 (0.74 g, 1.87 mmol) in CH₃CN (19 mL), Cs₂CO₃ (0.96 g, 2.95 mmol), NaI (55 mg, 0.37 mmol) and 2-chloroethyl methyl ether (0.86 mL, 9.42 mmol) were added, and the mixture was stirred at reflux for 20h. The reaction mixture was quenched with brine solution, and was extracted with CH₂Cl₂. The organic layers were dried (Na₂SO₄) filtered and evaporated to crude product, which was purified by flash column chromatography (CH₂Cl₂: Acetone, 95:5) to give 0.62 g (73 %) of the desired compound; IR (NaCl, cm⁻¹): 2942, 2879, 1714, 1675, 1609, 1459, 1394, 1308, 1269, 1152, 874; ¹H NMR (CDCl₃) δ 1.01 (s, 3H), 1.28 (s, 6H) 1.25-2.20 (m, 16H), 2.35-2.45 (m, 1H), 2.85-2.95 (m, 2H), 3.45 (s, 3H), 3.79 (t, 2H, J=4.7 Hz), 4.20 (t, 2H, J=4.6 Hz), 6.68 (s, 1H), 7.76 (s, 1H), 10.45 (s, 1H); ¹³C NMR (CDCl₃) δ 14.4, 23.3, 25.6, 26.0, 27.1, 27.7, 27.8, 30.4, 31.6, 31.9, 34.9, 37.8, 38.9, 43.4, 47.3, 48.7, 59.4, 68.3, 70.9, 93.6, 113.0, 123.0, 125.2, 133.1, 146.0, 159.2, 177.8, 189.6.

2-carboxy-3-(2"-methoxyethyloxy)-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (EM-1405). The aldehyde (130 mg, 0.29 mmol) was solubilized in pyridine (4 mL) and n-Bu₄NMnO₄ (140 mg, 2 eq., 0.38 mmol) (prepared by mixing the aqueous solution of KMnO₄ and n-Bu₄NBr in water and filtering the precipitate) was added to the above solution. After 16 h the mixture was poured in a solution of 300 mg of NaHSO₃ in 30 ml of 1 N HCl. The final product was then extracted with ethyl acetate and dried (Na₂SO₄). Evaporation of solvents under vacuum gave 140 mg of a semi-solid mixture, which was purified on C₁₈ reverse phase gel using MeCN:MeOH:H₂O in a proportion of 35:35:30 and then

- 258 -

40:35:25 to give the acid (44 mg, 32%); IR (KBr, cm^{-1}) 3274, 2944, 2890, 1723, 1613, 1422; ^1H NMR (CDCl_3) δ 10.96 (bs, 1H), 8.08 (s, 1H), 6.73 (s, 1H), 4.32 (t, 2H, $J=5.2$ Hz), 3.78 (t, 2H, $J=4.4$ Hz), 3.45 (s, 3H), 2.87-2.88 (m, 2H), 1.28 (s, 6H), 1.02 (s, 3H); ^{13}C NMR (CDCl_3) δ 177.7, 165.7, 155.2, 144.6, 134.6, 130, 115.7, 113.6, 93.5, 69.9, 69.2, 59.1, 48.6, 47.2, 43.4, 38.7, 37.7, 34.8, 31.7, 31.5, 29.9, 27.7, 27.6, 26.9, 25.9, 25.5, 23.2, 14.4.

2-carbomethoxy-3-(2"-methoxyethyloxy)-1,3,5(10)-estratrien 17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (EM-1402). The acid EM-1405 (44 mg, 0.094 mmol) was solubilized in a mixture of anhydrous methanol (2 mL) and anhydrous benzene (4 mL). Then, a 2M solution of TMSCHN_2 (250 μL , 0.5 mmol, 5 eq.) in hexane was added and the mixture was stirred for 4 h at room temperature. The solvents were removed under vacuum and the oil was purified on silica gel column using acetone:hexanes as an eluent to give the methyl ester (32 mg, 70%); IR (KBr, cm^{-1}) 2941, 2813, 1716, 1611, 1271; ^1H NMR (CDCl_3) δ 7.73 (s, 1H), 6.69 (s, 1H), 4.15 (t, 2H, $J=4.8$ Hz), 3.86 (s, 3H, $J=4.5$ Hz), 3.79 (t, 2H), 3.47 (s, 3H), 2.82-2.90 (m, 2H), 1.28 (s, 6H), 1.02 (s, 3H); ^{13}C NMR (CDCl_3) δ 177.7, 166.8, 156.5, 142.8, 132.5, 128.8, 118.0, 114.6, 93.5, 71.0, 69.1, 59.3, 51.7, 48.6, 47.2, 43.4, 38.9, 37.7, 34.7, 31.8, 31.5, 29.8, 27.7, 27.6, 27.1, 25.9, 25.5, 23.2, 14.4.

2-dimethylcarbamoyl-3-(2"-methoxyethyloxy) 1,3,5(10)-estratrien 17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (EM-1413): To a solution of the acid EM-1405 (50 mg, 0.11 mmol) in anhydrous CH_2Cl_2 (5 mL) at 0°C , were added pyridine (40 μL , 0.49 mmol) oxalyl chloride (30 μL , 0.34 mmol) and DMF (10 μL , 0.13 mmol). The mixture was allowed to warm to room temperature and stirred over a period of 3 h. The volatiles were removed under vacuum. The dry residue was dissolved in anhydrous CH_2Cl_2 (10 mL) under argon and cooled to 0°C . A 2M solution of dimethylamine (1 mL, 2.1 mmol) in THF was added and the temperature was raised to 25°C , and the mixture was stirred for 1 h. The reaction mixture was diluted with CH_2Cl_2 , washed with brine, dried (MgSO_4) and concentrated to dryness. The residue was purified by silica gel column chromatography with hexanes/acetone (7/3) to afford 35 mg (70%) of the dimethylamide. IR (NaCl , cm^{-1}): 2927, 2871, 1719, 1630, 1148, 1134; ^1H NMR (300 MHz, CDCl_3) δ 7.18 (s, 1H), 6.59 (s, 1H), 4.09 (m, 2H), 3.69 (m, 2H), 3.41 (s, 3H), 3.09 (s, 3H), 2.88 (s, 3H), 2.87-2.80 (m, 2H), 2.35-2.22 (m, 1H), 1.98-1.80 (m, 3H), 1.77-1.31 (m, 13H), 1.28 (s, 6H, $2\times\text{CH}_3$), 0.88 (s, 3H, 18-Me); ^{13}C NMR (75 MHz, CDCl_3) δ 177.8, 169.7, 152.4, 138.9, 133.1, 125.3, 124.4, 112.7, 93.6, 71.0, 68.2, 59.2, 48.7, 47.3, 43.6, 39.0, 38.3, 37.8, 34.9, 34.7, 31.9, 31.6, 29.8, 27.8, 27.6, 27.4, 26.0, 25.6, 23.3, 14.4.

- 259 -

2-carbamoyl-3-(2"-methoxyethoxy)-1,3,5(10)-estratrien 17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (EM-1424). The acid of EM-1405 (0.11 mmol) was dissolved in a mixture of CH₂Cl₂ (5 mL) and THF (5 mL) and cooled to 0°C. 28% of Aq. ammonium hydroxide (260 µL, 23 mmol) was added, and the mixture was allowed to warm to room temperature and stirred over a period of 3 h. The reaction mixture was then diluted with CH₂Cl₂, washed with brine, dried (MgSO₄) and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with hexanes/acetone (6/4) to afford 27 mg (45%) of the amide; IR (NaCl, cm⁻¹): 3446, 3335, 3178, 2926, 2872, 1717, 1664, 1589, 1427, 1151, 1134; ¹H NMR (300 MHz, CDCl₃) δ 8.11 (s, 1H), 7.98 (br.s, 1H), 6.67 (s, 1H), 5.64 (br.s, 1H), 4.23-4.20 (m, 2H), 3.79-3.76 (m, 2H), 3.42 (s, 3H), 2.89-2.86 (m, 2H), 2.52-2.45 (m, 1H), 2.16-1.30 (m, 16H), 1.28 (s, 6H, 2xCH₃), 1.01 (s, 3H, 18-Me); ¹³C NMR (75 MHz, CDCl₃) δ 177.8, 167.2, 154.9, 142.5, 133.5, 129.6, 118.9, 113.3, 93.6, 70.5, 68.1, 58.9, 48.7, 47.3, 43.6, 39.0, 37.8, 34.9, 31.9, 31.6, 29.8, 27.8, 27.7, 27.1, 26.1, 25.6, 23.3, 14.4.

- 260 -


Example 30

3-hydroxy derivatives of 2-cyano-1,3,5(10)-estratrien-17-spiro-(dimethyl- δ -lactone)

5

These syntheses are described in Scheme 26.

Scheme 26



10

- 261 -

Example 30A

2-oximino-1,3,5(10)-estratrien-3-ol-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (113). Under argon atmosphere, a solution of compound 112 (215 mg, 0.54 mmol) in anhydrous ethanol-pyridine 1-1 (4 mL) was treated with hydroxylamine hydrochloride (56.6 mg, 0.814 mmol) and stirred at room temperature for 25 min. The reaction mixture was evaporated, diluted with water, and extracted 3 times with dichloromethane. The combined organic phase was washed with brine, dried over sodium sulfate, filtered, and evaporated to provide the oxime 113 (217 mg, 98%): ¹H NMR (300 MHz, CDCl₃) δ 1.02 (s, 3H), 1.29 (s, 6H), 1.43-1.70 (m, 10H), 1.89-2.12 (m, 6H), 2.22-2.37 (m, 1H), 2.80-2.87 (m, 2H), 6.69 (s, 1H), 7.05 (s, 1H), 8.15 (broad s, 1H), 8.20 (s, 1H), 9.61 (s, 1H).

Example 30B

3-acetoxy-2-cyano-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (114a). A solution of compound 113 (180 mg, 0.44 mmol) and acetic anhydride (125 μL, 1.32 mmol) in pyridine (3.5 mL) was refluxed for 1 h. The reaction mixture was evaporated, diluted with dichloromethane, and washed 3 times with water, 1 time with saturated sodium bicarbonate and 1 time with brine. The organic phase was dried over magnesium sulfate, filtered, and evaporated. The crude mixture was purified by flash chromatography (dichloromethane to dichloromethane-ethyl acetate 19-1) to provide acetate 114a (145 mg, 76%): IR (CHCl₃) 2933, 2872, 2229, 1773, 1718, 1613, 1494, 1183 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.02 (s, 3H), 1.28 (s, 6H), 1.34-1.89 (m, 11H), 1.94-2.33 (m, 6H), 2.37 (s, 3H), 2.89-2.94 (m, 2H), 6.95 (s, 1H), 7.55 (s, 1H).

Example 30C

2-cyano-1,3,5(10)-estratrien-3-ol-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (114b). A solution of compound 114a (135 mg, 0.34 mmol) in methanol (10 mL) was treated with 10% potassium carbonate (1 mL) and stirred 30 min. The reaction mixture was acidified to pH 2 with 1 N hydrochloric acid and extracted 3 times with dichloromethane. The combined organic phase was washed with water, saturated sodium bicarbonate, and brine, dried over magnesium sulfate, filtered, and evaporated. The crude phenol 114b (115 mg, 85%) was directly used for the next step: ¹H NMR (300 MHz, CDCl₃) δ 0.97 (s, 3H), 1.29 (s, 6H), 1.26-2.14 (m, 16H), 2.21-2.28 (m, 1H), 2.82-2.86 (m, 2H), 6.69 (s, 1H), 6.91 (s, 1H), 7.35 (s, 1H).

Example 30D

3-alkyloxy-2-cyano-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (114c). Under argon atmosphere, a suspension of compound **114b**, alkyl iodide (5 equiv) and cesium carbonate (1.5 equiv) in anhydrous acetonitrile (1% W/V) was stirred for 16 h with refluxing condition if necessary. The reaction mixture was quenched with brine and extracted 3 times with dichloromethane. The combined organic phase was washed with brine, dried over magnesium sulfate, filtered, and evaporated. The crude mixture was purified by flash chromatography (dichloromethane to dichloromethane-ethyl acetate 10-1) and recrystallization (methanol) to provide compound **114c** (e.g., EM-1396, R=(CH₂)₂OCH₃, 75%): IR (CHCl₃) 3013, 2941, 2881, 2229, 1710, 1610, 1500, 1304, 1136 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.01 (s, 3H), 1.28 (s, 6H), 1.20-1.75 (m, 10H), 1.80-2.20 (m, 6H), 2.20-2.35 (m, 1H), 2.80-2.95 (m, 2H), 3.47 (s, 3H), 3.79 (t, J=4.8 Hz, 2H), 4.17 (t, J=4.8 Hz, 2H), 6.67 (s, 1H), 7.44 (s, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 14.41, 23.25, 25.58, 25.90, 26.96, 27.66, 27.74, 30.24, 31.59, 31.78, 34.79, 37.80, 38.68, 43.16, 47.20, 48.60, 59.55, 68.78, 70.71, 93.43, 99.55, 112.80, 116.98, 130.72, 133.31, 144.09, 158.29, 177.70.


- 263 -

Example 31
Synthesis of 1,3,5(10)-estratrien-6-one-17-spiro-(dimethyl- δ -lactones)


These syntheses are described in Schemes 27 and 28.

5

Scheme 27



Scheme 28



Example 31A

3-alkoxy-1,3,5(10)-estratrien-6-one-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (120). Under argon atmosphere, a solution of chromium (VI) oxide (10 equiv) in anhydrous dichloromethane (22% W/V) was treated with 3,5-dimethylpyrazole (10 equiv), cooled at -20 °C, and stirred 20 min. The reaction mixture was treated with a cool solution (-20 °C) of 3-alkoxy-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (89a) in anhydrous dichloromethane (29% W/V) and stirred 1.5 h. The reaction mixture was then poured on silica gel and eluted with dichloromethane to dichloromethane-ethyl acetate 3-1. The crude mixture was purified by flash chromatography (hexanes to hexanes-acetone 5-1) to provide compound 120 (e.g., EM-1394, R=Me, 11%): IR (CHCl₃) 2990, 2963, 1709, 1678, 1608, 1493, 1217, 1152 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.03 (s, 3H), 1.29 (s, 6H), 1.47-2.25 (m, 14H), 2.43-2.47 (m, 2H), 2.76 (dd, J=2.9 and 16.4 Hz, 1H), 3.85 (s, 3H), 7.11 (dd, J=2.8 and 8.6 Hz, 1H), 7.34 (d, J=8.6 Hz, 1H), 7.56 (d, J=2.8 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 14.32, 23.03, 25.37, 25.55, 27.67, 27.76, 31.53, 31.62, 34.61, 37.82, 40.39, 42.65, 44.15, 47.07, 48.61, 55.51, 93.20, 109.69, 121.58, 126.52, 133.29, 139.18, 158.27, 177.60, 197.53.

Example 31B

3-alkoxy-1,3,5(10)-estratrien-9α-ol-6-one-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (121). Under argon atmosphere, compound 89a in acetonitrile (5.5% W/V) was treated with copper iodide (0.01 equiv) and t-butyl hydroperoxide (6.7 equiv), and stirred and heated at 50 °C for 20 h. The reaction mixture was poured into 10% sodium sulfite and extracted with ethyl acetate. The organic phase was washed with saturated sodium bicarbonate, brine and water, dried over magnesium sulfate, filtered, and evaporated. The crude mixture was purified by flash chromatography (hexanes-ethyl acetate 19-1 to hexanes-ethyl acetate 7-3) to provide compound 121 (e.g., EM-1386, R¹=CH₃, 44%): IR (CHCl₃) 3603, 3486, 3012, 2985, 2872, 1710, 1682, 1604, 1494, 1288, 1248, 1144, 1030 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.04 (s, 3H), 1.29 (s, 6H), 1.40-1.80 (m, 5H), 1.80-2.23 (m, 8H), 2.35 (m, 1H), 2.43 (dd, J=2.5 and J=9.5 Hz, 1H), 2.52 (dd, J=3.7 and 17.6 Hz, 1H), 2.78 (dd, J=8.7 and 12.4 Hz, 1H), 3.86 (s, 3H), 7.13 (dd, J=2.9 and 8.7 Hz, 1H), 7.51 (d, J=8.7 Hz, 1H), 7.56 (d, J=2.9 Hz, 1H); ¹³C NMR (75 Hz, CDCl₃) δ 13.51, 22.75, 25.75, 27.54, 27.60, 27.70, 31.47, 32.18, 34.75, 37.77, 41.73, 41.96, 46.98, 55.49, 68.96, 93.30, 110.37, 121.24, 125.53, 132.75, 139.96, 159.46, 177.79, 197.85.

Example 31C

3,9 α -dialkoxy-1,3,5(10)-estratrien-6-one-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (122). A solution of compound 121 in methanol

(0.8% W/V) was treated with oxalic acid (4 equiv) and a drop of water and refluxed for 0.5 h. The reaction mixture was cooled at room

temperature, evaporated and diluted with ethyl acetate. The obtained solution was washed with 5% sodium bicarbonate and brine, dried over

magnesium sulfate, filtered, and evaporated. The crude mixture was purified by flash chromatography (hexanes-ethyl acetate 9-1 to hexanes-

ethyl acetate 7-3) to provide compound 122 (e.g., R¹,R²=CH₃, 35%): IR (CHCl₃) 2955, 2874, 2824, 1720, 1683, 1604, 1493, 1286, 1268, 1248, 1141 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.04 (s, 3H), 1.28 (s, 6H), 1.35-2.20 (m,

12H), 2.35 (m, 1H), 2.43 (dd, J=4.6 and 17.9 Hz, 1H), 2.64 (m, 1H), 2.80 (m, 1H), 2.83 (s, 3H), 3.86 (s, 3H), 7.08 (dd, J=2.8 and 8.4 Hz, 1H), 7.39 (d, J=8.4

Hz, 1H), 7.58 (d, J=2.8 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 13.79, 22.92, 24.48, 25.81, 27.37, 27.71, 27.77, 31.50, 34.74, 37.29, 37.82, 42.02, 42.74, 46.84, 49.27, 55.52, 72.96, 93.34, 110.89, 119.61, 127.56, 133.75, 136.72, 159.54, 177.79, 198.26.


- 267 -

Example 32
2,3-oximino-1,3,5(10)-estratrien-17-spiro-(dimethyl- δ -lactone)

This synthesis is described in Scheme 29.

5

Scheme 29



- 268 -

Example 32A

Synthesis of 1,3,5(10)-estratrien-(2,3-oximino)-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (EM-1407-CS). A solution of hydroxylamine-O-sulfonic acid (14 mg, 0.12 mmol) and sodium sulfate (2 mg, 0.014 mmol) in methanol-water 2-1 (1.5 mL) was treated with compound 110 (40 mg, 0.10 mmol) and stirred for 30 min. The reaction mixture was diluted with water (5 mL) and dichloromethane (5 mL), cooled at -10 °C, vigorously stirred for 15 min, treated with sodium bicarbonate (17 mg, 0.20 mmol), and stirred for 30 min. The reaction mixture was allowed to reach room temperature and stirred for 1 h. The two phases were separated, then the aqueous phase was extracted 4 times with dichloromethane. The combined organic phase was dried over magnesium sulfate, filtered, and evaporated. The crude mixture was purified by flash chromatography (hexanes to hexanes-acetone 19-1) to provide the 1,2-benzisoxazole EM-1407-CS (30 mg, 77%): IR (CHCl₃) 3013, 2937, 2872, 1708, 1625, 1507, 1299, 1153, 1017 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.03 (s, 3H), 1.29 (s, 6H), 1.30-1.80 (m, 10H), 1.80-2.20 (m, 5H), 2.20-2.45 (m, 2H), 3.01-3.06 (m, 2H), 7.32 (s, 1H), 7.61 (s, 1H), 8.61 (s, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 14.41, 23.38, 25.59, 26.11, 27.10, 27.67, 27.78, 30.15, 31.59, 31.84, 34.78, 37.81, 38.76, 43.71, 47.20, 49.00, 93.52, 108.70, 117.57, 119.62, 137.00, 140.62, 146.02, 160.96, 177.78.


Example 33

Synthesis of 2-methyl/2-trifluoromethyl-3-alkoxy-
1,3,5(10)-estratrien-17-spiro-(dimethyl- δ -lactone) derivatives

5


These syntheses are described in Schemes 30 and 31.

Scheme 30



10

Scheme 31



Example 33A

2-iodo-3-methoxy-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (123). Compound 89a (400 mg, 1.05 mmol), silver trifluoroacetate (254 mg, 1.15 mmol) and sodium bicarbonate (439 mg, 5.23 mmol) were mixed in dichloromethane (4 mL) at -30°C. Crushed iodine (278 mg 1.10 mmol) was added and the resulting mixture was stirred vigorously for 1 h during which the red color completely disappeared. The reaction mixture was then filtered and washed with dichloromethane (50 mL), and concentrated. The residue was purified by chromatography on silica gel using hexanes/ethyl acetate (80/20) to afford 412 mg (77%) of the 2-iodo compound as a white solid along with 10% of the 4-iodo compound; IR (KBr, cm⁻¹): 2955, 1712, 1461, 1288, 1140; ¹H NMR (300 MHz, CDCl₃) δ 1.0 (s, 3 H), 1.25-1.78 (m, 10 H), 1.28 (s, 6 H), 1.82-2.40 (m, 7 H), 2.80-2.84 (m, 2 H), 3.83 (s, 3 H), 6.54 (s, 1 H), 7.63 (s, 1 H); ¹³C NMR (75 MHz, CDCl₃) δ 14.4, 23.3, 25.6, 26.11, 27.3, 27.7, 27.8, 29.6, 31.6, 31.8, 34.8, 37.8, 38.9, 43.3, 47.2, 48.6, 56.3, 82.6, 93.5, 111.4, 134.6, 136.3, 138.2, 156.0, 177.8.

Example 33B

3-methoxy-2-methyl-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (EM-1412). The 2-iodoestrone derivative 123 (300 mg, 0.590 mmol) was dissolved in anhydrous THF (4 mL) and then cooled to -78°C. A 1.6 M solution of BuLi in hexane (390 µL, 0.620 mmol) was added following after 10 min., iodomethane (180 µL, 2.95 mmol) and after 5 min., carbon disulfide (39 µL, 0.65 mmol). The resulting mixture was stirred at -78°C for 1 h then warmed to room temperature. After 1 h, the solvent was removed and the residue was purified by column chromatography using hexanes/ethyl acetate (85/15) to give a white solid (104 mg, 44%). IR (KBr, cm⁻¹): 2932, 1718, 1507, 1202, 1154; ¹H NMR (300 MHz, CDCl₃) δ 1.02 (s, 3 H), 1.20-1.80 (m, 10 H), 1.29 (s, 6 H), 1.80-2.20 (m, 6 H), 2.18 (s, 3 H), 2.30-2.40 (m, 1 H), 2.75-2.90 (m, 2 H), 3.79 (s, 3 H), 6.55 (s, 1 H), 7.05 (s, 1 H); ¹³C NMR (75 MHz, CDCl₃) δ 14.4, 15.9, 23.3, 25.6, 26.2, 27.6, 27.6, 27.8, 29.6, 31.6, 32.1, 34.8, 37.8, 39.3, 43.6, 47.3, 48.7, 55.3, 93.7, 110.4, 123.8, 127.6, 131.4, 134.8, 155.7, 177.9.

Example 33C

3-methoxy-2-trifluoromethyl-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (EM-1409). A pressure reaction bottle was charged with activated copper powder (90 mg, 1.4 mmol), as a suspension in DMF (1 mL) and HMPA (0.8 mL). 2-Iodoestrone derivative 123 (180 mg, 0.354 mmol) was added and the resulting mixture was cooled to -78°C, and an excess of trifluoromethyl iodide was condensed. The pressure bottle was tightly closed and warmed to 130°C. Stirring was

- 272 -

maintained for 20 h. The mixture was cooled to room temperature and filtered on silica gel, and washed with a mixture of 25 mL of dichloromethane and 75 mL of ethyl acetate. Evaporation of solvents and column chromatography using hexanes/ethyl acetate (80/20) gave a white solid (104 mg, 65%); IR (KBr, cm^{-1}): 2938, 1713, 1623, 1509, 1299, 1120; ^1H NMR (300 MHz, CDCl_3) δ 1.02 (s, 3 H), 1.25-1.80 (m, 10 H), 1.29 (s, 3 H), 1.80-2.25 (m, 6 H), 2.34-2.42 (m, 1 H), 2.80-2.96 (m, 2 H), 3.86 (s, 3 H), 6.70 (s, 1 H), 7.45 (s, 1 H). ^{13}C NMR (75 MHz, CDCl_3) δ 14.4, 23.2, 25.5, 26.0, 27.1, 27.6, 27.7, 29.8, 31.5, 31.9, 34.7, 37.7, 38.9, 43.3, 47.2, 48.5, 93.5, 112.3, 116.0 (q, $J_{\text{C-F}}=31$ Hz), 123.9 (q, $J_{\text{C-F}}=272$ Hz), 123.9 (d, $J_{\text{C-F}}=6$ Hz), 131.7, 142.3, 155.2, 177.8, 196.7.

Example 33D

3-(2'-methoxyethoxy)-1,3,5(10)-estratrien-17-one (124). A mixture of estrone (10 g; 37 mmol), NaI (1.1 g, 7.4 mmol), Cs_2CO_3 (18.08 g; 55.5 mmol) and $\text{Br}(\text{CH}_2)_2\text{OCH}_3$ (15 mL; 156 mmol) in CH_3CN (200 mL) was refluxed for 1 h. The mixture was filtered over silica gel and washed successively with CH_2Cl_2 and EtOAc to give the ether (12.1 g; 99.4%); ^1H NMR (300 MHz, CDCl_3) δ 7.23 (d, 1H, $J=8.6$ Hz), 6.75 (dd, 1H, $J=2.6, 8.6$ Hz), 6.72 (s, 1H), 4.1 (t, 2H, $J=4.4$ Hz), 3.74 (t, 2H, $J=3.7$ Hz), 3.44 (s, 3H), 2.87 (dd, 2H, $J=4.25, 8.5$ Hz), 2.48 (dd, 1H, $J=8.4, 18.7$ Hz), 0.91 (s, 3H).

Example 33E

2-iodo-3-(2'-methoxyethyl)-1,3,5(10)-estratrien-17-one (125). The iodo compound was prepared in 73.5% yield (3.04 g) by following the method, described above; ^1H NMR (300 MHz, CDCl_3) δ 7.64 (s, 1H), 6.57 (s, 1H), 4.12 (t, 2H, $J=5.1$ Hz), 3.8 (t, 2H, $J=4.9$ Hz), 3.5 (s, 3H), 2.85 (dd, 2H, $J=3.9, 8.5$ Hz), 2.5 (dd, 1H, 8.8, 18.8 Hz), 0.90 (s, 3H).

Example 33F

3-(2'-methoxyethoxy)-2-trifluoromethyl-1,3,5(10)-estratrien-17-one (126) was prepared in 66.6% yield (581 mg) by the method, described above; ^1H NMR (300 MHz, CDCl_3) δ 7.45 (s, 1H), 6.72 (s, 1H), 4.15 (t, 2H, $J=5.1$ Hz), 3.77 (t, 2H, $J=5.1$ Hz), 3.45 (s, 3H), 2.91 (m, 2H), 2.5 (dd, 1H, 8.9, 18.8 Hz), 0.91 (s, 3H).

Example 33G

17 β -Hydroxy-3-(2'-methoxyethoxy)-17 α -(4'-(2"-tetrahydro-2"H-pyranyl)butyn-1'-yl)-2-trifluoromethyl-1,3,5(10)-estratriene (127) was prepared in 63% yield (523 mg) by the method, described above; ^1H NMR (300 MHz, CDCl_3) δ 7.42 (s, 1H), 6.67 (s, 1H), 4.64 (bs, 1H), 4.11 (t, 2H, $J=4.5$ Hz), 3.84-3.75 (m, 2H), 3.73 (t, 2H, $J=4.7$ Hz), 3.54-3.46 (m, 3H), 3.41 (s, 3H), 2.82 (bs, 2H), 2.71 (bs, 1H), 2.52 (t, 2H, 6.8 Hz), 0.81 (s, 3H).

Example 33H

17 β -Hydroxy-3-(2'-methoxyethoxy)-17 α -(4'-(2"-tetrahydro-2"H-pyranyl)butan-1'-yl)-2-trifluoromethyl-1,3,5(10)-estratriene (128) was prepared (the crude; 455 mg) by the method described above; ¹H NMR (300 MHz, CDCl₃) δ 7.44 (s, 1H), 6.7 (s, 1H), 4.59 (bs, 1H), 4.14 (t, 2H, J=5.1 Hz), 3.90-3.80 (m, 2H), 3.76 (t, 2H, J=5 Hz), 3.52-3.43 (m, 2H), 3.45 (s, 3H), 2.87-2.85 (m, 2H), 0.89 (s, 3H).

Example 33I

17 β -Hydroxy-3-(2'-methoxyethoxy)-17 α -(4'-hydroxybutan-1'-yl)-2-trifluoromethyl-1,3,5(10)-estratriene 17(129) was prepared (the crude; 386 mg) by the method described above; ¹H NMR (300 MHz, CDCl₃) δ 7.44 (s, 1H), 6.7 (s, 1H), 4.14 (t, 2H, J=4.9 Hz), 3.77 (t, 2H, J=5.1 Hz), 3.70 (t, 2H, J=5.8 Hz), 3.46 (s, 3H), 2.86 (m, 2H), 0.90 (s, 3H).

Example 33J

3-(2'-methoxyethoxy)-2-trifluoromethyl-1,3,5(10)-estratrien 17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (130) was prepared in 59% yield (for 3 steps) by the method, described above; ¹H NMR (300 MHz, CDCl₃) δ 7.44 (s, 1H), 6.7 (s, 1H), 4.14 (t, 2H, J=4.2 Hz), 3.77 (t, 2H, J=5.1 Hz), 3.45 (s, 3H), 2.91-2.90 (m, 2H), 1.02 (s, 3H).

Example 33H


3-(2'-methoxyethoxy)-2-trifluoromethyl-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (EM-1438) was prepared in 88.7% yield by the method described above; IR (KBr, cm⁻¹), 3419, 2988, 2939, 2879, 2818, 1718, 1622, 1508, 1298, 1154, 1052; ¹H NMR (300 MHz, CDCl₃) δ 7.43 (s, 1H), 6.7 (s, 1H), 4.13 (t, 2H, J=5.2 Hz), 3.76 (t, 2H, J=4.77 Hz), 3.44 (s, 3H), 2.87 (m, 2H), 2.36-3.32 (m, 1H), 1.27 (s, 6H), 1.01 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 177.7, 154.5, 142.2, 132.1, 123.9 (d, J_{C-F}=5.3 Hz), 123.8 (q, J_{C-F}=272 Hz), 116.6 (q, J_{C-F}=31 Hz), 113.7, 93.5, 70.8, 68.8, 59.3, 48.6, 47.2, 43.3, 38.9, 37.8, 34.8, 31.8, 31.6, 29.8, 27.7, 27.6, 27.1, 26.0, 25.5, 23.2, 14.4.

Example 34
Synthesis of 1,3,5(10)-estratrien-17-spiro-(diethyl- δ -lactone) derivatives

These syntheses are described in Scheme 32.

5

Scheme 32



Example 34A

3-t-butyl dimethylsilyloxy-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-diethyl-6'-oxo)tetrahydropyran (131). In a dry 25 mL flask under argon the lactone 87 (200 mg, 0.44 mmol) in THF (5 mL) was charged and cooled to 0°C. LiHMDS (1.1 mL, 1.1 mmol) was added dropwise. The mixture was stirred 15 minutes at 0°C and then cooled to -78°C. Ethyl iodide (176 µL, 2.2 mmol) was added, and stirred 1 h at this temperature, and then allowed to warm to room temperature over a period of 2 h. A saturated solution of NH₄Cl (5 mL) was added and the mixture was extracted with CH₂Cl₂. The organic layer was washed with a saturated solution of Na₂S₂O₃ and brine, dried (MgSO₄), and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with hexanes/acetone (9/1) as an eluent to afford 193 mg (86%) of diethyl compound; IR (NaCl, cm⁻¹): 2933, 2857, 1719, 1496, 1259, 1143, 957, 839; ¹H NMR (300 MHz, CDCl₃) δ 7.11 (d, 1H, J=8.4Hz), 6.62 (dd, 1H, J=2.1, 8.4Hz), 6.56 (s, 1H), 2.81-2.78 (m, 2H), 2.36-2.25 (m, 1H), 2.19-1.22 (m, 20H), 1.02 (s, 3H, 18-Me), 0.98 (s, 9H), 0.90 (app.q, 6H, J=7.5Hz), 0.19 (s, 6H); ¹³C NMR (75 MHz, CDCl₃) δ 176.6, 153.3, 137.6, 132.6, 125.9, 119.8, 117.1, 93.0, 48.6, 47.2, 45.3, 43.6, 39.0, 34.5, 31.9, 30.5, 29.5, 27.4, 25.9, 25.6, 24.3, 23.4, 18.1, 14.3, 8.2, -4.5.

Example 34B

1,3,5(10)-estratrien-3-ol-17(R)-spiro-2'-(5',5'-diethyl-6'-oxo)tetrahydropyran (EM-1416). The silyl ether (193 mg, 0.38 mmol) was treated with a 1M solution of TBAF (455 µL) to give the hydroxy compound (143 mg, 95%); IR (NaCl, cm⁻¹): 3349, 2967, 2930, 2878, 1696, 1682, 1503, 1454, 1146, 910, 732; ¹H NMR (300 MHz, CDCl₃) δ 7.10 (d, 1H, J=8.4Hz), 6.76 (s, 1H, OH), 6.66 (d, 1H, J=8.4 Hz), 6.60 (s, 1H), 2.82-2.77 (m, 2H), 2.36-2.28 (m, 1H), 2.17-1.22 (m, 20H), 0.98 (s, 3H, 18-Me), 0.91 (app.q, 6H, J=7.6Hz); ¹³C NMR (75 MHz, CDCl₃) δ 177.8, 154.0, 137.6, 137.6, 131.4, 126.1, 115.3, 112.9, 93.5, 48.5, 47.2, 45.4, 43.5, 39.1, 34.5, 31.9, 31.7, 30.6, 29.4, 27.3, 26.0, 25.6, 24.1, 23.3, 14.2, 8.7.

Example 34C

3-methoxy-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-diethyl-6'-oxo)tetrahydropyran (EM-1419). To the alcohol (19 mg, 0.063 mmol) and Cs₂CO₃ (31 mg, 0.094 mmol) in acetonitrile (2 mL), was added MeI (40 µL, 0.63 mmol) at room temperature. after 1 h, another MeI (40 µL) was added. The solution was diluted with CH₂Cl₂, washed with a 10% aq HCl and brine, dried (MgSO₄), and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with hexanes/EtOAc (9/1) to afford 19 mg (97%) of the 3-methoxy compound; IR (NaCl, cm⁻¹): 2935, 2877, 1718, 1500, 1462, 1256, 1142, 1037, 731; ¹H NMR

- 276 -

(300 MHz, CDCl₃) δ 7.20 (d, 1H, $J=8.6$ Hz), 6.71 (dd, 1H, $J=2.8, 8.6$ Hz), 6.63 (d, 1H, $J=2.4$ Hz), 3.78 (s, 3H), 2.87-2.84 (m, 2H), 2.35-2.31 (m, 1H), 2.17-1.26 (m, 20H), 1.02 (s, 3H, 18-Me), 0.90 (app.q, 6H, $J=7.5$ Hz); ¹³C NMR (75 MHz, CDCl₃) δ 176.6, 157.5, 137.8, 132.2, 126.2, 113.8, 111.5, 93.0, 55.2, 48.7, 47.2, 45.4, 43.7, 39.1, 34.6, 31.9, 30.6, 29.7, 27.5, 26.1, 25.7, 24.4, 23.4, 14.4, 8.7.

Example 34D


3-[2'-(N-piperidinyl)ethyl]oxy-1,3,5(10)-estratrien-17(R)-spiro-2'-(5',5'-dimethyl-6'-oxo)tetrahydropyran (EM-1434). The mixture of alcohol EM-1416 (60 mg, 0.15 mmol), K₂CO₃ (668 mg, 4.8 mmol) and 1-(2-chloroethyl)-piperidine monohydrochloride (834 mg, 4.5 mmol) in acetonitrile (25 mL) was refluxed for a period of 15 h. The pH was adjusted to a neutral with a 10% aq HCl and then, the mixture was extracted with EtOAc, washed with brine, dried (MgSO₄) and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with hexanes/acetone (5/1) to afford 35 mg (46%) of compound; IR (NaCl, cm⁻¹): 2934, 1719, 1499, 1256, 1142, 1037; ¹H NMR (300 MHz, CDCl₃): 7.18 (d, 1H, $J=8.6$ Hz), 6.70 (dd, 1H, $J=2.6, 8.6$ Hz), 6.63 (d, 1H, $J=2.3$ Hz), 4.07 (t, 2H, $J=6.0$ Hz), 2.87-2.81 (m, 2H), 2.75 (t, 2H, $J=6.0$ Hz), 2.51-2.48(m, 4H), 2.34-2.30 (m, 1H), 2.17-1.25 (m, 26H), 1.01 (s, 3H, 18-Me), 0.90 (app.q, 6H, $J=7.5$ Hz); ¹³C NMR (75 MHz, CDCl₃) δ 176.7, 156.7, 137.8, 132.3, 126.2, 114.6, 112.1, 93.0, 65.8, 57.9, 54.9, 48.6, 47.2, 45.4, 43.6, 39.1, 34.6, 31.9, 30.6, 29.7, 27.5, 26.1, 25.9, 25.7, 24.4, 24.2, 23.2, 14.4, 8.7.

Example 35

Synthesis of 1,3,5(10)-estratrien-17-spiro-(5"-allyl/5"-methoxycarbonyl/4"-methyl)- δ -lactone and lactenone

These syntheses are described in Scheme 33

Scheme 33



- a: $\text{NH}(\text{isopropyl})_2$, $n\text{BuLi}$, HMPA, THF, $\text{CH}_2=\text{CH}-\text{CH}_2\text{Br}$, $-78^\circ\text{C} \rightarrow$ room temperature
 b: 1M Bu_4NF , 2 h, room temperature.
 c: $\text{NH}(\text{isopropyl})_2$, $n\text{BuLi}$, HMPA, THF, NC COOCH_3 , -78°C
 d: $\text{NH}(\text{isopropyl})_2$, $n\text{BuLi}$, THF, 0°C .
 e: PhSeCl , $-78^\circ\text{C} \rightarrow$ room temperature
 f: H_2O_2 , CH_2Cl_2 , room temperature.
 g: 1M Bu_4NF , 0°C
 h: CuCN , Et_2O , room temperature, CH_3I .

Example 35A**3-hydroxy-1,3,5(10)-estratrien-17(R)-spiro-2'-(4',5'-dihydro-6'-oxo)-pyran.**

To a solution of 1.6 mmol of LDA in 20 mL of dry THF was added 380 mg (0.837 mmol) of lactone 87 in 20 mL of dry THF at 0 °C and the mixture was stirred for 30 min. Then, the temperature was dropped to -78 °C and 248 mg (1.29 mmol) of PhSeCl was added. The solution was stirred overnight and let warm to room temperature. The reaction mixture was quenched with water and extracted with EtOAc. The organic phase was washed with water and dried over MgSO₄. After evaporation of solvent, the crude compound was dissolved in 10 mL of CH₂Cl₂ and 0.5 mL of H₂O₂ (30% w/v). After 30 min at room temperature, water was added, and aqueous phase extracted with CH₂Cl₂. The organic phase was washed with water and dried over MgSO₄. The crude compound was purified by flash chromatography with hexanes/EtOAc (95:5) as eluent to give 133 mg (35%) of 3-(tert-butyltrimethylsilyloxy)-1,3,5(10)-estratrien-17(R)-spiro-2'-(4',5'-dihydro-6'-oxo)-tetrahydropyran. White solid; IR ν (KBr): 1722 (C=O, lactone); ¹H NMR (CDCl₃) δ 0.18 (s, 6H, Si(CH₃)₂), 0.97 (s, 9H, SiC(CH₃)₃), 1.01 (s, 3H, 18-CH₃), 2.81 (m, 2H, 6-CH₂), 6.03 (d, J₁ = 9.8 Hz, 1H, 3'-CH), 6.55 (d, 1H, J = 2.1 Hz, 4-CH), 6.60 (dd, J₁ = 2.5 Hz and J₂ = 8.5 Hz, 2H, 2-CH), 6.80 (m, 1H, 2'-CH), 7.09 (d, J = 8.4 Hz, 1H, 1-CH); ¹³C NMR (CDCl₃) δ -4.42 (Si(CH₃)₂), 14.06 (C-18), 22.94 (C-15), 25.68 (SiC(CH₃)₃), 26.23 (C-11), 27.42 (C-7), 29.49 (C-6), 31.35 (C-12), 34.26 (C-16), 36.13 (C-2'), 38.98 (C-8), 43.63 (C-9), 47.22 (C-13), 49.17 (C-14), 91.91 (C-17), 117.22 (C-2), 119.95 (C-4), 121.54 (C-1'), 126.01 (C-1), 132.44 (C-10), 137.59 (C-5), 144.21 (C-3'), 154.41 (C-3), 164.56 (C=O, lactone).

The TBDMS group of the above compound (133 mg, 0.294 mmol) was cleaved at 0 °C using 0.16 mL of 1 M Bu₄NF solution in THF (0.16 mmol). After evaporation of solvent, the crude compound was purified by flash chromatography with hexanes/EtOAc (7:3) as eluent to give 97 mg (97%) of 3-hydroxy-1,3,5(10)-estratrien-17(R)-spiro-2'-(4',5'-dihydro-6'-oxo)pyran (PB-132-140). White solid; IR ν (KBr): 3235 (OH, phenol), 1691 (C=O, lactone); ¹H NMR (CDCl₃ 90% and CD₃OD 10%) δ 0.84 (s, 3H, 18-CH₃), 2.62 (m, 2H, 6-CH₂), 5.86 (d, J₁ = 9.9 Hz, 1H, 3'-CH), 6.40 (d, 1H, J = 2.2 Hz, 4-CH), 6.45 (dd, J₁ = x Hz and J₂ = x Hz, 2H, 2-CH), 6.75 (m, 1H, 2'-CH), 6.93 (d, J = 8.4 Hz, 1H, 1-CH); ¹³C NMR (CDCl₃ 90% and CD₃OD 10%) δ 13.73 (C-18), 22.66 (C-15), 26.09 (C-11), 27.17 (C-7), 29.29 (C-6), 31.12 (C-12), 34.05 (C-16), 35.84 (C-1), 38.91 (C-8), 43.34 (C-9), 47.82 (C-13), under solvent pics (C-14), 92.15 (C-17), 112.58 (C-2), 115.02 (C-4), 120.82 (C-2'), 126.00 (C-1), 130.80 (C-10), 137.56 (C-5), 145.09 (C-3'), 154.28 (C-3), 165.36

(C=O, lactone). EI-HRMS: calcd for $C_{21}H_{26}O_3$ (M^+) 338.18820, found 338.18638

Example 35B

5 **3-hydroxy-1,3,5(10)-estratrien-17(R)-spiro-2'-(4'-methyl-6'-oxo)tetrahydropyran (PB-132-142).** To a solution of 24 mg (0.271 mmol) of CuCN in 5 mL of dry Et₂O at room temperature was added 0.377 mL (0.528 mmol) of CH₃I. After 30 min, a solution of 30 mg (0.066 mmol) of TBDMS-derivative of compound PB-132-140 in dry Et₂O was added at -78
10 °C. The solution was stirred overnight and let reheat to room temperature. The solution was then quenched at -20 °C with aqueous NH₄Cl and extracted with EtOAc. The organic phase was washed with water and dried over MgSO₄. The crude compound was purified by flash chromatography with hexanes/EtOAc (9:1) as eluent to give 24 mg (78%)
15 of intermediate compound. As described above the TBDMS group of this later compound was cleaved using 0.07 mL of 1 M Bu₄NF solution in THF (0.07 mmol) at 0 °C. After evaporation of solvent, the crude compound was purified by flash chromatography with hexanes/EtOAc (7:3) as eluent to give 17 mg (73% two steps) of β-methylated lactone PB-132-142.
20 White solid; IR ν (film): 3330 (OH, phenol), 1694 (C=O, lactone); ¹H NMR (CDCl₃) δ 0.99 (s, 3H, 18-CH₃), 1.04 (d, J = 6.2 Hz, 3H, CH₃ of lactone ring), 2.56 (dm, J = 13.9 Hz, 1H), 2.80 (m, 2H, 6-CH₂), 6.58 (s_{app}, 1H, 4-CH), 6.63 (dd, J₁ = 8.4 Hz and J₂ = 2.5 Hz, 1H, 2-CH), 7.12 (d, J = 8.4 Hz, 1H, 1-CH); ¹³C NMR (CDCl₃) δ 14.78 (C-18), 21.76 (C-1'), 22.90 (C-15),
25 25.05 (C-3'), 26.22 (C-11), 27.36 (C-7), 29.55 (C-6), 29.67 (CH₃ of lactone), 33.21 (C-12), 38.28 (C-16), 39.25 (C-8), 40.19 (C-2'), 43.45 (C-9), 48.14 (C-13), 49.37 (C-14), 93.63 (C-17), 112.82 (C-2), 115.31 (C-4), 126.37 (C-1), 131.87 (C-10), 138.01 (C-5), 153.73 (C-3), 172.23 (C=O, lactone). EI-HRMS: calcd for C₂₃H₃₀O₃ (M^+) 354.21948, found 354.21791.
30

Example 35C

3-hydroxy-1,3,5(10)-estratrien-17(R)-2'-(5'-allyl-6'-oxo)tetrahydropyran (PB-132-152). The allylation of lactone 87 (50 mg, 0.11 mmol) was
35 conducted at -78 °C with LDA (0.45 mmol), HMPA (0.12 mmol) and allylbromide (0.72 mmol). The mixture was stirred overnight and let warm to room temperature. Without purification the crude lactone was treated for 2 h with a solution in THF of 0.12 ml of 1 M Bu₄NF (0.12 mmol). Then, the crude allyl derivative was purified by flash
40 chromatography with hexanes/EtOAc (9:1) as eluent to give 33 mg (79% two step) of allyl-lactone PB-132-152. White solid; IR ν (film): 3348 (OH,

- 280 -

phenol), 1699 (C=O, lactone); ^1H NMR (CDCl_3) δ 1.00 (s, 3H, 18- CH_3), 2.82 (m, 2H, 6- CH_2), 5.09 (d, J = 8.8 Hz, 1H, $\text{CH}_2\text{CH}=\text{CH}_2$), 5.11 (d, J = 19.6 Hz, 1H, $\text{CH}_2\text{CH}=\text{CH}_2$), 5.79 (m, 1H, $\text{CH}_2\text{CH}=\text{CH}_2$), 6.57 (d, J = 2.5 Hz, 1H, 4-CH), 6.64 (dd, J_1 = 8.4 Hz and J_2 = 2.5 Hz, 1H, 2-CH), 7.13 (d, J = 8.4 Hz, 1H, 1-CH); ^{13}C NMR (CDCl_3) δ 14.34 (C-18), 20.25, 21.30 (C-2'), 21.63, 23.40 and 23.58 (C-15), 25.61, 26.09 (C-11), 27.28, 27.40, 28.27 (C-1'), 29.53 (C-6), 29.67 (C-1''), 31.95 (C-12), 34.00 (C-3'), 34.50 (C-16), 35.96, 38.13, 39.12 (C-8), 40.50, 43.63 (C-9), 47.22 (C-13), 48.62 and 48.76 (C-14), 92.85 and 93.57 (C-17), 112.81 (C-2), 115.30 (C-4), 117.35 and 117.63 (C-2''), 126.35 (C-1), 131.91 (C-10), 135.04 and 135.29 (C-3''), 137.96 (C-5), 153.78 (C-3), 173.87 and 174.79 (C=O, lactone).

Example 35D

3-hydroxy-1,3,5(10)-estratrien-17(R)-2'-(5'-methoxycarbonyl-6'-oxo)tetrahydropyran (PB-132-146). At 0 °C, a solution of lactone 87 (50 mg, 0.11 mmol) in dry THF was added to 0.41 mmol of LDA and the mixture was cooled to -78 °C. Then, HMPA (20 μL , 0.12 mmol) and NCCOOCH_3 (31 μL , 0.45 mmol) were added. Without purification the crude lactone was treated for 2 h with a solution in THF of 0.13 ml of 1 M Bu_4NF (0.13 mmol). The crude phenol was purified by flash chromatography with hexanes/ EtOAc (6:4) as eluent to give 32 mg (73% two steps) of methoxycarbonyl-lactone PB-132-146. White solid; IR ν (film): 3372 (OH, phenol), 1744, 1720, 1710 (C=O, lactone and COOCH_3); ^1H NMR (CDCl_3) δ 1.02 (s, 3H, 18- CH_3), 2.82 (m, 2H, 6- CH_2), 3.46 (dd, J_1 = 7.5 Hz and J_2 = 10.7 Hz, 0.5H, CH of lactone), 3.54 (dd, J_1 = 5.9 Hz and J_2 = 7.8 Hz, 0.5H, CH of lactone), 3.79 and 3.80 (2s, 3H, COOCH_3), 6.57 (s_{app} , 1H, 4-CH), 6.63 (dd, J_1 = 8.1 Hz and J_2 = 2.2 Hz, 1H, 2-CH), 7.13 (d, J = 8.4 Hz, 1H, 1-CH); ^{13}C NMR (CDCl_3) δ 14.33 (C-18), 20.00 and 20.68 (C-2'), 23.46 (C-15), 26.02 (C-11), 26.26 (C-1'), 27.39 (C-7), 29.52 (C-6), 29.68, 31.85 and 31.97 (C-12), 34.03 and 34.34 (C-16), 39.10 (C-8), 43.61 (C-9), 46.30, 47.43 and 47.93 (C-13), 48.72 and 48.83 (C-14), 52.79 (COOCH_3), 94.36 and 94.55 (C-17), 112.79 (C-2), 115.28 (C-4), 126.40 (C-1), 131.99 (C-10), 138.01 (C-5), 153.62 (C-3), 167.28 and 167.94 (COOCH_3), 169.93 (C=O, lactone); EI-HRMS: calcd for $\text{C}_{24}\text{H}_{30}\text{O}_5$ (M^+) 398.20932, found 398.21077.

Synthesis of preferred type 3 17 β -HSD inhibitors

Example 36

Example 36A

Syntheses of 3-thio-3-deoxy estrone derivatives

General procedure for 3-alkylation of 3-thio-3-deoxy-estrone. To a solution of 3-thio-3-deoxyestrone in DMF under Ar(g) was added 1.05 molar equivalent of NaH (60% in oil) at 0 °C. After 1 h, 1.2 molar equivalent of the appropriate alkyl halide chain was added and the solution was stirred at room temperature overnight. The solution was poured onto cold water then was extracted with EtOAc. The organic phase was washed with brine, dried with MgSO₄, filtered then evaporated under reduced pressure to give the crude product which was purified by flash chromatography on SiO₂ using a mixture of EtOAc/Hexanes.

3-Methoxymethylthio-Estra-1,3,5(10)-trien-17-one (EM-1064). Using 3-thioestrone (600 mg, 2.1 mmol) and chloromethyl methyl ether (202 mg, 2.51 mmol) to give EM-1064 as white solid (488 mg, 72%), Mp: 55°C, $[\alpha]^{25}_D + 88.9^\circ$ (c 1.6, CH₂Cl₂); IR: 2929, 2820, 2249, 1970, 1738, 1594, 1557, 1485, 1453, 1404, 1373, 1305, 1259, 1182, 1083, 1052, 1008, 951, 898, 860, 820, 777, 732, 693, 679, 582, 559, 483 cm⁻¹; ¹H NMR(CDCl₃) δ 0.91 (3H, s), 1.43-1.63 (6H, m), 1.95-2.49 (7H, m), 2.90 (2H, dd, J₁ = 4.6 Hz, J₂ = 4.0 Hz), 3.43 (3H, s), 4.93 (2H, s), 7.21-7.26 (3H, m). ¹³C NMR(CDCl₃) δ 13.8, 21.6, 25.7, 26.4, 29.3, 31.6, 35.9, 38.1, 44.3, 48.0, 50.5, 56.0, 76.6, 126.0, 128.0, 131.0, 132.5, 137.4, 138.7, 220.8. HRMS: 330.16534 C₂₀H₂₆O₂S.

3-Methylthioethylthio-Estra-1,3,5(10)-trien-17-one (EM-1065). Using 3-thioestrone (406 mg, 1.4 mmol) and 2-chloroethyl methyl sulfide (188 mg, 1.7 mmol) to give EM-1065 as a white solid (187 mg, 37%), Mp: 74°C, $[\alpha]^{25}_D - 58.2^\circ$ (c 2.0, CH₂Cl₂); IR: 2927, 2859, 2247, 1737, 1593, 1556, 1484, 1453, 1436, 1404, 1373, 1339, 1260, 1202, 1120, 1082, 1051, 1007, 964, 912, 859, 821, 777, 733, 646, 581, 559 cm⁻¹; ¹H NMR(CDCl₃) δ 0.91 (3H, s), 1.44-1.63 (6H, m), 1.95-2.55 (7H, m), 2.13 (3H, s), 2.70 (2H, dd, J₁ = 1.9 Hz, J₂ = 4.4 Hz), 2.89 (2H, dd, J₁ = 4.7 Hz, J₂ = 4.0 Hz), 3.08 (2H, dd, J₁ = 4.9 Hz, J₂ = 5.5 Hz), 7.12 (1H, d, J = 6.7 Hz), 7.16 (1H, s), 7.22 (1H, d, J = 8.2 Hz). ¹³C NMR(CDCl₃) δ 13.8, 15.5, 21.6, 25.7, 26.4, 29.3, 31.6, 33.7, 35.8, 38.1, 44.2, 48.0, 50.5, 126.1, 127.6, 130.7, 132.2, 137.5, 138.5, 220.7 ppm. HRMS: 360.15817 (C₂₁H₂₈OS₂).

Example 36B**Synthesis of estrone derivatives.**

5 **3-Methylthiomethoxy-1,3,5(10)-estratrien-17-one (EM-1066):** To a solution of estrone (2.0g, 7.39mmol) in anhydrous DMF under Ar (g), was added NaH (60% in oil, 0.26g, 11.0mmol). After the evolution of hydrogen had ceased, the solution was cooled in an ice bath for the addition of CH₃SCH₂Cl (3.56g, 36.9mmol, 3.08mL) and DMAP (0.09g, 7.0mmol). The solution was stirred in a cold room (4°C) for 16 hours. The reaction was stopped with cold water, extracted with ethyl acetate, wash with water and brine, dry over MgSO₄, filtered and concentrated under reduce pressure. The crude extract was purified by flash chromatography on silica gel column and eluted with EtOAc:hexanes (1:9), to give EM-1066 (0.7g, 30%) as a white solide; R_f 0.5 (3:7 EtOAc/Hexanes); M.p.65 °C; [α]_D²⁶ +116.4° (c 1.06, CHCl₃); IR (ν) 2919, 2864, 1735, 1604, 1577, 1497, 1448, 1375, 1282, 1255, 1211, 1151, 1051, 989, 885, 823, 787, 739, 640-690, 579cm⁻¹; ¹H NMR δ 2.24 (3H, s, CH₃-S), 5.12 (2H, s, S-CH₂-O), 7.21 (1H, d, J = 2.8Hz, 1'-CH), 6.76 (2H, dd, J₁ = 2.8 Hz and J₂ = 8.6 Hz, 2'-CH), 6.70 (1H, d, J = 8.0 Hz, 4'-CH).

Example 36C

25 **3-Methyloxymethoxy-1,3,5(10)-estratrien-17-one (EM-1070).** To a solution of estrone (55 mg, 0.203 mmole) in anhydrous dichloromethane (20 mL) under Ar (g) was added diisopropylethylamine (580.5 μL, 3.33 mmole). The solution was cooled down to 0 °C and chloromethylmethylether (110 μL, 1.45 mmole) was added. The solution was refluxed lightly overnight after which was added aqueous 1M HCl (40 mL). The solution was extracted 2 times with dichloromethane, washed with brine, dried with magnesium sulfate, filtered and concentrated in vacuo. The yellow solid was purified on silica gel (20g, 1:9 ethyl acetate/hexanes) to give EM-1070 as yellowish crystals (62 mg, 96%). m.p.; [α]_D²⁵ +103.9° (c 1.12, CDCl₃); IR (NaCl) 2926, 1737 (s, C=O), 1669, 1498, 1243, 1152, 1077, 1006 cm⁻¹; ¹H NMR (CDCl₃) δ 0.91 (3H, s, 18-CH₃), 1.25-1.78 (6H, m), 1.90-2.38 (5H, m), 2.40-2.55 (2H, m), 2.89 (2H, m, 6-CH₂), 3.48 (3H, s, CH₃O), 5.15 (2H, s, CH₃OCH₂), 6.79 (1H, d, J=2.4 Hz, 4-CH), 6.84 (1H, dd, J₁=8.4Hz and J₂=2.6Hz, 2-CH), 7.21 (1H, d, J=8.6 Hz, 1-CH).

Example 36D

3-Ethoxyethoxy-1,3,5(10)-estratrien-17-one (EM-1071). To a solution of estrone (495 mg, 1.83 mmole) in anhydrous acetonitrile (150 mL) under Ar (g) was added dry potassium carbonate (291 mg, 2.11 mmole) and 2-chloroethylethylether (2.6 mL, 23.77 mmole). The solution was refluxed for 36 hours then concentrated and ethyl acetate (175 mL) was added. The solution was washed with water (2 times), with brine (2 times), dried with magnesium sulfate, filtered and then concentrated in vacuo. The white solid was purified on RP-18 (40-63 μ m) gel (40 g, 100% methanol) to give EM-1071 as white crystals (588 mg, 94%). m.p.; $[\alpha]_D^{25} +129.6^\circ$ (c 3.06, CDCl_3); IR (NaCl) 2928, 2867, 1739 (s, C=O), 1609, 1574, 1499, 1454, 1373, 1310, 1281, 1255, 1158, 1122, 1064, 1007, 957, 924, 875, 818, 781, 650, 581 cm^{-1} ; ^1H NMR (CDCl_3) δ 0.91 (3H, s, 18- CH_3), 1.24 (3H, t, $J=6.7\text{Hz}$, CH_3CH_2), 1.24-1.78 (6H, m), 1.90-2.38 (5H, m), 2.40-2.55 (2H, m), 2.88 (2H, m, 6- CH_2), 3.60 (2H, q, $J=7.2\text{Hz}$, CH_3CH_2), 3.78 (2H, t, $J=5.2\text{Hz}$, $\text{CH}_2\text{CH}_2\text{O}$), 4.10 (2H, t, $J=4.8\text{Hz}$, CH_2OPh), 6.68 (1H, d, $J=2.5\text{Hz}$, 4-CH), 6.74 (1H, dd, $J_1=8.5\text{Hz}$ and $J_2=2.7\text{Hz}$, 2-CH), 7.19 (1H, d, $J=8.6\text{Hz}$, 1-CH).

Example 36E

3-Methoxyethoxy-1,3,5(10)-estratrien-17-one (EM-1073). To a solution of estrone (502 mg, 1.86 mmole) in anhydrous acetonitrile (250 mL) under Ar (g) was added potassium carbonate (547 mg, 3.96 mmole) and 2-chloroethylmethylether (16.6 mL, 182 mmole). The solution was refluxed for 72 hours, concentrated and ethyl acetate (175 mL) was added. The solution was washed with water (2 times) with brine (2 times), dried with magnesium sulfate, filtered and then concentrated in vacuo. The brownish powder was purified on silica gel (40g, 1:15 ethyl acetate/hexanes) to give EM-1073 as white crystals (232 mg, 38%). m.p. ; $[\alpha]_D^{25} +134.0^\circ$ (c 1.06, CHCl_3); IR (NaCl) 2927, 2872, 1738 (s, C=O), 1609, 1574, 1499, 1454, 1406, 1372, 1338, 1311, 1281, 1256, 1198, 1158, 1128, 1065, 1036, 1007, 954, 868, 818, 781 cm^{-1} ; ^1H NMR (CDCl_3) δ 0.90 (3H, s, 18- CH_3), 1.25-1.78 (6H, m), 1.90-2.38 (5H, m), 2.40-2.55 (2H, m), 2.87 (2H, m, 6- CH_2), 3.44 (3H, s, CH_3O), 3.73 (2H, t, $J=5.1\text{Hz}$, CH_3OCH_2), 4.09 (2H, t, $J=4.4\text{Hz}$, CH_2OPh), 6.68 (1H, d, $J=2.8\text{Hz}$, 4-CH), 6.74 (1H, dd, $J_1=8.5\text{Hz}$ and $J_2=2.8\text{Hz}$, 2-CH), 7.19 (1H, d, $J=8.6\text{Hz}$, 1-CH).

Example 36F


3-Butyloxy-1,3,5(10)-estratrien-17-one (EM-1074). To a solution of estrone (508mg, 1.88 mmole) in anhydrous dimethylformamide (75 mL) under Ar (g) was added 60% sodium hydride in oil (89mg, 2.23 mmole). After the evolution of hydrogen had ceased bromobutane (596 μ L, 5.55 mmole) was added. The reaction mixture was kept at 80 °C overnight after which was added 100g of ice. The solution was extracted 3 times with ethyl acetate, washed 4 times with brine, dried with magnesium sulfate, filtered and then concentrated in vacuo. The yellowish solid was purified on silica gel (40 g, 1:9 ethyl acetate/hexanes) to give EM-1074 as white crystals (559 mg, 91%). m.p.; $[\alpha]_D^{25} +138.5^\circ$ (c 0.53, CHCl₃); IR (NaCl) 3448, 2960, 2936, 2867, 1735 (s, C=O), 1612, 1571, 1493, 1474, 1439, 1390, 1349, 1280, 1257, 1222, 1185, 1156, 1115, 1055, 1007, 969, 918, 872, 821, 782, 738, 657, 581 cm^{-1} ; ¹H NMR (CDCl₃) δ 0.90 (3H, s, 18-CH₃), 0.96 (3H, t, J=7.3Hz, CH₃CH₂), 1.18-1.78 (10H, m), 1.90-2.30 (5H, m), 2.36-2.55 (2H, m), 2.88 (2H, m, 6-CH₂), 3.93 (2H, t, J=6.6Hz, CH₂O), 6.64 (1H, s, 4-CH), 6.70 (1H, d, J=8.5Hz, 2-CH), 7.18 (1H, d, J=8.6Hz, 1-CH).

Example 37

Synthesis of androstane derivatives

5 These syntheses are described in Scheme 34.

Scheme 34



Example 37A

Protection of the 17 β -alcohol with TBDMS. To a solution of dihydrotestosterone (DHT, 132) (5g, 17.2 mmol) in DMF was added imidazole (6 eq.) and TBDMSCl (5 eq.). The reaction was stirred overnight at room temperature. The mixture was poured onto ice and filtered. The resulting white precipitate was washed with water, dried over phosphorous pentoxide under reduced pressure for 24 h. A 85 to 90% yield was obtained.

17 β -[*(tert*-butyldimethylsilyl)oxy]-5 α -androstane-3-one (133). White solid; IR (KBr) ν 1719 (C=O, ketone); ^1H NMR (CDCl_3) δ -0.001 and 0.005 (s, 6H, $\text{Si}(\text{CH}_3)_2$), 0.71 (s, 3H, CH_3 -18), 0.87 (s, 9H, $\text{SiC}(\text{CH}_3)_3$), 1.01 (s, 3H, CH_3 -19), 3.54 (t, J = 8.2 Hz, 1H, CH-17); ^{13}C NMR (CDCl_3) δ -4.80 and -4.47, 11.41, 11.52, 18.11, 21.13, 23.56, 25.87, 28.98, 30.94, 31.36, 35.54, 35.78, 37.13, 38.21, 38.65, 43.36, 44.74, 46.84, 50.55, 54.15, 81.79, 212.03.

Example 37B

Alkylation of the carbonyl at position 3. To a solution of compound 133 (500 mg, 1.23 mmol) in dry THF (100 mL) at 0°C was added dropwise 3 eq. of commercially available Grignard's reagent, in dry THF. The mixture was allowed to react for 3 h at 0°C, then left over night at room temperature. A solution of saturated NH_4Cl was added and the crude product was extracted with EtOAc. The organic phase was washed with a saturated NaCl solution, dried over MgSO_4 and evaporated under reduced pressure. The 3 β -alkylated stereoisomer was easily separated from the 3 α -alkylated stereoisomer by flash chromatography on silica gel, using a mixture of hexanes and ethyl acetate as eluent. When the Grignard's reagent was generated *in situ* as in the case of ethylphenyl magnesium bromide, 5 eq. was prepared, by a well-known procedure, using the corresponding bromide, activated magnesium and iodide. The steroid was then dissolved in dry diethyl ether and added dropwise to the solution of reagent. The yields obtained were around 60% for the two stereoisomers.

3 β -benzyl-17 β -[*(tert*-butyldimethylsilyl)oxy]-3 α -hydroxy-5 α -androstane (134a). White solid (24%); IR (KBr) ν 3585 and 3460 (OH, alcohol); ^1H NMR (CDCl_3) δ 0.002 and 0.009 (s, 6H, $\text{Si}(\text{CH}_3)_2$), 0.69 (s, 3H, CH_3 -18), 0.75 (s, 3H, CH_3 -19), 0.88 (s, 9H, $\text{SiC}(\text{CH}_3)_3$), 2.71 (s, 2H, CH_2Ph), 3.54 (t, J = 8.2 Hz, 1H, CH-17), 7.20 to 7.34 (5H, Ph); ^{13}C NMR (CDCl_3) δ -4.82 and -4.50 ($\text{SiC}(\text{CH}_3)_3$), 11.25, 11.40, 18.08, 20.62, 23.50, 25.85, 28.41, 30.91, 31.62,

33.27, 33.81, 35.60, 35.84, 37.19, 40.10, 40.84, 43.30, 50.43, 50.69, 54.43, 71.22, 81.82 (C-17), 126.37, 128.09 (2X), 130.56 (2X), 137.06.

5 **3 α -hydroxy-3 β -(phenylethyl)-17 β [(*tert*-butyldimethylsilyl)oxy]-5 α -androstane (134b).** White solid (38%); IR (film) ν 3447 (OH, alcohol); ^1H NMR (CDCl_3) δ 0.018 and 0.025 (s, 6H, $\text{Si}(\text{CH}_3)_2$), 0.71 (s, 3H, CH_3 -18), 0.78 (s, 3H, CH_3 -19), 0.89 (s, 9H, $\text{SiC}(\text{CH}_3)_3$), 2.73 (m, 2H, Ph-CH_2), 3.56 (t, $J = 8.1$ Hz, 1H, CH-17), 7.18 to 7.31 (5H, Ph); ^{13}C NMR (CDCl_3) δ -4.77 and -4.46 ($\text{Si}(\text{CH}_3)_3$), 11.28, 11.44, 18.12 ($\text{SiC}(\text{CH}_3)_3$), 20.67, 23.54, 25.89
10 ($\text{SiC}(\text{CH}_3)_3$), 28.52, 29.60, 30.97, 31.66, 33.31, 33.92, 35.66, 36.04, 37.25, 40.03, 41.05, 43.35, 46.47, 50.76, 54.55, 71.50 (C-3), 81.86 (C-17), 125.68, 128.38 (4X), 142.82.

Example 37C

15 **Procedure for hydrolysis of TBDMS group and oxidation of the resulting alcohol.** The silylated ether was dissolved in a methanolic solution of HCl (2%, v/v) and the resulting mixture was stirred at room temperature for 3h. Water was then added and MeOH evaporated under vacuum. The resulting white precipitate was submitted to Jones'
20 oxidation without purification. To a stirred solution of crude alcohol in acetone at 0°C, Jones' reagent (2.7M chromic acid solution) was added dropwise. After 30 to 45 minutes, the reaction was completed.

Isopropanol and water were added and acetone was removed in vacuo. The remaining aqueous layer was extracted with EtOAc. The combined
25 organic phases were washed with brine, dried over MgSO_4 , filtered and evaporated under reduced pressure. The purification was done on silica gel, using HPLC grade solvents, EtOAc and hexanes as eluents.

30 **3 β -benzyl-3 α -Hydroxy- -5 α -androstane-17-one (CS-213).** White solid (88% for the two steps); IR (KBr) ν 3408 (OH, alcohol), 1732 (C=O, ketone); ^1H NMR (CDCl_3) δ 0.75 (s, 3H, CH_3 -19), 0.84 (s, 3H, CH_3 -18), 2.69 (s, 2H, CH_2Ph), 7.18 to 7.32 (5H, Ph); ^{13}C NMR (CDCl_3) δ 11.18, 13.78, 20.20, 21.71, 28.16, 30.79, 31.52, 33.18, 33.70, 35.64, 35.79, 35.88, 39.97, 40.69, 47.75, 50.39, 51.41, 54.22, 71.12, 126.40, 128.09 (2X), 130.51 (2X), 136.93, 221.27

35 **3 α -hydroxy-3 β -phenylethyl-5 α -androstane-17-one (EM-1324-CS).** White solid (82% for the two steps); IR (film) ν 3486 (OH, alcohol), 1737 (C=O, ketone); ^1H NMR (CDCl_3) δ 0.79 (s, 3H, CH_3 -19), 0.86 (s, 3H, CH_3 -18), 2.71 (m, 2H, Ph-CH_2), 7.18 to 7.30 (5H, Ph); ^{13}C NMR (CDCl_3) δ 11.21, 13.82, 20.26, 21.76, 28.26, 29.54, 30.87, 31.58, 33.27, 33.80, 35.10, 35.84, 36.07, 39.89, 40.90, 46.43, 47.80, 51.49, 54.35, 71.42, 125.69, 128.31 (2X), 128.39 (2X),
40 142.70, 221.31.

PHARMACEUTICAL COMPOSITION EXAMPLES

Set forth below, by way of example and not of limitation, are several pharmaceutical compositions utilizing a preferred active compound EM-1404. Other compounds of the invention or combination thereof, may be used in place of (or in addition to) EM-1404. The concentration of active ingredient may be varied over a wide range as discussed herein. The amounts and types of other ingredients that may be included are well known in the art.

EXAMPLE A

Composition suitable for injection

Ingredient	Weight % (by weight of total composition)
EM-1404	0.4
Ethanol	6.4
NaCl	0.8
Water	91.5
Benzyl alcohol	0.9

EXAMPLE B

Composition suitable for use as topical lotion

Ingredient	Weight % (by weight of total composition)
EM-1404	1.0
Ethanol	70.0
Propylene glycol	29.0

EXAMPLE C

Composition suitable for use as topical gel

Ingredient	Weight % (by weight of total composition)
EM-1404	1.0
Krucel	1.5
Ethanol	70.0
Propylene glycol	27.5

5

EXAMPLE D

Tablet

Ingredient	Weight % (by weight of total composition)
EM-1404	1.0
Gelatin	5.0
Lactose	67.5
Starch	26.5

10

EXAMPLE E

Gelatin capsule

Ingredient	Weight % (by weight of total composition)
EM-1404	2.0
Lactose hydrous	80.0
Starch	4.8
Cellulose microcrystalline	12.8
Magnesium stearate	0.4

EXAMPLE F

Composition suitable for use as topical gel


Ingredient	Weight % (by weight of total composition)
EM-1404	1.0
Ethanol	4.0
Polyethylene glycol	4.0
Gelatin	1.0
NaCl	0.9
Benzyl alcohol	1.0
Water USP	88.1

5 Other inhibitors of type 5 17β -hydroxysteroid dehydrogenase may be substituted for EM-1404 in the above formulations, as may an inhibitor of type 3 17β -hydroxysteroid dehydrogenase. Both type 3 and type 5 may be included together, in which case the combined weight percent of the two is preferably double that of EM-1404 alone, with a corresponding
10 reduction in the weight of the most prevalent excipient (e.g., water lactose, ethanol or the like).

The invention has been described in terms of preferred embodiments and examples, but is not limited thereby. Those of skill in the art will readily
15 recognize the broader applicability and scope of the invention which is limited only by the patent claims herein.

WHAT IS CLAIMED IS:

1. A method of inhibiting activity of type 5 17β -hydroxysteroid dehydrogenase comprising administering to a patient in need of such treatment a therapeutically effective amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase having the molecular structure:



10 wherein the dotted line is optional pi bond;

wherein A is selected from the group consisting of straight or branched C_1 - C_4 alkyl, $-OR^c$ (R^c being a C_1 - C_8 alkyl radical), and $-N(R^d)R^e$ (R^d and R^e being independently hydrogen or C_1 - C_8 alkyl or aryl), and unsaturated analogs of any of the foregoing definitions for substituent A;

15 wherein R^1 is selected from the group consisting of hydrogen and methyl and ethyl;

wherein R^6 is selected from the group consisting of hydrogen, and halogen, and C_1 - C_8 alkyl;

20 wherein R^a is selected from the group consisting of straight or branched C_1 - C_8 alkylene, C_3 - C_7 cycloalkylene; and

R^b is selected from the group consisting of hydrogen, substituted or unsubstituted phenyl, C_2 - C_{10} acyl, C_2 - C_{10} acyloxy, C_2 - C_{10} alkoxy carbonyl, and halogen.

2. The method of Claim 1 wherein the optional pi bond at 6 is present.

5 3. The method of Claim 1 wherein R^6 is methyl.

4. The method of Claim 1 wherein R^a is C_1 - C_6 alkylene.


10 5. The method of Claim 1 where A is either methyl or $-N(R^d)R^e$.

6. The method of Claim 1 where A is $-N(R^d)R^e$.

15 7. The method of Claim 6 wherein R^d is methyl.

8. The method of Claim 6 wherein R^e is C_1 - C_6 alkyl or C_7 - C_{12} phenyl alkyl.

20 9. A method of inhibiting activity of type 5 17β -hydroxysteroid dehydrogenase comprising administering to a patient in need of such treatment a therapeutically effective amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase having the molecular structure:



wherein the dotted line is an optional pi bond;

wherein $R^{16\beta}$ is selected from the group consisting of hydrogen,
 5 C_1 - C_8 alkyl, fluoro, chloro, C_1 - C_8 haloalkyl, a moiety which together with
 $R^{16\alpha}$ is C_4 - C_7 spirocycloalkyl, C_4 - C_7 halospirocycloalkyl, or $\text{---}R'^{16}$
 (R'^{16} being C_1 - C_3 alkyl) and unsaturated analogs of any of the foregoing
 definitions of $R^{16\beta}$;

wherein $R^{16\alpha}$ is selected from the group consisting of hydrogen,
 10 C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, a moiety which together with $R^{16\beta}$ forms
 C_4 - C_7 spirocycloalkyl, C_4 - C_7 halospirocycloalkyl, or $\text{---}R'^{16}$ (R'^{16}
 being C_1 - C_3 alkyl) and unsaturated analogs of any of the foregoing;

wherein $R^{15\alpha}$ is selected from the group consisting of hydrogen,
 15 C_1 - C_4 alkyl, C_1 - C_4 alkenyl and C_1 - C_4 alkynyl;

wherein R^{19} is either -H or -CH₃; and

wherein R^6 is selected from the group consisting of -H, -CH₃, and
 halo;

provided that $R^{16\beta}$, $R^{16\alpha}$, and $R^{15\alpha}$ are not simultaneously hydrogen.


10. The method of Claim 9 wherein $R^{16\alpha}$ is a larger substituent
 than $R^{16\beta}$.

11. The method of Claim 9 wherein R^6 is hydrogen.

12. The method of Claim 9 wherein the optional pi bond at position 1 is not present.

5 13. The method of Claim 9 wherein R^{16a} is a C_3 - C_5 alkyl chain.

14. A method of inhibiting activity of type 5 17β -hydroxysteroid dehydrogenase comprising administering to a patient in need of such treatment a therapeutically effective amount of an inhibitor of type 5
10 17β -hydroxysteroid dehydrogenase having the molecular structure:



wherein the dotted line is optional pi bond

15 wherein X is C_1 - C_3 alkyl;

wherein Y is hydrogen or an acyloxy moiety;

wherein R^6 is $-H$ or $-CH_3$;

wherein R^{16} is $-H$ or halo;

wherein R^1 is $-H$ or $-CH_3$.

20


15. The method of Claim 14 wherein R^6 is methyl.

16. The method of Claim 14 wherein the optional pi bond at position 1 is present.

17. The method of Claim 14 wherein Y is a C₃-C₆ fluoroacyloxy.

18. The method of Claim 14 wherein X is methyl.

19. A method of inhibiting activity of type 5 17 β -hydroxysteroid dehydrogenase comprising administering to a patient in need of such treatment a therapeutically effective amount of an inhibitor of type 5 17 β -hydroxysteroid dehydrogenase having the molecular structure:



wherein n is an integer from 1-2;

wherein the dotted lines are optional double bonds;

wherein X and Y are independently selected from the group consisting of -H, (C₁-C₃)alkyl, (C₂-C₃) alkenyl, and methoxycarbonyl;

wherein Z is selected from the group consisting of -H and (C₁-C₃)alkyl;

wherein R³ is selected from the group consisting of hydrogen, acyl, carboxyl, alkoxycarbonyl, substituted or unsubstituted carboxamide,

cyano, alkoxy, alkoxyalkoxy, alkythioalkoxy, acyloxy; hydroxy, halo, -O-SO₂R^a (R^a being selected from the group consisting of C₁-C₆ alkyl and C₆-C₁₀ aryl), and a moiety which, together with R₂, is a 5-6 member ring containing at least one oxygen and one nitrogen atom;

5 wherein R² is selected from the group consisting of hydrogen, amido, acyloxy, carboxyl, carboxamide, alkoxycarbonyl, cyano, halo, nitro, C₁-C₈ alkyl, and CF₃ and a moiety which, together with R₃, is a 5-6 member ring containing at least one oxygen and one nitrogen atom;

 wherein R⁴ is hydrogen or halo;


10 wherein R⁶ is selected from the group consisting of hydrogen and oxo;

 wherein R⁹ is -H or -OH;

 provided that X, Y, and Z are not all hydrogen when R³ is methoxy.

- 15
20. The method of Claim 19 wherein R³ is alkoxyalkoxy.
21. The method of Claim 19 wherein R³ is carboxyl or alkoxyl;
- 20 22. The method of Claim 19 wherein at least one of X, Y or Z is methyl.
23. The method of Claim 19 wherein R³ is carboxamide.
- 25 24. The method of Claim 19 wherein both X and Y are methyl.
25. The method of Claim 19 wherein n = 1 or 2.
26. The method of Claim 19 wherein R⁶ is oxo.

27. A method of inhibiting activity of type 5 17β -hydroxysteroid dehydrogenase comprising administering to a patient in need of such treatment a therapeutically effective amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase having the molecular structure:



wherein the dotted lines are optional pi bonds;

wherein $n = 1$ or 2 ; and

wherein a is either $-H$ or $-CH_3$;

wherein b and c are independently hydrogen or methyl;

wherein Z is oxygen or sulfur.


28. The pharmaceutical composition of Claim 27 wherein $n = 1$.

29. The method of Claim 27 wherein at least one of b or c is methyl.


30. The method of Claim 27 wherein both b and c are methyl.

31. The method of Claim 27 wherein Z is oxygen.


32. A method of inhibiting the activity of type 5
17 β -hydroxysteroid dehydrogenase comprising administering to a patient
in need of such treatment a therapeutically effective amount of an
inhibitor of type 5 17 β -hydroxysteroid dehydrogenase selected from the
group consisting of:




EM-1291




EM-1195-CS




CS-243




CS-245




EM-1183



EM-1097




EM-1273-CS




EM-1401


EM-1404




CS-237



EM-1078




EM-1196-CS




- 301 -

EM-1394




EM-1424




5

EM-1157-CS




EM-1125




- 302 -


EM-1402-CS




EM-1396



EM-1181




EM-1159




- 303 -

EM-1165




and

EM-1122




33. The method of Claim 32 wherein an inhibitor of 17 β -hydroxysteroid dehydrogenase selected from the group consisting of:

EM-1404




and

EM-1394




is administered.


34. A method of inhibiting activity of type 5 17β -hydroxysteroid dehydrogenase comprising administering to a patient in need of such treatment a therapeutically effective amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase selected from the group consisting of:




medroxyprogesterone acetate




megestrol acetate




chlormadinone acetate




1-dehydromegestrol acetate




melengestrol acetate



nomegestrol acetate




1-dehydromelengestrol acetate



cyproterone acetate


and compounds having the molecular structure:



- 5 wherein the dotted lines are optional pi bonds;
- wherein A is selected from the group consisting of straight or branched C₁-C₄ alkyl, -OR^c (R^c being a C₁-C₄ alkyl radical), and -N(R^d)R^e (R^d and R^e being independently hydrogen or C₁-C₈ alkyl or aryl), and unsaturated analogs of any of the foregoing definitions for substituent A;
- 10 wherein R¹ is selected from the group consisting of hydrogens, and methyl;
- wherein R⁶ is selected from the group consisting of hydrogen, halogen, and C₁-C₈ alkyl;
- wherein R₁₆ is selected from the group consisting of H, H and CH₂;
- 15 wherein R^a is selected from the group consisting of straight or branched C₁-C₈ alkylene, C₃-C₇ cycloalkylene; and R^b is selected from the

group consisting of hydrogen, substituted or unsubstituted phenyl, C₂-C₁₀ acyl, C₂-C₁₀ acyloxy, C₂-C₁₀ alkoxycarbonyl, and halogen.

35. A method of inhibiting activity of type 5 17 β -hydroxysteroid dehydrogenase comprising administering to a patient in need of such treatment a therapeutically effective amount of an inhibitor of type 5 17 β -hydroxysteroid dehydrogenase having the molecular structure:



wherein the dotted line is an optional pi bond;

wherein R^{16β} is selected from the group consisting of hydrogen, C₁-C₈ alkyl fluoro, chloro, C₁-C₈ haloalkyl, a moiety which together with R^{16α} forms C₄-C₇ spirocycloalkyl, C₄-C₇ halospirocycloalkyl, or ---R^{16} (R'¹⁶ being C₁-C₃ alkyl) and unsaturated analogs of any of the foregoing definitions of R^{16β};

wherein R^{16α} is selected from the group consisting of hydrogen, C₁-C₈ alkyl, C₁-C₈ haloalkyl, a moiety which together with R^{16β} forms C₄-C₇ spirocycloalkyl C₄-C₇ halospirocycloalkyl, or ---R^{16} (R'¹⁶ being C₁-C₃ alkyl) and unsaturated analogs of any of the foregoing;


wherein R^{15a} is selected from the group consisting of hydrogen, C_1 - C_4 alkyl, C_1 - C_4 alkenyl and C_1 - C_4 alkynyl;

wherein R^{19} is either -H or -CH₃; and

wherein R^6 is selected from the group consisting of -H, -CH₃, and halo;

provided that R^{16b} , R^{16a} , and R^{15a} are not simultaneously hydrogen.

36. A method of inhibiting activity of type 5 17 β -hydroxysteroid dehydrogenase comprising administering to a patient in need of such treatment a therapeutically effective amount of an inhibitor of type 5 17 β -hydroxysteroid dehydrogenase having the molecular structure:



wherein $n = 1$ or 2 ;

wherein the dotted lines are optional pi bonds;

wherein X and Y are independently selected from the group consisting of -H, , (C_1-C_3) alkyl, (C_2-C_3) alkenyl, and methoxycarbonyl;

wherein Z is selected from the group consisting of -H and (C_1-C_3) alkyl;

wherein R^3 is selected from the group consisting of acyl, carboxyl, alkoxycarbonyl, substituted or unsubstituted carboxamide, cyano, alkoxy,

alkoxyalkoxy, alkythioalkoxy, acyloxy; hydroxy, halo, $-O-SO_2R^a$ (R^a being selected from the group consisting of C_1-C_6 alkyl and C_6-C_{10} aryl), and a moiety which, together with R_2 , is a 5-6 member ring containing at least one oxygen and one nitrogen atom;

5 wherein R^2 is selected from the group consisting of hydrogen, amido, acyloxy, carboxyl, carboxmide, alkoxycarbonyl, cyano, halo, nitro, C_1-C_8 alkyl and CF_3 and a moiety which, together with R_3 , is a 5-6 member ring containing at least one oxygen and one nitrogen atom;


 wherein R^4 is hydrogen or halo;

10 wherein R^6 is selected from the group consisting of hydrogen and oxo;

 wherein R^9 is $-H$ or $-OH$;

 provided that X, Y and Z are not all hydrogen.

15 37. A method of inhibiting activity of type 5 17β -hydroxysteroid dehydrogenase comprising administering to a patient in need of such treatment a therapeutically effective amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase having the molecular structure:



20

 wherein the dotted lines are optional pi bonds;

wherein $n = 1$ or 2 ; and

wherein a is either H or CH_3 ;


wherein b and c are independently hydrogen or methyl;

wherein Z is oxygen or sulfur.

5

38. A method of inhibiting activity of type 5 17β -hydroxysteroid dehydrogenase comprising administering to a patient in need of such treatment a therapeutically effective amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase having the molecular structure:

10



wherein the dotted line is an optional pi bond;

15

wherein A is selected from the group consisting of straight or branched C_1 - C_4 alkyl, $-\text{OR}^c$ (R^c being a C_1 - C_8 alkyl radical), and $-\text{N}(\text{R}^d)\text{R}^e$ (R^d and R^e being independently hydrogen or C_1 - C_8 alkyl or aryl), and unsaturated analogs of any of the foregoing definitions for substituent A ;

wherein R^1 is selected from the group consisting of hydrogen and methyl;

20


wherein R^6 is selected from the group consisting of hydrogen, halogen, and C_1 - C_8 alkyl;

wherein R^a is selected from the group consisting of straight or branched C_1 - C_8 alkylene, C_3 - C_7 cycloalkylene; and

R^b is selected from the group consisting of hydrogen, substituted or unsubstituted phenyl, C_2 - C_{10} acyl, C_2 - C_{10} acyloxy, C_2 - C_{10} alkoxy carbonyl, and halogen;

provided that wherein A is methyl, R^a and R^b together have at least two carbon atoms and R^1 is methyl.

39. A method of inhibiting activity of type 5 17β -hydroxysteroid dehydrogenase comprising administering to a patient in need of such treatment a therapeutically effective amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase having the molecular structure:



wherein the dotted lines are optional pi bonds

wherein X is C_1 - C_3 alkyl;

wherein Y is hydrogen or an acyloxy moiety;


wherein R^6 is -H or - CH_3 ;

wherein R^{16a} is -H or halo;

wherein R^1 is -H or - CH_3 .

40. A pharmaceutical composition comprising a pharmaceutically acceptable excipient, diluent or carrier and a

therapeutically acceptable amount of an inhibitor of type 5
17 β -hydroxysteroid dehydrogenase having the molecular structure:



wherein the dotted lines are optional pi bonds;

5 wherein A is selected from the group consisting of straight or branched C₁-C₄ alkyl, -OR^c (R^c being a C₁-C₈ alkyl radical), and -N(R^d)R^e (R^d and R^e being independently hydrogen or C₁-C₈ alkyl or aryl), and unsaturated analogs of any of the foregoing definitions for substituent A;

10 wherein R¹ is selected from the group consisting of hydrogen and methyl;

wherein R⁶ is selected from the group consisting of hydrogen, halogen, and C₁-C₈ alkyl;

wherein R^a is selected from the group consisting of straight or branched C₁-C₈ alkylene, C₃-C₇ cycloalkylene; and

15 R^b is selected from the group consisting of hydrogen, substituted or unsubstituted phenyl, C₂-C₁₀ acyl, C₂-C₁₀ acyloxy, C₂-C₁₀ alkoxy carbonyl, and halogen;

provided that when A is methyl, R^a and R^b together have at least two carbon atoms, and R¹ is methyl.

41. The pharmaceutical composition of Claim 40 wherein the optional pi bond at 6 is present.

42. The method of Claim 40 wherein R⁶ is methyl.

43. The pharmaceutical composition of Claim 40 wherein R^a is C₁-C₆ alkylene.


44. The pharmaceutical composition of Claim 40 where A is either methyl or -N(R^d)R^e.

45. The pharmaceutical composition of Claim 40 where A is -N(R^d)R^e.

46. The pharmaceutical composition of Claim 45 wherein R^d is methyl.

47. The pharmaceutical composition of Claim 45 wherein R^e is C₁-C₆ alkyl or phenyl C₁-C₆ alkyl.

48. A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a therapeutically acceptable amount of an inhibitor of type 5 17 β -hydroxysteroid dehydrogenase having the molecular structure:



wherein the dotted line is an optional pi bond;

wherein $R^{16\beta}$ is selected from the group consisting of hydrogen,
 5 C_1 - C_8 alkyl, fluoro, chloro, C_1 - C_8 haloalkyl, a moiety which together with
 $R^{16\alpha}$ is C_4 - C_7 spirocycloalkyl, C_4 - C_7 halospirocycloalkyl, or $\text{---}R'^{16}$
 (R'^{16} being C_1 - C_3 alkyl) and unsaturated analogs of any of the foregoing
 definitions of $R^{16\beta}$;

wherein $R^{16\alpha}$ is selected from the group consisting of hydrogen,
 10 C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, a moiety which together with $R^{16\beta}$ forms
 C_4 - C_7 spirocycloalkyl, C_4 - C_7 halospirocycloalkyl, or $\text{---}R'^{16}$ (R'^{16}
 being C_1 - C_3 alkyl) and unsaturated analogs of any of the foregoing;

wherein $R^{15\alpha}$ is selected from the group consisting of hydrogen,
 15 C_1 - C_4 alkyl, C_1 - C_4 alkenyl and C_1 - C_4 alkynyl;

wherein R^{19} is either -H or -CH_3 ; and

wherein R^6 is selected from the group consisting of -H , -CH_3 , and
 halo;

provided that $R^{16\beta}$, $R^{16\alpha}$, and $R^{15\alpha}$ are not simultaneously hydrogen.


49. The pharmaceutical composition of Claim 48 wherein $R^{16\alpha}$ is
 a large substituent than $R^{16\beta}$.

50. The pharmaceutical composition of Claim 48 wherein R⁶ is hydrogen.

51. The pharmaceutical composition of Claim 48 wherein the optional pi bond at position 1 is not present.

52. The pharmaceutical composition of Claim 48 wherein R^{16a} is a C₃-C₅ alkyl chain.

53. A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a therapeutically acceptable amount of an inhibitor of type 5 17β-hydroxysteroid dehydrogenase having the molecular structure:



wherein the dotted line is an optional pi bond

wherein X is C₁-C₃ alkyl;

wherein Y is hydrogen or an acyloxy moiety;

wherein R⁶ is -H or -CH₃;

wherein R¹⁶ is -H or halo;

wherein R¹ is -H or -CH₃.


54. The pharmaceutical composition of Claim 53 wherein R⁶ is methyl.

55. The pharmaceutical composition of Claim 53 wherein the optional pi bond at position 1 is present.

56. The pharmaceutical composition of Claim 53 wherein Y is a C₃-C₆ fluoroacyloxy.

57. The pharmaceutical composition of Claim 53 wherein X is methyl.

58. A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a therapeutically acceptable amount of an inhibitor of type 5 17 β -hydroxysteroid dehydrogenase having the molecular structure:



wherein n is an integer from 1-2;

wherein the dotted lines are optional pi bonds;

wherein X and Y are independently selected from the group consisting of -H, , (C₁-C₃)alkyl, (C₂-C₃) alkenyl, and methoxycarbonyl;

wherein Z is selected from the group consisting of -H and (C₁-C₃)alkyl;

5 wherein R³ is selected from the group consisting of hydrogen acyl, carboxyl, alkoxycarbonyl, substituted or unsubstituted carboxamide, cyano, alkoxy, alkoxyalkoxy, alkythioalkoxy, acyloxy; hydroxy, halo, -O-SO₂R^a (R^a being selected from the group consisting of C₁-C₆ alkyl and C₆-C₁₀ aryl), and a moiety which, together with R₂, is a 5-6 member ring containing at least one oxygen and one nitrogen atom;

10 wherein R² is selected from the group consisting of hydrogen, amido, acyloxy, carboxyl, carboxamide, alkoxycarbonyl, cyano, halo, nitro, C₁-C₈ alkyl, and CF₃ and a moiety which, together with R₃, is a 5-6 member ring containing at least one oxygen and one nitrogen atom;

15 wherein R⁴ is hydrogen or halo;

 wherein R⁶ is selected from the group consisting of hydrogen and oxo;

 wherein R⁹ is -H or -OH;

 provided that X, Y, and Z are not all hydrogen.

20

59. The pharmaceutical composition of Claim 58 wherein R³ is alkoxyalkoxy.

25

60. The pharmaceutical composition of Claim 58 wherein R³ is carboxyl or alkoxyl;

61. The pharmaceutical composition of Claim 58 wherein at least one of X, Y or Z is methyl.


62. The pharmaceutical composition of Claim 58 wherein both X and Y are methyl.

63. The pharmaceutical composition of Claim 58 wherein $n = 1$ or 2.

64. The pharmaceutical composition of Claim 58 wherein R^6 is oxo.

65. The pharmaceutical composition of Claim 58 wherein R^3 is carboxamide.

66. A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a therapeutically acceptable amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase having the molecular structure:



wherein the dotted lines are optional pi bonds;

wherein $n = 1$ or 2; and

wherein a is either H or CH_3 ;

wherein b and c are independently hydrogen or methyl;
wherein Z is oxygen or sulfur.

67. The pharmaceutical composition of Claim 66 wherein $n = 1$.

5

68. The pharmaceutical composition of Claim 66 wherein at least one of b or c is methyl.

10


69. The pharmaceutical composition of Claim 66 wherein both b and c are methyl.

70. The pharmaceutical composition of Claim 66 wherein Z is oxygen.

15


71. A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a therapeutically acceptable amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase having a molecular structure selected from the group consisting of:

20




EM-1291


- 321 -




EM-1195-CS



CS-243




CS-245




EM-1183

5


EM-1097




EM-1273-CS




EM-1401




EM-1404




CS-237



EM-1078




EM-1196-CS




5


EM-1394




EM-1424



EM-1157-CS




EM-1125




5


EM-1402-CS




EM-1396




EM-1181



EM-1159




EM-1165




and

EM-1122




72. The pharmaceutical composition of Claim 71 wherein said inhibitor of 17 β -hydroxysteroid dehydrogenase is selected from the group consisting of:

EM-1404




and

and EM-1394



73. A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a therapeutically effective amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase having the molecular structure:



wherein the dotted line is optional pi bond;

wherein A is selected from the group consisting of straight or branched C_1 - C_4 alkyl, $-OR^c$ (R^c being a C_1 - C_8 alkyl radical), and $-N(R^d)R^e$ (R^d and R^e being independently hydrogen or C_1 - C_8 alkyl or aryl), and unsaturated analogs of any of the foregoing definitions for substituent A;

wherein R^1 is selected from the group consisting of hydrogen and methyl;


wherein R^6 is selected from the group consisting halogen and C_1 - C_8 alkyl;

wherein R^a is selected from the group consisting of straight or branched C_1 - C_8 alkylene, C_3 - C_7 cycloalkylene; and

R^b is selected from the group consisting of hydrogen, substituted or unsubstituted phenyl, C_2 - C_{10} acyl, C_2 - C_{10} acyloxy, C_2 - C_{10} alkoxy carbonyl, and halogen;

provided that when A is methyl, R^1 is methyl.

74. A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a therapeutically acceptable amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase having the molecular structure:



wherein the dotted lines are optional pi bonds

wherein X is C₁-C₃ alkyl;


wherein Y is hydrogen or an acyloxy moiety;

wherein R⁶ is -H or -CH₃;

wherein R¹⁶ is -H or halo;

wherein R¹ is -H or -CH₃.

75. An inhibitor of type 5 17β -hydroxysteroid dehydrogenase having the molecular structure:



wherein the dotted line is optional pi bond;

wherein A is selected from the group consisting of straight or
 5 branched C₁-C₄ alkyl, -OR^c (R^c being a C₁-C₈ alkyl radical), and -N(R^d)R^e
 (R^d and R^e being independently hydrogen or C₁-C₈ alkyl or aryl), and
 unsaturated analogs of any of the foregoing definitions for substituent A;

wherein R¹ is selected from the group consisting of hydrogen and
 methyl;

10 wherein R⁶ is selected from the group consisting of halogen and
 C₁-C₈ alkyl;

wherein R^a is selected from the group consisting of straight or
 branched C₁-C₈ alkylene, C₃-C₇ cycloalkylene; and

R^b is selected from the group consisting of hydrogen, substituted or
 15 unsubstituted phenyl, C₂-C₁₀ acyl, C₂-C₁₀ acyloxy, C₂-C₁₀ alkoxy carbonyl,
 and halogen;

provided that when A is methyl, R^a and R^b together have at least
 two carbon atoms, and R¹ is methyl.

76. The inhibitor of Claim 75 wherein the optional pi bond at 6 is present.

77. The inhibitor of Claim 75 wherein R^6 is methyl.

78. The inhibitor of Claim 75 wherein R^a is C_1 - C_6 alkylene.


79. The inhibitor of Claim 75 where A is either methyl or $-N(R^d)R^e$.

80. The inhibitor of Claim 75 where A is $-N(R^d)R^e$.

81. The inhibitor of Claim 80 wherein R^d is methyl.

82. The inhibitor of Claim 80 wherein R^e is C_1 - C_6 alkyl or phenyl C_1 - C_6 alkyl.

83. An inhibitor of type 5 17β -hydroxysteroid dehydrogenase having the molecular structure:



wherein the dotted line is an optional pi bond;

wherein $R^{16\beta}$ is selected from the group consisting of hydrogen, C_1 - C_8 alkyl, fluoro, chloro, C_1 - C_8 haloalkyl, a moiety which together with

$R^{16\alpha}$ is C₄-C₇ spirocycloalkyl, C₄-C₇ halospirocycloalkyl, or ---R^{16} (R^{16} being C₁-C₃ alkyl) and unsaturated analogs of any of the foregoing definitions for $R^{16\beta}$;

wherein $R^{16\alpha}$ is selected from the group consisting of hydrogen, C₁-C₈ alkyl, C₁-C₈ haloalkyl, a moiety which together with $R^{16\beta}$ is C₄-C₇ spirocycloalkyl, C₄-C₇ halospirocycloalkyl, or ---R^{16} (R^{16} being C₁-C₃ alkyl) and unsaturated analogs of any of the foregoing;

wherein $R^{15\alpha}$ is selected from the group consisting of hydrogen, C₁-C₄ alkyl, C₁-C₄ alkenyl and C₁-C₄ alkynyl;

wherein R^{19} is either -H or -CH₃; and

wherein R^6 is selected from the group consisting of -H, -CH₃, and halo;

provided that $R^{16\beta}$, $R^{16\alpha}$, and $R^{15\alpha}$ are not simultaneously hydrogen.


84. The inhibitor of Claim 83 wherein $R^{16\alpha}$ is a larger substituent than $R^{16\beta}$.

85. The inhibitor of Claim 83 wherein R^6 is hydrogen.

86. The inhibitor of Claim 83 wherein the optional pi bond at position 1 is not present.

87. The inhibitor of Claim 83 wherein $R^{16\alpha}$ is a C₃-C₅ alkyl.

88. An inhibitor of type 5 17β -hydroxysteroid dehydrogenase having the molecular structure:



5 wherein the dotted line is optional pi bond
wherein X is C_1 - C_3 alkyl;
wherein Y is hydrogen or an acyloxy moiety;
wherein R^6 is -H or - CH_3 ;
wherein R^{16} is -H or halo;
10 wherein R^1 is -H or - CH_3 .


89. The inhibitor of Claim 88 wherein R^6 is methyl.

15 90. The inhibitor of Claim 88 wherein the optional pi bond at position 1 is present.

91. The inhibitor of Claim 88 wherein Y is a C_3 - C_6 fluoroacyloxy.

20 92. The inhibitor of Claim 88 wherein X is methyl.

93. An inhibitor of type 5 17β -hydroxysteroid dehydrogenase having the molecular structure:



5 wherein n is an integer from 1-2;

wherein the dotted lines are optional pi bonds;

wherein X and Y are independently selected from the group consisting of -H, (C₁-C₃)alkyl, (C₂-C₃) alkenyl, and methoxycarbonyl;

10 wherein Z is selected from the group consisting of -H and (C₁-C₃)alkyl;

15 wherein R³ is selected from the group consisting of hydrogen, acyl, carboxyl, alkoxycarbonyl, substituted or unsubstituted carboxamide, cyano, alkoxy, alkoxyalkoxy, alkythioalkoxy, acyloxy; hydroxy, halo, -O-SO₂R^a (R^a being selected from the group consisting of C₁-C₆ alkyl and C₆-C₁₀ aryl), and a moiety which, together with R₂, is a 5-6 member ring containing at least one oxygen and one nitrogen atom;

20 wherein R² is selected from the group consisting of hydrogen, amido, acyloxy, carboxyl, carboxamide, alkoxycarbonyl, cyano, halo, nitro, C₁-C₈ alkyl, and CF₃ and a moiety which, together with R₃, is a 5-6 member ring containing at least one oxygen and one nitrogen atom;

wherein R⁴ is hydrogen or halo;

wherein R⁶ is selected from the group consisting of hydrogen and
oxo;

wherein R⁹ is -H or -OH;

provided that X, Y, and Z are not all hydrogen.

5

94. The inhibitor of Claim 93 wherein R³ is alkoxyalkoxy.

95. The inhibitor of Claim 93 wherein R³ is carboxyl
unsubstituted carboxamide or alkoxyl;

10

96. The inhibitor of Claim 93 wherein at least one of X, Y or Z is
methyl.

97. The inhibitor of Claim 93 wherein both X and Y are methyl.

15


98. The inhibitor of Claim 93 wherein n = 1.

99. The inhibitor of Claim 93 wherein R⁶ is oxo.

20

100. The inhibitor of Claim 93 wherein R³ is carboxamide.

101. An inhibitor of type 5 17β -hydroxysteroid dehydrogenase having the molecular structure:



wherein the dotted lines are optional pi bonds;

wherein $n = 1$ or 2 ; and

wherein a is either $-H$ or $-CH_3$;

wherein b and c are independently hydrogen or methyl;

wherein Z is oxygen or sulfur.


102. The inhibitor of Claim 101 wherein $n = 1$.

103. The inhibitor of Claim 101 wherein at least one of b or c is methyl.


104. The inhibitor of Claim 101 wherein both b and c are methyl.

105. The inhibitor of Claim 101 wherein Z is oxygen.


106 An inhibitor of type 5 17β -hydroxysteroid dehydrogenase having a molecular structure selected from the group consisting of:




EM-1291



EM-1195-CS




CS-243




CS-245

EM-1183




EM-1097




5


EM-1273-CS



EM-1401




EM-1404




10

CS-237




EM-1078




5


EM-1196-CS




EM-1394




EM-1424




EM-1157-CS




EM-1125




EM-1402-CS




EM-1396



EM-1181




EM-1159




5

EM-1165




and




EM-1122-CS

107. The inhibitor of Claim 106 wherein said inhibitor of
5 17 β -hydroxysteroid dehydrogenase selected from the group consisting of:




EM-1404

and




and EM-1394

108. A method of inhibiting type 3 17 β -hydroxysteroid dehydrogenase comprising administering to a patient in need of such treatment a therapeutically effective amount of an inhibitor of type 3 17 β -hydroxysteroid dehydrogenase having the molecular structure:




wherein R is selected from the group consisting of alkoxy, alkylthio, alkoxyalkoxy, alkoxyalkylthio, alkylthioalkoxy, and alkylthioalkylthio,

or




wherein n is an integer from 1 to 4.


109. The method of Claim 108 wherein said inhibitor is selected from the group consisting of:




EM-1071




EM-1065




EM-1066




EM-1064




EM-1074




EM-1073



EM-1070




CS-213




EM-1324-CS

110. A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a therapeutically acceptable amount of an inhibitor of type 3 17 β -hydroxysteroid dehydrogenase having the molecular structure:



wherein R is selected from the group consisting of alkoxy, alkylthio, alkoxyalkoxy, alkoxyalkylthio, alkylthioalkoxy, and alkylthioalkylthio,


or




wherein n is an integer from 1 to 4.

5


111. The pharmaceutical composition of Claim 110 wherein said inhibitor is selected from the group consisting of:




EM-1071




EM-1065




EM-1066




EM-1064




EM-1074




EM-1073



EM-1070




CS-213 and




EM-1324-CS

112 An inhibitor of type 3 17 β -hydroxysteroid dehydrogenase
 5 having the molecular structure:



wherein R is selected from the group consisting of alkoxyethoxy,
 10 alkoxyalkylthio, alkylthioalkoxy, and alkylthioalkylthio,


or




5

wherein n is an integer from 1 to 4.


113 The inhibitor of Claim 112 wherein said inhibitor is selected from the group consisting of:




EM-1071




EM-1065




EM-1066




EM-1064




EM-1074




EM-1073



EM-1070



CS-213 and



EM-1324-CS.

114. A method of treating, or reducing the risk of developing, prostate cancer, comprising administering to a patient in need of such treatment or reduction a therapeutically effective amount of an inhibitor of type 5 17 β -hydroxysteroid dehydrogenase, and an amount of an LHRH agonist or antagonist effective to reduce testicular secretion of sex steroids.

115. The method of claim 114, further comprising administering a therapeutically effective amount of an antiandrogen.

116. The method of claim 115, further comprising administering a therapeutically effective amount of a 5α -reductase inhibitor.

5 117. The method of claim 114, further comprising administering a therapeutically effective amount of a 5α -reductase inhibitor.

10 118. A method of treating, or reducing the risk of developing prostate cancer, comprising administering to a patient in need of such treatment or reduction a therapeutically effective amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase and of an inhibitor of type 3 17β -hydroxysteroid dehydrogenase.

15 119. The method of claim 118 further comprising a therapeutically effective amount of a 5α -reductase inhibitor.

120. The method of claim 118 further comprising a therapeutically effective amount of an LHRH agonist or antagonist.

20 121. The method of claim 118 further comprising a therapeutically effective amount of an antiandrogen.

25 122. The method of claim 118 further comprising a therapeutically effective amount of an LHRH agonist or antagonist and an antiandrogen.

123. The method of claim 118 further comprising a therapeutically effective amount of an LHRH agonist or antagonist, an antiandrogen, and a 5α -reductase inhibitor.

124. The method of claim 118 further comprising a therapeutically effective amount of an antiandrogen and a 5 α -reductase inhibitor.

5

125. The method of claim 118 further comprising a therapeutically effective amount of an LHRH agonist (or antagonist) and a 5 α -reductase inhibitor.

10

126. A method of treating, or reducing the risk of developing, benign prostatic hyperplasia comprising administering to a patient in need of such treatment or reduction, a therapeutically effective amount of an inhibitor of type 5 17 β -hydroxysteroid dehydrogenase.

15

127. The method of claim 126, further comprising administering to said patient a therapeutically effective amount of an agent selected from the group consisting of an antiestrogen or an aromatase inhibitor.

20

128. The method of claim 126, further comprising administering to said patient a therapeutically effective amount of an antiandrogen.

25

129. The method of claim 126, further comprising administering to said patient a therapeutically effective amount of an antiandrogen and a 5 α -reductase inhibitor.

130. The method of claim 126, further comprising administering to said patient a therapeutically effective amount of a 5 α -reductase inhibitor.

131. The method of claim 126, further comprising administering to said patient a therapeutically effective amount of a 5 α -reductase inhibitor and an antiestrogen or an aromatase inhibitor.

5 132. The method of claim 126, further comprising administering to said patient a therapeutically effective amount of a 5 α -reductase inhibitor, an antiandrogen, an antiestrogen or an aromatase inhibitor.

10 133. A method of treating or reducing the risk of developing, acne, seborrhea, hirsutism or androgenic alopecia, comprising administering to a patient in need of such treatment or reduction, a therapeutically effective amount of an inhibitor of type 5 17 β -hydroxysteroid dehydrogenase.

15 134. The method of claim 133, further comprising administering to said patient at therapeutically effective amount of an antiandrogen.

20 135. The method of claim 133, further comprising administering to said patient at therapeutically effective amount of a 5 α -reductase inhibitor.

25 136. The method of claim 133, further comprising administering to said patient at therapeutically effective amount of a 5 α -reductase inhibitor and an antiandrogen.

137. A method of treating, or reducing the risk of developing, polycystic ovarian syndrome comprising administering to a patient in need of such treatment or reduction a therapeutically effective amount of an inhibitor of type 5 17 β -hydroxysteroid dehydrogenase.

138. The method of claim 137, further comprising administering a therapeutically effective amount of an inhibitor of type 3 17 β -hydroxysteroid dehydrogenase.

5

139. A method of treating, or reducing the risk of developing, polycystic ovarian syndrome comprising administering to a patient in need of such treatment or reduction, a therapeutically effective amount of an inhibitor of type 3 17 β -hydroxysteroid dehydrogenase.

10

140. The method of claim 137 further comprising administering a therapeutically effective amount of an antiandrogen.

15

141. A method of treating, or reducing the risk of developing, polycystic ovarian syndrome comprising administering to a patient in need of such treatment or reduction a therapeutically effective amount of an inhibitor of type 5 17 β -hydroxysteroid dehydrogenase, an inhibitor of type 3 17 β -hydroxysteroid dehydrogenase, and an antiandrogen.

20

142. The method of claim 139 further comprising administering a therapeutically effective amount of an antiandrogen.

25

143. A method of treating, or reducing the risk of developing, breast cancer comprising administering to a patient in need of such treatment or reduction, a therapeutically effective amount of an inhibitor of type 5 17 β -hydroxysteroid dehydrogenase and a therapeutically effective amount of an antiestrogen.

144. The method of claim 143 further comprising administering a therapeutically effective amount of an LHRH agonist or antagonist.

5 145. The method of claim 143, further comprising administering a therapeutically effective amount of an androgenic compound.

146. The method of claim 145, further comprising administering an amount of an LHRH agonist effective to reduce ovarian secretion of sex steroids.

10 147. A method of treating, or reducing the risk of developing, endometriosis or leiomyoma comprising administering to a patient in need of such treatment or reduction, a therapeutically effective amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase.

15 148. The method of claim 147, further comprising administering to said patient a therapeutically effective amount of an antiestrogen or of an inhibitor of aromatase.

20 149. The method of claim 147, further comprising administering to said patient an amount of an LHRH agonist (or antagonist) effective to reduce ovarian secretion of sex steroids.

25 150. The method of claim 149, further comprising administering a therapeutically effective amount of an antiestrogen or of an aromatase inhibitor.

151. A method of inhibiting testicular hormonal secretions comprising administering to a patient in need of such inhibition an

amount of an inhibitor of type 3 17β -hydroxysteroid dehydrogenase effective to reduce testicular production of sex steroids.

5 152. The method of claim 151 further comprising administering a therapeutically effective amount of an antiandrogen.

 153. The method of claim 152 further comprising administering a therapeutically effective amount of a 5α -reductase inhibitor.

10 154. The method of claim 151, further comprising administering an LHRH agonist.

 155. The method of claim 154, further comprising administering an antiandrogen.

15 156. The method of claim 154, further comprising administering an antiandrogen and a 5α -reductase inhibitor.

 157. The method of claim 151, further comprising administering an LHRH antagonist.

 158. The method of claim 157, further comprising administering an antiandrogen.

25 159. The method of claim 157, further comprising administering an antiandrogen and a 5α -reductase inhibitor.

 160. A method of treating precocious puberty comprising administering to a male or female patient in need of such treatment a

therapeutically effective amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase.

5 161. The method of claim 160 comprising administering to a male patient a therapeutically effective amount of an LHRH agonist or antagonist.

10 162. The method of claim 160 comprising administering to a male or female patient a therapeutically effective amount of an antiandrogen.

 163. The method of claim 160 comprising administering to a male patient a therapeutically effective amount of an antiandrogen and an LHRH agonist or antagonist.

15 164. The method of claim 160 comprising administering to a male patient a therapeutically effective amount of an inhibitor of type 3 17β -hydroxysteroid dehydrogenase.

20 165. A method of treating precocious puberty comprising administering to a male or female patient in need of such treatment a therapeutically effective amount of an inhibitor of type 3 17β -hydroxysteroid dehydrogenase.

25 166. The method of claim 165 further comprising administering to a male patient a therapeutically effective amount of an LHRH agonist or antagonist.

167. The method of claim 165 further comprising administering to a male or female patient a therapeutically effective amount of an antiandrogen.

5 168. The method of claim 165 further comprising administering to a male patient a therapeutically effective amount of an antiandrogen and an LHRH agonist or antagonist.

169. A pharmaceutical composition comprising:

- 10 a) a pharmaceutically acceptable excipient, diluent or carrier;
- b) a therapeutically effective amount of at least one inhibitor of type 5 17β -hydroxysteroid dehydrogenase; and
- 15 c) a therapeutically effective amount of at least one antiandrogen.

20 170. A pharmaceutical composition of claim 169 wherein said composition further comprising a therapeutically effective amount of a 5α -reductase inhibitor.

25 171. A pharmaceutical composition of claim 169 wherein said composition further comprising a therapeutically effective amount of at least one antiestrogen or one aromatase inhibitor.

 172. A pharmaceutical composition of claim 170 wherein said composition further comprising a therapeutically effective amount of at least one antiestrogen or one aromatase inhibitor.

173. A pharmaceutical composition comprising:

- a) a pharmaceutically acceptable excipient, diluent or carrier;
- b) a therapeutically effective amount of at least one inhibitor of type 5 17β -hydroxysteroid dehydrogenase; and
- c) a therapeutically effective amount of at least one inhibitor of type 3 17β -hydroxysteroid dehydrogenase

174. A pharmaceutical composition comprising:

- a) a pharmaceutically acceptable excipient, diluent or carrier;
- b) a therapeutically effective amount of at least one inhibitor of type 3 17β -hydroxysteroid dehydrogenase; and
- c) a therapeutically effective amount of at least one antiandrogen.

175. A pharmaceutical composition comprising:

- a) a pharmaceutically acceptable excipient, diluent or carrier;
- b) a therapeutically effective amount of at least one inhibitor of type 3 17β -hydroxysteroid dehydrogenase; and
- c) a therapeutically effective amount of at least one 5α -reductase inhibitor.

176. A pharmaceutical composition of claim 174 wherein said composition further comprising a therapeutically effective amount of at least one 5α -reductase inhibitor.

177. A pharmaceutical composition of claim 173 wherein said composition further comprising a therapeutically effective amount of at least one antiandrogen.

5 178. A pharmaceutical composition of claim 173 wherein said composition further comprising a therapeutically effective amount of at least one 5 α -reductase inhibitor.

10 179. A pharmaceutical composition of claim 177 wherein said composition further comprising a therapeutically effective amount of at least one 5 α -reductase inhibitor.

180. A pharmaceutical composition comprising:

- 15 a) a pharmaceutically acceptable excipient, diluent or carrier;
- b) a therapeutically effective amount of at least one inhibitor of type 5 17 β -hydroxysteroid dehydrogenase; and
- c) a therapeutically effective amount of at least one 5 α -reductase inhibitor.

20 181. A pharmaceutical composition of claim 180 wherein said composition further comprising a therapeutically effective amount of at least one antiestrogen or one aromatase inhibitor.

25 182. A pharmaceutical composition comprising:

- a) a pharmaceutically acceptable excipient, diluent or carrier;
- b) a therapeutically effective amount of at least one inhibitor of type 5 17 β -hydroxysteroid dehydrogenase; and

- c) a therapeutically effective amount of at least one antiestrogen or one aromatase inhibitor.

5 183. A kit having a plurality of containers wherein contents of each container differ in whole or in part from content of another container, said kit comprising a therapeutically effective amount of at least one inhibitor of type 5 17β -hydroxysteroid dehydrogenase and a therapeutically effective amount of at least one antiandrogen.

10 184. A kit having a plurality of containers wherein contents of each container differ in whole or in part from content of another container, said kit comprising a therapeutically effective amount of at least one inhibitor of type 5 17β -hydroxysteroid dehydrogenase and a therapeutically effective amount of at least one inhibitor of type 3 17β -
15 hydroxysteroid dehydrogenase

185. A kit having a plurality of containers wherein contents of each container differ in whole or in part from content of another container, said kit comprising a therapeutically effective amount of at
20 least one inhibitor of type 3 17β -hydroxysteroid dehydrogenase and a therapeutically effective amount of at least one antiandrogen.

25 186. A kit having a plurality of containers wherein contents of each container differ in whole or in part from content of another container, said kit comprising a therapeutically effective amount of at least one inhibitor of type 3 17β -hydroxysteroid dehydrogenase and a therapeutically effective amount of at least one 5α -reductase inhibitor.

187. A kit having a plurality of containers wherein contents of each container differ in whole or in part from content of another container, said kit comprising a therapeutically effective amount of at least one inhibitor of type 5 17β -hydroxysteroid dehydrogenase and a therapeutically effective amount of at least one 5α -reductase inhibitor.

188. A kit having a plurality of containers wherein contents of each container differ in whole or in part from content of another container, said kit comprising a therapeutically effective amount of at least one inhibitor of type 5 17β -hydroxysteroid dehydrogenase and a therapeutically effective amount of at least one antiestrogen or one aromatase inhibitor.

189. A kit having a plurality of containers wherein contents of each container differ in whole or in part from content of another container, said kit comprising a therapeutic effective amount of at least one inhibitor of type 5 17β -hydroxysteroid dehydrogenase and an amount of at least one LHRH agonist or antagonist.

190. A kit having a plurality of containers wherein contents of each container differ in whole or in part from content of another container, said kit comprising a therapeutic effective amount of at least one inhibitor of type 3 17β -hydroxysteroid dehydrogenase and an amount of at least one LHRH agonist or antagonist.

191. A method of treating, or reducing the risk of developing, prostate cancer, comprising administering to a patient in need of such treatment or reduction a therapeutically effective amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase, and an amount of an LHRH

agonist or antagonist effective to reduce testicular secretion of sex steroids wherein the inhibitor of type 5 17β -hydroxysteroid dehydrogenase is not medroxyprogesterone acetate, megestrol acetate, chlormadinone acetate, 1-dehydromegestrol acetate, melengestrol acetate, nomegestrol acetate, 1-dehydromelengestrol acetate, and cyproterone acetate.

192. A method of treating, or reducing the risk of developing, benign prostatic hyperplasia comprising administering to a patient in need of such treatment or reduction, a therapeutically effective amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase wherein the inhibitor of type 5 17β -hydroxysteroid dehydrogenase is not medroxyprogesterone acetate, megestrol acetate, chlormadinone acetate, 1-dehydromegestrol acetate, melengestrol acetate, nomegestrol acetate, 1-dehydromelengestrol acetate, and cyproterone acetate.

193. A method of treating or reducing the risk of developing, acne, seborrhea, hirsutism or androgenic alopecia, comprising administering to a patient in need of such treatment or reduction, a therapeutically effective amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase wherein the inhibitor of type 5 17β -hydroxysteroid dehydrogenase is not medroxyprogesterone acetate, megestrol acetate, chlormadinone acetate, 1-dehydromegestrol acetate, melengestrol acetate, nomegestrol acetate, 1-dehydromelengestrol acetate, and cyproterone acetate.

194. A method of treating, or reducing the risk of developing, polycystic ovarian syndrome comprising administering to a patient in need of such treatment or reduction a therapeutically effective amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase wherein the

inhibitor of type 5 17β -hydroxysteroid dehydrogenase is not medroxyprogesterone acetate, megestrol acetate, chlormadinone acetate, 1-dehydromegestrol acetate, melengestrol acetate, nomegestrol acetate, 1-dehydromelengestrol acetate, and cyproterone acetate.

5

195. A method of treating, or reducing the risk of developing, breast cancer comprising administering to a patient in need of such treatment or reduction, a therapeutically effective amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase and a therapeutically effective amount of an antiestrogen wherein the inhibitor of type 5 17β -hydroxysteroid dehydrogenase is not medroxyprogesterone acetate, megestrol acetate, chlormadinone acetate, 1-dehydromegestrol acetate, melengestrol acetate, nomegestrol acetate, 1-dehydromelengestrol acetate, and cyproterone acetate.

10

15

196. A method of treating, or reducing the risk of developing, endometriosis or leiomyoma comprising administering to a patient in need of such treatment or reduction, a therapeutically effective amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase wherein the inhibitor of type 5 17β -hydroxysteroid dehydrogenase is not medroxyprogesterone acetate, megestrol acetate, chlormadinone acetate, 1-dehydromegestrol acetate, melengestrol acetate, nomegestrol acetate, 1-dehydromelengestrol acetate, and cyproterone acetate.

20

25

197. A method of treating precocious puberty comprising administering to a male or female patient in need of such treatment a therapeutically effective amount of an inhibitor of type 5 17β -hydroxysteroid dehydrogenase.

198. The method of claim 1 wherein the inhibitor of type 5 17 β -hydroxysteroid dehydrogenase is not medroxyprogesterone acetate, megestrol acetate, chlormadinone acetate, 1-dehydromegestrol acetate, melengestrol acetate, nomegestrol acetate, 1-dehydromelengestrol acetate, and cyproterone acetate.

199. The method of claim 38 wherein the inhibitor of type 5 17 β -hydroxysteroid dehydrogenase is not medroxyprogesterone acetate, megestrol acetate, chlormadinone acetate, 1-dehydromegestrol acetate, melengestrol acetate, nomegestrol acetate, 1-dehydromelengestrol acetate, and cyproterone acetate.

200. The pharmaceutical composition of claim 40 wherein the inhibitor of type 5 17 β -hydroxysteroid dehydrogenase is not medroxyprogesterone acetate, megestrol acetate, chlormadinone acetate, 1-dehydromegestrol acetate, melengestrol acetate, nomegestrol acetate, 1-dehydromelengestrol acetate, and cyproterone acetate.

201. The pharmaceutical composition of claim 73 wherein the inhibitor of type 5 17 β -hydroxysteroid dehydrogenase is not medroxyprogesterone acetate, megestrol acetate, chlormadinone acetate, 1-dehydromegestrol acetate, melengestrol acetate, nomegestrol acetate, 1-dehydromelengestrol acetate, and cyproterone acetate.

202. The method of claim 139 wherein the inhibitor of type 3 17 β -hydroxysteroid dehydrogenase is not androsterone.

203. The method of claim 151 wherein the inhibitor of type 3 17 β -hydroxysteroid dehydrogenase is not androsterone.

204. The method of claim 165 wherein the inhibitor of type 3 17 β -hydroxysteroid dehydrogenase is not androsterone.




FIG. 1

SUBSTITUTE SHEET (RULE 26)




FIG. 2

SUBSTITUTE SHEET (RULE 26)




FIG. 3




FIG. 4

SUBSTITUTE SHEET (RULE 26)





FIG. 5

SUBSTITUTE SHEET (RULE 26)

Human skin hybridized with type 5 17β -HSD cRNA probe**FIG. 6**

Monkey ovary hybridized with type 5 17β -HSD





FIG. 7



Biosynthetic pathway of active androgens in the prostate.

X, inhibition target.

Fig. 8

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 September 1999 (16.09.1999)

PCT

(10) International Publication Number
WO 99/46279 A3

(51) International Patent Classification⁶: **A61K 31/00**,
31/57, 31/575, 31/565, 31/585, 31/22, 31/56, 45/06

(21) International Application Number: PCT/CA99/00205

(22) International Filing Date: 10 March 1999 (10.03.1999)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/077,510 11 March 1998 (11.03.1998) US
60/095,623 7 August 1998 (07.08.1998) US

(71) Applicant: **ENDORECHERCHE, INC.** [CA/CA]; 2989
de la Promenade, Sainte-Foy, Québec G1W 2J5 (CA).

(72) Inventors: **LABRIE, Fernand**; 2989 de la Promenade,
Sainte-Foy, Québec G1W 2J5 (CA). **BELANGER,**

Alain; 4031 Boisverdun, Cap-Rouge, Québec G1Y 3T7
(CA). **GAUTHIER, Sylvain**; 152, rue de la Modiste,
Saint-Augustin-de-Desmaures, Québec G3A 2L2 (CA).
LUU-THE, Van; 4460 de l'Estuaire, Chamy, Québec G6X
1C6 (CA). **MERAND, Yves**; 3101 Montreux, Sainte-Foy,
Québec G1W 3A1 (CA). **POIRIER, Donald**; 1588 des
Cassandres, L'Ancienne-Lorette, Québec G2E 5V1 (CA).
PROVENCHER, Louis; 7518 de la Sarcelle, Chamy,
Québec G6X 3R7 (CA). **SINGH, Shankar, Mohan**; 2816,
rue de Lanoraie, Sainte-Foy, Québec G1W 1M6 (CA).

(74) Agent: **MITCHELL, Richard, J.**; Marks & Clerk, P.O.
Box 957, Station B, Ottawa, Ontario K1P 5S7 (CA).

(81) Designated States (*national*): AL, AM, AT, AU, AZ, BA,
BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES,
FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP,
KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,

[Continued on next page]

(54) Title: INHIBITORS OF TYPE 5 AND TYPE 3 17 β -HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE



(57) Abstract: Novel methods of medical treatment and/or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and/or type 3 17 β -hydroxysteroid dehydrogenase. Novel inhibitors of type 5 17 β -hydroxysteroid dehydrogenase are also disclosed, as are novel inhibitors of type 3 17 β -hydroxysteroid dehydrogenase.

WO 99/46279 A3



MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW.

Published:

— With international search report.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(88) Date of publication of the international search report:

22 February 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/CA 99/00205

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/00 A61K31/57 A61K31/575 A61K31/565 A61K31/585
A61K31/22 A61K31/56 A61K45/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>J.E.F. REYNOLDS: "Martindale, The Extra Pharmacopoeia" 1996, ROYAL PHARMACEUTICAL SOCIETY, LONDON XP002114852</p> <p>page 530 -page 531 page 1476 -page 1477 page 1486 -page 1488 page 1494 -page 1497 page 1499</p> <p style="text-align: center;">--- -/--</p>	<p>1-5,34, 114-136, 143-150, 169,183, 189</p>

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel if it cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

Date of the actual completion of the international search

9 September 1999

Date of mailing of the international search report

- 3. 02. 00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

HOFF, P

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 99/00205

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 90 10462 A (ENDORECHERCHE INC) 20 September 1990 (1990-09-20)</p> <p>abstract page 14, last paragraph -page 18, paragraph 2 page 21, paragraph 2 page 22, paragraph 2; claims 1,6,11,12,20,29,36,37,41,46,47,62-105</p> <p style="text-align: center;">---</p>	<p>1-5,34, 143-146, 169-173, 180-184, 187-189</p>
X	<p>BE 898 057 A (MORTIMER CHRISTOPHER H) 15 February 1984 (1984-02-15)</p> <p>the whole document</p> <p style="text-align: center;">---</p>	<p>1-5,34, 133-136, 169,183</p>
X	<p>US 3 917 657 A (VAN KAMP HARMEN ET AL) 4 November 1975 (1975-11-04)</p> <p>the whole document</p> <p style="text-align: center;">---</p>	<p>34,126, 133,192, 193</p>
X	<p>WO 96 15794 A (BALANCE PHARMACEUTICALS INC) 30 May 1996 (1996-05-30) abstract; claims 1,4,7,8</p> <p style="text-align: center;">---</p>	<p>1-5,34, 137,147</p>
X	<p>GB 2 102 287 A (SCHERING AG) 2 February 1983 (1983-02-02)</p> <p>the whole document, in particular page 4, lines 10-12</p> <p style="text-align: center;">---</p>	<p>1-5,34, 126-128, 132,169, 171,172, 182,183, 188</p>
X	<p>WO 86 01402 A (SCHERING AG) 13 March 1986 (1986-03-13)</p> <p>the whole document</p> <p style="text-align: center;">---</p>	<p>1-5,34, 133,134, 169,183</p>
X	<p>US 4 684 635 A (ORENTREICH NORMAN ET AL) 4 August 1987 (1987-08-04)</p> <p>the whole document, in particular column 1, line 55 to column 2, line 20; claims 1,7</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	<p>1-5,34, 133-136, 169,170, 180,183, 187</p>

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 99/00205

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 2 018 591 A (SCHERING AG) 24 October 1979 (1979-10-24) the whole document, in particular page 3, lines 30-33 ---	1-5,34, 126-128, 169,171, 182,183, 188
X	DE 20 59 338 A (SCHERING) 15 June 1972 (1972-06-15) the whole document ---	34,160, 162,169
X	GB 870 286 A (BRITISH DRUG HOUSES LIMITED) 14 June 1961 (1961-06-14) the whole document, in particular page 2, lines 3-8 ---	1-5,34, 147,196
X	CHEMICAL ABSTRACTS, vol. 130, Columbus, Ohio, US; abstract no. 332443, UMEDA, HIROSHI ET AL: "Elimination of luteinizing hormone-releasing hormone-induced flare reaction by lead-in and combination therapies with chlormadinone acetate in patients with advanced prostate carcinoma - comparison with flutamide treatment -" XP002114853 abstract & DOKKYO J. MED. SCI. (1998), 25(1), 53-60, ---	1-5,34, 114,189
X	COUTINHO, E. M. ET AL: "Clinical management of leiomyomas with medroxyprogesterone acetate" INT. CONGR., SYMP. SEMIN. SER. (1995), 11(PROGRESS IN THE MANAGEMENT OF ENDOMETRIOSIS), 421-5, XP002114848 the whole document ---	1-5,34, 147
X	WEST, CHRISTINE P. ET AL: "Potential role for medroxyprogesterone acetate as an adjunct to goserelin (Zoladex) in the medical management of uterine fibroids" HUM. REPROD. (1992), 7(3), 328-32, XP002114849 the whole document ---	1-5,34, 147,149, 189
	-/--	

INTERNATIONAL SEARCH REPORT

Internat. Application No

PCT/CA 99/00205

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 108, Columbus, Ohio, US; abstract no. 16367, MACHIDA, TOYOHEI ET AL: "Hormone therapy for male genital cancer (prostatic cancer)" XP002114854 abstract & GAN TO KAGAKU RYOHO (1987), 14(10), 2845-52, ---	1-5,34, 114,189
X	CHEMICAL ABSTRACTS, vol. 103, Columbus, Ohio, US; abstract no. 27291, SHISEIDO CO., LTD., JAPAN: "Skin lotion containing chlormadinone acetate for acne treatment" XP002114855 abstract & JP 60 028926 A (SHISEIDO CO., LTD., JAPAN) 1983 ---	1-5,34, 133
X	DATABASE WPI Section Ch, Week 8533 Derwent Publications Ltd., London, GB; Class B01, AN 85-200303 XP002114857 & JP 60 126214 A (TEIKOKU HORMONE MFG CO LTD), 5 July 1985 (1985-07-05) abstract ---	1-5,34, 133
X	BIERICH, JURGEN R.: "Precocious and retarded puberty" SYMP. DEUT. GES. ENDOKRINOL. (1970), 16, 183-94, XP002114850 the whole document ---	1-5,34, 160,162, 169
X	CHEMICAL ABSTRACTS, vol. 116, Columbus, Ohio, US; abstract no. 99327, SUDO, KATSUICHI ET AL: "Neovascularization inhibitors containing steroid 17.beta.-carboxylic acid derivatives" XP002114856 abstract & JP 03 236324 A (TAKEDA CHEMICAL INDUSTRIES, LTD., JAPAN) 1990 ---	40,43
	-/--	

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/CA 99/00205

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FR 1 405 214 A (SOCIETE DES USINES CHIMIQUES RHONE-POULENC) 19 November 1965 (1965-11-19) page 1, right-hand column, last paragraph -page 2, left-hand column, paragraph 1 page 4, left-hand column, line 30 - line 33	73
X	--- R. WIECHERT ET AL.: "The progestational efficacy of 1-methyl and 1,2alpha-methylene steroids" ARZNEIMITTEL-FORSCH., vol. 15, no. 3, 1965, pages 244-246, XP002114851 the whole document	73
A	--- LUU-THE V ET AL: "CHARACTERISTICS OF HUMAN TYPES 1, 2 AND 3 17BETA-HYDROXYSTEROID DEHYDROGENASE ACTIVITIES: OXIDATION/REDUCTION AND INHIBITION" JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 55, no. 5/06, 1 January 1995 (1995-01-01), pages 581-587, XP000196678 ISSN: 0960-0760 the whole document	
A	--- WO 97 11162 A (ENDORECHERCHE INC ; LABRIE FERNAND (CA); LUU THE VAN (CA)) 27 March 1997 (1997-03-27) cited in the application the whole document -----	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 99/ 00205

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 1-8, 32, 34, 38, 114-138, 141-150, 160-164, 191-199 is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see ADDITIONAL SHEET

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Subject 1 see additional sheet for info

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Present claims

114-138,141-150,160-164,169-173,177-184,187-189,191-197,198-201 relate to compounds defined by reference to a desirable characteristic or property, namely "inhibitor of type 5 17beta-hydroxysteroid dehydrogenase", "LHRH agonist or antagonist", "antiandrogen", "antiestrogen", "androgenic compound", "5alpha-reductase inhibitor", "type 3 17beta-hydroxysteroid dehydrogenase", "aromatase inhibitor".

The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds mentioned in claims 1-8,32,34,38,40-47,71,73,75-82,106. For the other compounds defined by their properties and which lack support and disclosure, the search has been restricted to the general concept used in the present application for defining said compounds. Furthermore, claims 1-8,32,34,38 relate to the treatment of a disease which actually is not well defined. The use of the definition "inhibiting the activity of type 5 17beta-hydroxysteroid dehydrogenase" in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. The lack of clarity is such as to render a meaningful complete search impossible. Consequently, the search has been restricted to the diseases mentioned in claims 114-138,141-150,160-164.

Claims searched completely: 40-47,71,73,75-82,106

claims searched incompletely:

1-8,32,34,38,114-138,141-150,160-164,169-173,177-184,187-189,191-197,198-201

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-8,32(partially),34,38,40-47,71(partially),73,
75-82,106(partially),114-138(partially),
141-150(partially),160-164(partially),
169-173(partially),177-184(partially),
187-189(partially),191-197 (partialy),198-201

Method/composition for inhibiting activity of type 5
17beta-hydroxysteroid dehydrogenase comprising a compound
such as defined in claims 1,34,38,40,73,75, its use as an
inhibitor of type 5 17beta-hydroxysteroid dehydrogenase for
treating androgen and estrogen sensitive diseases.

2. Claims: 9-13,32(partially),35,48-52,71(partially),83-87,
106(partially),114-138(partially),
141-150(partially),160-164(partially),
169-173(partially),177-184(partially),
187-189(partially),191-197 (partialy)

Method/composition for inhibiting activity of type 5
17beta-hydroxysteroid dehydrogenase comprising a compound
such as defined in claims 9,35,48,83, its use as an
inhibitor of type 5 17beta-hydroxysteroid dehydrogenase for
treating androgen and estrogen sensitive diseases.

3. Claims: 14-18,32(partially),39,53-57,71(partially),74,
88-92,106(partially),114-138(partially),
141-150(partially),160-164(partially),
169-173(partially),177-184(partially),
187-189(partially),191-197 (partialy)

Method/composition for inhibiting activity of type 5
17beta-hydroxysteroid dehydrogenase comprising a compound
such as defined in claims 14,39,53,74,88, its use as an
inhibitor of type 5 17beta-hydroxysteroid dehydrogenase for
treating androgen and estrogen sensitive diseases.

4. Claims: 19-26,32(partially),33,36,58-65,71(partially),72,
93-100,106(partially),107,114-138(partially),
141-150(partially),160-164(partially),
169-173(partially),177-184(partially),
187-189(partially),191-197 (partialy)

Method/composition for inhibiting activity of type 5
17beta-hydroxysteroid dehydrogenase comprising a compound
such as defined in claims 19,33,36,58,72,93,107, its use as
an inhibitor of type 5 17beta-hydroxysteroid dehydrogenase
for treating androgen and estrogen sensitive diseases.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

5. Claims: 27-31,32(partially),37,66-70,71(partially),101-105,
106(partially),114-138(partially),
141-150(partially),160-164(partially),
169-173(partially),177-184(partially),
187-189(partially),191-197 (partialy)

Method/composition for inhibiting activity of type 5
17beta-hydroxysteroid dehydrogenase comprising a compound
such as defined in claims 27,37,66,101, its use as an
inhibitor of type 5 17beta-hydroxysteroid dehydrogenase for
treating androgen and estrogen sensitive diseases.

6. Claims: 108-113,139,140,151-159,165-168,174,175,176,185,
186,190,202-204 (all partially)

Method/composition for inhibiting activity of type 3
17beta-hydroxysteroid dehydrogenase comprising a estrone
derivative such as defined in claims 108-113, its use as an
inhibitor of type 3 17beta-hydroxysteroid dehydrogenase for
treating androgen and estrogen sensitive diseases.

7. Claims: 108-113,139,140,151-159,165-168,174,175,176,185,
186,190,202-204 (all partially)

Method/composition for inhibiting activity of type 3
17beta-hydroxysteroid dehydrogenase comprising a
androsterone derivative such as defined in claims 108-113,
its use as an inhibitor of type 3 17beta-hydroxysteroid
dehydrogenase for treating androgen and estrogen sensitive
diseases.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Application No

PCT/CA 99/00205

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9010462	A	20-09-1990	AT 128362 T	15-10-1995
			AU 5281990 A	09-10-1990
			AU 669767 B	20-06-1996
			CA 2050291 A	11-09-1990
			DE 69022722 D	02-11-1995
			DE 69022722 T	02-05-1996
			DK 462189 T	20-11-1995
			EP 0462189 A	27-12-1991
			ES 2077675 T	01-12-1995
			IE 62715 B	22-02-1995
			JP 2959838 B	06-10-1999
			JP 4504848 T	27-08-1992
			NZ 232870 A	26-01-1994
			NZ 244499 A	28-05-1999
			US 5550107 A	27-08-1996

BE 898057	A	15-02-1984	DE 3338339 A	26-04-1984
			ZA 8307859 A	28-11-1984

US 3917657	A	04-11-1975	NL 7003060 A	07-09-1971
			DE 2110115 A	16-09-1971
			FR 2085667 A	31-12-1971
			GB 1346326 A	06-02-1974
			SE 374268 B	03-03-1975

WO 9615794	A	30-05-1996	CA 2205897 A	30-05-1996
			EP 0792152 A	03-09-1997

GB 2102287	A	02-02-1983	DE 3121152 A	09-12-1982
			AU 563785 B	23-07-1987
			AU 8407582 A	25-11-1982
			BE 890522 A	29-03-1982
			CA 1186998 A	14-05-1985
			CH 648211 A	15-03-1985
			DK 354881 A	23-11-1982
			FR 2506158 A	26-11-1982
			IE 53394 B	09-11-1988
			IT 1139175 B	24-09-1986
			JP 1050207 B	27-10-1989
			JP 57193412 A	27-11-1982
			LU 83545 A	01-12-1981
			NL 8103875 A	16-12-1982
			SE 463074 B	08-10-1990
			SE 8104624 A	23-11-1982
			US 4598072 A	01-07-1986
			ZA 8203501 A	30-03-1983

WO 8601402	A	13-03-1986	DE 3432584 A	24-04-1986
			DE 3442857 A	22-05-1986
			AU 4805085 A	24-03-1986

US 4684635	A	04-08-1987	CA 1243609 A	25-10-1988
			US 5053403 A	01-10-1991

GB 2018591	A	24-10-1979	DE 2817157 A	25-10-1979
			AU 528179 B	21-04-1983
			AU 4560479 A	25-10-1979
			BE 875634 A	17-10-1979

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 99/00205

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2018591 A		CA 1134271 A	26-10-1982
		CH 641679 A	15-03-1984
		IT 1119733 B	10-03-1986
		JP 1005007 B	27-01-1989
		JP 1520155 C	29-09-1989
		JP 55013261 A	30-01-1980
		LU 81153 A	19-06-1979
		NL 7901961 A	19-10-1979
		SE 441977 B	25-11-1985
		SE 7903240 A	18-10-1979
		US 4310523 A	12-01-1982
		ZA 7901797 A	26-11-1980
DE 2059338 A	15-06-1972	BE 775905 A	26-05-1972
		GB 1377998 A	18-12-1974
		NL 7116178 A	30-05-1972
		ZA 7107597 A	30-08-1972
GB 870286 A		DE 1120446 B	
		FR 1333711 A	16-12-1963
		US 3356573 A	05-12-1967
JP 60028926 A	14-02-1985	JP 1719253 C	14-12-1992
		JP 4003363 B	23-01-1992
JP 60126214 A	05-07-1985	NONE	
JP 3236324 A	22-10-1991	JP 2985007 B	29-11-1999
FR 1405214 A	19-11-1965	NONE	
WO 9711162 A	27-03-1997	AU 6867896 A	09-04-1997
		CA 2232500 A	27-03-1997
		EP 0856048 A	05-08-1998
		JP 11511329 T	05-10-1999

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.